WO2004067521A1 - Thiazole derivatives and their use as vap-1 inhibitors - Google Patents

Thiazole derivatives and their use as vap-1 inhibitors Download PDF

Info

Publication number
WO2004067521A1
WO2004067521A1 PCT/JP2004/000708 JP2004000708W WO2004067521A1 WO 2004067521 A1 WO2004067521 A1 WO 2004067521A1 JP 2004000708 W JP2004000708 W JP 2004000708W WO 2004067521 A1 WO2004067521 A1 WO 2004067521A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazol
ethyl
disease
acetamide
amino
Prior art date
Application number
PCT/JP2004/000708
Other languages
French (fr)
Inventor
Takayuki Inoue
Takashi Tojo
Masataka Morita
Mitsuru Ohkubo
Kousei Yoshihara
Akira Nagashima
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to CA002514573A priority Critical patent/CA2514573A1/en
Priority to KR1020057013750A priority patent/KR101154163B1/en
Priority to JP2006502657A priority patent/JP4650412B2/en
Priority to EP04705519A priority patent/EP1587800A1/en
Publication of WO2004067521A1 publication Critical patent/WO2004067521A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a compound or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 inhibitor, a pharmaceutical composition comprising the compound or salt thereof as an active ingredient, a method for preventing or treating a vascular adhesion protein-1 associated disease, especially macular edema, use of the compound, salt thereof or composition, and the like.
  • VAP-1 Vascular adhesion protein-1
  • SSAO amine oxidase
  • the amine to be a substrate is unknown, it is considered to be methylamin ⁇ generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydes produced due to the amine oxidase activity in the molecule are important factors of adhesion activity.
  • VAP-1 enzyme activity in plasma increases in diabetic patients, whether type I or type II, and the increase is particularly remarkable in diabetic patients suffering from retinopathy complications (Diabetologia, 42 (1999) 233-237, Diabetic Medicine , 16 ( 1999 ) 514-521 ) .
  • VAP-1 is associated with the following diseases:
  • endothelium damage in diabetes, atherosclerosis and hypertension
  • a cardiovascular disorder associated with diabetes and uraemia pain associated with gout and arthritis
  • retinopathy in diabetes patients
  • an (connective tissue) inflammatory disease or condition rheumatoid arthritis, ankylosing spondylitis , psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatos
  • SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)] (see WO 02/38153) , and the like.
  • Macular edema is a common ocular abnormality resulting from a vast etiology and characterized by perturbation of the integrity of the blood-retinal barrier of the perifoveal capillaries and the optic nerve head.
  • Macular edema is known to include diabetic and non-diabetic ones .
  • Macular edema as a diabetic complication is a disease state that can occur in any stage of diabetic retinopathy, emerges before the onset of neovascularization and causes a serious visual disorder.
  • Macular area is a highly evolved part in retina and plays a key role in controlling the eyesight.
  • the macular area suffers from edema, how mild the change may be, it causes a significant failure of eyesight, and when left unattended, the edema causes irreversible changes of macular tissue, and it is considered to encourage progress of retinopathy.
  • laser beam photocoagulation and vitreous surgery have been tried as a symptomatic therapy.
  • irradiation of laser on the macular area is not easy and unnecessary laser treatments may produce side effects (e.g., possible encouragement of edema by causing inflammation) .
  • the vitreous surgery is considered to provide effect in 70 percent of macular edema, but physical and economical burden on patients is high, and the incidence of recurrence is also high.
  • These treatment methods are not usually employed in the initial stage of macular edema, particularly so in the stages when the decrease of vision is comparatively small. Accordingly, a drug treatment comparatively easily applicable from the early stages of the disease has been also demanded under the present circumstances.
  • VAP-1 inhibitor is useful for the prophylaxis or treatment of the disease, particularly macular edema, and completed the present invention.
  • the present invention provides the following.
  • R 1 —NH—X—Y—Z (I) wherein R 1 is acyl
  • X is a bivalent residue derived from optionally substituted thiazole;
  • Y is a bond, lower alkylene, lower alkenylene or -CONH-;
  • Z is a group of the formula:
  • R 3 is hydrogen, lower alkyl, lower alkylthio or -NH-R 4 wherein R 4 is hydrogen, -NH 2 or lower alkyl; or a pharmaceutically acceptable salt thereof.
  • R 2 is a group of the formula:
  • [6] The compound of [1] or a pharmaceutically acceptable salt thereof for use as a medicament.
  • a pharmaceutical composition which comprises, as an active ingredient, the compound of [1] or a pharmaceutically acceptable salt thereof.
  • R 1 is acyl
  • X is a bivalent residue derived from optionally substituted thiazole;
  • Y is a bond, lower alkylene, lower alkenylene or -CONH-;
  • Z is a group of the formula:
  • R 3 is hydrogen, lower alkyl, lower alkylthio or
  • Li is a leaving group and Z is as defined above, or a salt thereof;
  • VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic s
  • a VAP-1 inhibitor which comprises the compound of [1] or a pharmaceutically acceptable salt thereof.
  • a method for preventing or treating macular edema which method comprises administering to a subject in need thereof a VAP-1 inhibitor in an amount sufficient to treat said subject for macular edema.
  • VAP-1 inhibitor is N- ⁇ 4- [2- (4- ⁇ [amino (imino) ethyl] amino Jphenyl) ethyl] -1 ,3- thiazol-2-yl ⁇ acetamide , N- ⁇ 4-[2- (4- ⁇ [amino (imino) methyl] aminoJphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl ⁇ acetamide , N- ⁇ 4-[2- (4- ⁇ [hydrazino (imino) methyl] amino Jphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl ⁇ acetamide , N- ⁇ 4-[2-(4- ⁇ [hydrazino (imino)methyl] aminoJphenyl) ethyl] -1 , 3-thia
  • a method for preventing or treating a VAP-1 associated disease comprises administering an effective amount of the compound of [1] or a pharmaceutically acceptable salt thereof to a mammal.
  • VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis , psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica
  • VAP-1 associated disease is macular edema.
  • macular edema is diabetic macular edema.
  • the present invention is predicated on the discovery that an inhibitor of vascular adhesion protein-1 (VAP-1; also referred to as semicarbazide sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating a VAP-1 associated disease, especially macular edema, and the like.
  • VAP-1 vascular adhesion protein-1
  • SSAO semicarbazide sensitive amine oxidase
  • copper-containing amine oxidase copper-containing amine oxidase
  • the present invention provides Compound (I) or a pharmaceutically acceptable salt thereof useful as a VAP-1 inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, and the like.
  • Suitable "halogen” includes fluorine, chlorine, bromine and iodine.
  • lower is used to intend a group having 1 to 6, preferably 1 to 4 , carbon atom(s) , unless otherwise provided.
  • Suitable “lower alkyl” includes straight or branched alkyl having 1 to 6 carbon atom(s) , such as methyl, ethyl, propyl , isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C 1 -C 4 alkyl.
  • Suitable "lower alkylthio" includes lower alkylthio containing the above lower alkyl, such as methylthio, ethylthio, propylthio, isopropylthio , butylthio, isobutylthio, sec-butylthio , tert-butylthio , pentylthio, tert-pentylthio and hexylthio.
  • Suitable "lower alkylene” includes straight or branched alkylene having 1 to 6 carbon atom(s) , such as methylene, ethylene, trimethylene , tetramethylene , propylene, ethylidene and propylidene, in which more preferred one is C ⁇ -C alkylene.
  • the above lower alkenylene may be in E or Z form, respectively.
  • the lower alkenylene includes all E, Z-structures when it has 2 or more double bonds.
  • aryl includes C 6 -C 10 aryl such as phenyl and-- - naphthyl, in which more preferred one is phenyl.
  • the "aryl” may be substituted by 1 to 3 substituent (s) and the substitution sites are not particularly limited.
  • Suitable “aralkyl” includes aralkyl wherein the aryl moiety has 6 to 10 carbon atoms [i.e. the aryl moiety is C 6 - Cio aryl of the above “aryl”] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is C ⁇ -C 6 alkyl of the above “lower alkyl”], such as benzyl, phenethyl , 1- naphthylmethyl , 2-naphthylmethyl , 3-phenylpropyl , 4- phenylbutyl and 5-phenylpentyl .
  • the "optionally protected amino” means that an amino group may be protected with a suitable protecting group according to a method known per se , such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
  • the suitable "protecting group” includes tert-butoxycarbonyl (i.e., Boc) , an acyl group as mentioned below, substituted or unsubstituted aryl (lower) alkylidene [e.g., benzylidene, hydroxybenzylidene, etc.], aryl (lower) alkyl such as mono-, di- or triphenyl- (lower) alkyl [e.g., benzyl, phenethyl , benzhydryl, trityl, etc.] and the like.
  • Suitable "optionally protected amino” includes amino and tert-butoxycarbonylamino (i.e. -NHBoc) .
  • Suitable “heterocycle” includes “aromatic heterocycle” and “non-aromatic heterocycle”.
  • Suitable “aromatic heterocycle” includes 5 to 10- membered aromatic heterocycle containing 1 to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s) , and includes, for example, thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine and the like.
  • Suitable “non-aromatic heterocycle” includes 5 to 10— membered non-aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s) , and includes, for example, pyrrolidine, imidazoline, pyrazolidine , pyrazoline, piperidine, piperazine, morpholine, thiomorpholine , dioxolan, oxazolidine, thiazolidine, triazolidine and the like.
  • Suitable "acyl” includes acyl having 1 to 20 carbon atom(s) , such as formyl, alkylcarbonyl , arylcarbonyl , alkoxycarbonyl and aralkyloxycarbonyl .
  • Suitable “alkylcarbonyl” includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is C ⁇ -C 5 alkyl of the above “lower alkyl”] , such as acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl , in which more preferred one is C1-C 4 alkyl-carbonyl .
  • Suitable “arylcarbonyl” includes arylcarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e.
  • alkoxycarbonyl includes alkoxycarbonyl wherein the alkoxy moiety has 1 to 6 carbon atom(s) , such as methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , isopropoxycarbonyl, butoxycarbonyl , isobutoxycarbonyl , sec- butoxycarbonyl , tert-butoxycarbonyl , pentyloxycarbonyl , tert-pentyloxycarbonyl and hexyloxycarbonyl, in which more preferred one is alkoxycarbonyl wherein the alkoxy moiety has 1 to 4 carbon atom(s) .
  • Suitable “aralkyloxycarbonyl” includes aralkyloxycarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C 6 -C ⁇ 0 aryl of the above “aryl”] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e.
  • the alkyl moiety is Ci-C ⁇ alkyl of the above "lower alkyl”], such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl , 2-naphthylmethyloxycarbonyl , 3- phenylpropyloxycarbonyl , 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
  • lower alkyl such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl , 2-naphthylmethyloxycarbonyl , 3- phenylpropyloxycarbonyl , 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
  • Suitable "bivalent residue derived from thiazole" of the "bivalent residue derived from optionally substituted thiazole” includes
  • the “thiazole” may have 1 to 3 substituent (s) and the substitution sites are not particularly limited.
  • Suitable "substituent" of the above “optionally substituted thiazole” includes, for example,
  • alkoxycarbonyl which is as defined above, such as ethoxycarbonyl ; (3) optionally substituted aryl, which aryl is as defined above and the substitution sites are not particularly limited, such as phenyl and 4- (methylsulfonyl) phenyl ; (4) a group of the formula: -CONR a R b wherein R a is hydrogen, lower alkyl, aryl or aralkyl and R b is hydrogen, lower alkyl, aryl or aralkyl, wherein the lower alkyl, aryl and aralkyl are as defined above, such as N- methylaminocarbonyl , N-phenylaminocarbonyl , N,N- dimethylaminocarbonyl and N-benzylaminocarbonyl ;
  • aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -N0 2 , -S0 2 - (lower alkyl) wherein the lower alkyl is as defined above, -CF 3 and -O-aryl wherein the aryl is as defined above, and the substitution sites are not particularly limited;
  • (6) a group of the formula: -CONH- (CH 2 ) m -heterocycle wherein m is an integer of 0 to 6 ; the heterocycle is as defined above, such as pyridine;
  • -CO-heterocycle wherein the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of -CO- (lower alkyl) wherein the lower alkyl is as defined above, -CO-O- (lower alkyl) wherein the lower alkyl is as defined above, -S0 2 - (lower alkyl) wherein the lower alkyl is as defined above, oxo (i.e.
  • (9) a group of the formula: - (CH 2 ) 0 -heterocycle wherein o is an integer of 0 to 6; the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of oxo (i.e.
  • (10) a group of the formula: - (CH 2 ) p -NR i R j wherein p is an integer of 0 to 6;
  • R 1 is hydrogen, acyl, lower alkyl, aryl or aralkyl and
  • R j is hydrogen, acyl, lower alkyl, aryl or aralkyl wherein the acyl, lower alkyl, aryl and aralkyl are as defined above, and the lower alkyl may have 1 to 5 substituent (s) selected from the group consisting of a group of the formula: -CONR ⁇ 1 wherein R k is hydrogen, lower alkyl, aryl or aralkyl and R 1 is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
  • (11) a group of the formula: -CON(H or lower alkyl) - (CHR ra )q-T wherein q is an integer of 0 to 6; the lower alkyl is as defined above; R m is hydrogen, aralkyl which is as defined above, or alkyl which is as defined above, which may be substituted by 1 to 3 substituent (s) selected from the group consisting of -OH and -CONH 2 and the substitution sites are not particularly limited; and T is hydrogen; a group of the formula: -CONR n R° wherein R n is hydrogen, lower alkyl, aryl or aralkyl and R° is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl , aryl and aralkyl are as defined above; -NH-CO-R p wherein R p is lower alkyl which is as defined above or aralkyl which is as defined above; -NH-S0 2 - (low
  • substitution site on the aryl or heterocycle is any suitable position thereof, but not particularly limited.
  • substituted thiazole is methylsulfonylbenzyl.
  • (I) is not particularly limited.
  • substitution sites on the group are not particularly limited
  • Compound (I) may be protected according to the methods, which are known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
  • VAP-1 (VAP-1) associated disease comprise a disease selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, art rosis; endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients); an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polyc ondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica
  • VAP-1 associated disease and "prophylaxis or treatment of a vascular adhesion protein-1 (VAP-1) associated disease", particularly “preventing or treating macular edema” and “prophylaxis or treatment of macular edema” are intended to include administration of a compound having VAP-1 inhibitory activity (i.e. VAP-1 inhibitor) to a subject for therapeutic purposes, which may include prophylaxis, amelioration, prevention and cure of the above described VAP-1 associated disease, particularly macular edema.
  • VAP-1 inhibitor a compound having VAP-1 inhibitory activity
  • the subject is meant a target of the administration of VAP-1 inhibitor in the present invention, which is specifically various animals such as mammal, e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
  • mammal e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
  • VAP-1 inhibitor in an amount sufficient to treat the VAP-1 associated disease, especially macular edema.
  • Any VAP-1 inhibitor can be used in the method of the present invention as long as it is safe and efficacious.
  • VAP-1 inhibitor will be used to refer to such compounds, which include Compound (I) , and is intended to encompass all compounds that inhibit enzyme activity of VAP-1 at any and all points in the action mechanism thereof.
  • the compounds of the present invention and derivatives thereof, or compounds reported to have inhibited VAP-1 enzyme may include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1 ,3 , 4-oxadiazine derivatives, 2 , 6-diethoxybenzylamine , 2, 6-di (n- propoxy) benzylamine, 2 , 6-diisopropoxybenzylamine , 2, 6-di (n- butoxy) benzylamine, 2 , 6-bis (methoxymethoxy) benzylamine , 2,6- bis (methoxymethyl) benzylamine , 2 , 6-diethylbenzylamine , 2,6- di-n-propylbenzylamine , 2 , 6-bis (2-hydroxyethoxy) benzylamine , and the like.
  • VAP-1 inhibitor and in WO 93/23023 as an SSAO inhibitor, such as those described in Lyles et al . (Biochem. Pharmacol. 36:2847, 1987) and in USP 4650907, USP 4916151, USP 4943593, USP 4965288, USP 5021456, USP 5059714, USP 4699928, European patent application 295604, European patent application 224924 and European patent application 168013, are also encompassed in the VAP-1 inhibitor.
  • Compound (I) is preferably, N- ⁇ 4-[2- (4- ⁇ [amino (imino) methyl] amino Jphenyl) ethyl] -1,3- thiazol-2-yl ⁇ acetamide (hereinafter Compound A; see Production Example 1) ,
  • the VAP-1 inhibitor can be administered as a prodrug to a subject.
  • prodrug is intended to include all compounds that convert to the VAP-1 inhibitor in the body of administration subject.
  • the prodrug can be any pharmaceutically acceptable prodrug of VAP-1 inhibitor.
  • the VAP-1 inhibitor can be administered to an administration subject as a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt of VAP-1 inhibitor of the present invention is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like) , alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like) .
  • alkali metal salt e.g., sodium salt, potassium salt and the like
  • alkaline earth metal salt e.g., calcium salt, magnesium salt and the like
  • ammonium salt e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like
  • the VAP-1 inhibitor can be also formulated as a pharmaceutically acceptable acid addition salt.
  • the pharmaceutically acceptable acid addition salts for use in the pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
  • VAP-1 inhibitor represented by the formula (I)
  • a pharmaceutically acceptable acid addition salt such as (mono-, di- or tri-) ydrochloride and hydriodide, particuraly hydrochloride, is preferable.
  • the above-mentioned VAP-1 inhibitor may be commercially available or can be produced based on a known reference.
  • Compound (I) particularly Compound A: N- ⁇ 4-[2- (4- ⁇ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide, can be synthesized according to the Production Method given below.
  • the VAP-1 inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method by any suitable route.
  • Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconj nctival , intraocular, subretinal, suprachoroidal and retrobulbar administrations.
  • periocular e.g., subTenon's
  • subconj nctival e.g., subconj nctival
  • intraocular subretinal
  • suprachoroidal and retrobulbar administrations e.g., retrobulbar administrations.
  • the manner in which the VAP-1 inhibitor is administered is dependent, in part, upon whether the treatment of a VAP-1 associated disease is prophylactic or therapeutic.
  • the VAP-1 inhibitor is preferably administered as soon as possible after it has been determined that a subject such as mammal, specifically a human, is at risk for a VAP-1 associated disease (prophylactic treatments) or has begun to develop a VAP-1 associated disease (therapeutic treatments) . Treatment will depend, in part, upon the particular VAP-1 inhibitor to be used, the amount of the VAP-1 inhibitor to be administered, the route of administration, and the cause and extent, if any, of a VAP-1 associated disease realized.
  • suitable methods of administering a VAP-1 inhibitor which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular VAP-1 inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are merely exemplary and are in no way limiting.
  • the dose of the VAP-1 inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention should be sufficient to effect the desired response in the subject over a reasonable time frame.
  • dosage will depend upon a variety of factors, including the strength of the particular VAP-1 inhibitor to be employed, the age, species, conditions or disease states , and body weight of the subject, as well as the degree of a VAP-1 associated disease.
  • the size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular VAP- 1 inhibitor and the desired physiological effect. It will be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
  • Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. Generally, the VAP-1 inhibitor can be administered in the dose of from about 1 ⁇ g/kg/day to about 300 mg/kg/day, preferably from about 0.1 mg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner.
  • compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-1 inhibitor sufficient to treat a VAP-1 associated disease, especially macular edema, prophylactically or therapeutically as an active ingredient.
  • the carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
  • the VAP-1 inhibitor can be administered in various manners to achieve the desired VAP-1 inhibitory effect.
  • the VAP-1 inhibitors can be administered alone or in combination with pharmaceutically acceptable carriers or diluents , the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice.
  • the VAP-1 inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions.
  • the inhibitor may also be injected parenterally in the form of sterile solutions or suspensions!
  • Solid oral forms may contain conventional excipients, for instance, lactose, sucrose, magnesium stearate, resins, and like materials.
  • Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents.
  • Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or suspending agents.
  • additives such as saline or glucose, may be added to make the solutions isotonic.
  • the present inventive method also can involve the co- administration of other pharmaceutically active compounds.
  • co-administration is meant administration before, concurrently with, e.g., in combination with the VAP-1 inhibitor in the same formulation or in separate formulations, or after administration of a VAP-1 inhibitor as described above.
  • corticosteroids prednisone, methylprednisolone , dexamethasone, or triamcinolone acetinide
  • noncorticosteroid anti- inflammatory compounds such as ibuprofen or flubiprofen, can be co-administered.
  • vitamins and minerals e.g., zinc
  • anti-oxidants e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein)
  • micronutrients can be co-administered.
  • VAP-1 inhibitor according to the present invention is useful for preparing a medicament such as a therapeutic or prophylactic agent for the VAP-1 associated diseases.
  • Compound (I) is prepared in accordance with, but is not limited to, the following procedures. Those skilled in the art will recognize that the procedures can be modified according to the conventional methods known per se .
  • Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; Z is as defined above;
  • halogen e.g., chlorine, bromine, iodine
  • X is as defined above, in this case, > II ;
  • R 1 is acyl
  • L 2 is a leaving group such as -OH, halogen (e.g., chlorine,, bromine, iodine) , -O-acyl wherein the acyl is as defined above (e.g., -O-acetyl and the like).
  • halogen e.g., chlorine,, bromine, iodine
  • -O-acyl wherein the acyl is as defined above (e.g., -O-acetyl and the like).
  • Compound (1) is reacted with Compound (2) or its salt to give Compound (3) .
  • Suitable salt of Compound (2) may be the same as those exemplified for Compound (I) .
  • Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 11) .
  • the reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the conventional acylation method may be employed in the present invention.
  • Compound (4) may be commercially available or can be prepared in accordance with the methods known per se .
  • the reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
  • the reaction is also preferably carried out in the presence of a conventional base such as 4- dimethylaminopyridine, pyridine etc.
  • a liquid base can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (5) thus obtained can be isolated or purified by known separation or purification means , such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the acylation may be applied to Compound (1) in advance .
  • the nitrogen atom in Compound (1) , (2) , (3) or (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
  • L 3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; and R 1 , X and Z are as defined above.
  • halogen e.g., chlorine, bromine, iodine
  • Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8) .
  • Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I) .
  • the reaction is also usually carried out in the presence of triphenylphosphine and a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
  • a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
  • catalytic hydrogenation is preferable.
  • the catalytic hydrogenation is carried out in the presence of a catalyst such as palladium carbon, preferably 10% palladium carbon.
  • the catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
  • a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
  • the catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like.
  • a liquid acid can be also used as the solvent.
  • the reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) . Therefore, Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I) •
  • the nitrogen atom in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
  • L 4 is a hydrogen atom or a protecting group, which is known per se r such as tert-butox carbonyl as described in the above “optionally protected amino” (see Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , etc. ) ; and R 1 , X and Z are as defined above.
  • Compound (12) or a reactive derivative thereof, or its salt is reacted with Compound (13) or its salt to give an amidated compound (14) .
  • Suitable reactive derivative of Compound (12) includes an acid halide, an acid anhydride and an activated ester.
  • the suitable example may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, hologenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g.
  • substituted phosphoric acid e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, hologenated phosphoric acid, etc.
  • dialkylphosphorous acid e.g., sulfurous acid, thiosulfuric acid, alkanesulfonic acid (
  • pivalic acid pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.
  • aromatic carboxylic acid e.g., benzoic acid, etc.
  • a symmetrical acid anhydride an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole
  • Compound (12) and a reactive derivative thereof as well as Compound (13) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 7) .
  • the conventional amidation method may be employed in the present invention.
  • the reaction is usually carried out in a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
  • a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
  • the reaction is also preferably carried out in the presence of a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N'-carbonylbis (2- methylimidazole) triphenylphosphine , and an additive such as 1-hydroxybenzotriazole , 1-hydroxysuccinimide , 3 , 4-dihydro-3- hydroxy-4-oxo-l , 2 , 3-benzotriazine .
  • a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N'-carbonylbis (2- methylimidazole) triphenylphosphine
  • an additive such as 1-hydroxybenzotriazole , 1-
  • reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
  • Compound (14) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
  • the nitrogen atom in Compound (12) , (13) or (14) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
  • N- (4- (2- (4-Aminophenyl) ethyl) -1 , 3-thiazol-2- yl) acetamide (1.8 g) prepared in a similar manner according to Step 6 of Production Example 1, 2- (methylsulfanyl) -4 , 5- dihydro-1 ,3-thiazole (918 mg) , hydrochloric acid concentrate (0.57 ml) and 2-methoxyethanol (28 ml) were combined under nitrogen atmosphere, and stirred at 120°C for 10 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo . The residue was dissolved in tetrahydrofuran / water, and made basic with aqueous potassium carbonate.
  • N- (4- (2- (4-Aminophenyl) ethyl) -1 ,3-thiazol-2-yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, methyl ethanimidothioate hydriodide (166 mg) and methanol (3 ml) were combined, and refluxed for 1.5 hours . After cooled to room temperature , the mixture was concentrated in vacuo .
  • Aluminium chloride (1.63 g) was dissolved in 1,2- dichloroethane (15 mL) . Chloroacetylchloride (0.732 mL) was added to the mixture at 0 °C, and stirred additionally for 20 minutes, then N- (2-phenylethyl) acetamide
  • Step 2 N- ⁇ 2- [4- (2-Chloroacetyl) phenyl] ethyl ⁇ acetamide (1.06 g) and thiourea (505 mg) were dissolved in ethanol (20 mL) . The mixture was refluxed for 1 hour and allowed to cool to room temperature. The white solid was collected with filtration and washed with ethanol to give N- ⁇ 2- [4- (2-amino-l , 3-thiazol-4- yl) phenyl] ethyl ⁇ acetamide hydrochloride (1.19 g, 90.4%). MS m/z 262 (M++1) .
  • Step 5 tert-Butyl ⁇ 2- [4- (2-amino-l , 3-thiazol-4- ylJphenyl] ethyl ⁇ carbamate (290 mg) was dissolved in dichloromethane (5 mL) , then acetic anhydride (0.103 mL) , 4- dimethylaminopyridine (10 mg) and pyridine (0.147 mL) were added. The mixture was stirred overnight. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo .
  • Step 6 tert-Butyl (2- ⁇ 4- [2- (acetylamino) -1 , 3-thiazol-4- yl] phenyl ⁇ ethyl) carbamate (250 mg) was dissolved in ethyl acetate (4 mL) and 4 N hydrogen chloride in ethyl acetate (2 mL) . The solvent was evaporated in vacuo . The solid was washed with ethyl acetate and ethyl ether to give N- ⁇ 4-[4-(2- aminoethyl) phenyl] -1 , 3-thiazol ⁇ 2-ylJacetamide hydrochloride (220 mg, 106%) .
  • N- ⁇ 4- [4- (2-Aminoethyl) phenyl] -1 ,3-thiazol-2-ylJacetamide hydrochloride 200 mg
  • diisopropylethylamine 0.175 mL
  • the mixture was stirred at room temperature overnight, then evaporated in vacuo .
  • Step 2 ethyl 4-formyl-l , 3-thiazol-2-ylcarbamate
  • Step 3 N- ⁇ 4- [2- (3- ⁇ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2-ylJ acetamide
  • N- ⁇ 4- [2- (3-aminophenyl) ethyl] -1 ,3- thiazol-2-yl ⁇ acetamide (267 mg) in tetrahydrofuran (3 ml) was added N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (317 mg) at room temperature.
  • Step 4 N- ⁇ 4- [2- (3- ⁇ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] aminojphenyl) ethyl] -5-bromo-l ,3-thiazol-2- yljacetamide
  • N- ⁇ 4- [2- (3- ⁇ [N' ,N"-bis (tert- butoxycarbonyl) amino (imino)methyl] aminojphenyl) ethyl] -1,3- thiazol-2-yl ⁇ acetamide 115 mg
  • N ⁇ bromosuccinimide 44.7 mg
  • the resulting precipitate was collected by filtration, -washed with a mixed solvent of diisopropyl ether and n-hexane (1:1) .
  • the title compound was obtained as white powder (70 mg, 52.6%).
  • reaction mixture was stirred at room temperature for 6 hours , poured into ice- water, and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo .
  • N'- ( (E) -Ethanoyl) carbamimidothioic acid (2.74 g) and acetone (20 ml) were combined under nitrogen atmosphere. Then 2-bromomalonaldehyde (3.5 g) was added to the solution under reflux. The reaction mixture was refluxed for an hour, and cooled to room temperature. The precipitate was filtered in vacuo . The solid was washed with water and acetone, and purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N- (5-formyl- 1 ,3-thiazol-2-yl) acetamide (1.21 g) as an off-white solid, mp.
  • N- (4- ⁇ 2- [4- (aminomethyl) phenyl] ethyl ⁇ -l ,3- thiazol-2-yl) acetamide (20 mg) prepared in a similar manner according to Production Example 12, N,N'-bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (23 mg) and tetrahydrofuran (0.5 ml) was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica-gel with chloroform as an eluent.
  • Step 2 ethyl 2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) ethenyl] -1 , 3-thiazole-5-carboxylate
  • Step 2 Benzyl 4- (hydroxymethyl) -1 ,3-thiazol-2-ylcarbamate was prepared in a similar manner according to Step 2 of Production
  • Step 4 Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylcarbamate was prepared in a similar manner according to Step
  • Step 1 Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylcarbamate (2.7 g) prepared in a similar manner according to Step 4 of Production Example 24 and 6N hydrochloric acid (50 ml) were combined. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the precipitate was filtered in vacuo . The solid was washed with water and acetonitrile to give 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 , 3- thiazol—2-amine (1.34 g) as a yellow solid. mp. 278-278.5 °C
  • Step 3 N- ⁇ 4-[2-(4-Aminophenyl) ethyl] -1 ,3-thiazol-2-yl ⁇ benzamide was prepared in a similar manner according to Step 2 of
  • the reaction mixture was stirred at 0 °C for 2 hours, and poured into water. The mixture was extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual oil was dissolved in ethanol (55 ml) , and then thiourea (1.25 g) was added to the solution. The reaction mixture was refluxed for 1 hour under nitrogen atmosphere. After cooled to 0 °C, water was added to the solution.
  • Methyl 2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazole-4- carboxylate (8.8 g) was dissolved in pyridine (88 ml), and then acetyl chloride (6.7 ml) was added dropwise to the solution at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 30 minutes and at 50 °C for 2 hours. After cooled to 0 °C, water was added to the solution.
  • Step 8 Potassium peroxymonosulfate (408 mg) was suspended in water (1 ml) and tetrahydrofuran (1 ml), and then N- ⁇ 5-[4-
  • Step 2 of Production Example 27 in a similar manner according to Step 3 of Production Example 27 mp. 184-185 °C X H-NMR (DMSO-de), ⁇ (ppm): 1.46 (9H, s) , 2.15 (3H, s) , 2.79-
  • Step 4 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 156-158 °C
  • 5-carboxylic acid was prepared from 2- (acetylamino) -4- (2- ⁇ 4- [ (tert-butoxycarbonyl) amino] phenyl ⁇ ethyl) -1 ,3-thiazole-5- carboxylic acid in a similar manner according to Step 2 of
  • Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 ,3-thiazole- 5-carboxylic acid (106 mg) was suspended in THF (2 ml) under N 2 atmosphere. Bis (trimethylsilyl) acetamide (0.253 ml) was added to the suspension at r.t., and the mixture was stirred at r.t. for 15 minutes. Then, N,N' -bis (tert-butoxycarbonyl) -1H- pyrazole-1-carboxamidine (119 mg) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 20 hours, and concentrated in vacuo .
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • Step 2 The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. mp. 180-182.5 °C . . . .
  • Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 134-135.5 °C
  • Ethyl l- ⁇ [2- (acetylamino) -4- ⁇ 2- [4- ( ⁇ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl ⁇ amino) phenyl] ethyl J-l ,3-thiazol-5- yl] carbonyl ⁇ -4-piperidinecarboxylate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • the title compound was prepared in a similar manner according to Step 4 of Production Example 31.
  • Methyl 2-amino-5-phenyl-l ,3-thiazole-4-carboxylate (3 g) was dissolved in pyridine (30 ml) , and then acetyl chloride (2.73 ml) was added dropwise to the solution at 0 °C under N 2 atmosphere. The reaction mixture was stirred at r.t. for 1.5 hours. Water was added to the solution at 0 °C. The precipitate was filtered in vacuo , and the solid was washed with ethyl ether to give methyl 2- (acetylamino) -5-phenyl-l ,3- thiazole-4-carboxylate (2.37 g) as a pale brown solid, mp.
  • Step 1 To a suspension of copper (II) bromide (9.75 g) in AcOEt (150 ml) was added a solution of ethyl 2-oxo-4-phenylbutanoate (3 g) in 75 ml of CHC1 3 . The reaction mixture was refluxed for 23 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1) . The solvent was removed in vacuo to give ethyl 3-bromo-2-oxo-4- phenylbutanoate (4.2g) as a yellow liquid.
  • Step 7 Di-tert-butyl ⁇ (Z) -[ (4- ⁇ 2- [2- (acetylamino) -5-benzyl-l ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production
  • reaction mixture was stirred at 65 °C for 30 minutes under reduced pressure. 15% Aqueous H 2 S0 (35 ml) was added to the mixture, and the mixture was refluxed for 15 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual oil was dissolved in EtOH (20 ml) , and concentrated H 2 S0 (0.4 ml) was added dropwise to the solution. The reaction mixture was refluxed for 2 hours. After cooled to r.t., EtOH was removed in vacuo . AcOEt and water were added to the residue, and extracted.
  • Step 5 Ethyl 2- (acetylamino) -5- [4- (methylthio) benzyl] -1 ,3- thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 205-206 °C
  • the title compound was prepared in a similar manner according to the following Production Example 58.
  • Step 1 Ethyl 3- [4- (ethylthio) phenyl] propanoate was prepared from 4- (2-carboxyethyl) thiophenol in a similar manner according to Step 1 of Production Example 47.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)

Abstract

A compound of the formula (I): R1-NH-X-Y-Z (I) wherein R1 is acyl; X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene or -COHN-; and Z is a groupe of the formulae (II) or (III) wherein R2 is a specified substituent or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 (VAP-1) inhibitor for preventing or treating a VAP-1associated disease, especially macular edema.

Description

THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS
The present invention relates to a compound or a pharmaceutically acceptable salt thereof useful as a vascular adhesion protein-1 inhibitor, a pharmaceutical composition comprising the compound or salt thereof as an active ingredient, a method for preventing or treating a vascular adhesion protein-1 associated disease, especially macular edema, use of the compound, salt thereof or composition, and the like.
BΑCKGROUMD MIT Vascular adhesion protein-1 (hereinafter to be abbreviated as VAP-1) is an amine oxidase (semicarbazide sensitive amine oxidase, SSAO) which is abundant in human plasma, and shows remarkably increased expression in vascular endothelium and vascular smooth muscle of the inflammatory region. While the physiological role of VAP-1 has not been clarified until recently, VAP-1 gene was cloned in 1998, and VAP-1 has been reported to be a membrane protein that regulates rolling and migration of lymphocyte and NK cell as an adhesion molecule under regulation of expression by inflammatory cytokine. Although the amine to be a substrate is unknown, it is considered to be methylaminβ generated in any part of living organisms. It is also known that hydrogen peroxide and aldehydes produced due to the amine oxidase activity in the molecule are important factors of adhesion activity.
A recent report has documented that VAP-1 enzyme activity in plasma increases in diabetic patients, whether type I or type II, and the increase is particularly remarkable in diabetic patients suffering from retinopathy complications (Diabetologia, 42 (1999) 233-237, Diabetic Medicine , 16 ( 1999 ) 514-521 ) .
In addition, it has been reported that VAP-1 is associated with the following diseases:
(1) cirrhosis, essential stabilized hypertension, diabetes, arthrosis (see JP-A-61-239891 and USP 4,888,283);
(2) endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) (see WO 93/23023) ; (3) an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis , psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis, dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) ; a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous' stomatitis] ; a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia- reperfusion injury associated with ischemic stroke) ; a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease) ; a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris) ; a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy) , foot ulcers, joint problems, and increased risk of infection) ; a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) ; a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)]; chronic arthritis; inflammatory bowel diseases; skin dermatoses (see WO 02/02090, WO 02/02541 and US patent application publication No. 2002/0173521 Al) ; (4) diabetes mellitus (see WO 02/38152) ; and
(5) SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)] (see WO 02/38153) , and the like.
Under the present circumstances, a drug treatment or prophylaxis of the above diseases has been demanded.
Macular edema is a common ocular abnormality resulting from a vast etiology and characterized by perturbation of the integrity of the blood-retinal barrier of the perifoveal capillaries and the optic nerve head. Macular edema is known to include diabetic and non-diabetic ones . Macular edema as a diabetic complication is a disease state that can occur in any stage of diabetic retinopathy, emerges before the onset of neovascularization and causes a serious visual disorder. Macular area is a highly evolved part in retina and plays a key role in controlling the eyesight. Once the macular area suffers from edema, how mild the change may be, it causes a significant failure of eyesight, and when left unattended, the edema causes irreversible changes of macular tissue, and it is considered to encourage progress of retinopathy. At present, for macular edema, laser beam photocoagulation and vitreous surgery have been tried as a symptomatic therapy. However, irradiation of laser on the macular area is not easy and unnecessary laser treatments may produce side effects (e.g., possible encouragement of edema by causing inflammation) . The vitreous surgery is considered to provide effect in 70 percent of macular edema, but physical and economical burden on patients is high, and the incidence of recurrence is also high. These treatment methods are not usually employed in the initial stage of macular edema, particularly so in the stages when the decrease of vision is comparatively small. Accordingly, a drug treatment comparatively easily applicable from the early stages of the disease has been also demanded under the present circumstances.
DISCLOSURE OF INVENTION The present inventors have intensively worked on the problem of drug treatment of a VAP-1 associated disease and found that a VAP-1 inhibitor is useful for the prophylaxis or treatment of the disease, particularly macular edema, and completed the present invention. Thus, the present invention provides the following.
[1] A compound of the formula (I) [hereinafter sometimes referred to as Compound (I) ] :
R1—NH—X—Y—Z (I) wherein R1 is acyl;
X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000006_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and E is optionally protected amino, -N=CH2,
Figure imgf000006_0002
wherein Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a pharmaceutically acceptable salt thereof.
[2] The compound of [1] , wherein Z is a group of the formula:
Figure imgf000006_0003
wherein R2 is a group of the formula:
NH -G-NH NH-R4
(wherein G is a bond , -NHCOCH2- or lower alkylene and R4 is hydrogen , -NH2 or lower alkyl ) ; -NH2 ; -CH2NH2 ; -CH2ONH2 ; -CH2ON=CH2 ;
-CH3
Figure imgf000006_0004
NH
-N^NH or
^NH2 ; or a pharmaceutically acceptable salt thereof. [3] The compound of [2] , wherein R2 is a group of the formula:
NH -G-NH NH-R4
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl); -CH2NH2 ; -CH2ONH2; -CH2ON=CH2;
-CH3
Figure imgf000007_0001
or a pharmaceutically acceptable salt thereof.
[4] The compound of any of [1] to [3] , wherein R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.
[5] The compound of [1] , wherein the compound is
N-{4- [2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -1 ,3- thiazol-2-yl}acetamide ,
N-{4- [2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-yl}acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] aminoJphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-yl}acetamide,
N-{4- [2- (4-{ [hydrazino (imino) meth l] amino Jphenyl) ethyl] -1 , 3- thiazol-2-yl}acetamide, or N_ (4-{2- [4- (2-{ [amino (imino) methyl] amino} ethyl) phenyl] ethyl }-
1 , 3-thiazol-2-yl) acetamide , or a pharmaceutically acceptable salt thereof.
[6] The compound of [1] or a pharmaceutically acceptable salt thereof for use as a medicament. [7] A pharmaceutical composition, which comprises, as an active ingredient, the compound of [1] or a pharmaceutically acceptable salt thereof.
[8] A method for producing a compound of the formula (I) :
R1—NH—X—Y—Z (I) wherein
R1 is acyl;
X is a bivalent residue derived from optionally substituted thiazole; Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000008_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and E is optionally protected amino, -N=CH2,
Figure imgf000008_0002
wherein Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or
-NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a pharmaceutically acceptable salt thereof, which method comprises at least one step selected from the group consisting of (i) to (v) : (i) reacting Compound (1) :
Figure imgf000008_0003
with Compound (2) :
Figure imgf000008_0004
wherein Li is a leaving group and Z is as defined above, or a salt thereof;
(ii) reacting Compound (3) : H2N-X-Z wherein X and Z are as defined above, or a salt thereof with
Compound (4) : R1-^ wherein R1 is as defined above and L2 is a leaving group;
(iii) reacting Compound (6) : R1-NH-X-CHO wherein R1 and X are as defined above, or a salt thereof with Compound (7) : L3-CH2-Z wherein L3 is a leaving group and Z is as defined above, or a salt thereof;
(iv) reduction of Compound (10): RX-NH-X- (lower alkenylene) -Z wherein R1 , X and Z are as defined above, or a salt thereof to Compound (11): R1-NH-X- (lower alkylene) -Z wherein R1 , X and Z are as defined above, or a salt thereof; and
(v) reacting Compound (12) : R1-NH-X-COOH or a reactive derivative thereof, wherein R1 and X are as defined above, or a salt thereof with Compound (13) : L4-NH-Z wherein L4 is a hydrogen atom or a protecting group and Z is as defined above, or a salt thereof.
[9] A use of the compound of [1] or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-1 inhibitor.
[10] The use of [9] , wherein the compound is N-{4- [2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -1 ,3- thiazol-2-yl}acetamide , N-{4- [2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl J acetamide, N-{4- [2- (4-{ [hydrazino (imino) methyl] amino Jphenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 , 3-thiazol-2-ylJacetamide, N-{4- [2- (4-{ [hydrazino (imino) methyl] amino Jphenyl) ethyl]-l ,3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino) methyl] amino}ethyl) phenyl] ethyl }- 1 , 3-thiazol-2-yl) acetamide .
[11] A use of the compound of [1] or a pharmaceutically acceptable salt thereof for preparing a medicament for the prophylaxis or treatment of a VAP-1 associated disease. [12] The use of [11] , wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses , diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] and macular edema (diabetic and non-diabetic macular edema) . [13] The use of [12] , wherein said VAP-1 associated disease is macular edema .
[14] The use of [13] , wherein said macular edema is diabetic macular edema.
[15] The use of [13] , wherein said macular edema is non- diabetic macular edema. [16] A VAP-1 inhibitor, which comprises the compound of [1] or a pharmaceutically acceptable salt thereof.
[17] A method for preventing or treating macular edema, which method comprises administering to a subject in need thereof a VAP-1 inhibitor in an amount sufficient to treat said subject for macular edema.
[18] The method of [17] , wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (imino) ethyl] amino Jphenyl) ethyl] -1 ,3- thiazol-2-yl } acetamide , N-{4-[2- (4-{ [amino (imino) methyl] aminoJphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl }acetamide , N-{4-[2- (4-{ [hydrazino (imino) methyl] amino Jphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide , N-{4-[2-(4-{ [hydrazino (imino)methyl] aminoJphenyl) ethyl] -1 , 3- thiazol-2-yl} acetamide, or
N- (4-{2- [4- (2-{ [amino (imino) methyl] amino}ethyl) phenyl] ethyl }- 1 , 3-thiazol-2-yl) acetamide , or a pharmaceutically acceptable salt thereof. [19] A method for preventing or treating a VAP-1 associated disease, which method comprises administering an effective amount of the compound of [1] or a pharmaceutically acceptable salt thereof to a mammal. [20] The method of [19] , wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis , psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease) , a (chronic) skin inflammatory/ disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris) , a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] and macular edema (diabetic and non-diabetic macular edema) .
[21] The method of [20], wherein said VAP-1 associated disease is macular edema. [22] The method of [21], wherein said macular edema is diabetic macular edema.
[23] The method of [21], wherein said macular edema is non- diabetic macular edema. DETAILED DESCRIPTION OF THE INVENTION
The present invention is predicated on the discovery that an inhibitor of vascular adhesion protein-1 (VAP-1; also referred to as semicarbazide sensitive amine oxidase (SSAO) or copper-containing amine oxidase) is effective in treating or ameliorating a VAP-1 associated disease, especially macular edema, and the like. Accordingly, the present invention provides Compound (I) or a pharmaceutically acceptable salt thereof useful as a VAP-1 inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, and the like.
In the above and subsequent descriptions of the present specification, suitable examples and illustration of the " various definitions to be included within the scope of the invention are explained in detail as follows . Suitable "halogen" includes fluorine, chlorine, bromine and iodine.
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4 , carbon atom(s) , unless otherwise provided. Suitable "lower alkyl" includes straight or branched alkyl having 1 to 6 carbon atom(s) , such as methyl, ethyl, propyl , isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is C1-C4 alkyl. Suitable "lower alkylthio" includes lower alkylthio containing the above lower alkyl, such as methylthio, ethylthio, propylthio, isopropylthio , butylthio, isobutylthio, sec-butylthio , tert-butylthio , pentylthio, tert-pentylthio and hexylthio.
Suitable "lower alkylene" includes straight or branched alkylene having 1 to 6 carbon atom(s) , such as methylene, ethylene, trimethylene , tetramethylene , propylene, ethylidene and propylidene, in which more preferred one is Cχ-C alkylene.
Suitable "lower alkenylene" includes straight or branched alkenylene having 2 to 6 carbon atom(s), such as -CH=CH-, -CH2-CH=CH~, -CH2-CH=CH-CH2- , -CH2-CH2-CH=CH- , -CH=CH-CH=CH- , -CH=CH-CH2-CH2-CH2-, -CH=CH-CH=CH-CH2-CH2- and -CH=CH-CH=CH-CH=CH-, in which more preferred one is C2-C4 alkenylene .
The above lower alkenylene may be in E or Z form, respectively. Thus, those skilled in the art will recognize that the lower alkenylene includes all E, Z-structures when it has 2 or more double bonds.
.Su±table "aryl" includes C6-C10 aryl such as phenyl and-- - naphthyl, in which more preferred one is phenyl. The "aryl" may be substituted by 1 to 3 substituent (s) and the substitution sites are not particularly limited.
Suitable "aralkyl" includes aralkyl wherein the aryl moiety has 6 to 10 carbon atoms [i.e. the aryl moiety is C6- Cio aryl of the above "aryl"] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Cι-C6 alkyl of the above "lower alkyl"], such as benzyl, phenethyl , 1- naphthylmethyl , 2-naphthylmethyl , 3-phenylpropyl , 4- phenylbutyl and 5-phenylpentyl .
The "optionally protected amino" means that an amino group may be protected with a suitable protecting group according to a method known per se , such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like. The suitable "protecting group" includes tert-butoxycarbonyl (i.e., Boc) , an acyl group as mentioned below, substituted or unsubstituted aryl (lower) alkylidene [e.g., benzylidene, hydroxybenzylidene, etc.], aryl (lower) alkyl such as mono-, di- or triphenyl- (lower) alkyl [e.g., benzyl, phenethyl , benzhydryl, trityl, etc.] and the like.
Suitable "optionally protected amino" includes amino and tert-butoxycarbonylamino (i.e. -NHBoc) .
Suitable "heterocycle" includes "aromatic heterocycle" and "non-aromatic heterocycle". Suitable "aromatic heterocycle" includes 5 to 10- membered aromatic heterocycle containing 1 to 3 heteroatom(s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s) , and includes, for example, thiophene, furan, pyrrole, imidazole, pyrazole, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyridazine, pyrimidine, pyrazine and the like.
Suitable "non-aromatic heterocycle" includes 5 to 10— membered non-aromatic heterocycle containing 1 to 3 heteroatom (s) selected from nitrogen, oxygen and sulfur atoms besides carbon atom(s) , and includes, for example, pyrrolidine, imidazoline, pyrazolidine , pyrazoline, piperidine, piperazine, morpholine, thiomorpholine , dioxolan, oxazolidine, thiazolidine, triazolidine and the like. Suitable "acyl" includes acyl having 1 to 20 carbon atom(s) , such as formyl, alkylcarbonyl , arylcarbonyl , alkoxycarbonyl and aralkyloxycarbonyl .
Suitable "alkylcarbonyl" includes alkylcarbonyl wherein the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Cι-C5 alkyl of the above "lower alkyl"] , such as acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl and heptanoyl , in which more preferred one is C1-C4 alkyl-carbonyl . Suitable "arylcarbonyl" includes arylcarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C6-Cι0 aryl of the above "aryl"] , such as benzoyl and naphthoyl . Suitable "alkoxycarbonyl" includes alkoxycarbonyl wherein the alkoxy moiety has 1 to 6 carbon atom(s) , such as methoxycarbonyl , ethoxycarbonyl , propoxycarbonyl , isopropoxycarbonyl, butoxycarbonyl , isobutoxycarbonyl , sec- butoxycarbonyl , tert-butoxycarbonyl , pentyloxycarbonyl , tert-pentyloxycarbonyl and hexyloxycarbonyl, in which more preferred one is alkoxycarbonyl wherein the alkoxy moiety has 1 to 4 carbon atom(s) .
Suitable "aralkyloxycarbonyl" includes aralkyloxycarbonyl wherein the aryl moiety has 6 to 10 carbon atom(s) [i.e. the aryl moiety is C6-Cι0 aryl of the above "aryl"] and the alkyl moiety has 1 to 6 carbon atom(s) [i.e. the alkyl moiety is Ci-Cε alkyl of the above "lower alkyl"], such as benzyloxycarbonyl, phenethyloxycarbonyl, 1- naphthylmethyloxycarbonyl , 2-naphthylmethyloxycarbonyl , 3- phenylpropyloxycarbonyl , 4-phenylbutyloxycarbonyl and 5- phenylpentyloxycarbonyl .
Suitable "bivalent residue derived from thiazole" of the "bivalent residue derived from optionally substituted thiazole" includes
Figure imgf000017_0001
The "thiazole" may have 1 to 3 substituent (s) and the substitution sites are not particularly limited.
Suitable "substituent" of the above "optionally substituted thiazole" includes, for example,
(1) halogen which is as defined above;
(2) alkoxycarbonyl which is as defined above, such as ethoxycarbonyl ; (3) optionally substituted aryl, which aryl is as defined above and the substitution sites are not particularly limited, such as phenyl and 4- (methylsulfonyl) phenyl ; (4) a group of the formula: -CONRaRb wherein Ra is hydrogen, lower alkyl, aryl or aralkyl and Rb is hydrogen, lower alkyl, aryl or aralkyl, wherein the lower alkyl, aryl and aralkyl are as defined above, such as N- methylaminocarbonyl , N-phenylaminocarbonyl , N,N- dimethylaminocarbonyl and N-benzylaminocarbonyl ;
(5) a group of the formula: -CONH- (CH2) k~aryl wherein k is an integer of 0 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -N02, -S02- (lower alkyl) wherein the lower alkyl is as defined above, -CF3 and -O-aryl wherein the aryl is as defined above, and the substitution sites are not particularly limited;
(6) a group of the formula: -CONH- (CH2) m-heterocycle wherein m is an integer of 0 to 6 ; the heterocycle is as defined above, such as pyridine;
(7) a group of the formula: -CO-heterocycle wherein the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of -CO- (lower alkyl) wherein the lower alkyl is as defined above, -CO-O- (lower alkyl) wherein the lower alkyl is as defined above, -S02- (lower alkyl) wherein the lower alkyl is as defined above, oxo (i.e. =0) and a group of the formula: -CONRcRd wherein Rc is hydrogen, lower alkyl, aryl or aralkyl and Rd is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited; (8) a group of the formula: -(CH2)n-aryl wherein n is an integer of 1 to 6; the aryl is as defined above, which may have 1 to 5 substituent (s) selected from the group consisting of -S- (lower alkyl) wherein the lower alkyl is as defined above, -S02- (lower alkyl) wherein the lower alkyl is as defined above, -C02- (lower alkyl) wherein the lower alkyl is as defined above, -NHCO-O- (lower alkyl) wherein the lower alkyl is as defined above and a group of the formula: -CONReRf wherein Re is hydrogen, lower alkyl, aryl or aralkyl and Rf is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(9) a group of the formula: - (CH2) 0-heterocycle wherein o is an integer of 0 to 6; the heterocycle is as defined above, such as pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, which may have 1 to 5 substituent (s) selected from the group consisting of oxo (i.e. =0) ; -CO- (lower alkyl) wherein the lower alkyl is as defined above; -CO-0- (lower alkyl) wherein the lower alkyl is as defined above; -S02- (lower alkyl) wherein the lower alkyl is as defined above; -CO- (heterocycle) wherein the heterocycle is as defined above such as pyrrolidine, piperazine and morpholine, which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl and halogen, wherein the lower alkyl and halogen are as defined above, and the substitution sites are not particularly limited; and a group of the formula: -C0NRgRh wherein Rg is hydrogen, lower alkyl, aryl or aralkyl and Rh is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(10) a group of the formula: - (CH2) p-NRiRj wherein p is an integer of 0 to 6; R1 is hydrogen, acyl, lower alkyl, aryl or aralkyl and Rj is hydrogen, acyl, lower alkyl, aryl or aralkyl wherein the acyl, lower alkyl, aryl and aralkyl are as defined above, and the lower alkyl may have 1 to 5 substituent (s) selected from the group consisting of a group of the formula: -CONR^1 wherein Rk is hydrogen, lower alkyl, aryl or aralkyl and R1 is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above, and the substitution sites are not particularly limited;
(11) a group of the formula: -CON(H or lower alkyl) - (CHRra)q-T wherein q is an integer of 0 to 6; the lower alkyl is as defined above; Rm is hydrogen, aralkyl which is as defined above, or alkyl which is as defined above, which may be substituted by 1 to 3 substituent (s) selected from the group consisting of -OH and -CONH2 and the substitution sites are not particularly limited; and T is hydrogen; a group of the formula: -CONRnR° wherein Rn is hydrogen, lower alkyl, aryl or aralkyl and R° is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl , aryl and aralkyl are as defined above; -NH-CO-Rp wherein Rp is lower alkyl which is as defined above or aralkyl which is as defined above; -NH-S02- (lower alkyl) wherein the lower alkyl is as defined above; -S02- (lower alkyl) wherein the lower alkyl is as defined above; -heterocycle wherein the heterocycle is as defined above, such as pyridine, pyrrolidine and morpholine, which may have 1 to 3 substituent (s) such as oxo (i.e. =0) , and the substitution sites are not particularly limited; or -CO- (heterocycle) wherein the heterocycle is as defined above, such as piperidine and morpholine; and
(12) a group of the formula: - (CH2) r-CO- R wherein r is an integer of 1 to 6; Rfc is hydrogen, lower alkyl, aryl or aralkyl and Ru is hydrogen, lower alkyl, aryl or aralkyl wherein the lower alkyl, aryl and aralkyl are as defined above.
The substitution site on the aryl or heterocycle is any suitable position thereof, but not particularly limited.
Preferable "substituent" of the above "optionally substituted thiazole" is methylsulfonylbenzyl.
The substitution sites of R2 on the phenyl in Compound
(I) is not particularly limited.
H When Z is a group of the formula: — | " X-NH '
the substitution sites on the group are not particularly
limited. Particularly preferable.
Figure imgf000021_0001
Any nitrogen atom in the amino (i.e. -NH2) , imino (i.e.
=NH or -NH-) or the like contained in Compound (I) may be protected according to the methods, which are known to those skilled in the art, such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
When Compound (I) has an asymmetric carbon atom in the structure, those skilled in the art will recognize that Compound (I) includes all stereoisomers .
The "vascular adhesion protein-1 (VAP-1) associated disease" comprise a disease selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, art rosis; endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients); an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polyc ondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, Wegener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) ; a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] ; a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury associated with ischemic stroke) ; a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease); a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris); a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) ; a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) ; a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)]; chronic arthritis; inflammatory bowel diseases; skin dermatoses ; diabetes mellitus; SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure)]; macular edema (e.g., diabetic and non-diabetic macular edema) , and the like.
The "preventing or treating a vascular adhesion protein-1 (VAP-1) associated disease" and "prophylaxis or treatment of a vascular adhesion protein-1 (VAP-1) associated disease", particularly "preventing or treating macular edema" and "prophylaxis or treatment of macular edema" are intended to include administration of a compound having VAP-1 inhibitory activity (i.e. VAP-1 inhibitor) to a subject for therapeutic purposes, which may include prophylaxis, amelioration, prevention and cure of the above described VAP-1 associated disease, particularly macular edema. As used herein, by the "subject" is meant a target of the administration of VAP-1 inhibitor in the present invention, which is specifically various animals such as mammal, e.g., human, mouse, rat, swine, dog, cat, horse, bovine and the like, especially human.
The method comprises administration of VAP-1 inhibitor in an amount sufficient to treat the VAP-1 associated disease, especially macular edema. Any VAP-1 inhibitor can be used in the method of the present invention as long as it is safe and efficacious. Herein, "VAP-1 inhibitor" will be used to refer to such compounds, which include Compound (I) , and is intended to encompass all compounds that inhibit enzyme activity of VAP-1 at any and all points in the action mechanism thereof.
For example, the compounds of the present invention and derivatives thereof, or compounds reported to have inhibited VAP-1 enzyme (SSAO) may include fluoroallylamine derivatives, semicarbazide derivatives, hydrazide derivatives, hydrazino derivatives, 1 ,3 , 4-oxadiazine derivatives, 2 , 6-diethoxybenzylamine , 2, 6-di (n- propoxy) benzylamine, 2 , 6-diisopropoxybenzylamine , 2, 6-di (n- butoxy) benzylamine, 2 , 6-bis (methoxymethoxy) benzylamine , 2,6- bis (methoxymethyl) benzylamine , 2 , 6-diethylbenzylamine , 2,6- di-n-propylbenzylamine , 2 , 6-bis (2-hydroxyethoxy) benzylamine , and the like.
The above compounds can be exemplified as follows .
1) fluoroallylamine derivatives, semicarbazide derivatives and hydrazide derivatives described in WO 93/23023,
2) hydrazino derivatives described in WO 02/02090, 3) 1 ,3 , 4-oxadiazine derivatives described in WO 02/02541,
4) 4-alkyl-5-alkoxycarbonyl-4 ,5,6, 7-tetrahydroimidazo [4 , 5- c] pyridine derivatives described in WO 02/38153,
5) 2, 6-diethoxybenzylamine, 2 , 6-di (n-propoxy) benzylamine , 2,6- diisopropoxybenzylamine , 2 , 6-di (n-butoxy) benzylamine , 2,6- bis (methoxymethoxy) benzylamine, 2,6- bis (methoxymethyl) benzylamine , 2 , 6-diethylbenzylamine , 2 , 6-di- n-propylbenzylamine and 2 , 6-bis (2-hydroxyethoxy) benzylamine described in USP 4,888,283.
The compounds exemplified in the present invention as a VAP-1 inhibitor and in WO 93/23023 as an SSAO inhibitor, such as those described in Lyles et al . (Biochem. Pharmacol. 36:2847, 1987) and in USP 4650907, USP 4916151, USP 4943593, USP 4965288, USP 5021456, USP 5059714, USP 4699928, European patent application 295604, European patent application 224924 and European patent application 168013, are also encompassed in the VAP-1 inhibitor.
Of the above-mentioned compounds, preferred are Compound (I) , more preferably, N-{4-[2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -1,3- thiazol-2-yl} acetamide (hereinafter Compound A; see Production Example 1) ,
N-{4-[2- (4-{ [amino (imino) methyl] amino Jphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide (see Production Example 48) ,
N-{4- [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methy1sulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (see Production Example 50) , N_{4_ [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -1 ,3- thiazol-2-yl}acetamide (see Production Example 58) , and N- (4-{2- [4- (2-{ [amino (imino) methyl] amino}ethyl) phenyl] ethyl }- 1 , 3-thiazol-2-yl) acetamide (see Production Example 110), particularly N-{4- [2- (4-{ [amino (imino) methyl] amino }- phenyl) ethyl] -1 , 3-thiazol-2~yl} acetamide and derivatives thereof.
The term "derivative" is intended to include all compounds derived from the original compound.
In the present invention, the VAP-1 inhibitor can be administered as a prodrug to a subject. The term "prodrug" is intended to include all compounds that convert to the VAP-1 inhibitor in the body of administration subject. The prodrug can be any pharmaceutically acceptable prodrug of VAP-1 inhibitor. Moreover, the VAP-1 inhibitor can be administered to an administration subject as a pharmaceutically acceptable salt.
The pharmaceutically acceptable salt of VAP-1 inhibitor of the present invention is nontoxic and a pharmaceutically acceptable conventional salt, which is exemplified by salts with inorganic or organic base such as alkali metal salt (e.g., sodium salt, potassium salt and the like) , alkaline earth metal salt (e.g., calcium salt, magnesium salt and the like), ammonium salt, and amine salt (e.g., triethylamine salt, N- benzyl-N-methylamine salt and the like) .
The VAP-1 inhibitor can be also formulated as a pharmaceutically acceptable acid addition salt. Examples of the pharmaceutically acceptable acid addition salts for use in the pharmaceutical composition include those derived from mineral acids, such as hydrochloric, hydrobromic, hydriodic, phosphoric, metaphosphoric, nitric and sulfuric acids, and organic acids, such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic, gluconic, succinic and arylsulfonic acids, for example, p-toluenesulfonic acid.
As a pharmaceutically acceptable salt of VAP-1 inhibitor represented by the formula (I) , a pharmaceutically acceptable acid addition salt such as (mono-, di- or tri-) ydrochloride and hydriodide, particuraly hydrochloride, is preferable. The above-mentioned VAP-1 inhibitor may be commercially available or can be produced based on a known reference.
Also, Compound (I), particularly Compound A: N-{4-[2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide, can be synthesized according to the Production Method given below.
Those compounds or derivatives thereof that are not commercially available can be prepared using organic synthetic methods known in the art.
The VAP-1 inhibitor or a pharmaceutically acceptable salt thereof can be administered in accordance with the present inventive method by any suitable route. Suitable routes of administration include systemic, such as orally or by injection, topical, periocular (e.g., subTenon's), subconj nctival , intraocular, subretinal, suprachoroidal and retrobulbar administrations. The manner in which the VAP-1 inhibitor is administered is dependent, in part, upon whether the treatment of a VAP-1 associated disease is prophylactic or therapeutic. The VAP-1 inhibitor is preferably administered as soon as possible after it has been determined that a subject such as mammal, specifically a human, is at risk for a VAP-1 associated disease (prophylactic treatments) or has begun to develop a VAP-1 associated disease (therapeutic treatments) . Treatment will depend, in part, upon the particular VAP-1 inhibitor to be used, the amount of the VAP-1 inhibitor to be administered, the route of administration, and the cause and extent, if any, of a VAP-1 associated disease realized. One skilled in the art will appreciate that suitable methods of administering a VAP-1 inhibitor, which is useful in the present inventive method, are available. Although more than one route can be used to administer a particular VAP-1 inhibitor, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described routes of administration are merely exemplary and are in no way limiting.
The dose of the VAP-1 inhibitor administered to the administration subject such as animal including human, particularly a human, in accordance with the present invention should be sufficient to effect the desired response in the subject over a reasonable time frame. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the strength of the particular VAP-1 inhibitor to be employed, the age, species, conditions or disease states , and body weight of the subject, as well as the degree of a VAP-1 associated disease. The size of the dose also will be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular VAP- 1 inhibitor and the desired physiological effect. It will be appreciated by one of ordinary skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.
Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages, which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. Generally, the VAP-1 inhibitor can be administered in the dose of from about 1 μg/kg/day to about 300 mg/kg/day, preferably from about 0.1 mg/kg/day to about 10 mg/kg/day, which is given in a single dose or 2 to 4 doses a day or in a sustained manner. Pharmaceutical compositions for use in the present inventive method preferably comprise a "pharmaceutically acceptable carrier" and an amount of a VAP-1 inhibitor sufficient to treat a VAP-1 associated disease, especially macular edema, prophylactically or therapeutically as an active ingredient. The carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the compound, and by the route of administration.
The VAP-1 inhibitor can be administered in various manners to achieve the desired VAP-1 inhibitory effect. The VAP-1 inhibitors can be administered alone or in combination with pharmaceutically acceptable carriers or diluents , the properties and nature of which are determined by the solubility and chemical properties of the inhibitor selected, the chosen administration route, and standard pharmaceutical practice. The VAP-1 inhibitor may be administered orally in solid dosage forms, e.g., capsules, tablets, powders, or in liquid forms, e.g., solutions or suspensions. The inhibitor may also be injected parenterally in the form of sterile solutions or suspensions! Solid oral forms may contain conventional excipients, for instance, lactose, sucrose, magnesium stearate, resins, and like materials. Liquid oral forms may contain various flavoring, coloring, preserving, stabilizing, solubilizing, or suspending agents. Parenteral preparations are sterile aqueous or non-aqueous solutions or suspensions which may contain certain various preserving, stabilizing, buffering, solubilizing, or suspending agents. If desired, additives, such as saline or glucose, may be added to make the solutions isotonic.
The present inventive method also can involve the co- administration of other pharmaceutically active compounds. By "co-administration" is meant administration before, concurrently with, e.g., in combination with the VAP-1 inhibitor in the same formulation or in separate formulations, or after administration of a VAP-1 inhibitor as described above. For example, corticosteroids, prednisone, methylprednisolone , dexamethasone, or triamcinolone acetinide , or noncorticosteroid anti- inflammatory compounds, such as ibuprofen or flubiprofen, can be co-administered. Similarly, vitamins and minerals, e.g., zinc, anti-oxidants , e.g., carotenoids (such as a xanthophyll carotenoid like zeaxanthin or lutein) , and micronutrients can be co-administered.
In addition, the VAP-1 inhibitor according to the present invention is useful for preparing a medicament such as a therapeutic or prophylactic agent for the VAP-1 associated diseases.
Production Method of Compound (I)
Compound (I) is prepared in accordance with, but is not limited to, the following procedures. Those skilled in the art will recognize that the procedures can be modified according to the conventional methods known per se .
Procedure A: Synthesis of Compound (I) wherein Y is a bond
RX-L2
S 0 (4)
H2N A NH, L ι\^ 2N-X-Z >- R1-NH-X-Z
(1) (2) (3) (5)
wherein
Li is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; Z is as defined above;
.S-
X is as defined above, in this case, > II ;
R1 is acyl; and
L2 is a leaving group such as -OH, halogen (e.g., chlorine,, bromine, iodine) , -O-acyl wherein the acyl is as defined above (e.g., -O-acetyl and the like).
Formation of Thiazole Moiety X
Compound (1) is reacted with Compound (2) or its salt to give Compound (3) . Suitable salt of Compound (2) may be the same as those exemplified for Compound (I) .
Compounds (1) and (2) or its salt may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 11) . The reaction is usually carried out in a conventional solvent such as ethanol, acetone, dichloromethane, acetic acid, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (3) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
Acylation Compound (3) or its salt is reacted with Compound (4) to give Compound (5) . Since R1 is an acyl group, this reaction is an acylation.
The conventional acylation method may be employed in the present invention. Compound (4) may be commercially available or can be prepared in accordance with the methods known per se .
The reaction is usually carried out in a conventional solvent such as dichloromethane, chloroform, methanol, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is also preferably carried out in the presence of a conventional base such as 4- dimethylaminopyridine, pyridine etc. A liquid base can be also used as the solvent. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (5) thus obtained can be isolated or purified by known separation or purification means , such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
The acylation may be applied to Compound (1) in advance .
The nitrogen atom in Compound (1) , (2) , (3) or (5) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
Procedure B: Synthesis of Compound (I) wherein Y is lower alkylene such as ethylene (i.e. -CH2-CH2-) or lower alkenylene such as vinylene (i.e. -CH=CH-) , for example,
RX-NH-X-CHO + L3-CH2-Z ► R1-NH-X-CH=CH-Z
(6) (7) (8)
Reduction ^ R i-NH-X-CH2-CH2-Z
(9) wherein
L3 is a leaving group such as halogen (e.g., chlorine, bromine, iodine) ; and R1, X and Z are as defined above.
Formation of Olefin Compound
Compound (6) or its salt is reacted with Compound (7) or its salt to give an olefin compound (8) . Suitable salts of Compounds (6) and (7) may be the same as those exemplified for Compound (I) .
Compounds (6) and (7) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 1 and 3) . The reaction is usually carried out in a conventional solvent such as N,N-dimethylformamide, dimethylsulfoxide , tetrahydrofuran, dichloromethane, and other organic solvent which does not adversely affect the reaction, or a mixture thereof.
The reaction is also usually carried out in the presence of triphenylphosphine and a conventional base such as potassium tert-butoxide, sodium hydride, sodium hydroxide and the like.
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (8) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
Reduction
Compound (8) or its salt is reduced in accordance with a conventional method to give Compound (9) .
The conventional reduction includes hydrogenation, catalytic hydrogenation, etc.
Among others, catalytic hydrogenation is preferable.
The catalytic hydrogenation is carried out in the presence of a catalyst such as palladium carbon, preferably 10% palladium carbon.
The catalytic hydrogenation is usually carried out in a conventional solvent such as tetrahydrofuran, ethanol, ethyl acetate, and other solvent which does not adversely affect the reaction, or a mixture thereof.
The catalytic hydrogenation is also preferably carried out in the presence of a conventional acid such as acetic acid, hydrochloric acid and the like. A liquid acid can be also used as the solvent. The reaction temperature is not critical, and the reaction can be carried out under cooling to heating.
Compound (9) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) . Therefore, Compound (11) or a salt thereof can be prepared from Compound (10) or a salt thereof in a similar manner as described above. Suitable salts of Compounds (10) and (11) may be the same as those exemplified for Compound (I) •
RX-NH-X- (lower alkenylene) -Z (10)
Reduction i *- R-NH-X- (lower alkylene) -Z (11)
The nitrogen atom in Compound (6), (7), (8), (9), (10) or (11) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
Procedure C: Synthesis of Compound (I) wherein Y is -CONH-
R1-NH-X-COOH + L4-NH-Z *► R1-NH-X-CONH-Z
(12) (13) (14) wherein L4 is a hydrogen atom or a protecting group, which is known per ser such as tert-butox carbonyl as described in the above "optionally protected amino" (see Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , etc. ) ; and R1, X and Z are as defined above.
Amidation
Compound (12) or a reactive derivative thereof, or its salt is reacted with Compound (13) or its salt to give an amidated compound (14) . Suitable reactive derivative of Compound (12) includes an acid halide, an acid anhydride and an activated ester.
The suitable example may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, hologenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g. , pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [ (CH3) 2N+=CH-] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4- dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenyl thioester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); or an ester with an N-hydroxy compound (e.g., N,N-dimethlhydroxylamine, 1- hydroxy-2- (1H) -pyridone, N-hydroxysuccinimide, N- hydroxybenzotriazole, N-hydroxyphthalimide, l-hydroxy-6- chloro-lH-benzotriazole, etc.). These reactive derivatives can be optionally selected from them according to the kind of Compound (12) to be used. Suitable salts of Compound (12) and a reactive derivative thereof as well as Compound (13) may be the same as those exemplified for Compound (I).
Compound (12) and a reactive derivative thereof as well as Compound (13) or salts thereof may be commercially available or can be prepared in accordance with the methods known per se (see Production Example 7) .
The conventional amidation method may be employed in the present invention.
The reaction is usually carried out in a conventional solvent such as dichloromethane, methanol, ethanol, acetone, tetrahydrofuran, N,N-dimethylformamide, and any other organic solvent which does not adversely influence the reaction, or a mixture thereof.
The reaction is also preferably carried out in the presence of a conventional condensing agent such as 1-ethyl- 3- (3-dimethylaminopropyl) carbodiimide hydrochloride, N,N'- dicyclohexylcarbodiimide, N,N'-carbonylbis (2- methylimidazole) triphenylphosphine , and an additive such as 1-hydroxybenzotriazole , 1-hydroxysuccinimide , 3 , 4-dihydro-3- hydroxy-4-oxo-l , 2 , 3-benzotriazine .
The reaction temperature is not critical, and the reaction can be carried out under cooling to heating. Compound (14) thus obtained can be isolated or purified by known separation or purification means, such as concentration, concentration in vacuo , solvent extraction, crystallization, recrystallization, phase transfer, chromatography and the like, and can be converted to a salt same as those exemplified for Compound (I) .
The nitrogen atom in Compound (12) , (13) or (14) may be protected or deprotected, as necessary, in accordance with methods known per se such as the methods described in Protective Groups in Organic Synthesis, published by John Wiley and Sons (1980) , and the like.
The present invention is explained in more detail in the following by way of Production Examples and Examples , which are not to be construed as limitative. The test compound used in the Example was N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide (hereinafter Compound A) synthesized in Production Example 1. Production Example 1: Step 1
Figure imgf000037_0001
A mixture of 3-chloro-2-oxopropyl acetate (5 g) and thiourea (2.5 g) in ethanol (25 ml) was refluxed for 4 hours. The reaction mixture was cooled to ambient temperature and the resulting crystalline precipitate was collected by filtration and washed with ethanol (20 ml) to give (2-amino~l ,3-thiazol- 4-yl) methyl acetate hydrochloride (3.5 g) as white crystals. XH-NMR (DMSO-d6) , δ (ppm): 2.07 (3H, s) , 4.92 (2H, s) , 6.87 (1H, S ) .
MS : 173 (M+H) + Step 2
Figure imgf000037_0002
To a mixture of (2-amino-l ,3-thiazol-4-yl) methyl acetate hydrochloride (56 g) and pyridine (45 g) in dichloromethane
(560 ml) was added acetyl chloride (23 g) over a period of 30 minutes at 5°C, and the reaction mixture was stirred for 10 minutes at the same temperature. The reaction mixture was poured into water (500 ml) and extracted with chloroform (1 L) The organic layer was dried over sodium sulfate and concentrated in vacuo . The residual solid was collected by filtration with isopropyl ether to give (2- (acetylamino) -1 , 3- thiazol-4-yl) methyl acetate (47 g) as white crystals. 1H-NMR (CDCI3) , δ (ppm): 2.12 (3H, s) , 2.29 (3H, s) , 5.08 (2H, s) , 6.93(1H, s) . MS: 215(M+H)+ Step 3
Figure imgf000038_0001
A mixture of (2- (acetylamino) -1 ,3-thiazol-4-yl) methyl acetate (46 g) and potassium carbonate (30 g) in methanol (640 ml) was stirred for 3 hours at ambient temperature. The reaction mixture was concentrated in vacuo . The residue was diluted with chloroform, and the insoluble material was filtered off. The resulting solution was purified by flash column chromatography on silica-gel with methanol / chloroform (1/99) . The resulted solid was collected by filtration with isopropyl ether to give N- (4- (hydroxymethyl) -1 ,3-thiazol-2- yl) acetamide (35 g) as white crystals.
XH-NMR (DMSO-d6) , δ (ppm): 2.12(3H, s) , 4.44 (2H, d, J=5.0Hz), 5.20(1H, t, J=5.0Hz), 6.88(1H, s) , 12.02(1H, brs) . MS: 173(M+H) + Step 4
Figure imgf000038_0002
N- (4- (Hydroxymethyl) -1 ,3-thiazol-2-yl) acetamide (2.8 g) was dissolved in methanol (10 ml) and chloroform (200 ml) .
Then manganese (IV) oxide (28.3 g) was added to the solution under nitrogen atmosphere . The reaction mixture was stirred at room temperature for 7 hours , and filtered through a celite pad. The filtrate was concentrated in vacuo . The resulting solid was washed with ethyl ether to give N- (4-formyl-l , 3- thiazol-2-yl) acetamide (2.01 g) as an off-white solid, mp. 195.5-199°C
XH-NMR (DMSO-de) , δ (ppm): 2.17 (3H, s) , 8.28 (1H, s) , 9.79 (1H, s) , 12.47 (1H, brs) . Step 5
Figure imgf000039_0001
1- (Bromomethyl) -4-nitrobenzene (1.9 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2.5 hours. Then potassium tert-butoxide (1.19 g) and N- (4-formyl-l ,3-thiazol-2- yl) acetamide (1.5 g) were added and the mixture was stirred at room temperature for 14 hours. The reaction mixture was poured into ice-water and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —■ (1:2) as an eluent, and triturated with ethyl ether to give N-{4- [ (Z) -2- (4- nitrophenyl) ethenyl]-l ,3-thiazol-2-ylJ acetamide (1.59 g) as a yellow solid. mp. 155-157°C
XH-NMR (DMSO-de) , δ (ppm) : 2.13 (3H, s) , 6.64 (1H, d, J=12.5Hz) , 6.71(1H, d, J=12.5Hz) , 7.18(1H, s) , 7.79(2H, d, J=9.0Hz) ,
8.17(2H, d, J=9.0Hz) , 12.02(1H, brs) .
MS: 290(M+H)+
Step 6
Figure imgf000040_0001
A mixture of N-{4- [ (Z) -2- (4-nitrophenyl) ethenyl] -1 ,3- thiazol-2-yl} acetamide (2 g) and 10% palladium carbon (400 mg) in methanol (25 ml) , tetrahydrofuran (25 ml) and acetic acid (18 ml) was stirred under 4 atm hydrogen at ambient temperature for 5 hours . The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo . The residue was dissolved in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:2) -» ethyl acetate as an eluent, and triturated with ethyl alcohol / ethyl ether to give N- (4- (2- (4-aminophenyl) ethyl) -1 ,3-thiazol- 2-yl) acetamide (539.6 mg) as an off-white solid, mp. 102.5-104°C
XH-NMR (DMSO-de) , δ (ppm): 2.11 (3H, s) , 2.75 (4H, brs), 4.82 (2H, s) , 6.46(2H, d, J=8.5Hz), 6.69(1H, s) , 6.83(2H, d, J=8.5Hz), 12.07 (1H, brs) . MS: 262(M+H) + Step 7
Figure imgf000040_0002
Compound A
To a suspension of N- (4- (2- (4-aminophenyl) ethyl) -1 ,3- thiazol-2-yl) acetamide (26 g) in ethanol (500 ml) was added 4N hydrogen chloride in ethyl acetate (25 ml) and cyanamide (6.3 g) . The mixture was refluxed for 26 hours. The reaction mixture was cooled to ambient temperature and poured into a mixture of ethyl acetate (500 ml) and saturated sodium hydrogen carbonate solution (500 ml) . The resulted precipitate was collected by filtration and washed with water (300 ml) and ethanol (300 ml) to give N-{4- [2- (4-{ [amino (imino) methyl] - aminojphenyl) ethyl] -1 ,3-thiazol-2-ylJacetamide (18 g) as white crystals .
XH-NMR (DMSO-d6) , δ (ppm): 2.10(3H, s) , 2.85(4H, s) , 6.79 (1H, s) , 6.83 (2H, d, J=7Hz) , 7.10 (2H, d, J=7Hz) . MS: 304(M+H) +
Production Example 2: Synthesis of N- (4- (2- (4- (4 ,5-dihydro- 1 ,3-thiazol-2-ylamino) phenyl) ethyl) -1 ,3-thiazol-2-yl) acetamide
N- (4- (2- (4-Aminophenyl) ethyl) -1 , 3-thiazol-2- yl) acetamide (1.8 g) prepared in a similar manner according to Step 6 of Production Example 1, 2- (methylsulfanyl) -4 , 5- dihydro-1 ,3-thiazole (918 mg) , hydrochloric acid concentrate (0.57 ml) and 2-methoxyethanol (28 ml) were combined under nitrogen atmosphere, and stirred at 120°C for 10 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo . The residue was dissolved in tetrahydrofuran / water, and made basic with aqueous potassium carbonate. The mixture was extracted with ethyl acetate. The organic layer was dried over magnesium sulfate, and evaporated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (30:1 —> 20:1) as an eluent, and triturated with ethyl acetate to give N- (4- (2- (4- (4 , 5-dihydro-l , 3-thiazol-2- ylamino) phenyl) ethyl) -1 ,3-thiazol-2-yl) acetamide (484.7 mg) as an off-white solid. mp. 218-219.5 °C
1H-NMR (DMSO-d6) , δ (ppm): 2.11(3H, s) , 2.84 (4H, s) , 3.26 (2H, t, J=7.5Hz), 3.35(2H, t, J=7.5Hz), 4.02(1H, brs), 6.71(1H, brs), 7.05(2H, d, J=8.5Hz), 7.51(1H, brs), 9.25(1H, brs), 12 . 10 ( 1H , brs ) .
MS : 347 (M+H) +
Production Example 3: Synthesis of N- (4-{ (E) -2- [4- (4 ,5- dihydro-1 ,3-thiazol-2-ylamino) phenyl] ethenyl }-l ,3-thiazol-2- yl) acetamide Step 1
A mixture of 4-nitrobenzyl bromide (6..35 g) , triphenylphosphine (7.71 g) and N,N-dimethylformamide (50 ml) was stirred for 5 hours at room temperature. To the mixture were added potassium butoxide (3.96 g) , and then N- (4-formyl- 1 ,3-thiazol-2-yl) acetamide (5.0 g) prepared in a similar manner according to Step 4 of Production Example 1 , and the mixture was stirred for 13 hours at the same temperature. The reaction mixture was poured into ethyl acetate (200 ml) and water (200 ml) . The organic layer was washed with water (20 ml) , dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected and washed with 30%. ethyl acetate / diisopropyl ether to give N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -1 ,3-thiazol-2-yl} cetamide (7.8 g) . iR-NMR (DMSO-d6) , δ (ppm): 2.16 (3H, s) , 7.29 (1H, d, J=16Hz) , 7.48(1H, d, J=16Hz) , 7.88(2H, d, J=7Hz) , 8.22(2H, d, J=7Hz) . MS (M+H)=290 Step 2
A mixture of N-{4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3- thiazol-2-yl} acetamide (250 mg) , palladium on carbon (25 mg) and methanol (2.5 ml) was stirred under hydrogen atmosphere for 2 hours at ambient temperature. The catalyst was filtered off and the filtrate was concentrated in vacuo . The crystalline residue was collected and washed with isopropyl ether to give N- { 4- [ (E) -2- (4-aminophenyl) ethenyl] -1 ,3-thiazol- 2-yl} acetamide (160 mg) .
XH-NMR (DMSO-d6) , δ (ppm): 2.14 (3H, s) , 5.33 (2H, s) , 6.55 (2H, d, J=7Hz) , 6.82(1H, d, J=10Hz) , 6.44(1H, s) , 7.09(1H, d, J=10Hz ) , 7 . 20 (2H , d , J=7Hz ) . MS : 260 (M+H) + Step 3
A mixture of N-{4- [ (E) -2- (4-aminophenyl) ethenyl] -1 , 3- thiazol-2-yl} acetamide (200 mg) , 2- (methylsulfanyl) -4 , 5- dihydro-1 ,3-thiazole (103 mg) , hydrochrolic acid (0.064 ml) and 2-methoxyethanol (2 ml) was stirred at 120 °C for 8 hours. The reaction mixture was concentrated in vacuo . The residue was purified by silica-gel flash column chromatography with hexane: ethyl acetate (3:1) as an eluent. The crystalline residue was collected and washed with ethyl acetate to give N- (4-{ (E) -2- [4- (4 , 5-dihydro-l , 3-thiazol-2- ylamino) phenyl] ethenyl}-! ,3-thiazol-2-yl) acetamide (150 mg) . XH-NMR (CDCI3) , δ (ppm): 2.27 (3H, s) , 3.33-3.40 (2H, m) , 3.57- 3.65(2H, m) , 6.94(1H, s) , 7.05(1H, d, J=12Hz) , 7.29(1H, d, J=12Hz) , 7.30 (2H, d, J=7Hz), 7.57 (2H, d, J=7Hz) . MS: 345(M+H)+
Production Example 4: Synthesis of methyl N-(4-{2-[2- (acetylamino) -1 ,3-thiazol-4-yl] ethyl Jphenyl) imidothiocarbamate hydriodide Step 1
To an ice-cold solution of N- (4- (2- (4-aminophenyl) ethyl) - 1 ,3-thiazol-2-yl) acetamide (300 mg) prepared in a similar manner according to Step 6 of Production Example 1 in acetone (5 ml) was added benzoyl isothiocyanate (187 mg) and the mixture was refluxed for 2 hours . The reaction mixture was cooled to 0 °C. The precipitated crystals were filtered and washed with ice-cold acetone to give N-{4-[2-(4- { [ (benzoylamino) carbonothioyl] aminojphenyl) ethyl] -1 ,3-thiazol- 2-ylJ acetamide (359 mg) .
XH-NMR (CDCI3) , δ (ppm): 2.25 (3H, s) , 2.90-3.05 (4H, m) , 6.51(1H, s) , 7.21(2H, d, J=7Hz) , 7.50-7.70 (5H, m) , 7.89(2H, d, J=7Hz) , 9.03(1H, s) , 9.12(1H, s) . MS (M+H) =425 Step 2
A mixture of N-{4- [2- (4-{ [ (benzoylamino) carbonothioyl] aminojphenyl) ethyl]-l ,3-thiazol-2-ylJ acetamide (200 mg) , 6N aqueous sodium hydroxide (0.19 ml) and ethanol (2 ml) was stirred at 60 °C for 2 hours. The reaction mixture was cooled to ambient temperature and neutralized with IN hydrochloric acid (1.2 ml). The precipitated crystals were filtered and washed with water to give N- [4- (2- {4- [ (aminocarbonothioyl) - amino] phenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide (120 mg) .
XH-NMR (DMSO-d6) , δ (ppm) : 2.11 (3H, s) , 2.88 (4H, s) , 6.75 (1H, s) , 7.15(2H, d, J=7Hz) , 7.27 (2H, d, J=7Hz) , 9.60(1H, s) . MS (M+H)=321 Step 3 A mixture of N- [4- (2- {4- [ (aminocarbonothioyl) amino] phenyl }ethyl) -1 ,3-thiazol-2-yl] acetamide (100 mg) , methyl iodide (0.023 ml) and methanol (2 ml) was refluxed for 3 hours. The reaction mixture was concentrated in vacuo . The residue was diluted with ethyl acetate and stirred for 30 minutes. The precipitated crystals were filtered and washed with ethyl acetate to give methyl N- (4-{2- [2- (acetylamino) - 1 ,3-thiazol-4-yl] ethyl Jphenyl) imidothiocarbamate hydriodide (130 mg) . XH-NMR (DMSO-ds) , δ (ppm) : 2.13 (3H, s) , 2.68 (3H, s) , 2.87- 3.05(4H, m) , 6.75(1H, s) , 7.24(2H, d, J=7Hz) , 7.35(2H, d, J=7Hz) . MS (M+H)=463
Production Exam le 5: Synthesis of N- (4-{2- [4- (4 , 5-dihydro-lH- imidazol-2-ylamino) phenyl] ethyl J-l ,3-thiazol-2-yl) acetamide A mixture of N- (4- (2- (4-aminophenyl) ethyl) -1 ,3-thiazol-2- yl) acetamide (65 mg) prepared in a similar manner according to Step 6 of Production Example 1, ethyl 2- (methylsulfanyl) -4 ,5- dihydro-lH-imidazole-1-carboxylate (56 mg) , acetic acid (0.1 ml) , ethanol (0.9 ml) was stirred at 65 °C for 6 hours, and then refluxed for 5 hours . The reaction mixture was poured into ethyl acetate (5 ml) and saturated aqueous sodium bicarbonate. The precipitated solid was filtered, and the 5 solid was dissolved in 50% methanol/chloroform. The insoluble materials were filtered off and the filtrate was concentrated in vacuo . The solid residue was collected and washed with ethyl acetate to give N- (4- {2- [4- (4 , 5-dihydro-lH-imidazol-2- ylamino) phenyl] -ethyl}-l ,3-thiazol-2-yl) acetamide (40 mg) . 10 XH-NMR (DMSO-de) , δ (ppm) : 2.11 (3H, s) , 2.72 (4H, s) , 3.33 (4H, s) , 6.73(1H, s) , 6.85-7.08 (4H, m) . MS (M+H)=330
Production Example 6: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 , 3-thiazol-2-yl}-2- I5 methylpropanamide Step 1
To an ice-cold mixture of ethyl 2-amino-l ,3-thiazole-4- carboxylate (2 g) prepared in a similar manner according to Step 1 of the following Production Example 7, pyridine (1.3 20 ml) and dichloromethane (20 ml) was added isobutyryl chloride (0.91 ml) and stirred for 30 minutes. To the mixture was added saturated aqueous hydrogen bicarbonate (30 ml) , and the organic layer was separated, dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected 25 and washed with ethyl acetate to give ethyl 2-
(isobutyrylamino) -1 ,3-thiazole-4-carboxylate (1.34 g) . XH-NMR (CDCI3) r δ (ppm): 1.30 (6H, d, J=7Hz) , 1.40 (3H, t, J=7Hz) , 2.57-2.73 (1H, m) , 4.41(2H, q, J=7Hz) , 7.83(1H, s) , 8.98 (1H, s) . 0 MS: 243(M+H) + Step 2
To a mixture of ethyl 2- (isobutyrylamino) -1 , 3-thiazole-4- carboxylate (1.4 g) and tetrahydrofuran (28 ml) was added lithium borohydride (252 mg) portionwise, and the mixture was refluxed for 6 hours. The reaction mixture was cooled to 0 °C, quenched with methanol (5 ml) and concentrated in vacuo . The residue was suspended with 10% methanol / chloroform (100 ml) , and the insoluble materials were filtered off. The filtrate was purified by flash column chromatography on silica-gel with 5% methanol / chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give N-[4- (hydroxymethyl) -1 ,3-thiazol-2-yl] -2-methylpropanamide (1.0 g) . XH-NMR (CDC13) , δ (ppm): 1.32 (6H, d, J=5Hz) , 2.58-2.73 (1H, m) , 4.68 (2H, s) , 6.82 (1H, s) . MS (M+H)=200 Step 3
A mixture of N- [4- (hydroxymethyl) -1 ,3-thiazol-2-yl] -2- methylpropanamide (520 mg) , manganese (IV) oxide (2.26 g) , methanol (0.5 ml) and chloroform (5 ml) was stirred at ambient temperature for 18 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo . The crystalline residue was collected and washed with diisopropyl ether to give N- (4-formyl-l ,3-thiazol-2-yl) -2- methylpropanamide (365 mg) .
XH-NMR (CDCI3) , δ (ppm): 1.13 (6H, d, J=5Hz) , 2.60-2.77 (1H, m) , 7.86 (1H, s) . MS (M+H)=199 Step 4
A mixture of 4-nitrobenzyl bromide (381 mg) , triphenylphosphine (463 mg) and N,N-dimethylformamide (3 ml) was stirred for 5 hours at room temperature . To the mixture were added potassium butoxide (238 mg) and then N- (4-formyl- 1 ,3-thiazol-2-yl) -2-methylpropanamide (350 mg) , and the mixture was stirred for 13 hours at the same temperature. The reaction mixture was poured into ethyl acetate (20 ml) and water (20 ml) . The organic layer was washed with water (20 ml) , dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected and washed to give 2-methyl- N- { 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 , 3-thiazol-2- yljpropanamide (360 mg) . XH-NMR (CDC13) , δ (ppm): 1.25(6x2/3H, d, J=5Hz) , 1.30(6xl/3H, d, J=5Hz) , 2.50-5.70 (1H, m) , 6.63(1H, s) , 6.79(lx2/3H, s) , 6.97(lx2/3H, s) , 7.14(lxl/3H, d, J=12Hz) , 7.33(lxl/3H, d, J=12Hz) , 7.53(2x2/3H, d, J=7Hz) , 7.62(2xl/3H, d, J=7Hz) , 8.13(2x2/3H, d, J=7Hz) , 8.22(2xl/3H, d, J=7Hz) . MS (M+H)=318 Step 5
A mixture of 2-methyl-N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -1 ,3-thiazol-2-yl}propanamide (333 mg) , palladium on carbon (33 mg) , acetic acid (1 ml) , methanol (2 ml) and tetrahydrofuran (2 ml) was stirred under hydrogen atmosphere (4 atm) at ambient temperature for 5 hours. The catalyst was filtered off, and the filtrate was concentrated in vacuo . The residue was purified by flash column chromatography on silica gel with 5% methanol / ethyl acetate as an eluent. The solid residue was collected and washed with diisopropyl ether to give N- {4- [2- (4-aminophenyl) ethyl] -1 , 3- thiazol-2-yl}-2-methylpropanamide (260 mg) .
XH-NMR (CDCI3) , (ppm): 1.38 (6H, d, J=5Hz) , 2.57-2.73 (1H, m) , 2.39-2.43 (4H, m) , 6.45(1H, s) , 6.62(2H, d, J=7Hz) , 6.97(2H, d, J=7Hz) .
MS (M+H)=290 Step 6
The title compound was prepared in a similar manner according to Step 7 of Production Example 1. ιH-NMR (DMS0-d6) , δ (ppm): 1.01 (6H, d, J=5Hz) , 2.62-2.78 (1H, m) , 2.83(4H, s) , 6.72(2H, d, J=7Hz) , 6.75(1H, s) , 7.04(2H, d, J=7Hz) . MS (M+H)=332 Production Example 7: Synthesis of 2- (acetylamino) -N- (4-
{ [amino (imino) methyl] aminojphenyl) -1 ,3-thiazole-4-carboxamide
Step 1
A mixture of ethyl 3-bromo-2-oxopropanoate (100 g) , thiourea (39 g) and ethanol (500 ml) was refluxed for 2 hours. The reaction mixture was concentrated in vacuo . The crystalline residue was collected and washed with ethyl acetate to give ethyl 2-amino-l ,3-thiazole-4-carboxylate hydrobromide (116 g) . ifi- MR (DMSO-de) , δ (ppm): 1.28(3H, t, J=7Hz) , 4.26(2H, q, J=7Hz) , 7.60 (1H, s) . Step 2
To an ice-cold mixture of ethyl 2-amino-l ,3-thiazole-4- carboxylate hydrobromide (80 g) , pyridine (52.5 g) and dichloromethane (800 ml) was added acetyl chloride (27.3 g) dropwise at 0 °C , and the mixture was stirred for 30 minutes at the same temperature . The reaction mixture was washed with water (500 ml) , dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected and washed with ethyl acetate to give ethyl 2- (acetylamino) -1 ,3-thiazole~4- carboxylate (60 g) .
XH-NMR (DMSO-de) , δ (ppm): 1.29 (3H, t, J=7Hz) , 2.15 (3H, s) , 4.27 (2H, q, J=7Hz) , 8.03(1H, s) . MS (M+H)=215 Step 3
A mixture of ethyl 2- (acetylamino) -1 ,3-thiazole-4- carboxylate (2 g) , 2N sodium hydroxide (7 ml) and methanol (13 ml) was stirred at ambient temperature for 5 hours. The reaction mixture was neutralized by IN hydrochloric acid (14 ml) . The precipitated crystals were filtered and washed with water to give 2- (acetylamino) -1 ,3-thiazole-4-carboxylic acid (1.3 g) . XH-NMR (DMSO-de), δ (ppm): 2.14 (3H, s) , 7.94 (1H, s) . Step 4
A mixture of 2- (acetylamino) -1 ,3-thiazole-4-carboxylic acid (500 mg) , tert-butyl 4-aminophenylcarbamate (615 mg) , 1- ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (566 mg) , 1-hydroxybenzotriazole (399 mg) and dichloromethane (5 ml) was stirred at ambient temperature for 3 hours. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate, and the organic layer was concentrated in vacuo . The residue was purified by flash column chromatography on silica gel with 3% methanol / chloroform as an eluent. The crystalline residue was collected and washed with ethyl acetate to give tert-butyl 4- ({ [2- (acetylamino) - 1 ,3-thiazol-4-yl] carbonyl}amino) phenylcarbamate (580 mg) . XH-NMR (DMSO-d6) , δ (ppm) : 1.48 (9H, s) , 2.18 (3H, s) , 7.42 (2H, d, J=7Hz) , 7.61(2H, d, J=7Hz) , 7.91(1H, s) , 9.32(1H, s) , 9.63 (1H, s) . MS (M+H)=377 Step 5
To a solution of tert-butyl 4- ({ [2- (acetylamino) -1 ,3- thiazol-4-yl] carbonyl} amino) phenylcarbamate (85 mg) in methanol (1 ml) was added 4N hydrogen chloride in ethyl acetate (1 ml) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo . The solid residue was collected and washed with ethyl acetate to give 2- (acetylamino) -N- (4-aminophenyl) -1 ,3- thiazole-4-carboxamide hydrochloride (70 mg) . XH-NMR (DMSO-d6) , δ (ppm): 2.15(3H, s) , 7.42(2H, d, J=7Hz) , 7.37 (2H, d, J=7Hz) , 7.41(1H, s) . MS (M+H)=313 Step 6
A mixture of 2- (acetylamino) -N- (4-aminophenyl) -1 ,3- thiazole-4-carboxamide hydrochloride (70 mg) , cyanamide (11 mg) and 2-methoxyethanol (2 ml) was stirred at 100 °C for 72 hours. The reaction mixture was concentrated in vacuo . To the residue was added ethyl acetate (5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) . The precipitated solid was filtered and washed with ethyl acetate and water to give 2- (acetylamino) -N- (4- { [amino (imino) methyl] aminojphenyl) -1 ,3- thiazole-4-carboxamide (45 mg) .
XH-NMR (DMSO-d6) , δ (ppm): 2.18 (3H, s) , 7.60-7.88 (4H, br) , 7.95(1H, s) . MS (M+H)=319 Production Example 8: Synthesis of N-(4-{2-[4-
(ethanimidoylamino) phenyl] ethyl J-l , 3-thiazol-2-yl) acetamide
N- (4- (2- (4-Aminophenyl) ethyl) -1 ,3-thiazol-2-yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, methyl ethanimidothioate hydriodide (166 mg) and methanol (3 ml) were combined, and refluxed for 1.5 hours . After cooled to room temperature , the mixture was concentrated in vacuo . The residue was purified by flash column chromatography over NH silica gel with chloroform / methanol (20:1 → 10:1) as an eluent to give N-(4-{2-[4- (ethanimidoylamino) phenyl] ethyl J-l , 3-thiazol-2-yl) acetamide (165 mg) as a pale yellow amorphous substance.
XH-NMR (CDCI3) , δ (ppm): 2.03(3H, brs), 2.19 (3H, s) , 2.92 (4H, s) , 6.47(1H, s) , 6.78(2H, d, J=8.0Hz), 7.08(2H, d, J=8.0Hz). MS: 303(M+H) + Production Example 9 : Synthesis of N-[4-(2-{4-
[amino (imino) methyl] phenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide hydrochloride Step 1
4- (Bromomethyl)benzonitrile (1.73 g) , triphenylphosphine (2.31 g) and N,N-dimethylformamide (20 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours. Then potassium tert-butoxide (1.19 g) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (1.5 g) prepared in a similar manner according to Step 4 of Production Example 1 were added to the mixture, and stirred at room temperature for 3 hours. The reaction mixture was poured into ice-water, and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) as an eluent, and triturated with ethyl ether to give a mixture of N-{4- [ (Z) -2- (4-cyanophenyl) ethenyl] -1 ,3- thiazol-2-yl}acetamide and N-{4- [ (E) -2- (4- cyanophenyl) ethenyl] -1 ,3-thiazol-2-ylJ acetamide (Z : E = 3 : 1) (1.63 g) as a pale yellow solid, mp. 175-176 °C ^- MR (DMSO-d6) , δ (ppm): 2.13(3Hx3/4, s) , 2.16(3Hxl/4, s) , 6.59(lHx3/4, d, J=13.0Hz), 6.65(lHx3/4, d, J=13.0Hz), 7.11(lHx3/4, s) , 7.24(lHxl/4, d, J=16.0Hz), 7.28(lHxl/4, s) , 7.40(lHxl/4, d, J=16.0Hz), 7.65(2Hx3/4, d, J=8.5Hz), 7.74(2Hxl/4, d, J=8.5Hz), 7.75(2Hx3/4, d, J=8.5Hz), 7.83(2Hxl/4, d, J=8.5Hz), 12.00(1H, brs). MS: 270(M+H)+ Step 2
A mixture of N-{4- [ (Z) -2- (4-cyanophenyl) ethenyl] -1 ,3- thiazol-2-yl} acetamide and N-{4- [ (E) -2- (4- cyanop enyl) ethenyl] -1 ,3-thiazol-2-ylJacetamide (Z : E = 3 : 1) (1.5 g) , 10% palladium on carbon (323 mg) , methanol (20 ml) , tetrahydrofuran (10 ml) and acetic acid (5 ml) were combined. The reaction mixture was stirred under 4 atm hydrogen at ambient temperature for 9 hours , and filtered through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (1:1) —» chloroform / methanol (30:1) as an eluent, and triturated with ethyl ether to give N-{4- [2- (4-cyanophenyl) ethyl]-l ,3-thiazol-2- yljacetamide (1.18 g) as a colorless solid, mp. 205-206.5 °C
XH-NMR (DMSO-d6) , δ (ppm): 2.11 (3H, s) , 2.90 (2H, t, J=8.0Hz), 3.01(2H, t, J=8.0Hz), 6.73(1H, s) , 7.40(2H, d, J=8.0Hz), 7.74(2H, d, J=8.0Hz), 12.09 (1H, brs). MS: 272(M+H)+ Step 3
N-{4- [2- (4-Cyanophenyl) ethyl] -1 ,3-thiazol-2-ylJacetamide (600 mg) was dissolved in ethanol (5 ml) and chloroform (5 ml) , and then hydrochloric acid gas was bubbled at 0 °C for 5 minutes with stirring. The reaction mixture was stood for 15 hours, and concentrated in vacuo . The residual solid was washed with diethyl ether to give ethyl 4- {2- [2- (acetylamino) - 1 ,3-thiazol-4-yl] ethyl Jbenzenecarboximidoate hydrochloride (924.7 mg) as a pale green solid, mp. 129-130 °C
XH-NMR (DMSO-d6) , δ (ppm) : 1.48(3H, t, J=7.0Hz), 2.12(3H, s) , 2.95(2H, t, J=8.0Hz), 3.07 (2H, t, J=8.0Hz), 4.61(2H, q, J=7.0Hz), 6.72(1H, s) , 7.46(2H, d, J=8.5Hz), 8.02(2H, d, J=8.5Hz), 11.25(1H, brs), 11.98(1H, brs), 12.11(1H, brs). MS: 318(M+H)+ free Step 4
Ethyl 4-{2- [2- (acetylamino) -1 , 3-thiazol-4- yl] ethyl Jbenzenecarboximidoate hydrochloride (300 mg) was dissolved in ethanol (6 ml) . Then ammonium chloride (68 mg) and ammonia in methanol (1 ml) were added to the solution. The reaction mixture was refluxed for 5 hours under nitrogen atmosphere. After cooled to room temperature, the suspension was filtered in vacuo . The filtrate was concentrated in vacuo , and the residue was solidified with ethanol / diethyl ether to give N- [4- (2-{4- [amino (imino) methyl] phenyl}ethyl) -1 ,3-thiazol- 2-yl] acetamide hydrochloride (234 mg) as a colorless solid. mp. 229.5-231 °C
XH-NMR (DMSO-d6) , δ (ppm) : 2.12 (3H, s) , 2.94 (2H, t, J=8.0Hz) , 3.06(2H, t, J=8.0Hz) , 6.75(1H, s) , 7.44(2H, d, J=8.5Hz) , 7.76(2H, d, J=8.5Hz) , 12.10(1H, brs) . MS: 289(M+H)+ free
Production Example 10: Synthesis of N- (4- {2- [2- (acetylamino) - 1 ,3-thiazol-4-yl] ethyl}phenyl) -2-{ [amino (imino) methyl] aminoj- acetamide hydrochloride Step 1 A mixture of N- (4- (2- (4-aminophenyl) ethyl) -1 ,3-thiazol-2- yl) acetamide (100 mg) prepared in a similar manner according to Step 6 of Production Example 1, ( (tert- butoxycarbonyl) amino) acetic acid (74 mg) , l-ethyl-3- (3- dimeth laminopropyl) carbodiimide hydrochloride (81 mg) , 1- hydroxybenzotriazole (57 mg) and dichloromethane (5 ml) was stirred at ambient temperature for 3 hours . The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate, and the organic layer was concentrated in vacuo. The residue was purified by flash column chromatography on silica-gel with 3% methanol / chloroform as an eluent. The crystalline residue was collected and washed with ethyl acetate to give tert-butyl 2- [ (4-{2- [2- (acetylamino) -1 , 3- thiazol-4-yl] ethyl Jphenyl) amino] -2-oxoethylcarbamate (580 mg) . XH-NMR (CDC13) , δ (ppm): 1.47 (9H, s) , 2.25 (3H, s) , 2.92 (4H, s) , 3.92(2H, d, J=5Hz) , 6.46(1H, s) , 7.10(2H, d, J=7Hz) , 7.38(2H, d, J=7Hz) . MS (M+H)=419 Step 2
To a solution of tert-butyl 2- [ (4-{2- [2- (acetylamino) - 1 ,3-thiazol-4-yl] ethyl Jphenyl) amino] -2-oxoethylcarbamate (100 mg) in ethyl acetate (1 ml) was added 4N hydrogen chloride in ethyl acetate (1 ml) , and the mixture was stirred at ambient temperature for 103 hours. The precipitated solid was filtered and washed with ethyl acetate to give N-(4-{2-[2-
(acetylamino) -1 ,3-thiazol-4-yl] ethyl Jphenyl) -2-aminoacetamide hydrochloride (80 mg) .
XH-NMR (DMSO-d6) , δ (ppm): 2.11 (3H, s) , 2.87 (4H, s) , 6.70 (1H, s) , 7.17 (2H, d, J=7Hz) , 7.49 (2H, d, J=7Hz) .
MS (M+H)=319
Step 3
The title compound was prepared in a similar manner according to Step 7 of Production Example 1. !H- MR (DMSO-d6) , δ (ppm): 2.11(3H, s) , 2.80-2.95 (4H, m) ,
3.76(2H, s) , 6.70(1H, s) , 7.26(2H, df J=7Hz) , 7.49(2H, d,
J=7Hz) , 8.16 (2H, s) .
MS (M+H)=361
Production Example 11: Synthesis of N-{4-[4-(2- { [amino (imino) methyl] amino}ethyl) phenyl] -1 ,3-thiazol-2- ylj acetamide hydrochloride
Step 1
Aluminium chloride (1.63 g) was dissolved in 1,2- dichloroethane (15 mL) . Chloroacetylchloride (0.732 mL) was added to the mixture at 0 °C, and stirred additionally for 20 minutes, then N- (2-phenylethyl) acetamide
(1 g) in 1,2-dichloroethane (5 mL) was added dropwise. The mixture was stirred for 1 hour at room temperature, and then poured into ice water. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo .
The solid was washed with ethyl acetate and ethyl ether, and dried in vacuo to give N- (2- [4- (2-chloroacetyl) phenyl] ethyl }- acetamide as a white powder (1.18 g, 80.4%). XH-NMR (300 MHz, DMSO-d6) , δ (ppm): 7.92(2H, d, J=6Hz) ,
7.34(2H, d, J=6Hz) , 5.66(1H, br) , 4.70(2H, s) , 3.55-3.60 (2H, m) , 2.90-2.94(2H, m) , 1.98(3H, s) .
Step 2 N- {2- [4- (2-Chloroacetyl) phenyl] ethyl}acetamide (1.06 g) and thiourea (505 mg) were dissolved in ethanol (20 mL) . The mixture was refluxed for 1 hour and allowed to cool to room temperature. The white solid was collected with filtration and washed with ethanol to give N- {2- [4- (2-amino-l , 3-thiazol-4- yl) phenyl] ethyl} acetamide hydrochloride (1.19 g, 90.4%). MS m/z 262 (M++1) .
XH-NMR (300 MHz, DMSO-d6) , δ (ppm) : 7.93-7.96 (2H, m) , 7.69(2H, d, J=6Hz) , 7.30(2H, d, J=6Hz) , 7.16(1H, s) , 3.23-3.30 (2H, m) , 2.70-2.76(2H, m) , 1.78 (3H, s) . Step 3
N-{2- [4- (2-Amino-l ,3-thiazol-4-yl) phenyl] ethyl } acetamide (0.6 g) was dissolved in ethanol (10 mL) and hydrochloric acid concentrate (10 mL) . The mixture was refluxed for 5 hours. The solvent was evaporated in vacuo . The residue was washed with ethyl ether to give 4- [4- (2~aminoethyl) phenyl] -1 ,3- thiazol-2-amine dihydrochrolide (0.5 g, 84.6%). MS m/z 220 (M++1) . XH-NMR (300 MHz, DMSO-d6) , δ (ppm) : 8.15(3H, br) , 7.78(2H, d, J=6Hz) , 7.39 (2H, d, J=6Hz) , 7.24 (1H, s) , 3.03-3.10 (2H, m) , 2.90-2.98 (2H, m) . Step 4
4- [4- (2-Aminoethyl) phenyl] -1 ,3-thiazol-2-amine dihydrochrolide (0.45 g) was dissolved in 1,4-dioxane (10 mL) , water (3 mL) and IN sodium hydroxide solution (3.1 mL) . Di- tert-butyl dicarbonate (336 mg) was added at 0 °C. The mixture was stirred at room temperature overnight, then extracted with ethyl acetate, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo . The solid was washed with ethyl ether, and dried in vacuo to give tert-butyl {2- [4- (2-amino-l ,3-thiazol-4-yl) phenyl] ethylj- carbamate as a white solid (311 mg, 63.2%) . MS m/z 320 (M++1) . ^-NMR (300 MHz, DMSO-d6) , δ (ppm) : 7.69(2H, d, J=6Hz) , 7.18(2H, d, J=6Hz) , 7.02(2H, br) , 7.69(1H, s) , 3.10-3.27 (2H, m) , 2.65-2.72 (2H, m) , 1.37(9H, s) . Step 5 tert-Butyl {2- [4- (2-amino-l , 3-thiazol-4- ylJphenyl] ethyl} carbamate (290 mg) was dissolved in dichloromethane (5 mL) , then acetic anhydride (0.103 mL) , 4- dimethylaminopyridine (10 mg) and pyridine (0.147 mL) were added. The mixture was stirred overnight. The mixture was extracted with chloroform, washed with water and saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo . The solid was washed with ethyl ether, and dried in vacuo to give tert-butyl (2-{4- [2- (acetylamino) - 1 ,3-thiazol-4-yl] phenyl}ethyl) carbamate as a white solid (280 mg, 85.3%) .
MS m/z 362 (M++1) .
XH-NMR (300 MHz, DMSO-d6) , δ (ppm): 7.80(2H, d, J=6Hz) , 7.53(1H, s) , 7.24(2H, d, J=6Hz) , 6.90(1H, m) , 3.12-3.18 (2H, m) , 2.16-2.63 (2H, m) , 2.16(3H, s) , 1.37(9H, s) . Step 6 tert-Butyl (2-{4- [2- (acetylamino) -1 , 3-thiazol-4- yl] phenyl} ethyl) carbamate (250 mg) was dissolved in ethyl acetate (4 mL) and 4 N hydrogen chloride in ethyl acetate (2 mL) . The solvent was evaporated in vacuo . The solid was washed with ethyl acetate and ethyl ether to give N-{4-[4-(2- aminoethyl) phenyl] -1 , 3-thiazol~2-ylJacetamide hydrochloride (220 mg, 106%) . MS m/z 262 (M++1) . XH-NMR (300 MHz, DMS0-d6) , δ (ppm): 8.05 (3H, br) , 7.85(2H, d, J=6Hz) , 7.58(1H, s) , 7.32(2H, d, J=6Hz) , 3.12-3.18 (2H, m) , 2.88-2.94 (2H, m) , 2.16(3H, s) . Step 7
N-{4- [4- (2-Aminoethyl) phenyl] -1 ,3-thiazol-2-ylJacetamide hydrochloride (200 mg) and diisopropylethylamine (0.175 mL) were dissolved in tetrahydrofuran (5 mL) . The mixture was stirred at room temperature overnight, then evaporated in vacuo . The residue was purified with silica gel chromatography (5% methanol / chloroform) to give di-tert-butyl {[(2- {4- [2- (acetylamino) -1 , 3-thiazol-4- yl] phenyl} ethyl) amino]methylidene}-biscarbamate (268 mg, 79.2%) . MS m/z 504 (M++1) . Step 8
Di-tert-butyl { [ (2-{4- [2- (acetylamino) -1 ,3-thiazol-4- yl] phenyl} ethyl) mino]methylidene}biscarbamate (268 mg, 79.2%) (170 mg) was dissolved in 4 N hydrogen chloride in 1,4-dioxane (5 mL) . The mixture was stirred at room temperature for 2 days, and then evaporated in vacuo . The residue was washed with ethyl ether, dried in vacuo to give N-{4-[4-(2- { [amino (imino) methyl] amino } ethyl) phenyl] -1 ,3-thiazol-2- yljacetamide hydrochloride (50 mg, 43.6%). MS m/z 304 (M++1) . ^-NMR (300 MHz, DMSO-d6) , δ (ppm) : 7.83(2H, d, J=8Hz) , 7.62- 7.66(1H, m) , 7.56(1H, s) , 7.34(2H, d, J=8Hz) , 3.37-3.45 (2H, m) , 2.78-2.85(2H, m) , 2.16(3H, s) . Production Example 12: Synthesis of N-(4-{2-[4- (aminomethyl) phenyl] ethyl}-l ,3-thiazol-2-yl) acetamide Step 1
To a mixture of N- (4- {2- [4- (hydroxymethyl) phenyl] ethyl }- 1 ,3-thiazol-2-yl) acetamide (50 mg) prepared in a similar manner according to Step 3 of the following Production Example 16, carbon tetrabromide (72 mg) and dichloromethane (1 ml) was added triphenylphosphine (71 mg) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was purified by flash column chromatography on silica gel with 1% methanol / chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give N-(4- {2- [4- (bromomethyl) phenyl] ethyl }-l ,3-thiazol-2-yl) acetamide (48 mg) .
XH-NMR (CDCI3) , δ (ppm): 2.25 (3H, s) , 2.85-3.03 (4H, m) , 4.49(2H, s) , 6.48(1H, s) , 7.13(2H, d, J=7Hz) , 7.30(2H, d, J=7Hz) . MS (M+H)=339 Step 2
To a mixture of N- (4-{2- [4- (bromomethyl) phenyl] ethyl }- 1 ,3-thiazol-2-yl) acetamide (100 mg) , tetrahydrofuran (2 ml) and N,N-dimethylformamide (2 ml) was added sodium diformylimide (42 mg) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with water (3 ml) , and the precipitated solid was filtered and washed with water to give N- [4- (2- {4- [ (diformylamino) - methyl] phenyl}ethyl) -1 ,3-thiazol-2-yl] acetamide (80 mg) . XH-NMR (CDCI3) , δ (ppm): 2.23 (3H, s) , 2.83-3.00 (4H, m) , 4.72(2H, s) , 6.48(1H, s) , 7.10(2H, d, J=7Hz) , 7.38(2H, d, J=7Hz) . MS (M+H)=318 Step 3
To a solution of N- [4- (2~{4- [ (diformylamino) methyl] - phenyljet yl) -1 ,3-thiazol-2-yl] acetamide (56 mg) in methanol (0.5 ml) was added 4N hydrogen chloride in ethyl acetate (0.5 ml) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo . The residue was separated between chloroform (5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) , and the aqueous layer was extracted with chloroform (5 ml) . The organic layer was dried over sodium sulfate and concentrated in vacuo to give N- (4-{2- [4- (aminomethyl) phenyl] ethyl}-l ,3-thiazol-2- yl) acetamide (50 mg) . XH-NMR (DMSO-d6) , δ (ppm) : 2.12 (3H, s) , 2.80-3.00 (4H, m) , 3.92- 4 . 05 ( 2H , m) , 6 . 72 ( 1H , s) , 7 . 24 ( 2H , d, J=7Hz ) , 7 . 37 (2H , d, J=7Hz ) . MS (M+H) =276
Production Example 13: Synthesis of ethyl 4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylcarbamate hydrochloride Step 1 : ethyl 4- (hydroxymethyl) -1 , 3-thiazol~2-ylcarbamate
A mixed solution of ethyl 4- (chloromethyl) -1 ,3-thiazol-2- ylcarbamate (500 mg) in 1,4-dioxane (5 ml) and water (10 ml) was refluxed with stirring for 3.5 hours. After cooling, it was concentrated under reduced pressure. The mixture was partitioned between ethyl acetate and water. The organic phase was separated, washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of hexane and ethyl acetate (2:1) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless syrup (450 mg, 98.2%) . MS (ES+) ; 203 (M+H) +
XH-NMR (CDC13) , δ (ppm): 1.39 (3H, t, J=7.0Hz), 4.39 (2H, q,
J=7.0Hz), 4.61(2H, s) , 6.80(1H, s) .
Step 2 : ethyl 4-formyl-l , 3-thiazol-2-ylcarbamate
To a mixed solution of ethyl 4- (hydroxymethyl) -1 ,3- thiazol-2-ylcarbamate (446 mg) in chloroform (30 ml) and methanol (3 ml) was added portionwise manganese (IV) oxide chemicals treated (1.92 g) at room temperature. After the mixture was stirred at the same temperature for 2 hours , then treated manganese (IV) oxide chemicals (250 mg) was added again to the solution, and it was stirred at 50 °C for 3 hours. Manganese (IV) oxide was removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of hexane and ethyl acetate (4:1) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless powder
(470 mg, 106.4%) . XH-NMR (CDC13) , δ (ppm): 1.36 (3H, t, J=7.0Hz), 4.34 (2H, q,
J=7.0Hz), 7.83(1H, s) , 9.54(1H, br) , 9.88(1H, s) .
Step 3
Ethyl 4- [2- (4-nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylcarbamate (E-Z mixture) was obtained in a similar manner according to Step 5 of Production Example 1.
XH-NMR (CDC13) (cis-trans product mixture) , δ (ppm) : 1.20-
1.40(3H, m) , 4.20-4.40 (2H, m) , 6.60, 6.66(1.2H, ABq, J=13Hz) ,
6.74(0.6H, s) , 6.94(0.4H, s) , 7.12, 7.30(0.8H, ABq, J=16Hz) ,
7.53(1.2H, d, J=8.9Hz), 7.61(0.8H, d, J=8.9Hz), 8.11(1.2H, d, J=8.9Hz), 8.22(0.8H, d, J=8.9Hz).
Step 4
Ethyl 4- [2- (4-aminophenyl) ethyl] -1 ,3-thiazol-2- ylcarbamate was obtained in a similar manner according to Step
6 of Production Example 1. MS (ES+) ; 292 (M+H) +
XH-NMR (DMSO-d6) , δ (ppm) : 1.24 (3H, t, J=7.1Hz), 2.65-2.80 (4H, m) , 4.18(2H, q, J=7.1Hz), 4.82(2H, br) , 6.46(2H, d, J=8.5Hz),
6.69(1H, s) , 6.84(2H, d, J=8.5Hz).
Step 5 Ethyl 4- [2- (4-{N' ,N"-bis (tert-butox carbonyl) -
[amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylcarbamate was obtained in a similar manner according to Step
3 of the following Production Example 14.
XH-NMR (CDCI3) , δ (ppm): 1.29 (3H, t, J=7.0Hz), 1.40-1.70 (18H, m) , 2.94(4H, s) , 4.27(2H, q, J=7.0Hz), 6.45(1H, s) , 7.12 (2H, d,
J=8.4Hz), 7.48(2H, d, J=8.4Hz), 10.25(1H, s) .
Step 6
The title compound was prepared in a similar manner according to Step 5 of the following Production Example 14. MS (ES+) ; 334 (M+H) + free
XH-NMR (DMSO-d6) , δ (ppm): 1.24 (3H, t, J=7.0Hz), 2.80-3.00 (4H, m) , 4.19(2H, q, J=7.0Hz), 6.76(1H, s) , 7.14(2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 7.46(3H, br) , 9.91(1H, s) . Production Example 14: Synthesis of N-{4-[2-(3- { [amino (imino) methyl] aminojphenyl) ethyl] -5-bromo-l ,3-thiazol- 2-ylJacetamide hydrochloride Step 1: N-{4- [2- (3-nitrophenyl) ethenyl] -1 , 3-thiazol-2- ylj acetamide (E-Z mixture)
To a solution of 1- (bromomethyl) -3-nitrobenzene (276 mg) in N,N-dimethylformamide (7 mL) was added triphenylphosphine (335 mg) at room temperature. After the mixed solution was stirred for 4 hours, potassium tert-butoxide (172 mg) and N- (4-formyl-l ,3-thiazol-2-yl) acetamide (217 mg) were successively added to the solution at the same temperature. After the whole solution was stirred at room temperature for 5 hours, the mixture was poured into water, the pH of the aqueous layer was adjusted to 7 with IN-hydrochloric acid. The resulting mixture was extracted with ethyl acetate. The extract was washed with brine, dried over sodium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of n-hexane and ethyl acetate (4:1) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give brown powder of the title compound (E-Z mixture) (323 mg, 87.4%). XH-NMR (DMSO-dg) (cis-trans product mixture) , δ (ppm) : 2.11(2.49H, s) , 2.16(0.51H, s) , 6.66(1.66H, s) , 7.13(0.83H, s) , 7.28(0.17H, s) , 7.29, 7.46(0.34H, ABq, J=16Hz) , 7.60(1H, t, J=7.9Hz), 7.91(0.83H, d, J=7.9Hz), 8.01(0.17H, d, J=7.9Hz), 8.09-8.13 (1H, m) , 8.28(0.83H, m) , 8.38(0.17H, m) . Step 2: N-{4- [2- (3-aminophenyl) ethyl] -1 , 3-thiazol-2- yl } acetamide
N-{4- [2- (3-Nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylj acetamide (E,Z mixture) (315 mg) in a mixed solvent of methyl alcohol (3 ml) , tetrahydrofuran (6 ml) , and acetic acid (1 ml) was hydrogenated over 10% Palladium on carbon (50% wet, 200 mg) under 4.3 atmospheric pressure at room temperature for 3 hours. The catalyst was removed off by filtration, and the filtrate was evaporated in vacuo . The residue was poured into water, the pH of the aqueous layer was adjusted to 9 with aqueous sodium hydrogen carbonate. The resulting mixture was extracted with ethyl acetate. The extract was washed with brine, dried over magnesium sulfate and evaporated under reduced pressure. The resulting residue was purified by column chromatography on silica gel (9 g) using a mixed solvent of n- hexane and ethyl acetate (2:1 to 1:1) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give syrup. The syrup of the objective compound was changed to solid in freezer (275 mg, 96.6%) . MS (ES+) ; 262 (M+H) +
XH-NMR (CDC13) , δ (ppm): 2.23 (3H, s) , 2.80-3.00 (4H, m) , 3.60(2H, br) , 6.51(1H, s) , 6.45-6.65 (3H, m) , 7.06(1H, t, J=7.9Hz) , 9.45(1H, br) . Step 3 : N-{4- [2- (3-{ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2-ylJ acetamide To a solution of N-{4- [2- (3-aminophenyl) ethyl] -1 ,3- thiazol-2-yl} acetamide (267 mg) in tetrahydrofuran (3 ml) was added N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (317 mg) at room temperature. After the mixed solution was stirred for 3 days at the same temperature, and then evaporated under reduced pressure, the resulting residue was purified by column chromatography on silica gel (10 g) using a mixed solvent of n-hexane and ethyl acetate (4:1 to 3:2) . The fractions containing the objective compound were collected and evaporated under reduced pressure to give colorless foam of the title compound (316 mg, 61.4%). MS (ES+) ; 504 (M+H) + XH-NMR (CDC13) , δ (ppm): 1.40-1.80 (18H, m) , 2.25 (3H, s) ,
2.97 (4H, m) , 6.37(1H, m) , 6.53(1H, s) , 6.91(1H, d, J=7.9Hz), 7.23(1H, t, J=7.9Hz), 7.34(1H, s) , 7.52(1H, d, J=7.9Hz), 7.63- 7.64(1H, m) , 10.28(1H, s) . Step 4 : N-{4- [2- (3-{ [N' ,N"-bis (tert-butoxycarbonyl) amino- (imino) methyl] aminojphenyl) ethyl] -5-bromo-l ,3-thiazol-2- yljacetamide
To a suspension of N-{4- [2- (3-{ [N' ,N"-bis (tert- butoxycarbonyl) amino (imino)methyl] aminojphenyl) ethyl] -1,3- thiazol-2-yl} acetamide (115 mg) in methanol (3 ml) was added N~bromosuccinimide (44.7 mg) at room temperature. After the mixed solution was stirred at the same temperature for 1 hour, the resulting precipitate was collected by filtration, -washed with a mixed solvent of diisopropyl ether and n-hexane (1:1) . The title compound was obtained as white powder (70 mg, 52.6%).
MS (ES+) ; 582 (M+H) +
XH-NMR (CDCI3) , δ (ppm): 1.40-1.75 (18H, m) , 2.21 (3H, s) , 2.85- 3.00(4H, m) , 6.93(1H, d, J=7.9Hz), 7.23(1H, t, J=7.9Hz), 7.30(1H, s) , 7.51(1H, d, J=7.9Hz), 9.26(1H, br) , 10.26(1H, br) , 11.63 (1H, br) . Step 5
To a solution of N- {4- [2- (3-{ [N' ,N"-bis (tert- butoxycarbonyl) amino (imino) methyl] aminojphenyl) ethyl] -5-bromo- 1 ,3-thiazol-2-yl}acetamide (64 mg) in dichloromethane (0.5 ml) was added dropwise 4N-hydrogen chloride in 1,4-dioxane (2 ml) at room temperature. After being stirred at the same temperature for 20 hours, the reaction mixture was concentrated under reduced pressure. The resulting residue was • dissolved in a minimum methanol, and the solution was gradually diluted with ethyl acetate. The resulting precipitate was collected by filtration, washed with diisopropyl ether. The title compound was obtained as colorless powder (37 mg, 80.4%). MS (ES+) ; 382 (M+H) + free
XH~NMR (DMSO-d6) , δ (ppm): 2.14 (3H, s) , 2.80-3.00 (4H, m) , 7.00- 7.15(3H, m) , 7.35(1H, t, J=7.9Hz), 7.51(4H, br) , 10.01(1H, br) , 12.42 (1H, br) . Production Example 15: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5-bromo-l ,3-thiazol- 2-ylJacetamide hydrochloride Step 1-a
Di-tert-butyl { [ (4- {2- [2- (acetylamino) -1 ,3-thiazol-4- yl] ethyl Jphenyl) amino]methylidene}biscarbamate was prepared from the compound of Step 6 of Production Example 1 in a similar manner according to the following Step 5 of Production Example 18. mp. 275.5-276 °C XH-NMR (DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.11(3H, s) , 2.82-2.96 (4H, m) , 6.74(1H, s) , 7.18(2H, d, J=8.5Hz), 7.42(2H, d, J=8.5Hz), 9.94(1H, brs), 11.44(1H, brs), 12.09(1H, brs) . MS: 504 (M+H) + Step 1-b
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -1 , 3-thiazol-4- yl] ethyl Jphenyl) amino]methylidenejbiscarbamate (310 mg) prepared in a similar manner according to Step 5 of the following Production Example 18 was dissolved in methanol (6 ml) and tetrahydrofuran (3 ml) under nitrogen atmosphere. Then N-bromosuccinimide (164 mg) was added to the solution at 0 °C. The reaction mixture was stirred at room temperature for 4 hours, and concentrated in vacuo . Chloroform and saturated sodium hydrogen carbonate solution were added to the residue. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / ethyl acetate (2:1) as an eluent to give di-tert-butyl {[(4-{2-[2- (acetylamino) -5-bromo-l ,3-thiazol-4-yl] ethylJphenyl) amino] - methylidenejbiscarbamate (271.4 mg) as a colorless amorphous substance. iR-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.22 (3H, s) , 2.90(4H, s) , 7.13(2H, d, J=8.0Hz), 7.45(2H, d, J=8.0Hz). MS: 582 (M+H) + Step 2
Di-tert-butyl { [ (4- {2- [2- (acetylamino) -5-bromo-l ,3- thiazol-4-yl] ethylJphenyl) amino]methylidenejbiscarbamate (113 mg) and 4N hydrochloric acid in 1,4-dioxane solution (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo . The residue was washed with ethyl acetate to give N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -5- bromo-1 ,3-thiazol-2-ylJacetamide hydrochloride (16.8 mg) as a pale yellow amorphous solid.
XH-NMR (DMSO-d6) , δ (ppm) : 2.14(3H, s) , 2.82-2.97 (4H, m) , 7.14(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.40(3H, brs), 9.81(1H, brs), 12.41(1H, brs). MS: 382 (M+H) + free
Production Example 16 : Synthesis of N-[4-(2-{4- [ (aminooxy) methylJphenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide Step 1 [4- (Methoxycarbonyl) benzyl] (triphenyl) phosphonium bromide (6.06 g) and N,N-dimethylformamide (50 ml) were combined under nitrogen atmosphere. Then potassium tert-butoxide (1.66 g) and N- (4-formyl-l, 3-thiazol-2-yl) acetamide (2.1 g) prepared in a similar manner according to Step 4 of Production Example 1 were added to the suspension at 0 °C. The reaction mixture was stirred at room temperature for 6 hours , poured into ice- water, and extracted with ethyl acetate. The organic layer was washed with IN-hydrochloric acid, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1 -» 10:1) as an eluent, and triturated with ethyl ether to give a mixture of methyl 4-{ (Z) -2- [2- (acetylamino) - 1 ,3-thiazol-4-yl] ethenyl Jbenzoate and methyl 4-{(E)-2-[2- (acetylamino) -1 ,3-thiazol-4-yl] ethenyl Jbenzoate (Z : E = 3 : 1) (4.05 g) as a colorless solid, mp. 164-165.5 °C !H-NMR (DMSO-d6) , δ (ppm): 2.13(3Hx3/4, s) , 2.16(3Hxl/4, s) , 3.85(3H, s) , 6.61(2Hx3/4, s) , 7.05(lHx3/4, s) , 7.26(lHxl/4, d, J=15.5Hz), 7.27(lHxl/4, s) , 7.37(lHxl/4, d, J=15.5Hz), 7.64(2Hx3/4, d, J=8.5Hz), 7.69(2Hxl/4, d, J=8.5Hz), 7.90(2Hx3/4, d, J=8.5Hz), 7.94(2Hxl/4, d, J=8.5Hz), 12.05(1H, brs) .
MS: 303 (M+H) + Step 2
Methyl 4- { 2- [2- (acetylamino) -1 , 3-thiazol-4- yl] ethyl Jbenzoate was prepared in a similar manner according to Step 2 of Production Example 9. mp. 170-171 °C
XH-NMR (DMSO-de) , δ (ppm): 2.11 (3H, s) , 2.86-2.95 (2H, m) , 2.97- 3.05(2H, m) , 3.83(3H, s) , 6.72(1H, s) , 7.35(2H, d, J=8.5Hz), 7.87(2H, d, J=8.5Hz), 12.08(1H, brs). MS: 305 (M+H)+ Step 3
To a stirred solution of methyl 4- {2- [2- (acetylamino) - l,3-thiazol-4-yl] ethylJbenzoate (1.8 g) in dry tetrahydrofuran 5.12(2H, s) , 6.69(1H, s) , 7.23(2H, d, J=8.0Hz), 7.41(2H, d, J=8.0Hz), 7.86(4H, s) , 12.08(1H, brs). MS: 422 (M+H) + Step 5 N-{4-[2-(4-{ [ (l,3-Dioxo-l,3-dihydro-2H-isoindol-2- yl) oxy]methyl Jphenyl) ethyl] -1 ,3-thiazol-2-ylJ acetamide (200 mg) , methylhydrazine (0.038 ml) and dichloromethane (4 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours, and filtered in vacuo . The filtrate was washed with saturated sodium hydrogen carbonate solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was washed with acetonitrile to give N-[4-(2- {4- [ (aminooxy) methyl] phenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide (81.8 mg) as a colorless solid. mp. 130-130.5 °C . . .
XH-NMR (DMSO-d6) , δ (ppm) : 2.11 (3H, s) , 2.82-2.97 (4H, m) , 4.51(2H, s) , 6.01(2H, s) , 6.73(1H, s) , 7.17(2H, d, J=8.0Hz), 7.22(2H, d, J=8.0Hz), 12.09(1H, brs). MS: 292 (M+H) +
Production Example 17: Synthesis of N-{4-[2-(4- { [ (methyleneamino) oxy]methyl Jphenyl) ethyl] -1 ,3-thiazol-2- yl } acetamide N- [4- (2- {4- [ (Aminooxy) methyl] phenyl} ethyl) -1 ,3-thiazol-2- yl] acetamide (30 mg) prepared in a similar manner according to Production Example 16, 37% formaldehyde (8 μl) and dry methanol (1 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 6 hours and concentrated in vacuo . The residue was purified by preparative silica gel column chromatography with chloroform / methanol (20:1) as an eluent, and triturated with ethyl ether to give N-{4- [2- (4-{ [ (methyleneamino) oxy]methyl}-phenyl) ethyl] -1,3-
67 (36 ml) was added dropwise 1.0 M diisobutylaluminium hydride solution in toluene (20.7 ml) at -78 °C over 15 minutes under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1.5 hours , and then the reaction was quenched with water (1 ml) . The mixture was stirred at room temperature for 30 minutes, dried over anhydrous magnesium sulfate, and filtered through a pad of Celite. The solvent was evaporated in vacuo . The residual solid was washed with ethyl ether to give N- (4-{2- [4- (hydroxymethyl) phenyl] ethyl}-l ,3-thiazol-2- yl) acetamide (1.03 g) as a colorless solid, mp. 162-165 °C
XH-NMR (DMSO-d6) , δ (ppm) : 2.11 (3H, s) , 2.80-2.95 (4H, m) , 4.44(2H, d, J=5.5Hz), 5.09(1H, t, J=5.5Hz), 6.72(1H, s) , 7.14(2H, d, J=8.0Hz), 7.21(2H, d, J=8.0Hz), 12.08(1H, brs). MS: 277 (M+H) + Step 4
N- (4-{2- [4- (Hydroxymethyl) phenyl] ethyl}-l ,3-thiazol-2- yl)acetamide (250 mg) , 2-hydroxy-lH-isoindole-l ,3 (2H) -dione (155 mg) , triphenylphosphine (249 mg) and tetrahydrofuran (5 ml) were combined under nitrogen atmosphere, and then diethyl azodicarboxylate (0.15 ml) was added to the solution at 0 °C. The reaction mixture was stirred at room temperature for 6 hours , poured into saturated sodium hydrogen carbonate solution, and extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent, and triturated with ethyl acetate to give N-{4- [2- (4-{ [ (1 , 3- dioxo-1 ,3-dihydro-2H-isoindol-2-yl) oxy]methyl Jphenyl) ethyl] - 1 ,3-thiazol-2-ylJacetamide (218.2 mg) as a colorless solid, mp. 225-226 °C XH-NMR (DMSO-d6) , δ (ppm) : 2.11 (3H, s) , 2.82-3.00 (4H, ) ,
66 thiazol-2-yl} acetamide (20.9 mg) as a colorless solid, mp. 136.5-137 °C
XH-NMR (DMSO-d6) , δ (ppm): 2.11 (3H, s) , 2.83-2.97 (4H, m) , 5.01(2H, s) , 6.61(1H, d, J=7.5Hz), 6.73(1H, s) , 7.09(1H, d, J=7.5Hz), 7.18(2H, d, J=8.0Hz), 7.24(2H, d, J=8.0Hz), 12.08 (1H, brs) . MS: 304 (M+H) +
Production Example 18: Synthesis of N-{5-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- yljacetamide hydrochloride Step 1
A solution of 1 , 1 ,3 , 3-tetramethoxypropane (10 g) and hydrochloric acid concentrate (0.43 ml) in water (11 ml) was stirred at room temperature for 10 minutes. Bromine (3.14 ml) was added dropwise to the solution at room temperature over 50 minutes . The reaction mixture was stirred at room temperature for 20 minutes, and concentrated in vacuo . The residual solid was washed with water to give 2-bromomalonaldehyde (3.6 g) as a yellow solid. mp. 147-148 °C
XH-NMR (CDC13) , δ (ppm): 4.73-4.80 (1H, m) , 8.47 (2H, brs). MS: 149(M-H)+ Step 2
N'- ( (E) -Ethanoyl) carbamimidothioic acid (2.74 g) and acetone (20 ml) were combined under nitrogen atmosphere. Then 2-bromomalonaldehyde (3.5 g) was added to the solution under reflux. The reaction mixture was refluxed for an hour, and cooled to room temperature. The precipitate was filtered in vacuo . The solid was washed with water and acetone, and purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N- (5-formyl- 1 ,3-thiazol-2-yl) acetamide (1.21 g) as an off-white solid, mp. 235-235.5 °C XH-NMR (DMSO-d6) , δ (ppm): 2.21 (3H, s) , 8.41 (1H, s) , 9.95 (1H, s) , 12.71(1H, brs) . MS: 169(M-H) + Step 3 5 N-{5- [ (Z) -2- (4-Nitrophenyl) ethenyl] -1 , 3-thiazol-2- yljacetamide was prepared in a similar manner according to Step 5 of Production Example 1.
, mp. 221-223 °C
XH-NMR (DMSO-de) , δ (ppm): 2.07 (3H, s) , 6.63 (1H, d, J=12.0Hz), 0 6.92(1H, d, J=12.0Hz), 7.55(1H, s) , 7.62(2H, d, J=9.0Hz), 8.24(2H, d, J=9.0Hz), 12.16(1H, brs). MS: 290 (M+H) + Step 4
A mixture of N-{5- [ (Z) -2- (4-nitrophenyl) ethenyl] -1 ,3- 5 thiazol-2-yl} acetamide (1 g) and 10% palladium carbon (1.04 g) in ethyl acetate (100 ml) and N,N-dimethylformamide (20 ml) was stirred under 4 atm hydrogen at ambient temperature for 4 hours. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo . The residue was 0 purified by flash column chromatography over silica gel with chloroform / methanol (30:1 — 20:1) as an eluent, and triturated with ethyl ether to give N-{5-[2-(4- aminophenyl) ethyl] -1 ,3-thiazol-2-ylJacetamide (240.9 mg) as an off-white solid. 5 mp. 218-219.5 °C
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.70 (2H, t, J=7.5Hz), 2.92(2H, t, J=7.5Hz), 4.85(2H, s) , 6.47 (2Hr d, J=8.5Hz), 6.86(2H, d, J=8.5Hz), 7.08(1H, s) , 11.86(1H, brs). MS: 262 (M+H) + 0 Step 5
N-{5- [2- (4-Aminophenyl) ethyl] -1 ,3-thiazol-2-ylJ acetamide (100 mg) , N, ' -bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (119 mg) , N,N-dimethylformamide (1 ml) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at 50 °C for 5.5 hours. After cooled to room temperature, the reaction mixture was concentrated in vacuo . The residue was purified by preparative silica gel column chromatography with n-hexane / ethyl acetate (1:2) as an eluent to give di-tert-butyl { [ (4- {2- [2- (acetylamino) -1 , 3-thiazol-5-yl] ethyl Jphenyl) amino] - methylidenejbiscarbamate (93.9 mg) as a colorless solid, mp. 203-205 °C ^-NMR (DMSO-de) , δ (ppm) : 1.40 (9H, s) , 1.51 (9H, s) , 2.10 (3H, s) , 2.87 (2H, t, J=7.5Hz), 3.02(2H, t, J=7.5Hz), 7.11(1H, s) , 7.21(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 9.96(1H, brs), 11.43(1H, brs), 11.88(1H, brs). MS: 504 (M+H) + Step 6
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 105-107 °C XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.91 (2H, t, J=7.5Hz), 3.04(2H, t, J=7.5Hz), 7.14(1H, s) , 7.14(2H, d, J=8.5Hz),
7.32(2H, d, J=8.5Hz), 7.46(3H, brs), 9.89(1H, s) , 11.95(1H, brs) .
MS: 304 (M+H) + free
Production Example 19 : Synthesis of N-{4-[2-(4- { [imino (methylamino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide
A mixture of methyl N- (4- {2- [2- (acetylamino) -1 , 3-thiazol- 4-yl] ethyl Jphenyl) imidothiocarbamate hydriodide (50 mg) prepared in a similar manner according to Production Example 4, 40% methylamine in methanol (0.056 ml) and ethanol (1 ml) was stirred at ambient temperature for 20 hours. The precipitated crystals were filtered and washed with ethanol to give N-{4-[2-(4-{ [imino (methylamino) methyl] aminojphenyl) - ethyl] -1 ,3-thiazol-2-ylJ acetamide (18 mg) .
XH-NMR (DMSO-de), δ (ppm): 2.11 (3H, s) , 2.64 (3H, s) , 2.83 (4H, s) , 6.67 (2H, d, J=7Hz) , 6.73(1H, s) , 7.01(2H, d, J=7Hz) . MS (M+H) =318 Production Example 20: Synthesis of N-{4- [2- (4-{ [amino (imino) - methyl] aminojphenyl) ethyl] -5-chloro-l ,3-thiazol-2-ylJacetamide hydrochloride Step 1
Di-tert-butyl { [ (4-{2- [2- (acetylamino) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate (150 mg) prepared in a similar manner according to Step 5 of Production Example 18 was dissolved in methanol (1.5 ml) and tetrahydrofuran (3 ml) under nitrogen atmosphere. Then N- chlorosuccinimide (59.7 mg) was added to the solution at 0 °C. The reaction mixture was stirred at room temperature for 29 hours, and diluted in ethyl acetate. The organic solution was washed with saturated sodium hydrogen carbonate solution, - water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was washed with ethyl ether to give di-tert- butyl { [ (4-{2- [2- (acetylamino) -5-chloro-l , 3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate (111 mg) as an off-white solid, mp. 220-221 °C XH-NMR (DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.13 (3H, s) , 2.81-2.94 (4H, m) , 7.15(2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 9.95(1H, brs), 11.43(1H, brs), 12.38(1H, brs). MS: 538 (M+H) + Step 2 The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 82-84 °C XH-NMR (DMSO-de), δ (ppm) : 2.14 (3H, s) , 2.82-2.97 (4H, m) , 7.14(2H, d, J=8.5Hz) , 7.25(2H, d, J=8.5Hz) , 7.42(3H, brs) , 9.85(1H, brs) , 12.38(1H, brs) . MS: 338 (M+H) + free
Production Example 21: Synthesis of N-(4-{2-[4- ({ [amino (imino) methyl] amino Jmethyl) phenyl] ethyl J-l, 3-thiazol- 2-yl) acetamide hydrochloride Step 1
A mixture of N- (4-{2- [4- (aminomethyl) phenyl] ethyl}-l ,3- thiazol-2-yl) acetamide (20 mg) prepared in a similar manner according to Production Example 12, N,N'-bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (23 mg) and tetrahydrofuran (0.5 ml) was stirred at ambient temperature for 1 hour. The reaction mixture was concentrated in vacuo, and the residue was purified by flash column chromatography on silica-gel with chloroform as an eluent. The crystalline residue was collected and washed with diisopropyl ether to give di-tert-butyl { [ (4- {2- [2- (acetylamino) -1 , 3-thiazol-4- yl] ethyljbenzyl) amino]methylidene}biscarbamate (22 mg) . XH-NMR (CDC13) , δ (ppm): 1.47 (9H, s) , 1.50 (9H, s) , 2.24 (3H, s) , 2.87-3.03 (4H, m) , 6.50(1H, s) , 7.13(2H, d, J=7Hz) , 7.22(2H, d, J=7Hz) . MS (M+H) =518 Step 2
A mixture of di-tert-butyl {[ (4- {2- [2- (acetylamino) -1 ,3- thiazol-4-yl] ethyljbenzyl) amino]methylidenejbiscarbamate (20 mg) , dichloromethane (2 drops) and 4N hydrogen chloride in 1,4-dioxane (0.5 ml) was stirred for 15 hours. The precipitated crystals were filtered and washed with 1,4- dioxane to give N- (4-{2- [4- ( { [amino (imino) methyl] aminoj- methyl) phenyl] ethyl J-l, 3-thiazol-2-yl) acetamide hydrochloride (13 mg) .
XH-NMR (DMSO-de), δ (ppm) : 2.12(3H, s) , 2.80-3.00 (4H, m) , 4.32(2H, d, J=7Hz) , 6.73(1H, s) , 7.20(4H, s) , 8.04(1H, t, J=7Hz ) . MS (M+H) =318
Production Example 22: Synthesis of ethyl 2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazole-5- carboxylate hydrochloride Step 1
Ethyl 4-chloro-3-oxobutanoate (35 g) was dissolved in dichloromethane (70 ml), and then sulfuryl chloride (17.1 ml) in dichloromethane (20 ml) was added dropwise to the solution at 0 °C over 15 minutes under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 hours , and concentrated in vacuo . The residual oil, N'-((E)- ethanoyl) carbamimidothioic acid (25.1 g) and acetone (600 ml) were combined. The reaction mixture was refluxed for 2.5 hours. After cooled to room temperature, the mixture was concentrated in vacuo . The residual solid was washed with water and isopropyl ether to give -ethyl 2- (acetylamino) -4- (chloromethyl) -1 ,3-thiazole-5-carboxylate (21.2 g) as a pale yellow solid. mp. 164-165 °C
XH-NMR (DMSO-de), δ (ppm): 1.30 (3H, t, J=7.0Hz), 2.19 (3H, s) ,
4.29(2H, q, J=7.0Hz), 5.00(2H, s) , 12.72(1H, s) .
MS: 263 (M+H) +
Step 2: ethyl 2- (acetylamino) -4- [ (E) -2- (4- nitrophenyl) ethenyl] -1 , 3-thiazole-5-carboxylate
To a stirring solution of ethyl 2- (acetylamino) -4- (chlorometh l) -1 ,3-thiazole-5-carboxylate (1.0 g, 3.81 mmol) in N,N-dimethylformamide (20 mL) was added triphenylphosphine (1.2 g, 4.57 mmol) at room temperature. The resultant mixture was stirred at 65 °C for 5 hours. To the mixture was added potassium tert-butoxide (555 mg, 4.95 mmol) at 5 °C, and the resultant mixture was stirred at 5 °C for 30 minutes. p-Nitrobenzaldehyde (805 mg, 5.33 mmol) was added at 5 °C. After stirring for 1 hour at room temperature, the reaction was quenched with water, and the mixture was filtered to give the title compound (1.0 g, 72.7%) as a yellow solid. XH-NMR (CDC13) , δ (ppm): 1.40 (3H, t, J=7.2Hz), 2.33 (3H, s) , 4.38(2H, q, J=7.2Hz), 7.59(1H, d, J=16.0Hz), 7.70(2H, d, J=8.8Hz), 8.18(1H, d, J=16.0Hz), 8.22(2H, d, J=8.8Hz), 8.90 (1H, m) . Step 3
Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1,3- thiazole-5-carboxylate was prepared in a similar manner according to Step 6 of Production Example 1. H-NMR (CDCI3) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.27 (3H, s) , 2.84(2H, m) , 3.28(2H, m) , 3.56(2H, m) , 4.31(2H, q, J=7.0Hz), 6.61(2H, d, J=8.3Hz), 7.01(2H, d, J=8.3Hz), 9.12(1H, m) . Step 4
Ethyl 2- (acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert-butoxycarbonyl) imino ] methyl }- amino) phenyl] ethyl}-l ,3-thiazole-5-carboxylate was prepared in a similar manner according to Step 5 of Production Example 18. !H-NMR (CDCI3) , δ (ppm) : 1.36 (3H, t, J=7.4Hz) , 1.49 (9H, s) , 1.53(9H, s) , 2.25(3H, s) , 2.94(2H, m) , 3.34(2H, m) , 4.31(2H, q, J=7.4Hz) , 7.15(2H,' d, J=8.4Hz) , 7.41(2H, d, J=8.4Hz) , 9.69(1H, m) , 10.20(1H, s) , 11.63(1H, s) . Step 5 The title compound was prepared in a similar manner according to Step 2 of Production Example 15.
XH-NMR (DMSO-de), δ (ppm): 1.28 (3H, t, J=7.0Hz), 2.18 (3H, s) , 2.94(2H, m) , 3.28(2H, m) , 4.23(2H, q, J=7.0Hz), 7.16(2H, d, J=8.4Hz), 7.29(2H, d, J=8.4Hz), 7.37 (3H, s) , 9.71(1H, s) , 12.55(1H, s) .
Production Example 23: Synthesis of N-{4-[2-(4-
{ [ (ethylamino) (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide The title compound was prepared in a similar manner according to Production Example 19.
XH-NMR (DMSO-de), δ (ppm): 1.13(3H, t, J=6Hz) , 2.11(3H, s) , 2.70-3.00(6H, m) , 6.70(1H, s) , 6.77 (2H, d, J=7Hz) , 7.17(2H, d, J=7Hz) .
MS (M+H) =332
Production Example 24: Synthesis of benzyl 4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- carbamate Step 1
To an ice-cold mixture of ethyl 2-amino-l ,3-thiazole-4- carboxylate (5 g) , pyridine (3.36 ml) and dichloromethane (50 ml) was added benzyloxycarbonyl chloride (3.1 ml) , and the mixture was stirred at ambient temperature for 1 hour. The reaction mixture was washed with saturated aqueous sodium hydrogen bicarbonate (30 ml) , dried over sodium sulfate and concentrated in vacuo . The crystalline residue was collected and washed with diisopropyl ether to give ethyl 2- { [ (benzyloxy) carbonyl] amino J-l ,3-thiazole-4-carboxylate (5.1 g).
XH-NMR (CDCI3) , δ (ppm): 1.48 (3H, t, J=7Hz) , 4.38 (2H, q,
J=7Hz) , 5.27 (2H, s) , 7.36-7.44 (5H, m) , 7.82(1H, s) .
MS (M+H) =307
Step 2 Benzyl 4- (hydroxymethyl) -1 ,3-thiazol-2-ylcarbamate was prepared in a similar manner according to Step 2 of Production
Example 6.
XH-NMR (CDCI3) , δ (ppm): 4.56 (2H, s) , 5.27 (2H, s) , 6.80 (1H, s) ,
7.30-7.46 (5H, m) . MS (M+H) =265
Step 3
Benzyl 4-formyl-l ,3-thiazol-2-ylcarbamate was prepared in a similar manner according to Step 3 of Production Example 6. XH-NMR (CDCI3) , δ (ppm) : 5 . 29 (2H , s ) , 7 . 35-7 . 45 (5H , m) ,
7 . 81 ( 1H , s ) , 9 . 80 ( 1H , s ) .
MS (M+H) =263
Step 4 Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylcarbamate was prepared in a similar manner according to Step
4 of Production Example 6.
XH-NMR (DMSO-de), δ (ppm): 5.23(2x3/5H, s) , 5.25(2x2/5H, s) ,
6.56-6.70 (1H, m) , 7.23(1H, s) , 7.30-7.50 (5H, m) , 7.82(2x2/5H, d, J=7Hz) , 7.92 (2x3/5H d, J=7Hz) , 8.14(2x3/5H, d, J=7Hz) ,
8.21(2x2/5H, d, J=7Hz) .
MS (M+H) =382
Step 5
A mixture of benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3- thiazol-2-ylcarbamate (1.4 g) , palladium on carbon (140 mg) and methanol (2 ml) was stirred under hydrogen atmosphere (4 atm) at ambient temperature for 8 hours . The catalyst was filtered off, and the filtrate was concentrated in vacuo to give benzyl 4- [2- (4-aminophenyl) ethyl] -1 ,3-thiazol-2- ylcarbamate (1.2 g) .
XH-NMR (CDCI3) , δ (ppm): 2.77-2.90 (4H, m) , 5.22 (2H, s) ,
6.43(1H, s) , 6.60(2H, d, J=7Hz) , 6.92(2H, d, J=7Hz) , 7.32-
7.40 (5H, m) .
MS (M+H) =354 Step 6
A mixture of benzyl 4- [2- (4-aminophenyl) ethyl] -1 ,3- thiazol-2-ylcarbamate (25 mg) , cyanamide (6.0 mg) , 4N hydrogen chloride in ethyl acetate (0.018 ml) and ethanol (1 ml) was stirred at 100 °C for 72 hours. The reaction mixture was concentrated in vacuo . To the residue was added ethyl acetate
(5 ml) and saturated aqueous sodium hydrogen bicarbonate (5 ml) . The precipitated solid was filtered and washed with ethylacetate and water to give benzyl 4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- carbamate (15 mg) .
XH-NMR (DMSO-d6) , δ (ppm): 2.63-2.75 (4H, m) , 5.07 (2H, s) , 6.40(1H, s) , 6.94(2H, d, J=7Hz) , 7.25-7.40 (7H, m) . MS (M+H) =396
Production Example 25: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- yljbenzamide hydrochloride
Step 1 Benzyl 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3-thiazol-2- ylcarbamate (2.7 g) prepared in a similar manner according to Step 4 of Production Example 24 and 6N hydrochloric acid (50 ml) were combined. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the precipitate was filtered in vacuo . The solid was washed with water and acetonitrile to give 4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 , 3- thiazol—2-amine (1.34 g) as a yellow solid. mp. 278-278.5 °C
XH-NMR (DMSO-de), δ (ppm) : 7.02 (1H, s) , 7.33 (2H, s) , 7.77 (2H, d, J=8.5Hz), 8.25 (2H, d, J=8.5Hz). MS: 248 (M+H) + Step 2
4- [ (E) -2- (4-Nitrophenyl) ethenyl] -1 , 3-thiazol-2-amine (300 mg) and N,N-dimethylaniline (4 ml) were combined under nitrogen atmosphere, and then benzoyl chloride (0.31 ml) was added dropwise to the suspension. The reaction mixture was stirred at 110 °C for 2 hours. After cooled to room temperature, the mixture was diluted with ethyl acetate. The organic solution was washed with IN hydrochloric acid, water, saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was washed with ethyl ether to give N-{4- [ (E) -2- (4- nitrophenyl) ethenyl] -l,3-thiazol-2-yl}benzamide (298.6 mg) as a yellow solid. mp. 224.5-225 °C
XH-NMR (DMSO-de), δ (ppm): 7.40 (1H, d, J=16.0Hz), 7.45 (1H, s) , 7.53(1H, d, J=16.0Hz), 7.56(2H, t, J=7.0Hz), 7.66(1H, t,
J=7.0Hz), 7.84(2H, d, J=8.5Hz), 8.13(2H, d, J=7.0Hz), 8.23(2H, d, J=8.5Hz), 12.80(1H, brs).
MS: 352 (M+H) +
Step 3 N-{4-[2-(4-Aminophenyl) ethyl] -1 ,3-thiazol-2-yl}benzamide was prepared in a similar manner according to Step 2 of
Production Example 9.
XH-NMR (CDCI3) , δ (ppm): 2.82 (4H, s) , 3.57 (2H, brs), 6.53 (1H, s) , 6.61(2H, d, J=8.0Hz), 6.92(2H, d, J=8.0Hz), 7.50(2H, t, J=7.0Hz), 7.60(1H, t, J=7.0Hz), 7.93(2H, d, J=7.0Hz),
10.15 (1H, brs) .
MS: 324 (M+H) +
Step 4
Di-tert-butyl { [ (4-{2- [2- (benzoylamino) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. mp. 143-144 °C
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.95 (4H, s) , 6.86(1H, s) , 7.22(2H, d, J=8.5Hz), 7.44(2H, d, J=8.5Hz), 7.54(2H, t, J=7.5Hz), 7.63(1H, t, J=7.5Hz), 8.10(2H, d,
J=7.5Hz), 9.94(1H, s) , 11.44(1H, brs), 12.66(1H, brs).
MS: 566 (M+H) +
Step 5
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 229-232 °C
XH-NMR (DMSO-de), δ (ppm) : 2.91-3.05 (4H, m) , 6.88 (1H, s) ,
7.15(2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.44(3H, brs), 7.54(2H, t, J=7.5Hz) , 7.64(1H, t, J=7.5Hz) , 8.10(2H, d, J=7.5Hz) , 9.88 (1H, s) . MS: 366 (M+H) + free
Production Example 26: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- [4-
(methylsulfonyl) phenyl] -1 , 3-thiazol-2-yl } acetamide hydrochloride Step 1
4- (Methylsulfanyl) benzaldehyde (31.8 g) , (acetylamino) acetic acid (24.5 g) and acetic anhydride (35 ml) were combined, and then sodium acetate (8.57 g) was added to the suspension at room temperature under nitrogen atmosphere. The reaction mixture was refluxed for 3.5 hours. After cooled to room temperature, the mixture was poured into ice-water and ethyl acetate with stirring, and filtered in vacuo. The filtrate was separated. The organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue and the previously obtained solid were combined, and the mixture was purified by flash column chromatography over silica gel with chloroform / ethyl acetate (30:1) as an eluent, and triturated with isopropyl ether to give (4Z) -2-methyl-4- (4- (methylsulfanyl)benzylidene) -1 ,3-oxazol-5 (4H) -one (17.8 g) as a brown solid. mp. 154-155 °C
XH-NMR (DMSO-de), δ (ppm): 2.38 (3H, s) , 2.53 (3H, s) , 7.19 (1H, s) , 7.36(2H, d, J=8.5Hz), 8.12(2H, d, J=8.5Hz). Step 2
(4Z) -2-Methyl-4- (4- (methylsulfanyl) benzylidene) -1 ,3- oxazol-5 (4H) -one (17.5 g) , 1,4-dioxane (100 ml) and 4N- hydrochloric acid (27 ml) were combined. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the mixture was concentrated in vacuo. Ethyl acetate and water were added to the residue, and the precipitate was filtered in vacuo to give 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoic acid (6.7 g) as a pale brown solid, mp. 165-167 °C XH-NMR (DMSO-de), δ (ppm): 2.48 (3H, s) , 6.37 (1H, s) , 7.23 (2H, d, J=8.5Hz), 7.70(2H, d, J=8.5Hz), 9.44(1H, s) . MS: 209(M-H)+ Step 3
3- (4- (Methylsulfanyl) phenyl) -2-oxopropanoic acid (16.2 g) , N,N-dimethylformamide (81 ml) and 1,8- diazabicyclo [5.4.0]undec-7-ene (11.5 ml) were combined at 0 °C under nitrogen atmosphere. The mixture was stirred at the same temperature for an hour, and then iodomethane (9.59 ml) was added to the solution at the same temperature. The reaction mixture was stirred at room temperature for 4 hours , poured into IN-hydrochloric acid, and extracted with ethyl acetate (twice) . The combined organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / ethyl acetate (30:1) as an eluent, and triturated with isopropyl ether / n-hexane to give methyl 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoate (8.6 g) as a dark yellow solid. mp. 112-113 °C
XH-NMR (DMS0-d6), δ (ppm): 2.48 (3H, s) , 3.79 (3H, s) , 6.41 (1H, s) , 7.24(2H, d, J=8.5Hz), 7.72(2H, d, J=8.5Hz), 9.52(1H, brs). MS: 223(M-H) + Step 4 Methyl 3- (4- (methylsulfanyl) phenyl) -2-oxopropanoate (2.84 g) , pyridinium tribromide (4.95 g) , dichloromethane (140 ml) and acetic acid (0.5 ml) were combined at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at 0 °C for 2 hours, and poured into water. The mixture was extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual oil was dissolved in ethanol (55 ml) , and then thiourea (1.25 g) was added to the solution. The reaction mixture was refluxed for 1 hour under nitrogen atmosphere. After cooled to 0 °C, water was added to the solution. The precipitate was filtered in vacuo to give methyl 2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazole-4-carboxylate (2.67 g) as a brown solid, mp. 184-185 °C
XH-NMR (DMSO-d6) , δ (ppm): 2.50 (3H, s) , 3.64 (3H, s) , 7.25 (2H, d, J=8.5Hz), 7.34 (2H, d, J=8.5Hz). MS: 281 (M+H) + Step 5
Methyl 2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazole-4- carboxylate (8.8 g) was dissolved in pyridine (88 ml), and then acetyl chloride (6.7 ml) was added dropwise to the solution at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 30 minutes and at 50 °C for 2 hours. After cooled to 0 °C, water was added to the solution. The precipitate was filtered in vacuo , and the solid was washed with ethyl ether to give methyl 2- (acetylamino) -5- [4- (methylthio) phenyl] -1 ,3-thiazole-4- carboxylate (9.3 g) as an off-white solid, mp. 253-254.5 °C
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.52 (3H, s) , 3.70 (3H, s) , 7.30(2H, d, J=8.5Hz), 7.44(2H, d, J=8.5Hz). MS: 323 (M+H) + Step 6
Methyl 2- (acetylamino) -5- [4- (methylthio) phenyl] -1 ,3- thiazole-4-carboxylate (200 mg) was dissolved in tetrahydrofuran (2 ml) , and then lithium aluminium hydride (35.3 mg) was added portionwise to the solution at 0 °C. The reaction mixture was stirred at 0 °C for 30 minutes and at room temperature for 30 minutes, and quenched with methanol. Ethyl acetate and IN hydrochloric acid were added to the mixture, and extracted. The aqueous layer was extracted with ethyl acetate (twice) . The combined organic layer was washed with saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was dissolved in methanol (0.4 ml) and chloroform (7 ml) . Then manganase (IV) oxide (1.08 g) was added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give N-{4-formyl-5- [4- (methylthio) phenyl] -1 , 3-thiazol-2- ylj acetamide (153.6 mg) as a pale brown amorphous substance. XH-NMR (DMSO-d6), δ (ppm): 2.18 (3H, s) , 2.54 (3H, s) , 7.38 (2H, d, J=8.5Hz), 7.58(2H, d, J=8.5Hz), 9.77(1H, s) , 12.59(1H, brs) .
MS: 293 (M+H) + Step 7
N-{5- [4- (Methylthio) phenyl] -4- [ (E) -2- (4- nitrophenyl) ethenyl] -1 ,3-thiazol-2-ylJ acetamide was prepared in a similar manner according to Step 1 of Production Example
mp. 228-230 °C
XH-NMR (DMSO-de), δ (ppm): 2.19 (3H, s) , 2.54 (3H, s) , 7.32 (1H, d, J=16.0Hz), 7.40(2H, d, J=8.5Hz), 7.46(1H, d, J=16.0Hz),
7.47 (2H, d, J=8.5Hz), 7.79(2H, d, J=9.0Hz), 8.19(2H, d,
J=9.0Hz), 12.38 (1H, brs).
MS: 412 (M+H) +
Step 8 Potassium peroxymonosulfate (408 mg) was suspended in water (1 ml) and tetrahydrofuran (1 ml), and then N-{5-[4-
(methylthio) phenyl] -4- [ (E) -2- (4-nitrophenyl) ethenyl] -1 ,3- thiazol-2-yl} acetamide (182 mg) in tetrahydrofuran (3 ml) was added dropwise to the suspension at 0 °C. The reaction mixture was stirred at room temperature for 2 hours , and then water was added to the suspension. The precipitate was filtered in vacuo . The solid was washed with water and ethyl acetate to give N-{5-[4-(methylsulfonyl)phenyl]-4-[ (E)-2-(4- nitrophenyl) ethenyl] -1 ,3-thiazol-2-ylJacetamide (83 mg) as a yellow solid. mp. 294-295 °C
XH-NMR (DMSO-de), δ (ppm): 2.21 (3H, s) , 3.30 (3H, s) , 7.40 (1H, d, J=16.0Hz), 7.54(1H, d, J=16.0Hz), 7.82(2H, d, J=8.5Hz), 7.84(2H, d, J=8.5Hz), 8.05(2H, d, J=8.5Hz), 8.20(2H, d,
J=8.5Hz), 12.51(1H, brs).
MS: 442(M-H)+ - -
Step 9
N-{4-[2-(4-Aminophenyl)ethyl]-5-[4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide was prepared in a similar manner according to Step 2 of Production
Example 9. mp. 202-204 °C
XH-NMR (DMSO-d6), δ (ppm) : 2.17 (3H, s) , 2.77-2.88 (4H, m) , 3.24(3H, s) , 6.84(2H, brs), 6.45(2H, d, J=8.5Hz), 6.77 (2H, d,
J=8.5Hz), 7.49 (2H, d, J=8.5Hz), 7.91 (2H, d, J=8.5Hz),
12.34 (1H, brs) .
MS: 416 (M+H) +
Step 10 Di-tert-butyl {[ (4- {2- [2- (acetylamino) -5- (4-
(methylsulfonyl) phenyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. XH-NMR (DMSO-de), δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.17 (3H, s) , 2.97 (4H, s) , 3.24(3H, s) , 7.11(2H, d, J=8.5Hz), 7.38(2H, d, J=8.5Hz), 7.56(2H, d, J=8.5Hz), 7.92(2H, d, J=8.5Hz), 9.92(1H, s) , 11.43(1H, brs), 12.34(1H, brs). MS: 658 (M+H) + Step 11
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 145-146.5 °C 3-H-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.99 (4H, brs), 3.25 (3H, s) , 7.11(2H, d, J=8.0Hz), 7.22(2H, d, J=8.0Hz), 7.38(3H, brs), 7.57 (2H, d, J=8.0Hz), 7.94(2H, d, J=8.0Hz), 9.79(1H, s) , 12.36 (1H, brs) . MS: 458 (M+H) + free Production E ample 27 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-methyl-1 , 3- thiazole-5-carboxamide hydrochloride Step 1
Ethyl 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 ,3- thiazole-5-carboxylate (310 mg) prepared in a similar manner according to Step 3 of Production Example 22 was dissolved in tetrahydrofuran (6 ml) under nitrogen atmosphere. Then di (tert-butyl) dicarbonate (223 mg) in tetrahydrofuran (1 ml) was added to the solution at room temperature. The reaction mixture was refluxed for 2 hours . After cooled to room temperature, the mixture was concentrated in vacuo . The residual solid was washed with ethyl ether to give ethyl 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl }- ethyl) -1 ,3-thiazole-5-carboxylate (370.7 mg) as an off-white solid. mp. 213-214 °C
XH-NMR (DMSO-d6) , δ (ppm) : 1.26(3H, t, J=7.0Hz), 1.46(9H, s) ,
2.17 (3H, s) , 2.85(2H, t, J=7.5Hz), 3.23(2H, t, J=7.5Hz), 4.22(2H, q, J=7.0Hz), 7.04(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 9.23 (1H, brs), 12.55(1H, brs). MS: 434 (M+H) + Step 2 Ethyl 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) - amino]phenyl}ethyl) -1 ,3-thiazole-5-carboxylate (3 g) , 1N- aqueous sodium hydroxide solution (17.3 ml) and ethanol (30 ml) were combined, and the mixture was refluxed for 5 hours. After cooled to room temperature, the organic solvent was removed in vacuo . The aqueous solution was acidified (pH=4) with IN-hydrochloric acid, and extracted with ethyl acetate (twice) . The combined organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was dissolved in pyridine (45 ml) , and then acetyl chloride (1.48 ml) was added dropwise to the solution at 0 °C under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 13 hours , and pyridine was removed in vacuo . Water was added to the residue, and acidified with IN- hydrochloric acid. The precipitate was collected in vacuo . The solid was washed with water and ethyl ether to give 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) - amino] phenyl} ethyl) -1 ,3-thiazole-5-carboxylic acid (2.23 g) as an off-white solid, mp. 237-238 °C XH-NMR (DMSO-d6), δ (ppm) : 1.46 (9H, s) , 2.16 (3H, s) , 2.85(2H, m) , 3.23(2H, m) , 7.04(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 9.24 (1H, s) , 12.46 (1H, s) . MS: 404(M-H) + Step 3 A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1 , 3-thiazole-5- carboxylic acid (80 mg) , 30% methylamine in ethanol solution (0.02 ml), 1-hydroxybenzotriazole (29.3 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (39.7 mg) in dichloromethane (1 ml) and N,N-dimethylformamide (0.5 ml) was stirred at ambient temperature for 20 hours. The reaction mixture was poured into saturated sodium hydrogen carbonate solution, and extracted with chloroform. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give tert-butyl 4- (2- {2- (acetylamino) -5- [ (methylamino) carbonyl] -1 ,3-thiazol-4-yl} ethyl) phenylcarbamate (92.8 mg) as an off-white amorphous substance.
XH-NMR (DMSO-d6) , δ (ppm): 1.46 (9H, s) , 2.15 (3H, s) , 2.69 (3H, d, J=4.5Hz), 2.78-2.86 (2H, m) , 3.12-3.20 (2H, m) , 7.06(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.91(1H, q, J=4.5Hz), 9.22(1H, brs) , 12.34 (1H, brs) . MS: 419 (M+H) + Step 4 tert-Butyl 4- (2- {2- (acetylamino) -5- [ (methylamino) carbonyl]~1 ,3-thiazol-4-yl} ethyl) phenylcarbamate (95 mg) and trifluoroacetic acid (2 ml) were combined at 0 °C. x^.-, reaction mixture was stirred at room temperature for an hour, and concentrated in vacuo . The residue was dissolved in chloroform. The organic solution was washed with IN sodium hydroxide solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residue was purified by preparative silica gel column chromatography with chloroform / methanol (10:1) as an eluent to give 2- (acetylamino) -4- [2- (4- aminophenyl) ethyl] -N-methyl-1 ,3-thiazole-5-carboxamide (49 mg) as an off-white amorphous substance. ! H- MR (DMSO-de), δ (ppm) : 2.15(3H, s) , 2.68 (3H, d, J=4.5Hz), 2.67-2.75(2H, m) , 3.05-3.15 (2H, m) , 4.83(2H, brs), 6.47 (2H, d, J=8.5Hz), 6.84(2H, d, J=8.5Hz), 7.85(1H, q, J=4.5Hz), 12.33(1H, brs) . MS : 319 (M+H) + Step 5
Di-tert-butyl { [ (4- {2- [2- (acetylamino) -5- (methylaminocarbonyl) -1 ,3-thiazol-4-yl] ethyljphenyl) amino] - methylidenejbiscarbamate was prepared in a similar manner according to Step 5 of Production Example 18. mp. 245-246 °C
XH-NMR (DMSO-de), δ (ppm): 1.40 (9H, s) , 1.51 (9H, s) , 2.14 (3H, s) , 2.68(3H, d, J=4.5Hz), 2.85-2.94 (2H, m) , 3.14-3.25 (2H, m) , 7.17(2H, d, J=8.5Hz), 7.41(2H, d, J=8.5Hz), 7.88(1H, q, J=4.5Hz), 9.94(1H, s) , 11.44(1H, brs), 12.38(1H, brs). MS: 561 (M+H) + Step 6
The title compound was prepared in a similar manner according to Step 2 of Production Example 15. mp. 101-104 °C
XH-NMR (DMSO-de), δ (ppm) :- 2.16 (3H, s) , 2.67 (3H, d, J=4.5Hz), 2.86-2.96 (2H, m) , 3.16-3.26 (2H, m) , 7.14(2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz), 7.41(3H, brs), 7.99(1H, q, J=4.5Hz), 9.81(1H, s) , 12.36(1H, brs). MS: 361 (M+H) + free
Production Example 28 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-phenyl-1 ,3- thiazole-5-carboxamide hydrochloride Step 1
A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1 , 3-thiazole-5-carbox lic acid (80 mg) , aniline (0.019 ml), benzotriazole-1-yl-oxy-tris- pyrrolidino-phosphonium hexafluorophosphate (113 mg) and N,N- diisopropylethylamine (0.076 ml) in N,N-dimethylformamide (2 ml) was stirred at ambient temperature for 21 hours and at 55 °C for 3 hours. The reaction mixture was poured into IN hydrochloric acid, and extracted with chloroform. The organic layer was washed with water, saturated sodium hydrogen carbonate solution and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated in vacuo . The residual solid was washed with ethyl ether to give tert-butyl 4-{2- [2- (acetylamino) -5- (anilinocarbonyl) -1 ,3- thiazol-4-yl] ethyl}phenylcarbamate (57.2 mg) as a colorless solid. mp. 199-200 °C XH-NMR (DMSO-d6), δ (ppm): 1.46 (9H, s) , 2.18 (3H, s) , 2.81- 2.91(2H, m) , 3.14-3.24(2H, m) , 7.05(2H, d, J=8.5Hz), 7.08(1H, t, J=8.5Hz), 7.26-7.36(4H, m) , 7.64(2H, d, J=8.5Hz), 9.22(1H, brs), 9.95(1H, brs), 12.44(1H, brs). MS: 481 (M+H) + Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-phenyl-1 ,3- thiazole-5-carboxamide was prepared from tert-butyl 4-{2-[2- (acetylamino) -5- (anilinocarbonyl) -1 ,3-thiazol-4- yl] ethyl}phenylcarbamate in a similar manner according to Step 4 of Production Example 27. mp. 104-105 °C
XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.71-2.81 (2H, m) , 3.09- 3.18(2H, m) , 5.07 (2H, brs), 6.48(2H, d, J=8.0Hz), 6.85(2H, d, J=8.0Hz), 7.08(1H, t, J=8.0Hz), 7.33(2H, t, J=8.0Hz), 7.65(2H, d, J=8.0Hz), 9.93(1H, brs), 12.44(1H, brs). MS: 381 (M+H) +
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (anilinocarbonyl) -1 , 3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-phenyl-1 ,3- thiazole-5-carboxamide in a similar manner according to Step 5 of Production Example 18. XH-NMR (DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.18 (3H, s) , 2.87-2.98(2H, m) , 3.17-3.29 (2H, m) , 7.08(1H, t, J=8.0Hz), 7.16(2H, d, J=8.5Hz), 7.31(2H, t, J=8.0Hz), 7.41(2H, d, J=8.5Hz), 7.64(2H, d, J=8.0Hz), 9.93(2H, s) , 11.43(1H, brs), 12.46 (1H, brs) . MS: 623 (M+H) + Step 4
The title compound was prepared from di-tert-butyl {(Z)- [ (4- {2- [2- (acetylamino) -5- (anilinocarbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 152-155 °C
XH-NMR (DMSO-de), δ (ppm) : 2.19 (3H, s) , 2.90-3.01 (2H, m) , 3.17- 3.29(2H, m) , 7.09(1H, t, J=8.0Hz), 7.13(2H, d, J=8.0Hz), 7.26(2H, d, J=8.0Hz), 7.33(2H, t, J=8.0Hz), 7.40(3H, brs), 7.64(2H, d, J=8.0Hz), 9.79(1H, s) , 10.02(1H, s) , 12.46(1H, s) . MS: 423 (M+H) + free
Production Example 29 : Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N,N-dimethy1-1 ,3- thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl [4- (2- {2- (acetylamino) -5- [ (dimethylamino) carbonyl] -1 ,3-thiazol-4- yljethyl) phenyl] carbamate was prepared from the compound of Step 2 of Production Example 27 in a similar manner according to Step 3 of Production Example 27.
XH-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.14 (3H, s) , 2.84(4H, s) , 2.85(6H, s) , 7.01(2H, d, J=8.5Hz), 7.31(2H, d, J=8.5Hz), 9.21 (1H, brs), 12.33 (1H, brs). MS: 433 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N,N-dimethyl- 1 ,3-thiazole-5-carboxamide was prepared from tert-butyl [4- (2- {2- (acetylamino) -5- [ (dimethylamino) carbonyl] -1 ,3-thiazol-4- yl}ethyl) phenyl] carbamate in a similar manner according to
Step 4 of Production Example 27.
XH-NMR (DMSO-de), δ (ppm): 2.14 (3H, s) , 2.70-2.77 (4H, m) ,
2.86(6H, s) , 4.83(2H, s) , 6.45(2H, d, J=8.5Hz), 6.78(2H, d, J=8.5Hz), 12.32 (1H, brs).
MS: 333 (M+H) +
Step 3
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5-
[ (dimethylamino) carbonyl] -1 ,3-thiazol-4- yljethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N,N-dimethyl-
1 ,3-thiazole-5-carboxamide in a similar manner according to
Step 5 of Production Example 18.
XH-NMR (DMSO-de), δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.14 (3H, s) , 2.85(6H, s) , 2.89(4H, s) , 7.12(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 9.92(1H, s) , 11.43(1H, brs), 12.36(1H, brs).
MS: 575 (M+H) +
Step 4
The title compound was prepared from di-tert-butyl ((Z)- { [4- (2- {2- (acetylamino) -5- [ (dimethylamino) carbonyl]-! , 3- thiazol-4-yl}ethyl) phenyl] aminoJmethylidene) biscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 78-80 °C
XH-NMR (DMSO-d6) , δ (ppm): 2.15 (3H, s) , 2.81-2.96 (4H, m) , 2.88(6H, s) , 7.11(2H, d, J=8.5Hz), 7.18(2H, d, J=8.5Hz),
7.38(3H, brs), 9.77(1H, s) , 12.34(1H, s) .
MS: 375 (M+H) + free
Production Exam le 30 : Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N-benzyl-1 ,3- thiazole-5-carboxamide hydrochloride
Step 1 tert-Butyl [4- (2- { 2- (acetylamino) -5-
[ (benzylamino) carbonyl] -1 , 3-thiazol-4- yl}ethyl) phenyl] carbamate was prepared from the compound of
Step 2 of Production Example 27 in a similar manner according to Step 3 of Production Example 27. mp. 184-185 °C XH-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.15 (3H, s) , 2.79-
2.87 (2H, m) , 3.12-3.22 (2H, m) , 4.37 (2H, d, J=6.5Hz), 7.02(2H, d, J=8.5Hz), 7.18-7.36 (7H, m) , 8.56(1H, t, J=6.5Hz), 9.22(1H, brs) , 12.37 (1H, brs) .
MS: 495 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-benzyl-1 ,3- thiazole-5-carboxamide was prepared from tert-butyl [4-(2-{2-
(acetylamino) -5- [ (benzylamino) carbonyl] -1 , 3-thiazol-4- ylj ethyl) phenyl] carbamate in a similar manner according to Step 4 of Production Example 27. mp. 200-201 °C
XH-NMR (DMSO-de), δ (ppm): 2.15 (3H, s) , 2.66-2.76 (2H, m) , 3.07-
3.15(2H, m) , 4.38(2H, d, J=6.0Hz), 4.83(2H, s) , 6.46(2H, d,
J=8.5Hz), 6.81(2H, d, J=8.5Hz), 7.20-7.36 (5H, m) , 8.52(1H, t, J=6.0Hz), 12.32(1H, brs).
MS: 395 (M+H) +
Step 3
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5-
[ (benzylamino) carbonyl] -1 ,3-thiazol-4- yl}ethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from 2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] -N-benzyl-1 ,3- thiazole-5-carfooxamide in a similar manner according to Step 5 of Production Example 18.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s) , 2.85-2.94 (2H, m) , 3.16-3.25 (2H, m) , 4.37 (2H, d, J=6.0Hz),
7.12(2H, d, J=8.5Hz), 7.22-7.36 (5H, m) , 7.40(2H, d, J=8.5Hz),
8.32(1H, s) , 8.54(1H, t, J=6.0Hz), 9.94(1H, brs), 11.44(1H, brs) . MS : 637 (M+H) + Step 4
The title compound was prepared from di-tert-butyl ((Z)- { [4- (2- {2- (acetylamino) -5- [ (benzylamino) carbonyl]-! , 3-thiazol- 4-yl}ethyl) phenyl] amino Jmethylidene) biscarbamate in a similar manner according to Step 6 of Production Example 27. mp. 128-130 °C
XH-NMR (DMSO-d6), δ (ppm): 2.17 (3H, s), 2.85-2.96 (2H, m) , 3.16-3.27 (2H, m) , 4.36(2H, d, J=6.0Hz), 7.12(2H, d, J=8.5Hz), 7.17-7.35 (7H, m) , 7.40(3H, brs), 8.66(1H, t, J=6.0Hz), 9.78(1H, s) , 12.38(1H, s) . MS: 437 (M+H) + free
Production Example 31: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- (4-nitrobenzyl) - 1 ,3-thiazole-5-carboxamide hydrochloride Step 1
-A mixture of 2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl}ethyl) -1 ,3-thiazole-5-carboxylic acid (100 mg) , (4-nitrobenzyl) mine hydrochloride (46.5 mg) , 1-hydroxybenzotriazole (36.7 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (40.2 mg) in DMF (2 ml) was stirred at ambient temperature for 73 hours. The reaction mixture was poured into saturated NaHC0 , and extracted with CHCI3. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo to give tert-butyl (4- [2- (2- (acetylamino) -5-{ [ (4- nitrobenzyl) amino] carbonyl }-l ,3-thiazol-4- yl) ethyl] phenyl} carbamate (123.7 mg) as a pale yellow solid. mp. 204-205 °C XH-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.16(3H, s) , 2.77-
2.91(2H, m) , 3.12-3.27 (2H, m) , 4.49(2H, d, J=5.5Hz), 7.01(2H, d, J=8.5Hz), 7.32 (2H, d, J=8.5Hz), 7.52 (2H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz), 8.68(1H, t, J=5.5Hz), 9.21(1H, s) , 12 . 40 ( 1H , s ) . MS : 540 (M+H) + Step 2 tert-Butyl {4- [2- (2- (acetylamino) -5- { [ (4- nitrobenzyl) amino] carbonyl }-l ,3-thiazol-4- yl) ethyl]phenyl} carbamate (135 mg) and TFA (2 ml) were combined at 0 °C. The reaction mixture was stirred at room temperature for an hour, and concentrated in vacuo . The residue was dissolved in MeOH and CHC13, and made basic (pH=8) by lN-NaOH. The mixture was concentrated in vacuo . The residual solid was washed with water to give 2- (acetylamino) - 4- [2- (4-aminophenyl) ethyl] -N- (4-nitrobenzyl) -1 , 3-thiazole-5- carboxamide (92.5 mg) as a pale yellow solid, mp. 120-121 °C XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.65-2.81 (2H, m) , 3.04- 3.21(2H, m) , 4.49(2H, d, J=5.5Hz), 5.65(2H, brs), 6.54(2H, d, J=8.0Hz), 6.86(2H, d, J=8.0Hz), 7.54(2H, d, J=8.5Hz), 8.21(2H, d, J=8.5Hz), 8.67 (1H, t, J=5.5Hz), 12.39 (1H, s) . MS: 440 (M+H) + Step 3
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- (4- nitrobenzyl) -1 ,3-thiazole-5-carboxamide (83 mg) , N,N'- bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (58.6 mg) and THF (1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo . The residual solid was washed with AcOEt to give di- tert-butyl [ (Z)- ({4- [2- (2- (acetylamino) -5-{ [ (4- nitrobenzyl) amino] carbonyl}-! ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate (95.4 mg) as an off-white solid, mp. 251-253 °C
XH-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 1.51 (9H, s) , 2.16 (3H, s) , 2.81-2.98 (2H, m) , 3.16-3.29 (2H, m) , 4.49(2H, d, J=5.5Hz), 7.12(2H, d, J=8.0Hz) , 7.40(2H, d, J=8.0Hz) , 7.53(2H, d, J=8.5Hz) , 8.20(2H, d, J=8.5Hz) , 8.67(1H, t, J=5.5Hz) , 9.93(1H, s) , 11.44(1H, s) , 12.42(1H, s) . MS: 682 (M+H) + Step 4
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ (4- nitrobenzyl) amino] carbonyl }-l ,3-thiazol-4- yl) ethyl] phenyl}amino) methylidenejbiscarbamate (70 mg) and 4N HCI in 1,4-dioxane solution (1.5 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 14 hours. The solvent was removed in vacuo. The residue was washed with AcOEt to give 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- (4-nitrobenzyl) - 1 ,3-thiazole-5-carboxamide hydrochloride (63.7 mg) as a pale green solid, mp. 138-140 °C
XH-NMR (DMSO-d6) , δ (ppm) : 2.17 (3H, s) , 2.81-3.00 (2H, m) , 3.17- 3.30(2H, m) , 4.48(2H, d, J=5.5Hz), 7.12(2H, d, J=8.0Hz), 7.25(2H, d, J=8.0Hz), 7.40(3H, s) , 7.55(2H, d, J=8.0Hz), 8.21(2H, d, J=8.0Hz), 8.80(1H, t, J=5.5Hz), 9.81(1H, s) , 12.42(1H, s) . MS: 482 (M+H) + free
Production Example 32: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [4- (methylsulfonyl) benzyl] -1 ,3-thiazole-5-carboxamide hydrochloride Step 1
A mixture of 2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-5-carboxylic acid (120 mg) , [4- (methylthio) enzyl] amine (45.4 mg) , 1- hydroxybenzotriazole (44 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide hydrochloride (59.6 mg) in DMF (2 ml) was stirred at r.t. for 17 hours. The reaction mixture was poured into saturated NaHC03, and extracted with CHCI3. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHCI3 / AcOEt (1:1) as an eluent to give tert-butyl (4-{2- [2- (acetylamino) -5- ( { [4- (methylthio) benzyl] amino} carbonyl) - 1 ,3-thiazol-4-yl] ethyljphenyl) carbamate (163.5 mg) as an off- white solid, mp. 182-183 °C ^-NMR (DMSO-de), δ (ppm) : 1.46 (9H, s) , 2.15 (3H, s) , 2.45 (3H, s) , 2.77-2.91 (2H, m) , 3.09-3.24 (2H, m) , 4.32(2H, d, J=5.5Hz), 7.02(2H, d, J=8.5Hz), 7.22(4H, s) , 7.33(2H, d, J=8.5Hz), 8.54(1H, t, J=5.5Hz), 9.22(1H, s) , 12.36(1H, s) . MS: 541 (M+H) + Step 2
Potassium peroxymonosulfate (264 mg) was suspended in water (1 ml) and THF (1 ml), and then tert-butyl (4-{2-[2- (acetylamino) -5- ( { [4- (methylthio) benzyl] amino} carbonyl) -1,3- thiazol-4-yl] ethyljphenyl) carbamate (155 mg) in THF (2 ml) was added dropwise to the suspension at 0 °C. The reaction mixture was stirred at r.t. for an hour, and then water was added to the suspension. The solution was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo to give tert-butyl (4-{2- [2- (acetylamino) -5- ( { [4-
(methylsulfonyl) benzyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate (140.6 mg) as an off-white solid, mp. 192.5-193 °C XH-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.16 (3H, s) , 2.73- 2.90(2H, m) , 3.11-3.27 (2H, m) , 3.18(3H, s) , 4.47 (2H, d,
J=5.5Hz), 7.03(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.53(2H, d, J=8.5Hz), 7.89(2H, d, J=8.5Hz), 8.68(1H, t, J=5.5Hz), 9.22(1H, s) , 12.39 (1H, s) . MS : 573 (M+H) +
Step 3
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [4- (methylsulfonyl) benzyl] -1 , 3-thiazole-5-carboxamide was prepared in a similar manner according to Step 2 of Production
Example 31. mp. 78-80 °C
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.65-2.80 (2H, m) , 3.04-
3.22(2H, m) , 3.19(3H, s) , 4.46(2H, d, J=5.5Hz), 4.82(2H, s) , 6.46(2H, d, J=8.0Hz), 6.81(2H, d, J=8.0Hz), 7.53(2H, d,
J=8.0Hz), 7.89(2H, d, J=8.0Hz), 8.63(1H, t, J=5.5Hz),
12.39(1H, s) .
MS: 473 (M+H) +
Step 4 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [4-
(methylsulfonyl) benzyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.16 (3H, s) , 2.81-2.98(2H, m) , 3.18(3H, s) , 3.18-3.29 (2H, m) , 4.46(2H, d, J=5.5Hz), 7.14(2H, d, J=8.5Hz), 7.41(2H, d, J=8.5Hz),
7.54(2H, d, J=8.5Hz), 7.88(2H, d, J=8.5Hz), 8.67(1H, t,
J=5.5Hz), 9.94(1H, s) , 11.44(1H, s) , 12.41(1H, s) .
MS: 715 (M+H) + Step 5
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 94-96 °C
XH-NMR (DMSO-de), δ (ppm): 2.17 (3H, s) , 2.85-2.99 (2H, m) , 3.19(3H, s) , 3.19-3.30 (2H, m) , 4.46(2H, d, J=5.5Hz), 7.13(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.40(3H, s) , 7.54(2H, d,
J=8.5Hz), 7.89(2H, d, J=8.5Hz), 8.78(1H, t, J=5.5Hz), 9.80(1H, s) , 12.4K1H, s) . MS: 515 (M+H) + free
Production Example 33: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N- [4-
(trifluoromethyl) benzyl] -1 ,3-thiazole-5-carboxamide hydrochloride
Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [4-
(trifluoromethyl) benzyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from 2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-
5-carboxylic acid in a similar manner according to Step 1 of
Production Example 32.
XH-NMR (DMSO-de), δ (ppm): 1.46 (9H, s) , 2.16 (3H, s) , 2.73-
2.92(2H, m) , 3.12-3.25 (2H, m) , 4.45(2H, d, J=5.5Hz), 7.01(2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.47 (2H, d, J=8.5Hz),
7.69(2H, d, J=8.5Hz), 8.64(1H, t, J=5.5Hz), 9.22(1H, s) ,
12.39 (1H, s) .
MS: 563 (M+H) +
Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [4-
(trifluoromethyl) benzyl] -1 , 3-thiazole-5-carboxamide was prepared in a similar manner according to Step 2 of Production
Example 31. mp. 199-201 °C XH-NMR (DMSO-de) , δ (ppm) : 2.10 (3H, s) , 2.63-2.78 (2H, m) , 3.02-
3.18(2H, m) , 4.44(2H, d, J=5.5Hz) , 4.81(2H, s) , 6.46(2H, d,
J=8.0Hz) , 6.81(2H, d, J=8.0Hz) , 7.49(2H, d, J=8.0Hz) , 7.69(2H, d, J=8.0Hz) , 8.44(1H, t, J=5.5Hz) , 12.39(1H, s) .
MS: 463 (M+H) + Step 3
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [4-
(trifluoromethyl) benzyl] amino } carbonyl) -1 , 3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. mp. 188-190 °C
XH-NMR (DMSO-de), δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.16 (3H, s) , 2.83-2.97(2H, m) , 3.17-3.29 (2H, m) , 4.44(2H, d, J=5.5Hz), 7.12(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 7.48(2H, d,
J=8.0Hz), 7.69(2H, d, J=8.0Hz), 8.63(1H, t, J=5.5Hz), 9.94(1H, s) , 11.44(1H, s) , 12.40(1H, s) .
MS: 705 (M+H) +
Step 4 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 156-158 °C
XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.82-2.99 (2H, m) , 3.18-
3.31(2H, m) , 4.44(2H, d, J=5.5Hz), 7.12(2H, d, J=8.0Hz), 7.25(2H, d, J=8.0Hz), 7.40(3H, s) , 7.51(2H, d, J=8.0Hz),
7.71(2H, d, J=8.0Hz), 8.76(1H, t, J=5.5Hz), 9.81(1H, s) ,
12.41 (1H, s) . . ..
MS: 505 (M+H) + free
Production Example 34: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- (3-pyridinyl) -1 ,3- thiazole-5-carboxamide dihydrochloride
Step 1
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 ,3-thiazole-
5-carboxylic acid was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-5- carboxylic acid in a similar manner according to Step 2 of
Production Example 31. mp. 211.5-212 °C
XH-NMR (DMSO-de) , δ (ppm) : 2.15(3H, s) , 2.67-2.80 (2H, m) , 3.09-3.23 (2H, m) , 6.51(2H, d, J=8.0Hz) , 6.85(2H, d, J=8.0Hz) ,
12.44 (1H, brs) .
MS: 306 (M+H) +
Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 ,3-thiazole- 5-carboxylic acid (106 mg) was suspended in THF (2 ml) under N2 atmosphere. Bis (trimethylsilyl) acetamide (0.253 ml) was added to the suspension at r.t., and the mixture was stirred at r.t. for 15 minutes. Then, N,N' -bis (tert-butoxycarbonyl) -1H- pyrazole-1-carboxamidine (119 mg) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 20 hours, and concentrated in vacuo . The residue was dissolved in CHC13. The organic solution was washed with 1N-HC1 , water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual solid was washed with ethyl ether to give 2- (acetylamino) -4- {2- [4- ( { (Z)-[ (tert-butoxycarbonyl) amino] (tert- butoxycarbonyl) iminomethyl }amino) phenyl] ethyl}-1 , 3-thiazole-5- carboxylic acid (115.8 mg) as a pale brown solid. mp. 221.5-223 °C
XH-NMR (DMSO-d6) , δ (ppm) : 1.44(18H, brs), 2.16(3H, s) , 2.91(2H, t, J=7.0Hz), 3.26(2H, t, J=7.0Hz), 7..17(2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 9.95(1H, brs), 11.43(1H, brs), 12.48(1H, s) . MS: 548 (M+H) + Step 3
Di-tert-butyl ( (Z) -{ [4- (2- {2- (acetylamino) -5- [ (3- pyridinylamino) carbonyl] -1 , 3-thiazol-4- yl} ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMS0-d6) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.19 (3H, s) , 2.87-3.00 (2H, m) , 3.19-3.32 (2Hr m) , 7.16(2H, d, J=8.5Hz), 7.35(1H, dd, J=8.5 , 4.5Hz), 7.41(2H, d, J=8.5Hz), 8.07(1H, m) , 8.28(1H, dd, J=4.5 , 1.5Hz), 8.81(1H, d, J=1.5Hz), 9.93(1H, s) , 10.1K1H, s) , 11.43(1H, s) , 12.51(1H, s) . MS: 624 (M+H) + Step 4
The title compound was prepared' in a similar manner according to Step 4 of. Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.21 (3H, s) , 2.84-3.07 (2H, m) , 3.19- 3.39(2H, m) , 7.13(2H, d, J=7.5Hz), 7.28(2H, d, J=7.5Hz), 7.45(3H, brs), 7.37-8.81 (4H, m) , 9.93(1H, s) , 10.75(1H, s) , 12.61 (1H, s) .
MS: 424 (M+H) + free
Production Example 35: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- (4-phenoxybenzyl) - 1 , 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ (4- phenoxybenzyl) amino] carbonyl } -1 , 3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s) , 2.81-2.97 (2H, m) , 3.13-3.28 (2H, m) , 4.35(2H, d, J=5.5Hz), 6.97 (4H, d, J=8.5Hz), 7.11(1H, t, J=8.5Hz), 7.13(2H, d, J=8.5Hz), 7.29-7.41(6H, m) , 8.54(1H, t, J=5.5Hz), 9.93(1H, s) , 11.44(1H, brs), 12.37 (1H, brs). MS: 729 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.17 (3H, s) , 2.81-3.00 (2H, m) , 3.13- 3.30(2H, m) , 4.35(2H, d, J=5.5Hz), 6.98(4H, d, J=8.5Hz), 7.12(2H, d, J=8.5Hz), 7.13(1H, t, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.40(2H, t, J=8.5Hz), 7.46(3H, brs), 8.67(1H, t, J=5.5Hz), 9.92(1H, s) , 12.39(1H, brs). MS: 529 (M+H) + free
Production Example 36: Synthesis of ethyl 4- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-yl } carbonyl) -1-piperazinecarboxylate
Step 1
Ethyl 4-[ (2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl }-l ,3-thiazol-5- yl) carbonyl] -1-piperazinecarboxylate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm) : 1.17 (3H, t, J=7.0Hz), 1.39 (9H, brs) 1.50(9H, brs), 2.15(3H, s) , 2.90(4H, m) , 3.38(8H, brs),
4.03(2H, q, J=7.0Hz), 7.12(2H, d, J=8.5Hz), 7.41(2H, d,
J=8.5Hz), 9.94(1H, s) , 11.46(1H, brs), 12.40(1H, brs).
MS: 688 (M+H) +
Step 2 The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. mp. 180-182.5 °C . . . .
XH-NMR (DMSO-de), δ (ppm) : 1.18 (3H, t, J=7.0Hz), 2.07 (3H, s) ,
2.77 (4H, s) , 3.43(8H, brs), 4.05(2H, q, J=7.0Hz), 6.89(2H, d, J=7.5Hz), 7.02 (2H, d, J=7.5Hz).
MS: 488 (M+H) +
Production Example 37: Synthesis of N-{5- [ (4-acetyl-l- piperazinyl) carbonyl] -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- yl}acetamide
Step 1
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (4-acetyl-
1-piperazinyl) carbonyl] -1 ,3-thiazol-4- yljethyl) phenyl] aminoJmethylidene) iscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, brs), 1.50(9H, brs), 1.98(3H, s) , 2.15(3H, s) , 2.90(4H, m) , 3.40(8H, brs) , 7.13(2H, d, J=8.5Hz) , 7.41(2H, d, J=8.5Hz) , 9.93(1H, s) , 11.43(1H, brs) , 12.40 (1H, brs) .
MS: 658 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 2 of the following Production Example 48. mp. 206-207.5 °C
XH-NMR (DMSO-de), δ (ppm) : 2.01 (3H, s) , 2.05 (3H, s) , 2.73 (4H, s) , 3.42(8H, brs), 6.77-7.08 (4H, m) .
MS: 458 (M+H) +
Production Example 38: Synthesis of N-(4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- { [4- (methylsulfonyl) -1-piperazinyl] carbonyl J-l ,3-thiazol-2- yl) acetamide hydrochloride
Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (methylsulfonyl) -1-piperazinyl] carbonyl J-l ,3-thiazol-4- yl) ethyl] phenyl}amino)methylidene] biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
31.
^- MR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s) , 2.89(3H, s) , 2.82-2.96 (4H, m) , 3.01-3.13 (4H, m) , 3.44- 3.59(4H, m) , 7.14(2H, d, J=8.5Hz), 7.42(2H, d, J=8.5Hz),
9.94(1H, s) , 11.44(1H, brs), 12.40(1H, brs).
MS: 694 (M+H) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 118-119 °C
XH-NMR (DMSO-d6) , δ (ppm) : 2.16 (3H, s) , 2.90 (3H, s) , 2.83-
2.98(4H, m) , 3.06-3.18 (4H, m) , 3.50-3.61 (4H, m) , 7.12(2H, d, J=8 . 5Hz ) , 7 . 21 (2H , d , J=8 . 5Hz ) , 7 . 43 (3H , s) , 9 . 90 (1H , s ) ,
12 . 41 ( 1H , s) .
MS : 494 (M+H) + free
Production Example 39: Synthesis of N-[4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- (4- thiomorpholinylcarbonyl) -1 ,3-thiazol-2-yl] acetamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (4- thiomorpholinylcarbonyl) -1 , 3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32. XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s) , 2.45-2.6K4H, m) , 2.79-2.99 (4H, m) , 3.55-3.70 (4H, m) ,
7.13(2H, d, J=8.5Hz) -, • 7.41 (2H, d, J=8.5Hz), 9.92(1H, s) ,
11.44(1H, brs), 12.38(1H, brs).
Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 134-135.5 °C
XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.47-2.62 (4H, m) , 2.80-
3.00(4H, m) , 3.59-3.73 (4H, m) , 7.12(2H, d, J=8.5Hz), 7.20(2H, d, J=8.5Hz), 7.39(3H, s) , 9.80(1H, s) , 12.38(1H, s) .
MS: 433 (M+H) + free
Production xample 4-0: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [ (1 , l-dioxido-4- thiomorpholinyl) carbonyl] -1 ,3-thiazol-2-ylJ acetamide hydrochloride
Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [ (1,1- dioxido-4-thiomorpholinyl) carbonyl] -1 , 3-thiazol-4- yl}ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound obtained in Step 1 of Production Example 39 in a similar manner according to Step 2 of Production Example 32. mp. 270-271.5 °C
XH-NMR (DMSO-de), δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.15 (3H, s) , 2.85-2.96(4H, m) , 3.09-3.21 (4H, m) , 3.69-3.83 (4H, m) , 7.13(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 9.93(1H, s) , 11.47(1H, brs), 12.42(1H, brs). MS: 665 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 185-186 °C XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.92 (4H, s) , 3.11-
3.28(4H, m) , 3.76-3.91 (4H, m) , 7.12(2H, d, J=8.5Hz), 7.22(2H, d, J=8.5Hz), 7.40(3H, s) , 9.84(1H, s) , 12.40(1H, s) .
MS: 465 (M+H) + free
Production Example 41 : Synthesis of ethyl 1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-ylJ carbonyl) -4-piperidinecarboxylate hydrochloride Step 1
Ethyl l-{ [2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl} amino) phenyl] ethyl J-l ,3-thiazol-5- yl] carbonyl}-4-piperidinecarboxylate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (DMSO-d5) , δ (ppm) : 1.17 (3H, t, J=7.0Hz), 1.32-1.56 (2H, m) , 1.39(9H, s) , 1.50(9H, s) , 1.73-1.89 (2H, m) , 2.15(3H, s) , 2.44-2.64(lH, m) , 2.80-3.01 (6H, m) , 3.74-3. 3 (2H, m) , 4.06(2H, q, J=7.0Hz), 7.11(2H, d, J=8.5Hz), 7.41(2H, d, J=8.5Hz), 9.93(1H, s) , 11.45(1H, brs), 12.36(1H, brs). MS : 687 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm): 1.18 (3H, t, J=7.0Hz), 1.29-1.54 (2H, m) , 1.73-1.93 (2H, m) , 2.15(3H, s) , 2.44-2.71 (1H, m) , 2.79- 3.09(6H, m) , 3.79-3.96 (2H, m) , 4.09(2H, q, J=7.0Hz), 7.11(2H, d, J=8.5Hz), 7.19(2H, d, J=8.5Hz), 7.40(3H, s) , 9.83(1H, s) , 12.37(1H, s) . MS: 487 (M+H) + free
Production Example 42: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- ylj carbonyl) -4-piperidinecarboxamide hydrochloride Step 1 Ethyl l-[ (2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- • butoxycarbonyl) imino]methyl}amino) phenyl] ethyl J-l ,3-thiazol-5- yl) carbonyl] -4-piperidinecarboxylate (277.9 mg) , IN-NaOH (1.01 ml) and 1,4-dioxane (3 ml) were combined at 0 °C, and the reaction mixture was stirred at r.t. for 3 hours. The mixture was neutrallized with 1N-HC1, and the organic solvent was evaporated in vacuo . The residual aqueous solution was extracted with AcOEt. The organic layer was washed with water and brine , dried over anhydrous MgS0 , and concentrated in vacuo to give 1- [ (2- (acetylamino) -4-{2- [4- ({ (Z) -[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl}-l ,3-thiazol-5- yl) carbonyl] -4-piperidinecarboxylic acid (262.4 mg) as a pale yellow amorphous substance. ifj-NMR (DMSO-de), δ (ppm) : 1.28-1.59 (2H, m) , 1.45 (18H, s) ,
1.72-1.90 (2H, m) , 2.15(3H, s) , 2.40-2.59 (1H, m) , 2.78-3.03 (6H, m) . 3.77-3.94(2H, m) , 7.12(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 9.94(1H, brs), 11.44(1H, brs), 12.36(1H, s) . MS : 659 (M+H) + Step 2
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (aminocarbonyl) -1-piperidinyl] carbonyl}-1 ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared in a similar manner according to Step 1 of Production Example 32. H-NMR (DMSO-de), δ (ppm): 1.29-1.55 (2H, m) , 1.39 (9H, s) , 1.50(9H, s) , 1.62-1.79 (2H, m) , 2.14(3H, s) , 2.22-2.43 (1H, m) , 2.78-2.99 (6H, m) , 3.89-4.07 (2H, m) , 6.80(1H, s) , 7.14(2H, d, J=8.5Hz), 7.27 (1H, s) , 7.41(2H, d, J=8.5Hz), 9.93(1H, s) , 11.44(1H, brs), 12.36(1H, s) . MS: 658 (M+H) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d5) , δ (ppm) : 1.27-1.52 (2H, m) , 1.64- 1.79(2H, m),-2.15(3H, s) , 2.25-2.44 (2H, m) , .2.76-3.02 (6H, m) , 6.82(1H, br) , 7.11(2H, d, J=8.5 Hz), 7.19(2H, d, J=8.5 Hz), 7.34(1H, br) , 7.41(4H, s) , 9.83(1H, s) , 12.36(1H, s) . MS: 458 (M+H) + free
Production Example 43: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yljcarbonyl) ~N-methyl-4-piperidinecarboxamide hydrochloride Step 1 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ( {4-
[ (methylamino) carbonyl] -1-piperidinyl } carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 1 of Production Example 42 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (DMSO-de), δ (ppm) : 1.30-1.75 (4H, m) , 1.39 (9H, s) , 1.50(9H, s) , 2.14(3H, s) , 2.22-2.42 (1H, m) , 2.55(2H, d, J=4.5Hz), 2.78-2.99 (6H, m) , 3.90-4.03 (2H, m) , 7.14(2H, d, J=8.5Hz) , 7.41(2H, d, J=8.5Hz) , 7.73(1H, q, J=4.5Hz) , 9.93(1H, s) , 11.43(1H, brs) , 12.36(1H, brs) .
MS: 672 (M+H) +
Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.29-1.52 (2H, m) , 1.60-
1.77 (2H, m) , 2.15(3H, s) , 2.55(3H, d, J=4.5 Hz), 2.78-2.98 (6H, m) , 3.88-4.06 (3H, m) , 7.11(2H, d, J=8.5 Hz), 7.19(2H, d, J=8.5 Hz), 7.37 (4H, br) , 7.81(1H, m) , 9.75(1H, s) , 12.36(1H, s) .
MS: 472 (M+H) + free
Production Example 44: Synthesis of 1- ( {2- (acetylamino) -4- [2-
(4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl } carbonyl) - ,N-dimethyl-4-piperidinecarboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4-
[ (dimethylamino) carbonyl] -1-piperidinyl } carbonyl) -1 ,3-thiazol-
4-yl] ethyljphenyl) aminoJmethylidene}biscarbamate was prepared from the compound obtained in Step 1 of Production Example 42 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (DMSO-de), δ (ppm) : 1.30-1.70 (4H, m) , 1.39 (9H, s) ,
1.50(9H, s) , 2.15(3H, s) , 2.80(3H, s) , 2.79-3.01 (7H, m) , 3.00(3H, s) , 3.88-4.06 (2H, m) , 7.13(2H, d, J=8.5Hz), 7.41(2H, d, J=8.5Hz), 9.92(1H, s) , 11.42(1H, brs), 12.36(1H, brs).
MS: 686 (M+H) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.27-1.51 (2H, m) , 1.55-
1.72(2H, m) , 2.15(3H, s) , 2.80(3H, s) , 2.81-3.00 (6H, m) ,
3.03(3H, s) , 3.89-3.96 (3H, m) , 7.11(2H, d, J=8.5 Hz), 7.20(2H, d , J=8 . 5 Hz ) , 7 . 37 (4H , br) , 9 . 79 ( 1H , s ) , 12 . 36 ( 1H , s ) . MS : 486 (M+H) +
Production Example 45: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5-phenyl-l ,3-thiazol- 2-ylJ acetamide hydrochloride Step 1
2-Oxo-3-phenylpropanoic acid (20 g) , DMF (100 ml) and DBU (18.2 ml) were combined at 0 °C under N2 atmosphere, and the mixture was stirred at 0 °C for an hour. Then iodomethane (15.2 ml) was added to the solution at 0 °C. The reaction mixture was stirred at r.t. for 3 hours, and poured into 1N- HC1. The mixture was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CHC13 / AcOEt (30:1) as an eluent, and triturated with IPE / n- Hexane to give methyl 2-oxo-3-phenylpropanoate (11.2 g) as a pale yellow wax. XH-NMR (CDCI3) , δ (ppm): 3.92 (3H, s) , 6.42 (1H, s) , 6.53 (1H, s) , 7.28-7.42 (3H, m) , 7.77(2H, dd, J=8.5 , 1.5Hz). MS: 179 (M+H) + Step 2
Methyl 2-oxo-3-phenylpropanoate (11 g) , pyridinium tribromide (24.1 g) , CH2C12 (490 ml) and AcOH (1.5 ml) were combined at 0 °C under N2 atmosphere. The reaction mixture was stirred at 0 °C for 1.5 hours , poured into water and participated. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo . The residual oil was dissolved in EtOH (190 ml) , and then thiourea (6.11 g) was added to the solution. The reaction mixture was refluxed for an hour under N2 atmosphere. After cooled to 0 °C, water was added to the solution. The precipitate was filtered in vacuo to give methyl 2-amino-5-phenyl-l ,3-thiazole-4-carboxylate (6.63 g) as an off-white solid, mp. 208-208.5 °C
XH-NMR (DMSO-de), δ (ppm): 3.67 (3H, s) , 7.38-7.53 (5H, m) . MS: 235 (M+H) + Step 3
Methyl 2-amino-5-phenyl-l ,3-thiazole-4-carboxylate (3 g) was dissolved in pyridine (30 ml) , and then acetyl chloride (2.73 ml) was added dropwise to the solution at 0 °C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1.5 hours. Water was added to the solution at 0 °C. The precipitate was filtered in vacuo , and the solid was washed with ethyl ether to give methyl 2- (acetylamino) -5-phenyl-l ,3- thiazole-4-carboxylate (2.37 g) as a pale brown solid, mp. 224.5-225.5 °C ifl- MR (DMSO-d6) , δ (ppm): 2.16 (3H, s) , 3.68 (3H, s) , 7.39- 7.57 (5H, m) , 12.56 (1H, s) . MS: 277 (M+H) + Step 4
Methyl 2- (acetylamino) -5-phenyl-l , 3-thiazole-4- carboxylate (2.34 g) was suspended in THF (23 ml), and then lithium aluminium hydride (482 mg) was added portionwise to the solution at 0 °C. The reaction mixture was stirred at 0 °C for 1.5 hours and quenched with MeOH. AcOEt and IN HCI were added to the mixture, and the mixture was extracted. The aqueous layer was extracted with AcOEt (twice) . The combined organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual solid was dissolved in MeOH (5 ml) and CHC13 (90 ml) . Then manganase (IV) oxide (11 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N- (4-formyl-5-phenyl-l ,3-thiazol-2-yl)' acetamide (705.2 mg) as a brown amorphous substance.
XH-NMR (DMSO-de), δ (ppm): 2.19 (3H, s) , 7.49-7.58 (3H, m) , 7.60- 7.69(2H, m) , 9.78(1H, s) , 12.60(1H, s) . MS: 247 (M+H) + Step 5
1- (Bromomethyl) -4~nitrobenzene (1.03 g) , triphenylphosphine (1.25 g) and DMF (14 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 6 hours. Then potassium tert-butoxide (629 mg) and N-(4- formyl-5-phenyl-l ,3-thiazol-2-yl) acetamide (690 mg) were added to the mixture, and the mixture was stirred at r.t. for 13 hours. The reaction mixture was poured into ice-water, and extracted with AcOEt. The organic layer was washed with 1N- HCI, water and brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with. CHC13 / AcOEt (1:1) as an eluent to give a mixture of N-{4- [ (E) -2- (4- nitrophenyl) vinyl] -5-phenyl-l ,3-thiazol-2-ylJacetamide and N- {4- [ (Z) -2- (4-nitrophenyl) vinyl] -5-phenyl-l ,3-thiazol-2- yljacetamide (E : Z = 2 , : 1) (1.02 g) as an orange wax. XH-NMR (DMSO-de), δ (ppm) : 2.13(3Hxl/3, s) , 2.19(3Hx2/3, s) , 6.65(lHxl/3, d, J=12.5Hz), 6.78(lHxl/3, d, J=12.5Hz), 7.32(lHx2/3, d, J=15.5Hz), 7.39-7.59 (5H+lHx2/3 , m) , 7.61(2Hxl/3, d, J=9.0Hz), 7.77(2Hx2/3, d, J=9.0Hz),
8.13(2Hxl/3, d, J=9.0Hz), 8.19(2Hx2/3, d, J=9.0Hz), 12.33 (1H, brs) .
MS: 366 (M+H) +
Step 6 A mixture of N- { 4- [ (E) -2- (4-nitrophenyl) vinyl] -5-phenyl- l,3-thiazol-2-yl} acetamide and N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -5-phenyl-l ,3-thiazol-2-ylJ acetamide (E : Z = 2 : 1) (600 mg) , 10% palladium carbon (657 mg) , MeOH (6 ml) , THF (6 ml) and AcOH (1 ml) were combined. The reaction mixture was stirred under 3 atm H2 at r.t. for 3.5 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo .
IN-NaOH was added to the residue, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over MgS04, and concentrated in vacuo to give
N-{4- [2- (4-aminophenyl) ethyl] -5-phenyl-l ,3-thiazol-2- ylj acetamide (528.6mg) as a pale brown amorphous substance.
XH-NMR (DMSO-d6) , δ (ppm): 2.15 (3H, s) , 2.80 (4H, s) , 4.82(2H, s) , 6.45(2H, d, J=8.5Hz), 6.7'8(2H, d, J=8.5Hz), 7.21-7.44 (5H, m) , 12.18 (1H, brs) .
MS: 338 (M+H) +
Step 7
Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5-phenyl-l , 3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.21 (9H, s) , 1.44 (9H, s) , 2.15 (3H, s) , 2.83-2.98 (4H, m) , 7.10(2H, d, J=8.5Hz), 7.22-7.47 (7H, m) , 9.92(1H, s) , 11.43(1H, s) , 12.22(1H, s) .
MS: 580 (M+H) +
Step 8
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 80-82 °C
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.83-3.08 (4H, m) ,
7.11(2H, d, J=8.0Hz), 7.21(2H, d, J=8.0Hz), 7.29-7.54 (8H, m) ,
9.94(1H, s) , 12.22(1H, brs).
MS: 380 (M+H) + free Production Example 46: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5-benzyl-l ,3-thiazol-
2-ylJ acetamide hydrochloride
Step 1 To a suspension of copper (II) bromide (9.75 g) in AcOEt (150 ml) was added a solution of ethyl 2-oxo-4-phenylbutanoate (3 g) in 75 ml of CHC13. The reaction mixture was refluxed for 23 hours, cooled to r.t., and filtered through a short pad of silica gel eluting with AcOEt / n-hexane (1:1) . The solvent was removed in vacuo to give ethyl 3-bromo-2-oxo-4- phenylbutanoate (4.2g) as a yellow liquid.
XH-NMR (CDCI3) , δ (ppm): 1.37 (3H, t, J=7.0Hz), 3.25 (1H, dd, J=14.5, 7.5Hz), 3.54(1H, dd, J=14.5, 7.5Hz), 4.35(2H, q, J=7.0Hz), 5.27(1H, d, J=7.5Hz), 7.18-7.41 (5H, m) . Step 2
Ethyl 3-bromo-2-oxo-4-phenylbutanoate (5.8 g) was dissolved in EtOH (110 ml) , and then thiourea (3.1 g) was added to the solution. The reaction mixture was refluxed for 2 hours under N2 atmosphere. The cooled reaction mixture was evaporated in vacuo . The residual solid was suspended (pH=8) in saturated NaHC03 and water. The solid was collected by filtration, and purified by flash column chromatography over silica gel with CHC13 / MeOH (10:1) as an eluent to give ethyl 2-amino-5-benzyl-l ,3-thiazole-4-carboxylate (808.2 mg) as a yellow wax.
XH-NMR (DMSO-d6), δ (ppm) : 1.25 (3H, t, J=7.0Hz), 4.21 (2H, q, J=7.0Hz), 4.33(2H, s) , 7.02(2H, s) , 7.11-7.39 (5H, m) . MS: 263 (M+H) +
Ethyl 2- (acetylamino) -5-benzyl-l , 3-thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 178-180 °C ifj-NMR (DMSO-de), δ (ppm) : 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) , 4.28(2H, q, J=7.0Hz), 4.48(2H, s) , 7.19-7.39 (5H, m) , 12.41(1H, s) . MS: 305 (M+H) + Step 4
Ethyl 2- (acetylamino) -5-benzyl-l , 3-thiazole-4-carboxylate (1.0 g) was dissolved in THF (20 ml) , and then lithium borohydride (124 mg) was added portionwise to the solution at 0 °C. The reaction mixture was refluxed for 4.5 hours and quenched with MeOH. The mixture was concentrated in vacuo, and purified by flash column chromatography over silica gel with CHCI3 / MeOH (20:1) as an eluent. The residual amorphous substance was dissolved in MeOH (1 ml) and CHC13 (8 ml) . Then manganase (IV) oxide (1.26 g) was added to the solution under N2 atmosphere. The reaction mixture was stirred at r.t. for 12 hours, and filtered through a celite pad. The filtrate was concentrated in vacuo. The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N- (5-benzyl-4-formyl-l ,3-thiazol-2- yl) acetamide (251 mg) as a pale yellow solid, mp. 191-192.5 °C
XH-NMR (DMSO-de), δ (ppm) : 2.12 (3H, s) , 4.53 (2H, s) , 7.19- 7.40(5H, m) , 10.04(1H, s) , 12.34(1H, s) . MS: 261 (M+H) + Step 5
N- { 5-Benzyl-4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 , 3-thiazol-2- yljacetamide was prepared in a similar manner according to Step 5 of Production Example 45. Z : E = 2 : 1
XH-NMR (DMSO-de) , δ (ppm) : 2.08(3Hx2/3, s) , 2.12(3Hxl/3, s) , 4.08(2Hx2/3, s) , 4.34(2Hxl/3, s) , 6.72(lHx2/3, d, J=12.5Hz) , 6.86(lHx2/3, d, J=12.5Hz) , 7.17-7.39 (5H+2Hxl/3 , m) , 7.66(2Hx2/3, d, J=9.0Hz) , 7.92(2Hxl/3, d, J=9.0Hz) , 8.14(2Hx2/3, d, J=9.0Hz) , 8.22(2Hxl/3, d, J=9.0Hz) , 11.85(lHx2/3, s) , 12.16 (lHxl/3 , s) . MS: 380 (M+H) + Step 6 N-{ 4- [2- (4-Aminophenyl) ethyl] -5-benzyl-l , 3-thiazol-2- ylj acetamide was prepared in a similar manner according to
Step 6 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm): 2.07 (3H, s) , 2.59-2.85 (4H, m) , 3.85(2H, s) , 4.84(2H, s) , 6.46(2H, d, J=8.5Hz), 6.78(2H, d,
J=8.5Hz), 7.07 (2H, d, J=8.0Hz), 7.16-7.31 (3H, m) , 11.96(1H, s) .
MS: 352 (M+H) +
Step 7 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5-benzyl-l ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.07 (3H, s) , 2.85(4H, s) , 3.89(2H, s) , 7.05-7.33 (7H, m) , 7.42(2H, d,
J=8.5Hz), 9.95(1H, s) , 11.44(1H, s) , 11.99(1H, s) . -MS: 594 (M+H) +
Step 8
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. mp. 97-99 °C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.86(4H, s) , 3.93 (2H, s) , 7.05-7.37 (9H, m) , 7.47(3H, s) , 9.98(1H, s) , 12.01(1H, brs) . MS: 394 (M+H) + free
Production Exam le 7 : Synthesis of N-{4-[2-(4- aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2- yl } acetamide
Step 1
3- (4-Mercaptophenyl)propanoic acid (5 g) , K2C03 (11.4 g) and DMF (30 ml) were combined, and iodomethane (5.12 ml) was added dropwise to the mixture at 0 °C under N2 atmosphere. The reaction mixture was stirred at r.t. for 13 hours, and poured into ice-water. The mixture was extracted with AcOEt. The organic layer was washed with water (twice) and brine, dried over anhydrous MgS04, and concentrated in vacuo to give methyl 3- [4- (methylthio) phenyl] propanoate (4.19 g) as pale yellow oil.
XH-NMR (CDC13) , δ (ppm): 2.47 (3H, s) , 2.61 (2H, t, J=8.0Hz), 2.91(2H, t, J=8.0Hz), 3.67 (3H, s) , 7.12(2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz) . Step 2 Sodium methoxide, 28% solution in MeOH (3.67 ml) , was added dropwise to the mixture of methyl 3- [4- (methylthio) phenyl] propanoate (4 g) and diethyl oxalate (5.17 ml) at 0 °C with stirring. The reaction mixture was stirred at 65 °C for 30 minutes under reduced pressure. 15% Aqueous H2S0 (35 ml) was added to the mixture, and the mixture was refluxed for 15 hours. After cooled to r.t., the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual oil was dissolved in EtOH (20 ml) , and concentrated H2S0 (0.4 ml) was added dropwise to the solution. The reaction mixture was refluxed for 2 hours. After cooled to r.t., EtOH was removed in vacuo . AcOEt and water were added to the residue, and extracted. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (6:1) as an eluent to give ethyl 4- [4- (methylthio) phenyl] -2- oxobutanoate (2.43 g) as a yellow liquid.
XH-NMR (CDCI3) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.46 (3H, s) , 2.92(2H, t, J=7.0Hz), 3.16 (2H, t, J=7.0Hz), 4.31(2H, q, J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.20 (2H, d, J=8.5Hz). Step 3
Ethyl 3-bromo-4- [4- (methylthio) phenyl] -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production
Example 46.
XH-NMR (CDCI3) , δ (ppm): 1.37 (3H, t, J=7.0Hz), 2.47 (3H, s) ,
3.20(1H, dd, J=14.5, 7.5Hz), 3.49(1H, dd, J-14.5, 7.5Hz), 4.35(2H, q, J=7.0Hz), 5.22(1H, d, J=7.5Hz), 7.17(2H, d,
J=8.5Hz), 7.20 (2H, d, J=8.5Hz).
Step 4
Ethyl 2-amino-5- [4- (methylthio) benzyl] -1 ,3-thiazole-4- carboxylate was prepared in a similar manner according to Step 2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm) : 1.25 (3H, t, J=7.0Hz), 2.44 (3H, s) ,
4.20(2H, q, J=7.0Hz), 4.28(2H, s) , 7.02(2H, s) , 7.19(4H, s) .
MS: 309 (M+H) +
Step 5 Ethyl 2- (acetylamino) -5- [4- (methylthio) benzyl] -1 ,3- thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 205-206 °C
XH-NMR (DMSO-de), δ (ppm) : 1.28 (3H, t, J=7.0Hz), 2.09 (3H, s) , 2.45(3H, s) , 4.27(2H, q, J=7.0Hz), 4.43(2H, s) , 7.22(4H, s) ,
12.41(1H, s) .
MS: 351 (M+H) +
Step 6
N-{4-Formyl-5- [4- (methylthio) benzyl] -1 ,3-thiazol-2- yl} acetamide was prepared in a similar manner according to
Step 4 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s) , 2.45 (3H, s) , 4.48 (2H, s) , 7.23(4H, s) , 10.03(1H, s) , 12.33(1H, s) .
MS: 307 (M+H) + Step 7
N-{ 5- [4- (Methylthio) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJacetamide was prepared in a similar manner according to Step 5 of Production Example 45. Z : E = 2 : 1
^•H-NMR (DMSO-de), δ (ppm): 2.08(3Hx2/3, s) , 2.12(3Hxl/3, s) , 2.44(3H, s) , 4.04(2Hx2/3, s) , 4.30(2Hxl/3, s) , 6.71(lHx2/3, d, J=12.5Hz), 6.84(lHx2/3, d, J=12.5Hz), 7.18(4Hx2/3, s) , 7.23(4Hxl/3, s) , 7.24(lHxl/3, d, J=15.5Hz), 7.40(lHxl/3, d, J=15.5Hz), 7.65(2Hx2/3, d, J=9.0Hz), 7.92(2Hxl/3, d, J=9.0Hz), 8.12(2Hx2/3, d, J=9.0Hz), 8.22(2Hxl/3, d, J=9.0Hz), 11.85(lHx2/3, brs), 12.16 (lHxl/3 , brs). MS: 426 (M+H) + Step 8
N-{5- [4- (Methylsulfonyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJacetamide was prepared in a similar manner according to Step 2 of Production Example 32. Z : E = 2 : 1 ! H- MR (DMSO-de), δ (ppm) : 2.09(3Hx2/3, s) , 2.13(3Hxl/3, s) , 3.18(3H, s) , 4.24(2Hx2/3, s) , 4.49(2Hxl/3, s) , 6.73(lHx2/3, d, J=12.5Hz), 6.86(lHx2/3, d, J=12.5Hz), 7.33(lHxl/3, d, J=15.5Hz), 7.41-7.97 (5/3H, m) , 7.48(2Hx2/3, d, J=9.0Hz), 7.55(2Hxl/3, d, J=9.0Hz), 7.65(2Hx2/3, d, J=9.0Hz), 7.85(2Hx2/3, d, J=9.0Hz), 8.14(2Hx2/3, d, J=9.0Hz),
8.22(2Hxl/3, d, J=9.0Hz), 11.90 (1HX2/3 , s) , 12.22 (lHxl/3 , s) . MS: 458 (M+H) + Step 9
The title compound was prepared in a similar manner according to Step 6 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.58-2.87 (4H, m) , 3.18(3H, s) , 3.98(2H, s) , 4.85(2H, s) , 6.46(2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz), 7.82(2H, d, J=8.5Hz) , 12.02 (1H, s) . MS: 430 (M+H) +
Production Example 48: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino}phenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide Step 1
Di-tert-butyl ( (Z)-{ [4- (2- {2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-4- ylj ethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from the compound obtained in Example 47 in a similar manner according to Step 3 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.08 (3H, s) , 2.86(4H, s) , 3.16(3H, s) , 4.03(2H, s) , 7.13(2H, d,
J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 7.81(2H, d, J=8.5Hz), 9.97 (1H, s) , 11.45(1H, s) , 12.05(1H, s) .
MS: 672 (M+H) +
Step 2
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1 , 3-thiazol-4- yl}ethyl) phenyl] amino Jmethylidene) biscarbamate (953 mg) and 4N
HCI in 1,4-dioxane solution (10 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 7 hours. The solvent was removed in vacuo . The residue was dissolved in water and AcOEt. The solution was made basic (pH=8) by saturated NaHCU3. The precipitate was filtered in vacuo to give N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide (667.7 mg) as a pale yellow solid. mp. 228-229.5 °C H-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.79 (4H, m) , 3.18 (3H, s) , 4.05(2H, s) , 6.72(2H, d, J=8.0Hz), 6.99(2H, d, J=8.0Hz),
7.37(2H, d, J=8.5Hz), 7.84(2H, d, J=8.5Hz).
MS: 472 (M+H) + Production Example 49: Synthesis of N-{4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide hydrochloride The title compound was prepared from the ■ compound obtained in Step 1 of Production Example 48 in a similar manner according to Step 4 of Production Example 31. mp. 107-110 °C XH-NMR (DMSO-d6) , δ (ppm): 2.09 (3H, s) , 2.87 (4H, s) , 3.19 (3H, s) , 4.08(2H, s) , 7.13(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.40(2H, d, J=8.5Hz), 7.44(3H, s) , 7.85(2H, d, J=8.5Hz), 9.94(1H, s) , 12.05(1H, brs). MS: 472 (M+H) + free Production Example 50: Synthesis of N-{4-[2-(4-
{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide Step 1
To a ice-cold solution of N- {4- [2- (4-aminophenyl) ethyl] - 5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-ylJ acetamide (247.6 mg) in acetone (4.8 ml) was added benzoyl isothiocyanate (94.1 mg) , and the mixture was stirred at r.t. for 1 hour. Water was added to the mixture, and the mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual amorphous substance was dissolved in EtOH (5 ml) , and 6N-NaOH (0.288 ml) was added to the solution at 0 °C. The reaction mixture was stirred at r.t. for 2 hours, and neutralized with 1N-HC1 at 0 °C. The mixture was extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was solidified with ethyl ether to give N-{4-(2-{4- [ (aminocarbonothioyl) aminoJphenyl} ethyl) -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-yl J acetamide (290.7 mg) as an off-white solid, mp. 102-103 °C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.85 (4H, s) , 3.18 (3H, s) , 4.03(2H, s) , 7.11(2H, d, J=8.5Hz), 7.30(2H, d, J=8.5Hz), 7.36(2H, d, J=8.5Hz) , 7.84(2H, d, J=8.5Hz) , 9.64(1H, s) ,
12.04 (1H, s) .
MS: 489 (M+H) +
Step 2 A mixture of N-{4-(2-{4-
[ (aminocarbonothioyl) aminoJphenyl} ethyl) -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (281.8 mg) , methyl iodide (0.0431 ml) and MeOH (3 ml) was refluxed for 3.5 hours. The reaction mixture was concentrated in vacuo. The residue was diluted with AcOEt and stirred for 30 minutes. The precipitated crystals were filtered and washed with AcOEt to give methyl N- [4- (2- {2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1 , 3-thiazol-4- yljethyl) phenyl] imidothiocarbamate hydroiodide (291.5 mg) as an off-white amorphous solid.
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.68 (3H, s) , 2.90 (4H, s) , 3.18(3H, s) , 4.07(2H, s) , 7.22(2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.39(2H, d, J=8.5Hz), 7.86(2H, d, J=8.5Hz),
9.22(1H, brs), 11.11(1H, brs), 12.03(1H, s) . MS: 503 (M+H) + free
Step 3
The title compound was prepared in a similar manner according to the following Production Example 58.
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.87 (4H, s) , 3.19 (3H, s) , 4.08(2H, s) , 7.12(2H, d, J=8.5Hz), 7.23(2H, d, J=8.5Hz),
7.41(2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz), 8.92(2H, brs),
12.03 (1H, brs) .
MS: 487 (M+H) +
Production Example 51: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- [4-
(ethylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide hydrochloride
Step 1 Ethyl 3- [4- (ethylthio) phenyl] propanoate was prepared from 4- (2-carboxyethyl) thiophenol in a similar manner according to Step 1 of Production Example 47.
^-NMR (CDCI3) , δ (ppm): 1.23 (3H, t, J=7.0Hz), 1.29 (3H, t, J=7.0Hz), 2.60(2H, t, J=8.5Hz), 2.82-2.99 (4H, m) , 4.12(2H, q, J=7.0Hz), 7.12 (2H, d, J=8.5Hz), 7.26 (2H, d, J=8.5Hz). Step 2
Ethyl 4- [4- (ethylthio) phenyl] -2-oxobutanoate was prepared in a similar manner according to Step 2 of Production Example 47.
XH-N R (CDCI3) , δ (ppm): 1.31 (3H, t, J=7.0Hz), 1.36 (3H, t,
J=7.0Hz), 2.92(2H, q, J=7.0Hz), 2.93(2H, t, J=7.0Hz), 3.16(2H, t, J=7.0Hz), 4.27 (2H, q, J=7.0Hz), 7.08(2H, d, J=9.0Hz),
7.26 (2H, d, J=9.0Hz) . Step 3
Ethyl 3-bromo-4- [4- (ethylthio) phenyl] -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production
Example 46.
XH-NMR (CDCI3) , δ (ppm): 1.31 (3H, t, J=7.5Hz), 1.38 (3H, t, J=7.5Hz), 2.93(2H, q, J=7.5Hz), 3.21(1H, dd, J=14.5, 7.5Hz),
3.49(1H, dd, J=14.5, 7.5Hz), 4.35(2H, q, J=7.5Hz), 5.23(1H, t,
J=7.5Hz), 7.16(2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz).
Step 4
Ethyl 2-amino-5- [4- (ethylthio) benzyl] -1 ,3-thiazole-4- carboxylate was prepared in a similar manner according to Step
2 of Production Example 46.
XH-NMR (DMSO-d6) , δ (ppm): 1.22 (6H, t, J=7.0Hz), 2.94 (2H, q,
J=7.0Hz), 4.20(2H, q, J=7.0Hz), 4.29(2H, s) , 7.03(2H, s) ,
7.18(2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz). MS: 323 (M+H) +
Step 5
Ethyl 2- (acetylamino) -5- [4- (ethylthio) benzyl] -1 ,3- thiazole-4-carboxylate was prepared in a similar manner according to Step 3 of Production Example 45. mp. 189.5-190 °C
XH-NMR (DMSO-de), δ (ppm): 1.21 (3H, t, J=7.5Hz), 1.28 (3H, t,
J=7.0Hz), 2.09(3H, s) , 2.95(2H, q, J=7.5Hz), 4.27 (2H, q, J=7.0Hz), 4.44(2H, s) , 7.22(2H, d, J=8.5Hz), 7.26(2H, d,
J=8.5Hz) , 12.42 (1H, s) .
MS: 365 (M+H) +
Step 6
N- { 5- [4- (Ethylthio) benzyl] -4-formyl-l , 3-thiazol-2- yl} acetamide was prepared in a similar manner according to
Step 4 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 1.21 (3H, t, J=7.5Hz), 2.17 (3H, s) ,
2.95(2H, q, J=7.5Hz), 4.49(2H, s) , 7.26(4H, s) , 10.03(1H, s) ,
12.34(1H, s) . Step 7
N-{ 5- [4- (Ethylthio) benzylJ -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared in a similar manner according to Step 5 of Production Example 45.
Z : E = 3 : 2 !H-NMR (DMSO-de), δ (ppm) : 1.20(3H, t, J=7.5Hz), 2.08(3Hx3/5, s) , 2.12(3Hx2/5, s) , 2.93(2H, q, J=7.5Hz), 4.05(2Hx3/5, s) ,
4.31(2Hx2/5, s) , 6.71(lHx3/5, d, J=12.5Hz), 6.84(lHx3/5, d,
J=12.5Hz), 7.13-8.16(6H+4/5H, m) , 8.12(2Hx3/5, d, J=9.0Hz),
8.22(2Hx2/5, d, J=9.0Hz), 11.86 (1HX3/5 , brs), 12.18 (1HX2/5 , brs) .
MS: 440 (M+H) +
Step 8
N-{5-[4-(Ethylsulfonyl)benzyl]-4-[ (Z)-2-(4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared in a similar manner according to Step 2 of Production Example 32.
Z : E = 3 : 2
XH-NMR (DMSO-de), δ (ppm) : 1.06 (3H, t, J=7.5Hz), 2.09(3Hx3/5, s) , 2.13(3Hx2/5, s) , 3.25(2H, q, J=7.5Hz), 4.24(2Hx3/5, s) , 4.50(2Hx2/5, s) , 6.73(lHx3/5, d, J=12.5Hz), 6.87(lHx3/5, d, J=12.5Hz), 7.43-8.31 (8H+4/5H, m) , 11.91 (1HX3/5 , brs),
Figure imgf000124_0001
MS: 472 (M+H) + Step 9
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [4- (ethylsulfonyl) benzyl] -1 , 3-thiazol-4- yljethyl) phenyl] amino Jmethylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. ifl-NMR (DMSO-de), δ (ppm) : 1.05 (3H, t, J=7.5Hz), 1.39 (9H, s) , 1.51(9H, s) , 2.09(3H, s) , 2.85(4H, s) , 3.22(2H, q, J=7.5Hz), 4.04(2H, s) , 7.11(2H, d, J=8.5Hz), 7.32(2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 7.77 (2H, d, J=8.5Hz), 9.97 (1H, s) , 11.44(1H, s) , 12.05(1H, s) . MS: 686 (M+H) + Step 10
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 1.07 (3H, t, J=7.5Hz), 2.09 (3H, s) , 2.86(4H, s) , 3.26(2H, q, J=7.5Hz), 4.09(2H, s) , 7.13(2H, d, J=8.0Hz), 7.24(2H, d, J=8.0Hz), 7.44(3H, brs), 7.60(2H, d, J=8.0Hz), 7.81(2H, d, J=8.0Hz), 9.89(1H, s) , 12.05(1H, brs). MS: 486 (M+H) + free Production Example 52: Synthesis of ethyl {4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ carbamate Step 1
N~{4- [2- (4-Aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide (300 mg) was dissolved in THF (3 ml) under N2 atmosphere. Then di (tert- butyl) dicarbonate (168 mg) in THF (3 ml) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 14 hours, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CHC13 / AcOEt (1:1) as an eluent to give tert-butyl [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) - benzyl] -1 ,3-thiazol-4-ylJethyl) phenyl] carbamate (248.5 mg) as an off-white amorphous substance .
1H-NMR (DMSO-de), δ (ppm): 1.47 (9H, s) , 2.08 (3H, s) , 2.82 (4H, s) , 3.16(3H, s) , 3.99(2H, s) , 7.00(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 9.24(1H, s) , 12.03 (1H, s) . MS: 530 (M+H) + Step 2 tert-Butyl [4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-4-yl } ethyl) phenyl] - carbamate (230 mg) , IN-NaOH (1.09 ml) and EtOH (5 ml) were combined, and the mixture was refluxed for 16 hours. After cooled to r.t., the organic solvent was removed in vacuo . The aqueous solution was neutrallized with 1N-HC1 , and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHCI3 / MeOH (30:1) as an eluent to give tert-butyl [4- (2- {2-amino-5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-4- yljethyl) phenyl] carbamate (151.2 mg) as an off-white amorphous substance. XH-NMR (DMSO-d6), δ (ppm) : 1.47 (9H, s) , 2.58-2.82 (4H, m) ,
3.16(3H, s) , 3.84(2H, s) , 6.73(2H, s) , 7.02(2H, d, J=8.5Hz), 7.21(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.77(2H, d, J=8.5Hz) , 9.24 (1H, s) . MS: 488 (M+H) + Step 3 tert-Butyl [4- (2-{2-amino-5- [4- (methylsulfonyl) benzyl] - 1 ,3-thiazol-4-ylJ ethyl) phenyl] carbamate (140 mg) was dissolved in pyridine (2 ml) under N2 atmosphere. Then, ethyl chloroformate (30.2 ml) was added to the solution at 0 °C. The reaction mixture was stirred at r.t. for 2 hours, and concentrated in vacuo . The residue was dissolved in AcOEt, and washed with 1N-HC1, water and brine. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo to give ethyl {4- (2-{4- [ (tert-butoxycarbonyl) aminoJphenyl} ethyl) -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-yl} carbamate (155.8 mg) as an off-white amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 1.21 (3H, t, J=7.0Hz), 1.47 (9H, s) , 2.79(4H, s) , 3.16(3H, s) , 3.97(2H, s) , 4.14(2H, q, J=7.0Hz), 7.00(2H, d, J=8.5Hz), 7.24(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 9.54(1H, s) , 11.64(1H, brs). MS: 560 (M+H) + Step 4 Ethyl {4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -
5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } carbamate (140 mg) and 4N HCI in 1,4-dioxane solution (3 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 2 hours. The solvent was removed in vacuo . The residue was dissolved in water and AcOEt. The mixture was made basic (pH=8) by IN-NaOH. The organic layer was washed with water and brine, dried over anhydrous MgS0 , and concentrated in vacuo to give ethyl {4- [2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } carbamate (125.6mg) as an off-white amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 1.21 (3H, t, J=7.0Hz), 2.60-2.80 (4H, m) , 3.18(3H, s) , 3.97 (2H, s) , 4.14(2H, q, J=7.0Hz), 4.85(2H, brs), 6.46(2H, d, J=8.5Hz), 6.77 (2H, d, J=8.5Hz), 7.29(2H, d, J=8.5Hz), 7.82(2H, d, J=8.5Hz), 11.62(1H, brs). MS: 460 (M+H) + Step 5
Di-tert-butyl ( (Z) -{ [4- (2-{2- [ (ethoxycarbonyl) amino] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-4- yljethyl) phenyl] aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. 1H-NMR (DMSO-de), δ (ppm): 1.21 (3H, t, J=7.0Hz), 1.39 (9H, s) , 1.51(9H, s) , 2.84(4H, s) , 3.16(3H, s) , 4.01(2H, s) , 4.14(2H, q, J=7.0Hz), 7.13 (2H, d, J=8.5Hz), 7.33 (2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz), 7.81(2H, d, J=8.5Hz), 9.97(1H, s) , 11.45(1H, s) , 11.61(1H, brs). MS: 702 (M+H) + Step 6 The title compound was prepared in a similar manner according to Step 2 of Production Example 48.
XH-NMR (DMSO-de), δ (ppm): 1.17 (3H, t, J=7.0Hz), 2.57 (4H, s) , 3.17(3H, s) , 4.01(2H, q, J=7.0Hz), 4.03(2H, s) , 7.00(4H, s) , 7.42(2H, d, J=8.5Hz), 7.83(2H, d, J=8.5Hz). MS: 502 (M+H) +
Production Example 53: Synthesis of N-{4-{2-[4- (aminomethyl) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1 ,3- thiazol-2-yl } acetamide Step 1 [4- (Methoxycarbonyl) benzyl] (triphenyl) phosphonium bromide
(4.81 g) and DMF (60 ml) were combined under N2 atmosphere. Then potassium tert-butoxide (1.32 g) and N-{4-formyl-5- [4- (methylthio) benzyl] -1 ,3-thiazol-2-ylJ acetamide (3 g) were added to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 18 hours, poured into ice-water, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CHC13 / AcOEt (2:1) as an eluent. The solid was suspended in AcOEt, and the suspension was filtered. The filtrate was concentrated in vacuo to give methyl 4-((Z)- 2- {2- (acetylamino) -5- [4- (methylthio) benzyl] -1 ,3-thiazol-4- yljvinyl) benzoate (4.16 g) as a yellow amorphous substance. XH-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.43 (3H, s) , 3.84 (3H, s) , 3.96(2H, s) , 6.67 (1H, d, J=12.5Hz), 6.74(1H, d, J=12.5Hz),
7.11(2H, d, J=8.5Hz), 7.17(2H, d, J=8.5Hz), 7.50(2H, d,
J=8.5Hz), 7.85(2H, d, J=8.5Hz), 11.88(1H, s) . MS: 439 (M+H) +
Step 2
Methyl 4- ( (Z) -2-{2- (acetylamino) -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-4-ylJvinyl) benzoate was prepared in a similar manner according to Step 2 of Production Example 32.
Z : E = 2 : 1
XH-NMR (DMSO-de), δ (ppm): 2.08(3Hx2/3, s) , 2.12(3Hxl/3, s) ,
3.18(3H, s) , 3.84(3Hx2/3, s) , 3.86(3Hxl/3, s) , 4.15(2Hx2/3, s) , 4.47(2Hxl/3, s) , 6.68(lHx2/3, d, J=12.5Hz), 6.77(lHx2/3, d, J=12.5Hz), 7.30(lHxl/3, d, J=15.5Hz), 7.43 (2H, d, J=8.5Hz),
7.50-7.97 (19/3H, m) , 11.93 (1HX2/3 , s) , 12.19 (lHxl/3 , s) .
MS: 471 (M+H) +
Step 3
Methyl 4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-4-ylJ ethyl) benzoate was prepared in a similar manner according to Step 6 of Production
Example 45. mp. 209-210 °C
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.94 (4H, m) , 3.17 (3H, s) , 3.84(3H, s) , 4.01(2H, s) , 7.25(2H, d, J=8.5Hz), 7.28(2H, d, J=8.5Hz), 7.76(2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz),
12.05 (1H, brs) .
MS: 473 (M+H) +
Step 4 To a stirred solution of methyl 4- (2-{2- (acetylamino) -5-
[4- (methylsulfonyl) benzyl] -1 , 3-thiazol-4-yl } ethyl) benzoate (2 g) in dry THF (40 ml) was added dropwise 1.0M diisobutylaluminium hydride solution in toluene (14.8 ml) at -78 °C under N2 atmosphere. The reaction mixture was stirred at r.t. for 4 hours, and then quenched with MeOH. AcOEt and 1N- HC1 were added to the mixture, and extracted. The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CHC13 / MeOH (20:1) as an eluent to give N- {4- {2- [4- (hydroxymethyl) phenyl] ethyl }- 5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (552.3 mg) as a colorless solid. mp. 209.5-211 °C
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.86 (4H, s) , 3.17 (3H, s) , 4.01(2H, s) , 4.46(2H, d, J=5.5Hz), 5.12(1H, t, J=5.5Hz), 7.09(2H, d, J=8.0Hz), 7.20(2H, d, J=8.0Hz), 7.28(2H, d, J=8.5Hz), 7.80(2H, d, J=8.5Hz), 12.04(1H, brs). MS: 445 (M+H) + Step 5
N- { 4-{ 2- [4- (Hydroxymethyl) phenyl] ethyl } -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-ylJacetamide (539.5 mg) , CH2C12 (5 ml) and DMF (5 ml) were combined under N2 atmosphere. Then, Et3N (0.211 ml) and MsCl (0.108 ml) were added to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 3.5 hours. The reaction mixture was poured into water, and extracted with CHC13. The organic layer was washed with brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual solid was washed with ethyl ether to give N-{4-{2-[4- (chloromethyl) phenyl] ethyl} -5- [4- (methylsulfonyl) benzyl] -1,3- thiazol-2-yl} acetamide (537.5 mg) as an off-white solid, mp. 202-203 °C H-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.88 (4H, s) , 3.17 (3H, s) , 4.01(2H, s) , 4.73(2H, s) , 7.15(2H, d, J=8.0Hz), 7.30(2H, d, J=8.5Hz), 7.34(2H, d, J=8.0Hz), 7.81(2H, d, J=8.5Hz), 12.05(1H, brs) . MS: 463 (M+H) + Step 6
N- { 4- { 2- [4- (Chloromethyl) phenyl] ethyl } -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide (150 mg) was suspended in CH3CN (6 ml) , and then 28% ammonia solution (0.4 ml) was added to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 16 hours, and concentrated in vacuo . The residual solid was washed with water, and purified by preparative silica gel chromatography with CHCI3 / MeOH (10:1) as an eluent to give N-{4-{2-[4- (aminomethyl) phenyl] ethyl} -5- [4- (methylsulfonyl) benzyl] -1 ,3- thiazol-2-yl} acetamide (32.1mg) as a pale yellow amorphous substance.
XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.85 (4H, s) , 3.17 (3H, s) , 3.69(2H, s) , 4.01(2H, s) , 7.07 (2H, d, J=8.0Hz), 7.21(2H, d, J=8.0Hz), 7.29(2H, d, J=8.5Hz), 7.80(2H, d, J=8.5Hz). MS: 444 (M+H) +
Production Example 54: Synthesis of N-{4-{2- [4- (4 ,5-dihydro- 1 ,3-thiazol-2-ylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide A mixture of N- { 4- [2- (4-aminophenyl) ethyl] -5- [4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ -acetamide (200 mg) , 2- (methylsulfanyl) -4, 5-dihydro-l ,3-thiazole (62 mg) , concentrated HCI (0.064 ml) and 2-methoxyethanol (3 ml) was stirred at 120 °C for 13 hours under N2 atmosphere. After cooled to r.t., the reaction mixture was made basic with saturated NaHC03. The mixture was extracted with AcOEt. The organic layer was dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHC13 / MeOH (10:1) as an eluent to give N- { 4_ { 2- [4- (4 , 5-dihydro-l , 3-thiazol-2-ylamino) phenyl] ethyl } -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-ylJ acetamide (139.8 mg) as a pale yellow amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.82 (4H, s) , 3.16 (3H, s) , 3.17-3.34(4H, m) , 3.98(2H, s) , 6.99(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.45(2H, brd, J=8.5Hz), 7.80(2H, d, J=8.5Hz), 9.24(1H, brs), 12.04(1H, s) . MS: 515 (M+H) + Production Example 55: Synthesis of N-{4-{2- [4- (4 ,5-dihydro- lH-imidazol-2-ylamino) phenyl] ethyl}-5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide
A mixture of N-{ 4- [2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide (150 mg) , ethyl 2- (methylthio) -4 , 5-dihydro-lH-imidazole-l-carboxylate (78.9 mg) , AcOH (0.3 ml) and EtOH (3 ml) was refluxed for 7 hours under N2 atmosphere. After cooled to r.t., the reaction mixture was made basic with saturated NaHCC>3. The mixture was extracted with AcOEt. The organic layer was washed with brine, dried over anhydrous MgS04, and concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHC13 / MeOH (10:1) as an eluent. The amorphous substance was solidified with ethyl ether to give N-{4-{2- [4- (4 , 5- dihydro-lH-imidazol-2-ylamino) phenyl] ethyl J-5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (17.9 mg) as an off-white amorphous solid, mp. 139-140 °C
XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.71-2.87 (4H, m) , 3.18(3H, s) , 3.25-3.41 (4H, m) , 4.03(2H, s) , 6.95(4H, s) , 7.32(2H, d, J=8.5Hz), 7.82(2H, d, J=8.5Hz). MS: 498 (M+H) +
Production Exam le 56: Synthesis of N-{4-{2-[4- (ethanimido lamino) phenyl] ethyl J-5- [4- (methylsulfonyl) benzyl] - 1 , 3-thiazol-2-yl} acetamide N-{4-[2-(4-Aminophenyl)ethyl]-5-[4-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (200 mg) , methyl ethanimidothioate hydroiodide (202 mg) and MeOH (4 ml) were combined under N2 atmosphere. The reaction mixture was refluxed for 3 hours. After cooled to room temperature, the mixture was concentrated in vacuo . The residue was purified by preparative NH silica gel chromatography with CHC13 / MeOH (10:1) as an eluent. The amorphous substance was solidified with ethyl ether to give N-{4-{2-[4-
(ethanimidoylamino) phenyl] ethyl J-5- [4- (methylsulfonyl) benzyl] - 1 ,3-thiazol-2-ylJacetamide (102.4 mg) as a pale yellow amorphous solid, mp. 81.5-83 °C iR- MR (CDCI3) , δ (ppm): 1.83 (3H, brs), 2.08 (3H, s) , 2.81 (4H, m) , 3.18(3H, s) , 4.02(2H, s) , 6.64(2H, brd, J=8.5Hz), 6.99(2H, d, J=8.5Hz), 7.36(2H, d, J=8.5Hz), 7.83(2H, d, J=8.5Hz), 12.03 (1H, brs) . MS: 471 (M+H) + Production Example 57: Synthesis of N-[4-(2-{4-
[ (iminomethyl) aminoJphenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide
N-{4- [2- (4-Aminophenyl) ethyl] -1 ,3-thiazol-2-ylJacetamide (150 mg) was dissolved in THF (2 ml) and pH=7 buffer (2 ml) . Then, ethyl imidoformate hydrochloride (1.26 g) was added to the solution at 0 °C. The reaction mixture was stirred at 0 °C for 2 hours, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with CH3CN / water (7:3) as an eluent. The oil was purified again by preparative silica gel chromatography with CHC13 / MeOH (5:1) as an eluent to give N-[4-(2-{4-
[ (iminomethyl) amino] phenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide (110 mg) as pale brown oil.
XH-NMR (DMSO-de), δ (ppm) : 2.12(3H, s) , 2.81-3.01 (4H, m) , 6.71(1H, s) , 7.09-8.00 (7H, m) , 12.07 (1H, s) . MS: 289 (M+H) +
Production Example 58: Synthesis of N-{4-[2-(4-
{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- yl } acetamide A mixture of methyl N- (4-{2- [2- (acetylamino) -1 , 3-thiazol-
4-yl] ethyljphenyl) imidothiocarbamate hydroiodide (100 mg) , hydrazine monohydrate (0.0525 ml) and THF (3 ml) was stirred at r.t. for 95 hours. The precipitate was filtered off. The filtrate was concentrated in vacuo . The residue was purified by preparative silica gel chromatography with CHC13 / MeOH
(10:1) as an eluent to give N-{4-[2-(4-
{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- yljacetamide (62.7 mg) as a pale pink solid. mp. 216.5-218 °C
XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s) , 2.92 (4H, m) , 6.75 (1H, s) , 7.12(2H, d, J=8.5Hz), 7.27 (2H, d, J=8.5Hz), 8.88(1H, brs),
12.07 (1H, brs) .
MS: 319 (M+H) + Production Example 59: Synthesis of N- (4-{2- [4- (2-amino-2- iminoethyl) phenyl] ethyl }-l , 3-thiazol-2-yl) acetamide
Step 1
N- (4-{2- [4- (Chloromethyl) phenyl] ethyl J-l , 3—thiazol-2- yl) acetamide was prepared from N-(4-{2-[4- (hydroxymethyl) phenyl] ethyl J-l, 3-thiazol-2-yl) acetamide in a similar manner according to Step 5 of Production Example 53. mp. 145-146 °C
XH-NMR (DMSO-de), δ (ppm): 2.11(3H, s) , 2.82-2.99 (4H, m) ,
4.72(2H, s) , 6.73(1H, s) , 7.20(2H, d, J=8.0Hz), 7.33(2H, d, J=8.0Hz), 12.08 (1H, brs).
MS: 295 (M+H) +
Step 2
NaCN (115 mg) , KI (130 mg) and water (1.8 ml) were combined, and then a solution of N-(4-{2-[4- (chloromethyl) phenyl] ethyl J-l ,3-thiazol-2-yl) acetamide (230 mg) in DMF (7 ml) was added dropwise to the mixture at 0 °C.
The reaction mixture was stirred at r.t. for 19 hours, poured into water, and extracted with CHC13. The organic layer was washed with brine, dried over anhydrous MgS04 and concentrated in vacuo . The residual solid was washed with ethyl ether to give N- (4-{2- [4- (cyanomethyl) phenyl] ethyl J-l ,3-thiazol-2- yl) acetamide (149.1 mg) as a colorless solid. mp. 160-161 °C
XH-NMR (DMSO-de), δ (ppm): 2.11 (3H, s) , 2.82-2.97 (4H, m) , 3.97 (2H, s) , 6.73(1H, s) , 7.21(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 12.08(1H, brs). MS: 286 (M+H) + Step 3
N- (4- {2- [4- (Cyanomethyl) phenyl] ethyl } -1 ,3-thiazol-2- yl) acetamide (600 mg) was dissolved in MeOH (5 ml) and CHC13 (5 ml) , and then HCI gas was bubbled at 0 °C for 5 minutes with stirring. The reaction mixture was stood for 17 hours, and concentrated in vacuo . The residual solid was washed with ethyl ether to give methyl 2- (4- {2- [2- (acetylamino) -1 ,3- thiazol-4-yl] ethyljphenyl) ethanimidoate hydrochloride (632.5 mg) as an off-white solid, mp. 77-78 °C ifi-NMR (DMSO-de), δ (ppm) : -2.12 (3H, s) , 2.88 (4H, s) , 4.92 (6H, brs), 6.75(1H, s) , 7.10-7.20 (4H, m) , 12.11(1H, brs). MS: 318 (M+H) + free Step 4
Methyl 2- (4-{2- [2- (acetylamino) -1 , 3-thiazol-4- yl] ethyljphenyl) ethanimidoate hydrochloride (600 mg) was dissolved in EtOH (12 ml) . Then ammonium chloride (136 mg) and ammonia in methanol (2 ml) were added to the solution. The reaction mixture was refluxed for 4 hours under N2 atmosphere. After cooled to r.t., the suspension was filtered in vacuo . The filtrate was concentrated in vacuo , and the residue was solidified with EtOH / diethyl ether to give N- (4-{2- [4- (2- amino-2-iminoethyl) phenyl] ethyl J-l , 3-thiazol-2-yl) acetamide hydrochloride (338.6 mg) as an off-white solid. mp . 190 . 5-192 °C
XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s) , 2.89 (4H, m) , 3.68 (2H, s) , 6.74(1H, s) , 7.20(2H, d, J=8.0Hz), 7.39(2H, d, J=8.0Hz). MS: 303 (M+H) + free Step 5
N-(4-{2-[4-(2-Amino-2-iminoethyl)phenyl]ethyl}-l,3- thiazol-2-yl) acetamide hydrochloride (67 mg) was dissolved in water (1 ml) and CH3CN (1 ml) . The solution was made basic (pH=8) with saturated NaHC03, and concentrated in vacuo . The residue was purified by preparative NH silica gel chromatography with CH3CN / water (7:3) as an eluent to give N- (4- {2- [4- (2-amino-2-iminoethyl) phenyl] ethyl J-l ,3-thiazol-2- yl) acetamide (26 mg) as an off-white amorphous substance. XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 2.89 (4H, m) , 3.59 (2H, s) , 6.72(1H, s) , 7.20(2H, d, J=8.0Hz), 7.30(2H, d, J=8.0Hz), 9.38 (3H, brs) . MS: 303 (M+H) +
Production Example 60: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylthio) benzyl] -1 ,3-thiazol-2-ylJ acetamide Step 1
A mixture of N-{5- [4- (methylthio) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJacetamide and N-{5-[4- (methylthio) benzyl] -4- [ (E) -2- (4-nitrophenyl) vinyl] -1 ,3- thiazol-2-yl} acetamide (Z : E = 2 : 1) (570 mg) was dissolved in CH2C12 (6 ml) under N2 atmosphere. Then m-CPBA (254 mg) was added portionwise to the solution at 0 °C. The reaction mixture was stirred at r.t. for 1.5 hours, and diluted in MeOH / CHC13. The organic solution was washed with lN-Na2C03, water and brine, dried over MgS0 , and concentrated in vacuo to give a mixture of N-{5- [4- (methylsulfinyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide and N-{5-[4- (methylsulfinyl) benzyl] -4- [ (E) -2- (4-nitrophenyl) vinyl] -1 , 3- thiazol-2-yl} acetamide (Z : E = 2 : 1) (282.8 mg) as a yellow amorphous substance.
Z : E = 2 : 1
XH-NMR (DMSO-de), δ (ppm): 2.08(3Hx2/3, s) , 2.13(3Hxl/3, s) , 2.71(3H, s) , 4.18(2Hx2/3, s) , 4.44(2Hxl/3, s) , 6.73(lHx2/3, d,
J=12.5Hz), 6.87(lHx2/3, d, J=12.5Hz), 7.34(lHxl/3, d,
J=15.5Hz), 7.41-8.17 (7/3H, m) , 7.41(2Hx2/3, d, J=8.0Hz),
7.50(2Hxl/3, d, J=8.0Hz), 7.63(2Hx2/3, d, J=8.0Hz),
7.93(2Hxl/3, d, J=8.0Hz), 8.14(2Hx2/3, d, J=8.0Hz), 8.22(2Hxl/3, d, J=8.0Hz), 11.89 (1HX2/3 , s) , 12.20 (lHxl/3 , s) .
MS: 442 (M+H) +
Step 2
N-{4- [2- (4-Aminophenyl) ethyl] -5- [4- (methylsulfinyl) benzyl] -1 , 3-thiazol-2-yl }acetamide was prepared in a similar manner according to Step 6 of Production
Example 45.
XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.62-2.84 (4H, m) ,
2.70(3H, s) , 3.94(2H, s) , 4.85(2H, s) , 6.46(2H, d, J=8.5Hz),
6.77 (2H, d, J=8.5Hz), 7.23(2H, d, J=8.5Hz), 7.58(2H, d, J=8.5Hz) , 12.00(1H, s) .
MS: 414 (M+H) +
Step 3
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [4-
(methylsulfinyl) benzyl] -1 , 3-thiazol-4- yl}ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (DMSO-d6) , δ (ppm): 1.39 (9H, s) , 1.51 (9H, s) , 2.08 (3H, s) , 2.69(3H, s) , 2.86(4H, s) , 3.98(2H, s) , 7.12(2H, d,
J=8.5Hz), 7.26(2H, d, J=8.0Hz), 7.43(2H, d, J=8.5Hz), 7.57 (2H, d, J=8.0Hz), 9.95(1H, s) , 11.43(1H, s) , 12.02(1H, s) .
MS: 656 (M+H) +
Step 4
The title compound was prepared in a similar manner according to Step 2 of Production Example 48. mp. 159.5-161 °C
XH-NMR (DMSO-de), δ (ppm): 2.07 (3H, s) , 2.44 (3H, s) , 2.79 (4H, s) , 3.86(2H, s) , 6.78(2H, d, J=8.5Hz), 7.02(2H, d, J=8.5Hz), 7.04.(2H, d, J=8.5Hz), 7.30(2H, d, J=8.5Hz). MS: 440 (M+H) +
Production Example 61: Synthesis of N-{4-[4-(3- { [amino (imino) methyl] amino Jpropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1 , 3-thiazol-2-yl}acetamide hydrochloride Step 1
To a solution of methyl 4-{ [4- (methylthio) phenyl] acetyl Jbenzoate (5 g) in dichloromethane (250 ml) were added acetic acid (0.65 ml) and pyridinium bromide perbromide (6.51 g) at 0 °C, and the mixture was stirred for lh at the same temperarure. The reaction mixture was poured into water (250 ml) and extracted with ethyl acetate (250 ml) . The organic layer was washed with water and brine, dried over magnesium sulfate and evapolated. The residue was washed with diisopropylethyl ether and collected by filtration to give methyl 4-{2-bromo [4- (methylthio) phenyl] acetyl Jbenzoate as an off-white solid. XH-NMR (CDC13) , δ (ppm): 2.47 (3H, s) , 3.94 (3H, s) , 6.33 (3H, s) , 7.23(2H, d, J=8.5Hz), 7.43(2H, d, J=8.5Hz). Step 2
Methyl 4-{2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazol-4- yl Jbenzoate was prepared in a similar manner according to Step 2 of Production Example 46. XH-NMR (DMSO-de), δ (ppm) : 2.47 (3H, s) , 3.83 (3H, s) , 7.08- 7.32(4H, m) , 7.52(2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz). MS: 357.1 (M+H) + Step 3
To a solution of methyl 4-{2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazol-4-yl Jbenzoate (100 mg) in tetrahydrofuran (4 ml) was added portionwise lithium aluminium hydride (21.3 mg) , and the mixture was stirred for lh at 20 °C. To the reaction mixture were added ethyl acetate (10 ml) and water (3 ml) . The resulting precipitate was removed by filtration, and the filtrate was washed with brine, dried over sodium sulfate and evaporated to give (4-{2-amino-5- [4- (methylthio) phenyl] -1 ,3-thiazol-4-yl Jphenyl) methanol as a yellow solid, that was used as crude in the next reaction. ifi-NMR (DMSO-de), δ (ppm): 2.46 (3H, s) , 4.46 (2H, d, J=6.0Hz), 5.17 (t, 1H, J=5.5Hz), 7.13(d, 2H, J=5.5Hz), 7.17 (d, 2H, J=5.5Hz), 7.20 (d, 2H, J=8.5Hz), 7.34 (d, 2H, J=8.5Hz). MS: 329.2 (M+H) + Step 4 To a suspension of (4~{2-amino-5- [4- (methylthio) phenyl] -
1 ,3-thiazol-4-yl Jphenyl) methanol (89.3 mg) in dichloromethane (1 ml) were added pyridine (0.11 ml) and acetylchloride (42.5 μl) at 0 °C, and the mixture was stirred at the same temperature for 1 hr. To the reaction mixture was added 1N- hydrochloric acid (10 ml) , and the mixture was extracted with ethyl acetate (20 ml x 2) . The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated to give a crude green solid (77.6 mg) . To a solution of the crude green solid in dichloromethane (3 ml) was added 3- chloroperbenzoic acid (80.7 mg) at 0 °C, and the mixture was stirred for 2 hr at 20 °C. To the reaction mixture was added saturated sodium hydrogencarbonate aqueous solution (10 ml) , and the mixture was extracted with ethyl acetate (20 ml x 2) , washed with water and brine, dried over magnesium sulfate, and evaporated to give 4-{2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1 ,3-thiazol-4-yl}benzyl acetate as a brown solid. XH-NMR (CDCI3) , δ (ppm): 1.77 (3H, s) , 2.14 (3H, s) , 3.10 (3H, s) , 5.12(2H, s) , 7.32(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 7.52(2H, d, J=8.5Hz), 7.88(2H, d, J=8.5Hz), 11.1(1H, brs). MS: 467.0 (M+Na) + Step 5 5 To a suspension of 4- {2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1 ,3-thiazol-4-yl}benzyl acetate (1.218 g) in metanol (24 ml) was added pottasium carbonate (379 mg) at 20 °C, and the mixture was stirred for- 1 h. To the reaction mixture was added 0. IN-hydrochloric acid (27.4 ml), and the ι° mixture was extracted with chloroform (500 ml) , dried over magnesium sulfate and evaporated to give N-{4-[4- (hydroxymethylJphenyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3- thiazol-2-yl} acetamide as a yellow solid. XH-NMR (CDCls) , δ (ppm): 1.87 (3H, s) , 3.09 (3H, s) , 4.72 (2H, s) ,
15 7.31(2H, d, J=8.5Hz), 7.42(2H, d, J=8.5Hz), 7.51(2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 10.83(1H, brs). MS: 425.0 (M+Na) + Step 6
To a solution of N-{4- [4- (hydroxymethyl) phenyl] -5- [4-
20 (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJacetamide (867.4 mg) in methanol (0.6 ml) and chloroform (10 ml) was added manganese (IV) oxide (6.65 g) at 20 °C under N2 atmosphere, and the mixture was stirred for 19 hrs . The reaction mixture was filtered through a celite pad. The filtrate was evaporeted to
25 give N-{4- (4-formylphenyl) -5- [4- (methylsulfonyl) phenyl] -1 ,3- thiazol-2-yl} acetamide as a yellow solid, that was used as crude in the next reaction.
XH-NMR (DMSO-d6), δ (ppm): 2.20 (3H, s) , 3.26 (3H, s) , 7.63 (2H, d, J=8.5Hz), 7.64(2H, d, J=8.0Hz), 7.90(2H, d, J=8.0Hz),
30 7.92(2H, d, J=8.5Hz), 10.00(1H, s) , 12.5(1H, brs). Step 7
To a suspension of N-{ 4- (4-formylphenyl) -5- [4- (methylsulfonyl) phenyl]-l,3-thiazol-2-yl}acetamide (360 mg) in chloroform (7 ml) was added
(carbethoxymethylene) triphenylphosphorane (626 mg) at 20 °C, and the mixture was stirred for lh. The reaction mixture was evaporated. The residue was purified by column chromatography over silica gel (150 ml) with hexane / ethyl acetate (1:1-1:2) as an eluent to give ethyl (2E) -3- (4- {2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-4-yl Jphenyl) acrylate as a pale yellow solid. XH-NMR (CDC13) , δ (ppm): 1.34(3H, t, J=7.0Hz), 1.93(3H, s) , 3.10(3H, s) , 4.28(2H, q, J=7.0Hz), 6.45(1H, d, J=16.1Hz), 7.48(4H, s) , 7.54(2H, d, J=8.5Hz), 7.67(2H, d, J=16.1Hz), 7.89(2H, d, J=8.5Hz), 10.39(1H, s) . MS: 493.1 (M+Na) + Step 8 To a suspension of ethyl (2E) -3- (4- {2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1 ,3-thiazol-4-yl Jphenyl) acrylate (306.5 mg) in tetrahydrofuran (3 ml) was added portionwise lithium borohydride (271 mg) at 0 °C, and the mixture was stirred for 6.5 h at 20 °C. The reaction mixture was poured into a mixture of saturated ammonium chloride aqueous solution (50 ml) and chloroform (50 ml) at 0 °C. The organic layer was separeted, dried over maganesium sulfate and evaporarted to give a crude yellow solid (300 mg) . The residue was purified by column chromatography over silica gel (80 ml) with hexane / ethyl acetate (1:2-1:5) as an eluent to give N-{4-[4-(3- hydroxypropyl) henyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3- thiazol-2-yl}acetamide as a pale yellow solid. XH-NMR (CDCI3) , δ (ppm): 1.71 (3H, s) , 1.80-1.99 (2H, m) , 2.61- 2.82(2H, m) , 3.09(3H, s) , 3.69(2H, dd, J=6.0 , 10.0Hz), 7.17 (2H, d, J=8.0Hz), 7.37(2H, d, J=8.5Hz), 7.53(2H, d, J=8.5Hz), 7.87 (2H, d, J=8.5Hz), 11.1 (1H, s) . MS: 431.20 (M+l)+ Step 9 To a solution of N-{4- [4- (3-hydroxypropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide (75 mg) in tetrahydrofuran (0.7 ml) were added triphenylphosphine (68.5 mg) and carbon tetrabromide (86.7 mg) at 0 °C, and the mixture was stirred for lh at 20 °C. The reaction mixture was purified by preparative thin-layer chromatography over silica gel with hexane / ethyl acetate (1:2) as an eluent to give N-{4-[4-(3- bromopropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol- 2-ylJ acetamide as colorless oil. ifj-NMR (DMSO-d5) , δ (ppm) : 1.67 (3H, s) , 2.08-2.28 (2H, m) , 2.80(2H, t, J=7.5Hz), 3.10(3H, s) , 3.41(2H, t, J=6.5Hz), 7.18(2H, d, J=8.0Hz), 7.39(2H, d, J=8.0Hz), 7.53(2H, d, J=8.5Hz), 7.87(2H, d, J=8.5Hz), 11.1(1H, s) . MS: 515.0 (M+Na) + Step 10
To a solution of N-{4- [4- (3-bromopropyl) phenyl]-5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-yl}.acetamide (82 mg) in N,N-dimethylformamide (0.82 ml) was added phthalimide potassium salt (30.8 mg) , and the mixture was stirred for 2hrs . at 50 °C. The reaction mixture was cooled to 20 °C, then water was added to the reaction mixture, and the mixture was extracted with ethyl acetate, washed with brine, dried over magnesium sulfate and evaporated to give a crude material (92.0 mg) . The crude material was purified by preparative thin-layer chromatography over silica gel to give N-{4-{4-[3- (1 ,3-dioxo-1 ,3-dihydro-2H-isoindol-2-yl) propylJphenylJ-5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide . XH-NMR (CDCI3) , δ (ppm): 1.72 (3H, s) , 1.90-2.13 (2H, m) , 2.60- 2.79(2H, m) , 3.09(3H, s) , 3.74(2H, t, J=7.3Hz), 7.18(2H, d, J=8.0Hz), 7.37 (2H, d, J=8.0Hz), 7.52 (2H, d, J=8.5Hz), 7.66- 7.78(2H, m) , 7.80-7.92 (4H, m) , 11.0(1H, s) . MS: 582.1 (M+Na) + Step 11 To a solution of N-{4-{4- [3- (1 ,3-dioxo-l ,3-dihydro-2H- isoindol-2-yl)propyl] phenyl J-5- [4- (methylsulfonyl) phenyl] -1 ,3- thiazol-2-ylJ acetamide (53.2 mg) in acetonitrile (0.5 ml) was added hydrazine monohydrate (46.1 μl) , and the mixture was stirred at 50 °C for 30 min. The volatiles were evaporated. To the mixture was added chloroform (1 ml) , and an insoluble material was removed by filtration. The filtrate was purified by preparative thin-layer chromatography over NH silica gel with chloroform / methanol (10:1) as an eluent to give N-{4- [4_ (3-aminopropyl) phenyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3- thiazol-2-yl} acetamide as a yellow solid.
XH-NMR (DMSO-d5), δ (ppm): 1.69 (3H, s) , 1.69-1.88 (2H, m) , 2.60- 2.74(2H, m) , 2.76(2H, t, J=7.0Hz), 3.09(3H, s) , 7.15(2H, d, J=8.5Hz), 7.36(2H, d, J=8.5Hz), 7.53(2H, d, J=8.5Hz), 7.86(2H, d, J=8.5Hz) .
MS: 428.2 (M-H)~ Step 12
Di-tert-butyl ( (E)-{ [3- (4- (2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-4- yl}phenyl)propyl] amino Jmethylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.50 (9H, s) , 1.87- 1.97(2H, m) , 2.01(3H, s) , 2.69(2H, t, J=8.1Hz), 3.09(3H, s) , 3.41-3.54 (2H, m) , 7.16(2H, d, J=8.lHz), 7.36(2H, d, J=8.1Hz), 7.54(2H, d, J=8.5Hz), 7.87(2H, d, J=8.4Hz), 8.38(1H, t, J=5.lHz), 9.87(1H, brs), 11.5(1H, s) . MS: 694.2 (M+Na) + Step 13 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.72-1.85 (2H, m) , 2.19(3H, s) , 2.58- 2.66(2H, m) , 3.08-3.18 (2H, m) , 3.25(3H, s) , 6.65-7.58 (4H, brs) , 7.21(2H, d, J=8.4Hz) , 7.36(2H, d, J=8.1Hz) , 7.56(2H, d,
J=8.4Hz) , 7.67 (1H, t\ J=5.1Hz) , 7.89 (2H, d, J=8.4Hz) , 12.4(1H, s) .
MS: 472.1 (M+H) + free Production Example 62: Synthesis of N-{4-(2-{4-
[ (aminooxy) methyl] phenyl}ethyl) -5- [4- (methylsulfonyl) phenyl] -
1 , 3-thiazol-2-yl}acetamide
Step 1
Methyl 4- ( (E) -2-{2- (acetylamino) -5- [4- (methylthio) phenyl] -1 ,3-thiazol-4-yl}vinyl) benzoate was prepared from N- {5- [4- (methylthio) phenyl] -4-formyl-l ,3- thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 53.
XH-NMR (DMSO-de), δ (ppm) : 2.12(3Hxl/3, s) , 2.19(3Hx2/3, s) , 2.54(3H, s) , 3.85(3H, s) , 6.55(lHxl/3, d, J=12.6Hz),
6.73(lHxl/3, d, J=12.6Hz), 7.17-7.72 (8H+2Hx2/3 , m) ,
7.84(2Hxl/3, d, J=8.5Hz), 7.93(2Hx2/3, d, J=8.5Hz), 12.31(1H, brs) .
MS: 423.1 (M-H) " Step 2
Methyl 4- ( (E) -2- {2- (acetylamino) -5- [4-
(methylsulfonyl) phenyl] -1 ,3-thiazol-4-yl}vinyl) benzoate was prepared in a similar manner according to Step 2 of Production
Example 32. XH-NMR (DMSO-de), δ (ppm): 2.15(3Hxl/5, s) , 2.21(3Hx4/5, s) ,
3.24(3Hxl/5, s) , 3.30(3Hx4/5, s) , 3.84(3Hxl/5, s) ,
3.85(3Hx4/5, s) , 6.64(lHxl/5, d, J=12.6Hz), 6.81(lHxl/5, d,
J=12.6Hz), 7.31(lHx4/5, d, J=15.6Hz), 7.52(lHx4/5, d,
J=15.6Hz), 7.30-8.11(8H, m) , 12.24 (lHxl/5 , s) , 12.49 (1HX4/5 , s) .
MS: 479.0 (M+Na) +
Step 3
Methyl 4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1 , 3-thiazol-4-yl } ethyl) benzoate was prepared in a similar manner according to Step 6 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm): 2.31 (3H, s) , 2.97-3.07 (4H, m) , 3.08(3H, s) , 3.91(3H, s) , 7.09(2H, d, J=8.1Hz), 7.32(2H, d, J=8.1Hz), 7.87 (4H, d, J=8.1Hz), 8.75(1H, s) . MS: 481.0 (M+Na) + Step 4
N- {4- { 2- [4- (Hydroxymethyl) phenyl] ethyl } -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide was prepared in a similar manner according to Step 4 of Production Example 53.
XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.96 (4H, s) , 3.24 (3H, s) , 4.43(2H, s) , 7.06(2H, d, J=8.1Hz), 7.18(2H, d, J=8.1Hz), 7.50(2H, d, J=8.4Hz), 7.91(2H, d, J=8.4Hz), 12.33(1H, s) . MS: 453.1 (M+Na) + Step 5
N-{4- {2- [4- (Hydroxymethyl) phenyl] ethyl J-5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide (100 mg) , N-hydroxyphthalimide (39.8 mg) , triphenylphosphine (64 mg) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere, then, diethyl azodicarboxylate (40 wt% solution in toluene) (0.111 ml) was added to the solution at 0 °C, and the mixture was stirred at 20 °C for 5 hrs. The reaction mixture was poured into saturated sodium hydrogen carbonate aqueous solution, and extracted with chloroform. The organic layer was washed with brine, dried over magnesium sulfate, filtered and evaporated. The crude material was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (30:1) as an eluent to give N-{4- [2- (4-{ [ (1 ,3-dioxo- 1 ,3-dihydro-2H-isoindol-2-yl) oxy]methyl Jphenyl) ethyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide as a yellow foam. XH-NMR (CDCI3) , δ (ppm): 2.30 (3H, s) , 2.95-3.00 (4H, m) , 3.09(3H, s) , 5.15(2H, s) , 7.04(2H, d, J=8.1Hz), 7.21-7.92 (10H, m) , 9.31(1H, brs) . MS: 598.1 (M+Na) +, 574.0 (M-H)~ Step 6
To a solution of N-{4- [2- (4-{ [ (1 ,3-dioxo-l ,3-dihydro-2H- isoindol-2-yl) oxy]methyl Jphenyl) ethyl] -5- [4-
(methylsulfonyl)phenyl]-l,3-thiazol-2-yl}acetamide (116.8 mg) in N,N-dimethylformamide (1.1 ml) was added methylhydrazine (11.9 μl) under N2 atmosphere, and the mixture was stirred at 20 °C for 4hrs . The reaction mixture was concentrated in vacuo . Ethyl acetate was added to the residue, and the precipitate was filtered off. The filtrate was concentrated in vacuo to give a crude yellow solid (105.1 mg) . The crude material was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (30:1) as an eluent to give a pale yellow powder. The obtained powder was washed with acetonitrile, and the precipitate was collected by filtration to give N- { 4- (2- {4- [ (aminooxy) methyl] phenyl} ethyl) -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-yl}acetamide (8.4 mg) as a white solid.
XH-NMR (DMSO-de), δ (ppm) : 2.17(3H, s) , 2.91-3.02 (4H, m) , 3.24(3H, s) , 4.51(2H, s) , 5.98(2H, s) , 7.09(2H, d, J=8.1Hz), 7.19(2H, d, J=8.1Hz), 7.51(2H, d, J=8.4Hz), 7.91(2H, d, J=8.1Hz), 12.33 (1H, brs). MS: 468.0 (M+H) +
Production Exmple 63: Synthesis of N-{4-{2-[4- ( { [amino (imino) methyl] aminojmethyl) phenyl] ethyl}-5- [4- (methylsulfonyl) phenyl] -1 , 3-thiazol-2-yl } acetamide hydrochloride Step 1
N- { 4- {2- [4- (Bromomethyl) phenyl] ethyl } -5- [4- (methylsulfonyl) phenyl] -1 , 3-thiazol-2-yl } acetamide was prepared from N- (4- [2- {4- (hydroxymethyl) phenyl } ethyl] -5- [4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-yl) acetamide in a similar manner according to Step 9 of Production Example 61. XH-NMR (DMSO-de), δ (ppm) : 2.17 (3H, s) , 2.90-3.10 (4H, m) , 3.23(3H, s) , 4.67(2H, s) , 7.10(2H, d, J=8.1Hz), 7.31(2H, d, J=8.1Hz), 7.48(2H, d, J=8.4Hz), 7.90(2H, d, J=8.4Hz), 12.33(21H, s) . MS: 491.0 (M-H)~ Step 2 To a solution of N-{ 4- {2- [4- (bromomethyl) phenyl] ethyl}-5-
[4- (methylsulfonyl) phenyl] -1 ,3-thiazol-2-yl}acetamide (70 mg) in N,N-dimethylformamide (1 ml) was added diformimide sodium salt (13.5 mg) , and the mixture was stirred for 10 min at 20 °C. To the reaction mixture was added water, the mixture was extracted with ethyl acetate, washed with water twice, dried over magnesium sulfate, and evaporated to give a crude diformimide compound. The diformimide compound was suspended in cone, hydrocloric acid (200 μl) , ethanol (2 ml) and methanol (0.5 ml) . The reaction mixture was stirred at 20 °C for 3hrs . , then at 50 °C for 3hrs . The volatails were evaporated. To the residue was added saturated sodium hydrogen carbonate aqueous solution, the mixture was extracted with chloroform, dried over maganesium sulfate and evaporated to give crude N-{4-(2- {4- [aminomethy1Jphenyl} ethyl) -5- [4- (methylsulfonyl) phenyl] - 1 ,3-thiazol-2-yl}acetamide, that was used as crude in the next reaction. MS: 428.8 (M+H) + Step 3
Di-tert-butyl ( (E) -{ [4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) phenyl] -1 , 3-thiazol-4- yl} ethyl) benzyl] amino Jmethylidene) biscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. XH-NMR (CDCI3) , δ (ppm): 1.48 (9H, s) , 1.51 (9H, s) , 2.30 (3H, s) , 2.98(4H, s) , 3.08(3H, s) , 4.57 (2H, d, J=5.1Hz) , 7.04(2H, d,
J=8.1Hz) , 7.17 (2H, d, J=8.1Hz) , 7.38(2H, d, J=8.4Hz) , 7.91(2H, d, J=8.4Hz) , 8.54(1H, t, J=5.1Hz) , 8.79(1H, s) , 11.53(1H, s) .
MS: 672.2 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 2.18 (3H, s) , 2.90-3.05 (4H, m) ,
3.25(3H, s) , 4.31(2H, d, J=6.2Hz), 6.65-7.73 (4H, brs), 7.14(2H, d, J=8.1Hz), 7.18(2H, d, J=8.1Hz), 7.52(2H, d,
J=8.4Hz), 7.93(2H, d, J=8.4Hz), 12.35(1H, s) .
MS: 506.0 (M-H)~
Production Example 64: Synthesis of methyl 4-({2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl]-l , 3-thiazol-5- yljmethyl) benzoate hydrochloride
Step 1
Ethyl 4- (4-iodophenyl) -2-oxobutanoate was prepared from
Ethyl 3- (4-iodophenyl) propanoate in a similar manner according to Step 2 of Production Example 47.
XH-NMR (CDC13) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 2.90 (2H, t,
J=7.5Hz), 3.15(2H, t, J=7.5Hz), 4.31(2H, q, J=7.0Hz), 6.96(2H, d, J=8.0Hz) , 7.61 (8.5Hz) .
MS: 331.0 (M-H)~ Step 2
Ethyl 3-bromo-4- (4-iodophenyl) -2-oxobutanoate was prepared in a similar manner according to Step 1 of Production
Example 46.
XH-NMR (CDCI3) , δ (ppm): 1.38 (3H, t, J=7.0Hz), 3.19 (1H, dd, J=7.5, 14.6Hz), 3.47(1H, dd, J=7.5 , 14.6Hz), 4.36(2H, q, J=7.0Hz), 5.21(1H, dd, J=7.5 , 7.5Hz), 7.00(2H, d, J=8.5Hz), 7.65 (2H, d, J=8.5Hz) . MS: 369.2 Step 3
Ethyl 3-bromo-4- (4-iodophenyl) -2-oxobutanoate (1.32 g) was dissolved in ethanol (26 ml) , and then, thiourea (244 mg) was added to the solution. The reaction mixture was refluxed for 1 h under nitrogen atmosphere. The cooled reaction mixture was evaporated in vacuo . The crude material was triturated with diethyl ether to give ethyl 2-amino-5- (4-iodobenzyl) -1 ,3- thiazole-4-carboxylate hydrobromide as a pale yellow solid. XH-NMR (DMSO-de), δ (ppm): 1.27 (3H, t, J=7.0Hz), 4.28 (2H, q, J=7.0Hz), 4.31(2H, s) , 7.10(2H, d, J=8.5Hz), 7.69(2H, d, J=8.5Hz) .
MS: 389.0 (M+H) +, 411.0 (M+Na) + Step 4
Ethyl 2-amino-5- (4-iodobenzyl) -1 , 3-thiazole-4-carboxylate hydrobromide (1.386 g) was dissolved in dichloromethane (14 ml) under nitrogen atmosphere. Then, pyridine (0.765 ml) and acethyl chloride (0.336 ml) were added dropwise to the solution at 0 °C. The reaction mixture was stirred at 20 °C for lh. The organic solution was washed with IN-hydrochloric acid, water and brine, dried over magnesium sulfate, and concentrated in vacuo . The residue was washed with diisopropyl ether to give ethyl 2- (acetylamino) -5- (4-iodobenzyl) -1 ,3- thiazole-4-carboxylate as a white solid. XH-NMR (DMSO-de), δ (ppm): 1.27 (3H, t, J=7.0Hz), 2.09 (3H, s) , 4.26(2H, q, J=7.0Hz), 4.43(2H, s) , 7.10(2H, d, J=8.0Hz), 7.67 (2H, d, J=8.0Hz), 12.44(1H, s) . MS: 431.0 (M+H) +, 453.0 (M+Na) + Step 5
N- [4-Formyl-5- (4-iodobenzyl) -1 , 3-thiazol-2-yl] acetamide was prepared in a similar manner according to Step 4 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm) : 2.11 (3H, s) , 4.48 (2H, s) , 7.11 (2H, d, J=8.5Hz), 7.68(2H, d, J=8.5Hz), 10.00(1H, s) . MS : 409 . 0 (M+Na) + Step 6
N-{ 5- (4-Iodobenzyl) -4- [2- (4-nitrophenyl) vinyl] -1,3- thiazol-2-yl} acetamide was prepared in a similar manner according to Step 5 of Production Example 45.
XH-NMR (CDCI3) , δ (ppm): 2.07(3Hx2/3, s) , 2.15(3Hxl/3, s) , 3.96(2Hx2/3, s) , 4.12(2Hxl/3, s) , 6.63(lHx2/3, d, J=12.6Hz), 6.70(lHx2/3, d, J=12.6Hz), 6.94(2Hx2/3, d, J=8.0Hz), 6.99(2Hxl/3, d, J=8.0Hz), 7.12(lHxl/3, d, J=15.6Hz), 7.25(lHxl/3, d, J=15.6Hz), 7.39(2Hx2/3, d, J=9.0Hz), 7.56(2Hxl/3, d, J=8.5Hz), 7.62(2Hx2/3, d, J=8.0Hz), 7.65(2Hxl/3, d, J=8.5Hz), 8.00(2Hx2/3, d, J=8.5Hz), 8.22(2Hxl/3, d, J=8.5Hz), 9.85 (lHxl/3 r s) , 10.18 (1HX2/3 , s) . MS: 528.0 (M+H) + Step 7
To a solution of a mixture of N-{5- (4-iodobenzyl) -4- [ (Z) 2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide and N-{5- (4-iodobenzyl) -4- [ (E) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2- ylj acetamide (Z:E=2:1) (558.2 mg) in methanol (2.8 ml) and N,N-dimethylformamide (5.5 ml) were added palladium (II) acetate (49.6 mg) , 1 ,3-bis (diphenylphosphino) propane (109 mg) and triethylamine (308 μl) . Carbon monooxide gas was bubbled through the solution for 30 min at 25 °C. Then the reaction mixture was stirred for 6 hrs. at 70 °C under carbon monooxide atmosphere. The reaction mixture was cooled to 25 °C, diluted with ethyl acetete, washed with brine, dried over magnesium sulfate and evaporated to give a crude yellow foam (645 mg) . The crude foam was purified by flash column chromatography over silica gel with toluene / ethyl acetate (2:1-3:2) as an eluent, and triturated with ethyl ether to give a mixture of N-{5- (4- (methoxycarbonyl) benzyl) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide and N-{5-(4- (methoxycarbonyl) benzyl) -4- [ (E) -2- (4-nitrophenyl) vinyl] -1 , 3- thiazol-2-yl}acetamide (Z:E=2:3) as a yellow solid. XH-NMR (CDCI3) , δ (ppm): 2.09(3Hx2/5, s) , 2.20(3Hx3/5, s) , 3.9K3H, s) , 4.10(2Hx2/5, s) , 4.25(2Hx3/5, s) , 7.27(2Hx2/5, s) , 7.14(lHx3/5, d, J=15.6Hz), 7.25(2Hx2/5, d, J=9.0Hz), 7.29(lHx3/5, d, J=15.6Hz), 7.31(2Hx3/5, d, J=8.5Hz), 7.38(2Hx2/5, d, J=9.0Hz), 7.57(2Hx3/5, d, J=8.5Hz), 7.97(2Hx2/5, d, J=8.5Hz), 7.99(2Hx2/5, d, J=9.0Hz), 8.00(2Hx3/5, d, J=8.5Hz), 8.20(2Hx3/5, d, J=9.0Hz), 9.55(lHx3/5, brs), 10.11 (1HX2/5 , brs). MS: 460.1 (M+Na) + Step 8
Methyl 4- ( {2- (acetylamino) -4- [2- (4-aminophenyl) ethyl] - 1 ,3-thiazol-5-yl}methyl) benzoate was prepared in a similar manner according to Step 6 of Production Example 45. XH-NMR (CDCI3) , δ (ppm): 2.20 (3H, s) , 2.80 (4H, s) , 3.40-
3.67 (2H, m) , 3.83(2H, s) , 3.90(3H, s) , 6.57 (2H, d, J=8.5Hz), 6.84(2H, d, J=8.5Hz), 7.09(2H, d, J=8.0Hz), 7.91(2H, d, J=8.5Hz) , 8.96 (1H, brs) . MS: 410.2 (M+H) +, 432.2 (M+Na) + Step 9
Methyl 4- [ (2- (acetylamino) -4-{2- [4- ( { (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl }-l ,3-thiazol-5- yl) methyl]benzoate was prepared in a similar manner according to Step 3 of Production Example 31.
XH-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.54 (9H, s) , 2.20 (2H, s) , 2.83(4H, s) , 3.88(2H, s) , 3.89(3H, s) , 7.03(2H, d, J=8.5Hz), 7.17 (2H, d, J=8.0Hz), 7.44(2H, d, J=8.0Hz), 7.93(2H, d, J=8.5Hz), 9.09(1H, brs), 10.24(1H, s) , 11.64(1H, s) . MS: 652.3 (M+H) +, 652.3 (M+Na) + Step 10
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.86 (4H, s) , 3.83 (3H, s) , 3.96-4.10(2H, m) , 7.13(2H, d, J=8.5Hz), 7.24(2H, d, J=9.0Hz), 7.28(2H, d, J=8.5Hz), 7.35(4H, s) , 7.89(2H, d, J=8.0Hz), 9.71(1H, s) , 12.01(1H, s) . MS: 452.2 (M+H) ~ free
Production Example 65: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 , 3-thiazol-5- yljmethyl) -N,N-dimethylbenzamide hydrochloride Step 1 Methyl 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazol-5- yl] methyl Jbenzoate was prepared from the compound obtained in Step 8 of Production Example 64 in a similar manner according to Step 1 of Production Example 52. iR-NMR (CDCI3) , δ (ppm): 1.52(9H, s) , 2.23(3H, s) , 2.81(4H, s) , 3.86(2H, s) , 3.90(3H, s) , 6.93(2H, d, J=8.0Hz), 7.13(2H, d, J=8.5Hz), 7.19(2H, d, J=8.0Hz), 7.91(2H, d, J=8.5Hz), 8.48- 9.69 (1H, brs) . MS: 510.2 (M+H) +, 532.3 (M+Na) + Step 2
Methyl 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl}ethyl) -1 ,3-thiazol-5- yl]methyl Jbenzoate (287.7 mg) , lN-sodium hydroxide (1.41 ml) and ethanol (2.9 ml) were combined, and the mixture was refluxed for 3 hrs. After cooling to 25 °C, the organic solvent was removed in vacuo . The aqueous solution was acidified with IN-hydrochloric acid (pH=4) , and the precipitate was filtered in vacuo to give 312.5 mg of a pale yellow solid. The solid was dissolved in pyridine (4.3 ml) under nitrogen atmosphere, and then, acethyl chloride (0.12 ml) was added dropwise to the solution at 0 °C. The reaction mixture was stirred at 25 °C for 3 hrs., and pyridine was removed in vacuo . The residue was suspended in water, and acidified with IN-hydrochloric acid. The precipitate was collected in vacuo . The solid was washed with water and diethyl ether to give 4- { [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1 , 3-thiazol-5- yl]methyl}benzoic acid as a pale yallow solid.
XH-NMR (DMSO-de), δ (ppm): 1.47 (9H, s) , 2.08 (3H, s) , 2.70- 2.90(4H, m) , 3.92(2H, s) , 6.99(2H, d, J=8.4Hz), 7.10(2H, d, J=8.0Hz), 7.33(2H, d, J=8.0Hz), 7.81(2H, d, J=8.4Hz), 9.24(1H, s) , 12.00(1H, s) , 12.84(1H, brs). Ms: 494.4 (M-H) " Step 3
To a solution of 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazol-5- yl]methyl Jbenzoic acid (50 mg) in 0.5 ml of dichloromethane were added methylamine hydrochloride (10.7 mg) , 1- hydroxybenzotriazole (20.4 mg) and l-ethyl-3- (3- dimethylaminopropyl) carbodiimide (55.3 μl) , then, the mixture was stirred for 3 hrs. at 25 °C. The reaction mixture was diluted with 10 ml of chloroform and washed with water and brine. The organic layer was dried over magnesium sulfate and evaporated under vaccum. The residue was triturated with ethyl acetate and diisopropylether, and collected by filtration to give tert-butyl {4- [2- (2- (acetylamino) -5- {4- [ (dimethylamino) carbonyl] benzyl } -1 ,3-thiazol-4- yl) ethyl] phenyl} carbamate as a pale yellow solid.
XH-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.23 (3H, s) , 2.83 (4H, s) , 2.95(3H,s), 3.09(3H, s) , 3.82(2H, s) , 6.47-6.81 (1H, brs), 6.94(2H, d, J=8.1Hz), 7.05(2H, d, J=8.1Hz), 7.18(2H, d, J=8.1Hz), 7.28(2H, d, J=8.1Hz), 8.50-9.09 (1H, brs). MS: 523.3 (M+H) +, 545.2 (M+Na) + Step 4 tert-Butyl {4- [2- (2- (acetylamino) -5-{4- [ (dimethylamino) carbonyl] benzyl J-l ,3-thiazol-4- yl) ethyl] phenyl} carbamate (39.1 mg) and trifluoroacetic acid (1 ml) were combined at 0 °C. The reaction mixture was stirred at 25 °C for 2 hrs., and concentrated in vacuo . The residue was added to chloroform (20 ml) and lN-sodium hydroxide (10 ml) . The oraganic layer was separated, dried with magnesium sulfate, and evaporated to give yellow oil (33.3 mg) . The crude yellow oil, N,N' -bis (tert-butoxycarbonyl) -lH-pyrazole-1- carboxamidine (45.8 mg) and tetrahydrofuran (0.5 ml) were combined under nitrogen atmosphere, and the mixture was stirred at 25 °C for 34 hrs. To the reaction mixture was added N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (11 mg) , and the mixture was stirred at 50 °C for 3 hrs. Then, the mixture was concentrated in vacuo . The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give di-tert- butyl [ (E)-( {4- [2- (2- (acetylamino) -5- {4- [ (dimethylamino) carbonyl] benzyl }-l ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate as colorless oil (12.9 mg) . ^- MR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.21 (3H, s) , 2.85(4H, s) , 2.96(3H, brs), 3.08(3H, brs), 3.86(2H, s) , 7.06(2H, d, J=8.5Hz), 7.14(2H, d, J=8.1Hz), 7.33(2H, d, J=8.5Hz), 7.46(2H, d, J=8.5Hz), 8.81-9.21 (1H, brs), 10.25(1H, s) , 11.63 (1H, s) . MS: 665.3 (M+H) +, 687.2 (M+Na) +
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMS0-d6), δ (ppm) : 2.09 (3H, s) , 2.86 (4H, s) , 2.88 (3H, s) , 2.96(3H, s) , 3.97(2H, s) , 7.12(2H, d, J=8.4Hz), 7.16(2H, d, J=8.1Hz), 7.23(2H, d, J=8.4Hz), 7.32(2H, d, J=8.1Hz), 7.34(4H, s) , 9.70(1H, s) , 12.01(1H, s) . MS: 465.2 (M+H) + free Production Example 66: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yljmethyl) -N-methylbenzamide hydrochloride Step 1 tert-Butyl {4- [2- (2- (acetylamino) -5- {4- [ (methylamino) carbonyl] benzyl J-l ,3-thiazol-4- yl) ethyl] phenyl} carbamate was prepared from the compound obtained in Step 2 of Production Example 65 in a similar manner according to Step 3 of Production Example 65. iR-NMR (CDCI3) , δ (ppm): 1.52(9H, s) , 2.23(3H, s) , 2.78-
2.89(4H, m) , 3.00(3H, d, J=4.8Hz), 3.83(2H, s) , 6.20(2H, d, J=4.8Hz), 6.36-6.78 (1H, brs), 6.94(2H, d, J=8.4Hz), 7.05(2H, d, J=8.4Hz), 7.18(2H, d, J=8.4Hz), 7.63(2H, d, J=8.4Hz), 8.60- 9.09 (1H, brs) . MS: 509.2 (M+H) +, 531.2 (M+Na) + Step 2
Di-tert-butyl [ (E) -( {4- [2- (2- (acetylamino) -5- {4- [ (methylamino) carbonyl] benzyl J-l ,3-thiazol-4- yl) ethyl] phenyl}amino) methylidenejbiscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.54 (9H, s) , 2.22 (3H, s) , 2.83(4H, s) , 2.99(3H, d, J=4.8Hz), 3.86(2H, s) , 6.16(1H, d, J=4.0Hz), 7.01(2H, d, J=8.4Hz), 7.13(2H, d, J=8.4Hz), 7.42(2H, d, J=8.4Hz), 7.66(2H, d, J=8.4Hz), 8.77-9.10 (1H, brs), 10.24(1H, s) , 11.62(1H, s) . MS: 651.3 (M+H) +, 673.3 (M+Na) +
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 2.08 (3H, s) , 2.76 (3H, d, J=4.8Hz), 2.86(4H, s) , 3.98(2H, s) , 7.13(2H, d, J=8.4Hz), 7.19(2H, d, J=8.1Hz), 7.23(2H, d, J=8.4Hz), 7.30(4H, s) , 7.74(2H, d, J=8.1Hz), 8.38(2H, d, J=4.4Hz), 9.62(1H, s) , 11.99(1H, s) . MS : 451 . 3 (M+H) " free
Production Example 67: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] amino }phenyl) ethyl] -5- [ (dimethylamino) methyl] -1 , 3-thiazol-2-yl } acetamide dihydrochloride Step 1
To a solution of N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3- thiazol-2-yl} acetamide (500 mg) in acetic acid (3 ml) were added dimethylamine hydrochloride (169 mg) and paraformaldehyde (62.2 mg) , and the mixture was stirred at 100 °C (bath temp.) for 2 hrs. The solvent was removed in vacuo , and the mixture was adjusted to pH=9 with saturated sodium hydrogen carbonate aqueous solution, extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and evaporated. The crude compound was purified by flash column chromatography over silica gel with dichloromethane / methanol (100:1) — (20:1) as an eluent to give N-{5- [ (dimethylamino) methyl] -4- [ (Z) -2- (4- nitrophenyl) vinylJ -1 ,3-thiazol-2-ylJacetamide as a yellow amorphous substance.
XH-NMR (CDCI3) , δ (ppm): 2.08 (3H, s) , 2.26 (6H, s) , 3.47 (2H, s) , 6.63(1H, d, J=12.6Hz), 6.70(1H, d, J=12.6Hz), 7.43(2H, d, J=9.0Hz), 8.03(2H, d, J=9.0Hz), 10.20(1H, brs). MS: 347 (M+H) +, 369 (M+Na) + Step 2
N-{4- [2- (4-Aminophenyl) ethyl] -5- [ (dimethylamino) methyl] - 1 ,3-thiazol-2-ylJacetamide was prepared in a similar manner according to Step 6 of Production Example 45. XH-NMR (CDCI3) , δ (ppm): 2.19 (6H, s) , 2.23(3H,s), 2.80 (4H, s) , 3.30(2H, s) , 3.56(2H, s) , 6.60(2H, d, J=8.4Hz), 6.91(2H, d, J=8.4Hz), 8.54-8.84 (1H, brs). MS: 317.2 (M-H)~ Step 3 Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5-
[ (dimethylamino) methyl] -1 ,3-thiazol-4- ylj ethyl) phenyl] aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 7 of Production Example 45. XH-NMR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 2.21 (6H, s) ,
2.22(3H, s) , 2.87 (4H, s) , 3.36(2H, s) , 7.09(2H, d, J=8.5Hz),
7.46(2H, d, J=8.5Hz), 8.89-9.97 (IH, brs), 10.24(1H, s) ,
11.63(1H, s) .
MS: 561.3 (M+H) +, 583.3 (M+Na) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-d6), δ (ppm) : 2.16 (3H, s) , 2.66 (3H, s) , 2.68 (3H, s) , 2.96(4H, s) , 4.37(2H, d, J=4.8Hz), 7.15(2H, d, J=8.4Hz), 7.32(2H, d, J=8.4Hz), 7.51(4H, s) , 10.08(1H, s) , 10.64(1H, t,
J=4.8Hz) , 12.33 (IH, s) .
MS: 361.1 (M+H) + .. - .
Production Example 68: Synthesis of N-{5- [ (4-acetyl-l- piperazinyl) methyl] -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide dihydrochloride
Step 1
N-{5-[ (4-Acetyl-l-piperazinyl) methyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl]-l ,3-thiazol-2- ylj acetamide in a similar manner according to Step 1 of
Production Example 67.
XH-NMR (CDCI3) , δ (ppm) : 2.08 (6H, s) , 2.34-2.59 (4H, m) , 3.41-
3.53(2H, m) , 3.56(2H, s) , 3.58-3.69 (2H, m) , 6.62(1H, d, J=12.6Hz) , 6.68(1H, d, J=12.6Hz) , 7.45(2H, d, J=8.5Hz) ,
8.05(2H, d, J=9.0Hz) , 10.18(1H, s) .
MS: 452.0 (M+Na) +
Step 2 N-{5- [ (4-Acetyl-l-piperazinyl) methyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJacetamide (1080 mg) , methanol (2 ml), tetrahydrofuran (2 ml), acetic acid (0.3 ml) and then 10% palladium on carbon (150 mg) were combined under nitrogen atmosphere. The mixture was stirred under 3 atm hydrogen for 3 hrs. at 25 °C. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give a crude material (192.3 mg) . To the residue was added saturated sodium hydrogen carbonate aqueous solution, and the mixture was extracted with chroloform. The organic layer was washed with brine, dried over MgS0 , and concentrated in vacuo to give a pink amorphous substance (124.7 mg) . The pink amorphous substance (124.7 mg) , N,N'-bis (tert-butoxycarbonyl) -lH-pyrazole-1-carboxamidine (93.6 mg) and tetrahydrofuran (2 ml) were combined under nitrogen atmosphere. The reaction mixture was stirred at 25 °C for 14 hrs., and concentrated in vacuo . The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give di- tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (4-acetyl-l- piperazinyl) methyl] -1 ,3-thiazol-4- ylj ethyl) phenyl] aminojmethylidenejbiscarbamate as colorless oil (121.1 mg) . XH-NMR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 2.06 (3H, s) , 2.24(3H, s) , 2.20-2.32 (2H, m) , 2.33-2.44 (2H, m) , 2.74-2.96 (4H, m) , 3.30-3.45(4H, m) , 3.52-3.65 (2H, m) , 7.04(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 8.85-10.17 (IH, brs), 10.25(1H, s) , 11.63(1H, s) . MS: 644.3 (M+H) +, 666.1 (M+H) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 2.03 (3H, s) , 2.16 (3H, s) , 2.75- 3.15(8H, m) , 3.16-3.63 (4H, m) , 4.40(2H, s) , 7.15(2H, d, J=8.0Hz), 7.32(2H, d, J=8.0Hz), 7.49(4H, s) , 10.07(1H, s) , 11.29 (IH, brs), 12.33 (IH, s) MS: 444.2 (M+H) + free Production Example 69: Synthesis of N-(4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- { [4- (methylsulfonyl) -1-piperazinyl] methyl J-l ,3-thiazol-2- yl) acetamide dihydrochloride Step 1 N-{5-{ [4- (Methylsulfonyl) -1-piperazinyl] methyl} -4- [ (Z)-2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2-yl} acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinylJ-l , 3-thiazol-2- yljacetamide in a similar manner according to Step 1 of Production Example 67. XH-NMR (CDC13) , δ (ppm): 2.08 (3H, s) , 2.54-2.66 (4H, m) , 2.80(3H, s) , 3.19-3.34 (4H, m) , 3.58(2H, s) , 6.61(1H, d, J=12.1Hz)-, 6.69 (IH, d, J=12.1Hz), 7.45(2H, d, J=8.5Hz), 8.04(2H, d, J=8.5Hz), 10.09(1H, s) . MS: 467.2 (M+H) +, 488.1 (M+Na) + Step 2
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (methylsulfonyl) -1-piperazinyl] methyl J-l ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s) , 2.41-2.56 (4H, m) , 2.76(3H, s) , 2.80-2.89 (4H, m) , 3.12-3.27 (4H, m) , 3.42(2H, s) , 7.05(2HP d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 8.57-9.61 (IH, brs), 10.25(1H, s) , 11.63(1H, s) . MS: 680.3 (M+H) ", 702.2 (M+Na)" Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.97 (4H, s) , 3.00 (3H, s) , 3.05-3.28(4H, m) , 3.28-3.48 (2H, m) , 3.59-3.81 (2H, m) , 4.35-4.60(2H, brs), 7.16(2H, d, J=8.1Hz), 7.32(2H, d, J=8.1Hz), 7.39(4H, s) , 9.84(1H, s) , 10.64-10.89 (IH, brs), 12.34 (IH, s) . MS: 480.1 (M+H)" free
Production Example 70: Synthesis of N-[4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- (4- thiomorpholinylmethyl) -1 ,3-thiazol-2-yl] acetamide dihydrochloride Step 1
N- [4- [ (Z) -2- (4-Nitrophenyl) vinylj -5- (4- thiomorpholinylmethyl) -1 ,3-thiazol-2-yl] acetamide was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2- ylj acetamide in a similar manner according to Step 1 of Production Example 67.
XH-NMR (CDC13) , δ (ppm): 2.08 (3H, s) , 2.57-2.86 (8H, m) , 3.53(2H, s) , 6.62(1H, d, J=12.6Hz), 6.68(1H, d, J=12.6Hz), 7.43(2H, d, J=9.0Hz), 8.0332(2H, d, J=9.0Hz), 10.16(1H, s) . MS: 405.1 (M+H) +, 427.1 (M+Na) + Step 2
Di-tert-butyl { (Z)-[ (4- { 2- [2- (acetylamino) -5- (4- thiomorpholinylmethyl) -1 , 3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 2 of Production Example 68. ^-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 2.22 (3H, s) , 2.63(8H, s) , 2.80-2.90 (4H, m) , 3.39(2H, s) , 7.06(2H, d, J=8.5Hz), 7.45(2H, d, J=8.5Hz), 8.82-9.39 (IH, brs), 10.24(1H, s) , 11.63 (IH, s) . MS: 619.3 (M+H) +, 641.2 (M+Na) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (DMSO-de), δ (ppm) : 2.16 (3H, s) , 2.69-2.87 (2H, m) , 2.97(4H, s) , 3.02-3.19 (4H, m) , 3.48-3.61 (2H, m) , 4.42(2H, s) , 7.15(2H, d, J=8.4Hz), 7.31(2H, d, J=8.4Hz), 7.40(4H, s) , 9.86(1H, s) , 1051-10.69 (IH, brs), 12.34(1H, s) . MS: 419.2 (M+H)" free Production Example 71: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino }phenyl) ethyl] -N- [2- (dimethylamino) - 2-oxoethyl] -1 , 3-thiazole-5-carboxamide hydrochloride Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ( { [2- (dimethylamino) - 2-oxoethyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) aminoJphenyl} ethyl) -1 ,3-thiazole- 5-carboxylic acid in a similar manner according to Step 1 of Production Example 32. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.46 (9H, s) , 2.15(3H, s) , 2.72, 2.85(3H, s) , 2.89, 2.98(3H, s) , 3.16(4H, m) , 4.01(2H, m) , 7.07 (2H, d, J=8.2 Hz), 7.32(2H, d, J=8.2 Hz), 7.87-. 7.95(1H, m) , 9.21(1H, s) , 12.36(1H, s) . MS: 490 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [2- (dimethylamino) -2-oxoethyl] -1 ,3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16 (3H, s) , 2.85 (3H, s) , 2.86-2.98 (5H, m) , 3.22(2H, dd, J=8.9 , 5.3 Hz), 4.01(2H, d, J=5.3 Hz), 7.27 (2H, d, J=8.5 Hz), 7.33(2H, d, J=8.5 Hz), 7.94(1H, t, J=5.3 Hz), 10.15(2H, br) , 12.38(1H, s) . MS: 390 (M+H) + free Step 3
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [2- (dimethylamino) -2-oxoethyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39(9H, s) , 1.51(9H, s) , 2.15(3H, s) , 2.85(3H, s) , 2.85-2.94 (2H, m) , 2.97 (3H, s) , 3.17-
3.26(2H, m) , 4.00-4.04 (2H, m) , 7.19(1H, d, J=8.0 Hz) , 7.42(2H, d, J=8.0 Hz) , 7.88(1H, t, J=5.4 Hz) , 9.93(1H, s) , 11.43(1H, s) , 12.38 (IH, s) .
MS: 632 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16(3H, s) , 2.84(3H, s) , 2.89-2.695 (2H, m) , 2.98(3H, s) , 3.19-3.26 (2H, m) , 3.99(2H, m) ,
7.13(2H, d, J=8.0 Hz), 7.28(2H, d, J=8.0 Hz), 7.43(4H, br) ,
7.97(1H, br) , 9.86(1H, s) , 12.38(1H, s) .
MS: 432 (M+H) + free
Production Example 72: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [3- (dimethylamino) -
3-oxopropyl] -1 , 3-thiazole-5-carboxamide hydrochloride
Step 1 tert-Butyl (4-{2- [2- (acetylamino) -5- ( { [3~ (dimethylamino) -
3-oxopropyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from 2- (acetylamino) -4-
(2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-
5-carboxylic acid in a similar manner according to Step 1 of
Production Example 32.
XH-NMR (200MHz, DMSO-de) , δ (ppm) : 1.46 (9H, s) , 2.14 (3H, s) , 2.55(2H, m) , 2.73-2.94 (8H, m) , 3.14(2H, dd, J=9.1 , 6.1 Hz) ,
3.37 (2H, m) , 7.05(2H, d, J=8.5 Hz) , 7.32(2H, d, J=8.5 Hz) ,
7.89(1H, m) , 9.21(1H, s) , 12.33(1H, s) .
MS: 504 (M+H) + Step 2
2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -N- [3- (dimethylamino) -3-oxopropyl] -1 , 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.15(3H, s) , 2.57(2H, m) ,
2.81(3H, s) , 2.84-2.98 (5H, m) , 3.20(2H, dd, J=8.9 , 5.4 Hz),
3.36(2H, dd, J=12.8, 7.1 Hz), 7.26(2H, d, J=8.6 Hz), 7.32(2H, d, J=8.6 Hz), 7.95(1H, t, J=5.4 Hz), 10.04(2H, br) , 12.35(1H, br) .
MS: 403 (M+H) + free
Step 3
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [3- (dimethylamino) -3-oxopropyl] amino } carbonyl) -1 , 3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.50 (9H, s) , 2.14(3H, s) , 2.80(3H, s) , 2.81-2.93 (2H, m) , 2.94(3H, s) , 3.13-
3.29(6H, m) , 3.34-3.43 (2H, m) , 7.17(2H, d) , 7.42(2H, d) ,
7.89(1H, m) , 9.93(1H, s) , 11.43(1H, s) , 12.34(1H, m) .
MS: 646 (M+H) +
Step 4 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-ds) , δ (ppm) : 2.16(3H, s) , 2.56(2H, m) ,
2.81(3H, s) , 2.87-2.95(5H, m) , 3.19(2H, m) , 3.34(2H, m) , 7.11- 7.38(4H, m) , 7.43(4H, s) , 8.02(1H, m) , 8.55(1H, br) , 9.88(1H, br) , 12.36(1H, s) .
MS: 445 (M+H) + free
Production Example 73: Synthesis of 2- (acetylamino) -N- [2- (acetylamino) ethyl] -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 , 3-thiazole-5- carboxamide hydrochloride
Step 1 tert-Butyl (4- {2- [2- (acetylamino) -5- ({ [2- (acetylamino) ethyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) aminoJphenyl} ethyl) -1 ,3-thiazole-
5-carboxylic acid in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.46 (9H, s) , 1.79 (3H, s) ,
2.14(3H, s) , 2.84(2H, m) , 3.16-3.22 (6H, m) , 7.06(2H, d, J=8.5
Hz), 7.33(2H, d, J=8.5 Hz), 7.99(2H, m) , 9.21(1H, s) ,
12.33 (IH, s) . MS. 490 (M+H) +
Step 2
2- (Acetylamino) -N- [2- (acetylamino) ethyl] -4- [2- (4- - aminophenyl) ethyl] -1 , 3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.79 (3H, s) , 2.15 (3H, s) ,
2.90-2.98 (2H, dd, J=10.1, 6.6 Hz) , 3.14-3.26 (6H, m) , 7.27 (2H, d, J=8.9 Hz) , 7.32(2H, d, J=8.9 Hz) , 7.97-8.06 (2H, m) , 10.18(2H. br) , 12.35(1H, s) .
MS: 390 (M+H) + free
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [2- (acetylamino) ethyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino] methylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39(9H, s) , 1.51(9H, s) , 1.79(3H, s) , 2.15(3H, s) , 2.89(2H, m) , 3.18(6H, m) , 7.18(2H, d, J=8.0 Hz) , 7.42(2H, d, J=8.0 Hz) , 7.95(2H, m) , 9.93(1H, s) ,
11.43 (IH, s) , 12.35(1H, s) .
MS: 632 (M+H) + Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.79 (9H, s) , 2.16 (9H, s) , 2.91(2H, m) , 3.10-3.25 (6H, m) , 7.14(2H, d, J=8.2 Hz), 7.27 (2H, d, J=8.2 Hz), 7.42(4H, br) , 7.97(1H, br) , 8.08(1H, br) ,
9.83 (IH, s) , 12.36 (IH, s) .
MS: 432 (M+H) + free
Production Example 74: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-{ 2-
[ (methylsulfonyl) amino] ethyl J-l ,3-thiazole-5-carboxamide hydrochloride
Step 1 tert-Butyl [4- (2- {2- (acetylamino) -5- [ ( {2- [ (methylsulfonyl) amino] ethyl } amino) carbonyl] -1 , 3-thiazol-4- ylj ethyl) phenyl] carbamate was prepared from 2- (acetylamino) -4-
(2-{4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-
5-carboxylic acid in a similar manner according to Step 1 of
Production Example 32. ^-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.46(9H, s) , 2.15(3H, s) ,
2.79-2.89 (5H, m) , 3.05-3.32 (6H, m) , 7.04-7.14 (3H, m) , 7.33(2H, d, J=8.3 Hz), 8.01(1H, br) , 9.20(1H, s) , 12.35(1H, s) .
MS: 526 (M+H) +
Step 2 2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl]-N-{2-
[ (methylsulfonyl) amino] ethyl }-l ,3-thiazole-5-carboxamide hydrochloride was prepared in a similar manner according to
Step 2 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.15(3H, s) , 2.89(3H, s) ,
2.89-3.27 (8H, m) , 7.12(1H, t, J=5.7 Hz), 7.24(2H, d, J=8.5
Hz), 7.32(2H, d, J=8.5 Hz), 8.05(1H, t, J=5.4 Hz), 9.95(2H, br) , 12.36(1H, s) .
MS: 425 (M+H) + free
Step 3
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ ({2-
[ (methylsulfonyl) amino] ethyl}amino) carbonyl] -1 , 3-thiazol-4- yljethyl) phenyl] aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d5) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) ,
2.15(3H, s) , 2.80-2.97 (5H, m) , 3.00-3.14 (2H, m) , 3.15-3.30 (4H, m) , 7.11(1H, m) , 7.17 (2H, d, J=8.5 Hz), 7.42(2H, d, J=8.5 Hz),
8.01(lHr m) , 9.93(1H, s) , 11.43(1H, s) , 12.37(1H, s) .
MS: 668 (M+H) +
Step 4
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. white powder
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.16 (3H, s) , 2.90-2.96 (5H, m) , 3.08(2H, m) , 3.19-3.29 (4H, q) , 7.14(2H, d, J=8.3 Hz),
7.28(2H, d, J=8.3 Hz), 7.43(4H, br) , 8.07(1H, m) , 9.87 (IH, s) , 12.38(1H, s) .
MS: 467 (M+H) + free
Production xam le 75: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N- [3- (dimethylamino) -
3-oxopropyl] -N-methyl-1 , 3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ [3-
(dimethylamino) -3-oxopropyl] (methyl) amino] carbonyl J-l ,3- thiazol-4-yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.39(9H, s) , 1.50(9H, s) , 2.14(3H, s) , 2.56(2H, t, J=7.3 Hz), 2.78(3H, s) , 2.84-2.88 (6H, m) , 2.93(3H, s) , 3.47 (3H, m) , 7.12(2H, d, J=8.4 Hz), 7.40(2H, d, J=8.4 Hz), 9.92(1H, s) , 11.43(1H, s) , 12.34(1H, s) . MS: 659 (M+Na) + Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.15 (3H, s) , 2.50-2.60 (6H, m) , 2.79(3H, s) , 2.87 (3H, s) , 2.94(3H, s) , 3.39-3.64 (2H, m) , 7.09-7.26 (4H, m) , 7.46(4H, br) , 9.96(1H, s) , 12.35(1H, s) . MS: 460 (M+H) + free
Production Example 76: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-{3- [benzyl (methyl) amino] -3-oxopropyl J-l ,3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ ({3- [benzyl (methyl) amino] -3-oxopropyl } amino) carbonyl] -1 ,3-thiazol- 4-yl}ethyl) phenyl] aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.83 (9H, s) , 1.50 (9H, s) , 1.98-2.15 (3H, m) , 2.60-2.63 (2H, m) , 2.80-2.90 (5H, m) , 3.17- 3.21(2H, m) , 3.42-3.47 (2H, m) , 4.50-4.57 (2H, m) , 7.12-7.43 (9H, m) , 7.95(1H, m) , 9.93(1H, s) , 11.44(1H, s) , 12.4(1H, s) . MS: 722 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16, 2.30 (3H, s) , 2.64(2H, m) , 2.64(2H, m) , 2.80-2.90 (5H, m) , 3.14-3.25 (2H, m) , 3.43- 3.47 (2H, m) , 4.51-4.57 (2H, m) , 7.08-7.42 (9H, m) , 8.02-8.04 (IH, m) , 9.83-9.87 (IH, m) , 12.36(1H, m) . MS: 522 (M+H) + free
Production Example 77: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [4- (dimethylamino) - 4-oxobutyl] -1 ,3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [4- (dimethylamino) -4-oxobutyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.39 (9H, s) , 1.50 (9H, s) , 1.68(2H, tt, J=6.8 Hz), 2.14(3H, s) , 2.30(2H, t, J=6.8 Hz), 2.80(3H, s) , 2.82-2.95(2H, m) , 2.92(3H, s) , 3.10-3.28 (4H, m) , 7.18(2H, d, J=8.5 Hz), 7.39(2H, d, J=8.5 Hz), 9.92(1H, s) , 11.43(1H, br) , 12.3(1H, br) . MS: 682 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.69 (2H, m) , 2.16 (2H, s) , 2.31(2H, t, J=7.2 Hz), 2.81(3H, s) , 2.87-2.95 (2H, m) , 2.93(3H, s) , 3.16-3.24 (4H, m) , 3.57(3H, s) , 7.11-7.44 (4H, m) , 8.06- 8.23(1H, m) , 9.83-9.92 (IH, m) , 12.35(1H, s) . MS: 460 (M+H) + free
Production Example 78: Synthesis of (2R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino)methyl] aminojphenyl) ethyl] -1 , 3-thiazol- 5-ylJ carbonyl) -N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { (2R)-2-
[ (dimethylamino) carbonyl] -1-pyrrolidinylJ carbonyl) -1 ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production
Example 34 in a similar manner according to Step 1 of
Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39(9H, s) , 1.50(9H, s) , 1.60-1.93(3H, m) , 2.06-2.30 (IH, m) , 2.14(3H, s) , 2.66-
3.14(10H, m) , 3.20-3.50 (2H, m) , 4.89(1H, m) , 7.16(2H, d, J=8.0
Hz), 7.41(2H, d, J=8.0 Hz), 9.92(1H, s) , 11.41(1H, s) ,
12.34(1H, s) .
MS: 694 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.60-2.00 (3H, m) , 2.15,
2.48(3H, s x2) , 2.65-3.50 (12H, m) , 3.60-3.75 (2H, m) , 7.09- 7.17(2H, d x2) , 7.23-7.31 (2H, d x2) , 7.47 (3H, br) , 9.94(1H, br) , 12.35, 12.59(1H, s x2) .
MS: 472 (M+H) + free
Production Example 79 : Synthesis of (2S) -1- ( {2- (acetylamino) -
4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-ylJ carbonyl) -N,N-dimethyl-2-pyrrolidinecarboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { (2S)-2-
[ (dimethylamino) carbonyl] -1-pyrrolidinylJ carbonyl) -1 ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production
Example 34 in a similar manner according to Step 1 of
Production Example 32. XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.39 (3H, s) , 1.50 (9H, s) , 1.60-1.94(H, m) , 2.14(3H, s) , 2.10-2.36 (IH, m) , 2.67-3.11 (10H, m) , 3.30-3.52 (2H, m) , 4.88(1H, m) , 7.16(2H, d, J=8.0 Hz), 7.41(2H, d, J=8.0 Hz), 9.92(1H, s) , 11.41(1H, s) , 12.34(1H, s) .
MS: 694 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. ifj-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.60-2.00 (3H, m) , 2.15, 2.48(3H, s x2) , 2.65-3.50 (12H, m) , 3.60-3.75 (2H, m) , 7.09- 7.17 (2H, d x2) , 7.23-7.31 (2H, d x2) , 7.47(3H, br) , 9.94(1H, br) , 12.35, 12.59(1H, s x2) . MS: 472 (M+H) + free Production Example 80: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] amino}phen l) ethyl] -N- [2- (methylsulfonyl) ethylj -1 , 3-thiazole-5-carboxamide hydrochloride Step 1 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [2-
(methylsulfonyl) ethylj amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39 (9H, s) , 1.57 (9H, s) , 2.15(3H, s) , 2.87 (2H, dd, J=8.8 , 6.5 Hz), 3.02(3H, s) , 3.19- 3.28(2H, dd, J=9.0 , 5.5 Hz), 3.30-3.36 (2H, m) , 3.59(2H, dd, J=12.0, 6.0 Hz), 7.17(2H, d, J=8.4 Hz), 7.42(2H, d, J=8.4 Hz), 8.17(1H, s) , 9.93(1H, s) , 11.44(1H, s) , 12.40(1H, s) . MS: 675 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.16(3H, s) , 2.88.-2.96 (2H, m) , 3.03(3H, s) , 3.20-3.30 (4H, m) , 3.33-3.60 (2H, m) , 7.12- 7.18(2H, m) , 7.26-7.46 (2H, d) , 7.46(4H, br) , 8.27 (IH, t) , 9.94(1H, s) , 12.41 (IH, s) . MS: 453 (M+H) + free
Production Example 81: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl]-N- (4- pyridinylmethyl) -1 , 3-thiazole-5-carboxamide dihydrochloride Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [ (4- pyridinylmethyl) amino] carbonylJ-l ,3-thiazol-4- yl) ethyl]phenyl}amino)methylidene]biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.40-1.50 (18H, br) , 2.15 (3H, s) , 2.89(2H, m) , 3.22(2H, m) , 4.39(2H, d, J=5.7 Hz), 7.09- 7.18(2H, m) , 7.32-7.44 (3H, m) , 7.66(1H, m) , 8.43-8.62 (3H, m) , 9.94(1H, s) , 11.44(1H, s) , 12.40(1H, s) . MS: 660 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm): 2.18(3H, s) , 2.92(2H, m) , 3.13-3.28 (2H, m) , 4.63(2H, m) , 7.12(2H, d, J=8.4 Hz), 7.24(2H, d, J=8.4 Hz), 7.47 (4H, br) , 7.93 (2H, d, J=6.3 Hz), 8.88 (3H, m) , 10.00(1H, s) , 12.43(1H, s) . MS: 438 (M+H) + free Production Example 82: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- (3- pyridinylmethyl) -1 , 3-thiazole-5-carboxamide dihydrochloride Step 1 Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [ (3- pyridinylmethy'l) amino] carbonylJ-l ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidene] biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMS0-d6) , δ (ppm) : 1.39(9H, s) , 1.50(9H, s) , 2.16(3H, s) , 2.89(2H, dd, J=8.6 , 6.7 Hz), 3.22(2H, dd, J=8.6 , 5.7 Hz), 4.38(2H, d, J=5.7 Hz), 7.13(2H, d, J=8.4 Hz), 7.25(2H, s x2, J=5.7 Hz), 7.41(2H, d, J=8.4 Hz), 8.50(2H, s x2, J=5.0 Hz), 8.62(1H, dd, J=5.0 , 5.7 Hz), 9.93(1H, s) , 11.43 (IH, s) , 12.41 (IH, s) . MS: 660 (M+Na) + Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.17 (3H, s) , 2.92(2H, m) , 3.23(2H, m) , 4.56(2H, m) , 7.10-7.31 (4H, m) , 7.45(4H, br) , 8.01(1H, dd, J=8.1, 5.9 Hz), 8.82(1H, d, J=8.0 Hz), 8.84(2H, s) , 8.96(1H, s) , 12.45(1H, s) . MS: 438 (M+H) + free
Production Example 83: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-{ 2- [ (2- phenylacetyl) amino] ethyl J-l ,3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ ({2-[ (2- phenylacetyl) amino] ethyl} amino) carbonyl] -1 ,3-thiazol-4- yl} ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39(9H, s) , 1.51(9H, s) , 2.15(3H, s) , 2.88(2H, m) , 3.25-3.31 (6H, m) , 3.38(2H, s) , 7.15-
7.44(7H, m) , 7.32(2H, d, J=8.3 Hz) , 7.98(1H, br) , 8.11(1H, i br) , 9.93(1H, s) , 11.43(1H, s) , 12.35(1H, s) . MS: 730 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.16(3H, s) , 2.90(2H, br) , 3.20(6H, m) , 7.11-7.31 (9H, m) , 7.38(3H, s) , 8.06-8.16 (2H, m) , 9.75(1H, s) , 12.33(1H, s) . MS: 508 (M+H) + free
Production Example 84: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino)methyl] amino}phenyl) eth l] -N- [5- (dimethylamino) - 5-oxopentyl] -1 ,3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { [5- (dimethylamino) -5-oxopentyl] amino}carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 1.39 (9H, s) , 1.39-1.50 (4H, m) , 1.57 (9H, s) , 2.14(3H, s) , 2.29(2H, br) , 2.79(3H, s) , 2.84- 2.94(2H, m) , 2.94(3H, s) , 3.15-3.23 (4H, m) , 7.16(2H, d, J=8.3 Hz), 7.42(2H, d, J=8.3 Hz), 7.97(1H, br) , 9.93(1H, s) , 11.44(1H, s) , 12.35(1H, s) . MS: 696 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.39-1.56 (4H, m) , 2.16 (2H, m) , 2.29(3H, s) , 2.83-2.98 (5H, m) , 3.06-3.28 (4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5 Hz), 7.40(3H, br) , 8.06(1H, br) , 9 . 79 (IH , s) .
MS : 474 (M+H) + free
Production Example 85: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino jphenyl) ethyl] -N- [3- (benzylamino) -3- oxopropyl] -1 , 3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [3-
(benzylamino) -3-oxopropyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example
32.
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.39 (9H, s) , 1.50 (9H, s) ,
2.15(3H, s) , 2.45(2H, t, J=7.2 Hz), 2.73(2H, m) , 3.20(2H, m) , 3.39(2H, m) , 4.26(2H, d, J=5.8 Hz), 7.15-7.28 (7H, m) , 7.41(2H, d, J=8.4 Hz), 8.02(1H, t, J=5.5 Hz), 8.40(1H, t, J=5.5 Hz),
9.93(1H, s) , 11.4(1H, br) , 12.3(1H, br) .
MS: 730 (M+Na) +
Step 2 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH~NMR (200MHz, DMSO-d6) , δ (ppm): 2.16 (3H, s) , 2.41 (2H, t,
J=7.0 Hz), 2.90(2H, m) , 3.20(2H, m) , 3.39(2H, m) , 3.63(2H, m) ,
4.27(2H, d, J=5.8 Hz), 7.11-7.37 (9H, m) , 7.37 (4H, s) , 8.09(1H, t, J=5.5 Hz), 8.43(1H, t, J=6.0 Hz), 9.74(1H, s) , 12.35(1H, s) .
MS: 508 (M+H) + free
Production Example 86: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N- [6- (dimethylamino) -
6-oxohexyl] -1 , 3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [6-
(dimethylamino) -6-oxohexyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.13-1.50 (24H, m) , 2.14 (3H, s) , 2.24(2H, t, J=8.0 Hz), 2.78(3H, s) , 2.88(2H, m) , 2.92(3H, s) , 3.07-3.25(4H, m) , 7.16(2H, d, J=8.5 Hz), 7.42(2H, d, J=8.5 Hz), 7.95(1H, t, J=5.52 Hz), 9.94(1H, s) , 11.4(1H, s) , 12.3(1H, s) . MS: 710 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.27-1.34 (2H, m) , 1.47 (4H, m) , 2.16(3H, s) , 2.26(2H, t, J=7.2 Hz), 2.79(3H, s) , 2.94(3H, s) , 2.90-2.94 (2H, m) , 3.17(4H, m) , 7.13(2H, d, J=8.3 Hz), 7.26(2H, d, J=8.3 Hz), 7.47(4H, br) , 8.05(1H, t, J=5.4 Hz), 9.93 (IH, s) . MS: 488 (M+H) + free Production Example 87: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [3- (4- morpholinyl) propyl] -1 , 3-thiazole-5-carboxamide dihydrochloride Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [3- (4- morpholmyl) propyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. ! H- MR (200MHz, DMSO-d6) , δ (ppm) : 1.58(9H, br) , 1.62(2H, m) , 2.14(3H, s) , 2.31(6H, m) , 2.88(2H, m) , 2.19(4H, m) , 3.58(4H, m) , 7.14(2H, d, J=8.4 Hz), 7.41(2H, d, J=8.4 Hz), 7.95(1H, t, J=5.2 Hz), 9.94(1H, s) , 11.45(1H, s) , 12.30(1H, s) . MS: 696 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.90-2.00 (2H, br) , 2.17 (3H, s) , 2.83-3.15(6H, m) , 3.15-3.30 (4H, m) , 3.30-3.44 (2H, m) , 3.77-4.00 (4H, m) , 7.14(2H, d, J=8.5 Hz), 7.26(2H, d, J=8.5 Hz), 7.44(4H, br) , 8.20(1H, t, J=5.5 Hz), 9.92(1H, s) , 11.01 (IH, s) , 12.38(1H, s) . MS: 474 (M+H) + free
Production Example 88: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [3- (2-oxo-l- pyrrolidinyl) propyl] -1 , 3-thiazole-5-carboxamide hydrochloride Step 1 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [3- (2-oxo- 1-pyrrolidinyl) propyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) amino]methylidene}biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMS0-d5) , δ (ppm) : 1.41 (9H. br) , 1.49 (9H, br) , 1.64(2H, t, J=6.9 Hz) , 1.90(2H, m) , 2.14(3H, s) , 2.17 (2H, m) , 2.91(2H, m) , 3.16(6H, m) , 3.32(2H, m) , 7.16(2H, d, J=8.4 Hz) , 7.41(2H, d, J=8.4 Hz) , 7.93(1H, t, J=5.6 Hz) , 9.93(1H, br) , 11.73 (IH, br) . MS: 694 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. iR-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.65(2H, m) , 1.91(2H, m) , 2.16(3H, s) , 2.20(2H, q, J=7.5 Hz) , 2.90(2H, m) , 3.02-3.27 (6H, m) , 3.33(2H, t, J=7.5 Hz) , 7.16(2H, d, J=8.5 Hz) , 7.26(2H, d, J=8.5 Hz) , 8.03(1H, br) , 9.92(1H, s) , 12.35(1H, s) . MS : 472 (M+H) + free
Production Example 89: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-hexyl-1 ,3-thiazole- 5-carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (hexylamino) carbonyl] -1 , 3-thiazol-4- yljethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, DMS0-d6) , δ (ppm) : 0.85(3H, t, J=6.4 Hz), 1.25(9H, s) , 1.35-1.60 (17H, br) , 2.14(3H, s) , 2.88(2H, m) , 3.15(4H, m) , 7.14(2H, d, J=8.5 Hz), 7.41(2H, d, J=8.5 Hz), 7.92(1H, t, J=5.7 Hz), 10.00(1H, br) , 11.60(1H, br) . MS: 653 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. iR-NMR (200MHz, DMS0-d6 (+D20) ) , δ (ppm) : 0.86(3H, t, J=6.53 Hz), 1.18-1.57 (8H, m) , 2.16(3H, s) , 2.91(2H, dd, J=9.5 , 6.0 Hz), 3.16(4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5 Hz), 8.05(1H, br) , 9.91(1H, s) , 12.33(1H, s) . MS: 431 (M+H)+ free Production Example 90: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [4-oxo-4- (1- piperidinyl) butyl] -1 ,3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [4-oxo-4- (1-piperidinyl) butyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32 .
XH-NMR (200MHz, DMSO-d6) , δ (ppm): 1.29-1.59 (20H, m) , 1.69(2H, m) , 2.14(3H, s) , 2.30(2H, t, J=7.5 Hz), 2.89(4H, m) , 3.32- 3.45(4H, m) , 7.16(2H, d, J=8.0 Hz), 7.41(2H, d, J=8.0 Hz), 7.99(1H, t, J=5.2 Hz), 9.94(1H, s) , 11.43(1H, br) . MS: 722 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.30-1.79 (8H, m) , 2.16 (3H, s) , 2.3K2H. t, J=7.5 Hz), 2.92(2H, m) , 3.18(4H, m) , 3.38(4H, m) , 7.13(2H, d, J=8.0 Hz), 7.25(2H, d, J=8.0 Hz), 7.43(4H, br) , 8.09(1H, t, J=6.0 Hz), 9.87 (IH, s) , 12.34(1H, s) . MS: 500 (M+H) + free Production Example 91: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [4- (4-morpholinyl) - 4-oxobutyl] -1 , 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [4- (4- morpholmyl) -4-oxobutyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.40(9H, s) , 1.50(9H, s) , 1.71(2H, m) , 2.14(3H, s) , 2.32(2H, t, J=7.3 Hz), 2.89(2H, dd, J=10.1, 6.9 Hz), 3.19(4H, m) , 3.42(4H, m) , 3.51(4H, m) , 7.16(2H, d, J=8.3 Hz), 7.42(2H, d, J=8.3 Hz), 7.99(2H, t, J=5.3 Hz), 9.94(1H, s) , 11.44(1H, s) , 12.33(1H, s) . MS: 724 (M+Na) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : .1.70 (2H, m) , 2.16 (3H, s) , 2.33(2H, t, J=7.0 Hz), 2.91(2H, m) , 3.19(4H, m) , 3.42(4H, m) , 3.53(4H, m) , 7.13(2H, d, J=8.5 Hz), 7.25(2H, d, J=8.5 Hz), 7.44(4H, br) , 8.07 (IH, t, J=5.0 Hz), 9.89(1H, s) , 12.34(1H, s) .
MS: 502 (M+H) + free
Production Example 92: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N- [4-
(methylsulfonyl) phenyl] -1 , 3-thiazole-5-carboxamide hydrochloride Step 1
Di-tert-butyl { (Z) - [ (4- {2- [2- (acetylamino) -5- ( { [4- (methylthioJphenyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. H-NMR (200MHz, DMSO-d5) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.18(3H, s) , 2.45(3H, s) , 2.82-3.00 (2H, m) , 3.17-3.30 (2H, m) , 7.13(2H, d, J=8.5 Hz), 7.23(2H, d, J=8.5 Hz), 7.41(2H, d,
J=8.5 Hz), 7.61(2H, d, J=8.5 Hz), 9.92(2H, s) , 11.43(1H, s) , 12.45(1H, s) . MS: 691 (M+Na) + Step 2 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({ [4- (methylsulfonyl) phenyl] amino} carbonyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 2 of Production Example 32. XH-NMR (200MHz, DMSO-d5) , δ (ppm) : 1.39 (9H, s) , 1.51 (9H, s) , 2.18(3H, s) , 2.81-3.03 (2H, m) , 3.18(3H, s) , 3.19-3.30 (2H, m) , 7.16(2H, d, J=8.5 Hz), 7.41(2H, d, J=8.5 Hz), 7.86(2H, d, J=9.0 Hz), 7.93(2H, d, J=9.0 Hz), 9.92(1H, s) , 10.34(1H, s) , 11.42(1H, s) , 12.52(1H, s) . MS : 723 (M+Na) + Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. 5 XH-NMR (200MHz, DMS0-d6) , δ (ppm): 2.20 (3H, s) , 2.84-3.07 (2H, m) , 3.17-3.32 (2H, m) , 3.18(3H, s) , 7.12(2H, d, J=8.5 Hz), 7.37 (4H, br) , 7.86(2H, d, J=9.0 Hz), 7.92(2H, d, J=9.0 Hz), 9.76(1H, s) , 10.42(1H, s) . MS: 501 (M+H) + free ι° Production Example 93: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N- [ (IS) -2- (dimethylamino) -l-methyl-2-oxoethyl] -1 , 3-thiazole-5- carboxamide hydrochloride Step 1
15 Di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ({[ (IS) -2-
(dimethylamino) -l-methyl-2-oxoethyl] amino} carbonyl) -1 ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of
20 Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.40(3H, d, J=7.0 Hz), 1.49(9H, s) , 1.53(9H, s) , 2.22(3H, s) , 2.95(2H, m) , 3.00(3H, s) , 3.10(3H, s) , 3.26(2H, m) , 5.01(1H, dt, J=7.0 Hz), 6.87(1H, d, J=7.5 Hz), 7.14(2H, d, J=8.5 Hz), 7.40(2H, d, J=8.5 Hz),
25 9.57(1H, br) , 10.20(1H, s) , 11.62(1H, s) . MS: 646 (M+H) +
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. 30 XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.23(3H, d) , 2.16(3H, s) , 2.84(3H, s) , 2.87-2.95 (2H, m) , 3.03(3H, s) , 3.15-3.24 (2H, m) , 3.56(1H, s) , 4.78(3H, t, J=7.0 Hz), 7.13(2H, d, J=8.4 Hz), 7.25(2H, d, J=8.4 Hz), 8.09(1H, d, J=7.0 Hz), 9.67(1H, s) , 12.35(1H, s) .
MS: 446 (M+H) + free
Production Example 94: Synthesis of 2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -N- [ (IS) -l-benzyl-2- (dimethylamino) -2-oxoethyl] -1 ,3-thiazole-5-carboxamide hydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { [ (1S)-1- benzyl-2- (dimethylamino) -2-oxoethyl] amino} carbonyl) -1 ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production
Example 34 in a similar manner according to Step 1 of
Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.48 (9H, s) , 1.52 (9H, s) , 2.22(3H, s) , 2.68(3H, s) , 2.84-2.97 (5H, m) , 3.06(2H, d, J=7.5
Hz) , 3.17 (H, dd, J=8.0, 6.0 Hz) , 5.26(1H, q, J=7.5 Hz) ,
6.80(1H, d, J=8.0 Hz) , 7.08(2H, d, J=8.0 Hz) , 7.14-7.33 (5H, m) , 7.39(2H, d, J=8.0 Hz) , 9.96(1H, br) , 10.19(1H, s) ,
11.61(1H, s) . MS. 722 (M+H) +
Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-de), δ (ppm) : 2.15 (3H, s) , 2.82-3.15 (13H, m) , 4.91(1H, q, J=6.7 Hz), 7.09(4H, s) , 7.16-7.31 (5H, m) ,
7.36(4H, br) , 8.31(1H, d, J=7.7 Hz), 9.71(1H, s) , 12.33(1H, s) .
MS: 522 (M+H) + free
Production Example 95: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methy1] aminojphenyl) ethyl] -N- [ (IS) -2-
(dimethylamino) -1- (hydroxymethyl) -2-oxoethyl] -1 ,3-thiazole-5- carboxamide hydrochloride
Step 1 Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { [ (IS) -2- (dimethylamino) -1- (hydroxymethyl) -2-oxoethyl] amino} carbonyl) - 1 ,3-thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.48 (9H, s) , 1.52 (9H, s) , 2.23(3H, s) , 2.94(2H, dd, J=7.0 Hz), 3.01(3H, s) , 3.14(3H, s) , 3.26(2H, dd, J=7.0 Hz), 3.78-3.86 (3H, br) , 5.04(1H, m) , 6.85(1H, d, J=7.5 Hz), 7.08(2H, d, J=8.5 Hz), 7.37 (2H, d, J=8.5 Hz), 9.70(1H, br) , 10.20(1H, s) , 11.61(1H, s) . MS: 662 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.16, 2.19(3H, s x2) , 2.85- 3.50(10H, m) , 3.60-3.69 (2H, m) , 4.81(1H, m) , 7.14(2H, m) , 2.27 (2H, m) , 7.39(4H, br) , 7.91(1H, br) , 8.48(1H, br) , 9.77, 9.94(1H, s x2) , 12.37, 12.61(1H, s x2) . MS: 462 (M+H) + free
Production Example 96: Synthesis of 2- (acetylamino) -4- [2- (4- { [amino (imino) methyl] aminojphenyl) ethyl] -N-{ (1S,2S) -1- [ (dimethylamino) carbonyl] -2-hydroxypropylJ-l ,3-thiazole-5- carboxamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2- (2- (acetylamino) -5- [ ({ (1S,2S)- 1- [ (dimethylamino) carbonyl] -2-hydroxypropyl } amino) carbonyl] - 1 ,3-thiazol-4-ylJ ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.18(3H, d, J=6.5 Hz), 1.48(9H, s) , 1.52(9H, s) , 2.22(3H, s) , 2.95(2H, m) , 2.99(3H, s) , 3.16(3H, s) , 3.20-3.32(2H, m) , 4.06-4.12 (2H, m) , 5.02(1H, dd, J=9.0, 1.5 Hz), 6.55(1H, d, J=9.0 Hz), 7.09(2H, d, J=8.0 Hz), 7.38(2H, d, J=8.0 Hz), 9.70(1H, br) , 10.20(1H, s) , 11.62 (IH, s) . MS: 676 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.35(3H, d, J=6.5 Hz), 2.19(3H, s) , 2.85-2.97 (6H, m) , 3.11(3H, s) , 3.26(2H, m) ,
4.67(1H, br) , 5.40(1H, m) , 7.15(2H, d, J=8.3 Hz), 7.28(2H, d, J=8.3 Hz), 7.43(4H, br) , 8.43(3H, br) , 9.93(1H, s) , 12.59(1H, s) . MS: 475 (M+H) + free Production Example 97: Synthesis of (2S) -2- [( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-y1 } carbonyl) aminoj -N1 ,Nx-dimethyIpentanediamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ ({ (IS) -4- amino-1- [ (dimethylamino) carbonyl] -4-oxobutyl } amino) carbonyl] - 1 , 3-thiazol-4-ylJethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from the compound obtained in Step 2 of Production Example 34 in a similar manner according to Step 1 of Production Example 32. XH-NMR (200MHz, CDC13) , δ (ppm) : 1.49 (9H, s) , 1.53 (9H, s) ,
1.86-2.19 (2H, m) , 2.22-2.37 (5H, m) , 2.89(2H, m) , 2.99(3H, s) , 3.05-3.16 (5H, m) , 3.20-3.41 (IH, m) , 5.06(1H, m) , 6.27 (IH, br) , 6.35(1H, br) , 6.81(1H, d, J=7.5 Hz), 7.09(2H, d, J=8.5 Hz), 7.4K2H, d, J=8.5 Hz), 10.21(1H, s) , 10.55(1H, br) , 11.62(1H, s) .
MS: 703 (M+H) + Step 2
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (200MHz, DMSO-d5) , δ (ppm): 1.70-2.00 (2H, m) , 2.16(5H, m) , 2.84(3H, s) , 2.91(2H, m) , 3.08(3H, s) , 3.19(2H, m) ,
4.75(1H, m) , 6.79(1H, m) , 7.12(2H, d, J=8.3 Hz), 7.25(2H, d, J=8.3 Hz), 7.39(4H, br) , 8.13(1H, d) , 9.77(1H, s) , 12.35(1H, s) .
MS: 503 (M+H) + free
Production Example 98: Synthesis of N-{4-[2-(4-
{ [imino (methylamino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide
The title compound was prepared from the compound obtained in Step 2 of Production Example 50 in a similar manner according to Production Example 58.
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.79 (3H, s) , 2.86 (4H, s) , 3.18(3H, s) , 4.08(2H, s) , 4.43(2H, m) , 7.08(2H, d,
J=8.5Hz), 7.22(2H, d, J=8.5Hz), 7.39 (2H, d, J=8.5Hz), 7.85(2H, d, J=8.5Hz), 12.05 (IH, brs).
MS: 486 (M+H) +
Production Example 99: Synthesis of (2S) -1- ( {2- (acetylamino) - 4_ [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-
5-yl Jmethyl) -N ,N-dimethyl-2-pyrrolidinecarboxamide dihydrochloride
Step 1 . . tert-Butyl {4- [2- (2- (acetylamino) -5- { [methoxy (methyl) amino] carbonyl J-l ,3-thiazol-4- yl) ethyl] phenyl} carbamate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-
5-carboxylic acid in a similar manner according to Step 1 of
Production Example 32. ^- MR (CDC13) , δ (ppm): 1.46 (9H, s) , 2.15(3H, s) , 2.74-
2.93(2H, m) , 3.12-3.29 (2H, m) , 3.22(3H, s) , 3.59(3H, s) ,
7.05(2H, d, J=8.5Hz), 7.33(2H, d, J=8.5Hz), 9.21(1H, s) ,
12.34 (IH, s) . MS : 471 . 1 (M+Na) + Step 2
To a solution of the compound obtained in Step 1 (3.93 g) in THF (80 mL) was added lithium aluminium hydirde (499 mg) slowly (over 15 min) at 5-10 °C (under ice-cooling) . The mixture was stirred at 5 °C for lh. 30 mL of aquaous solution of sodium pottasium tartrate (1M) was added slowly under ice- cooling, and then the mixture was stirred for another 0.5 h at r.t. The mixture was extracted with ethyl acetate, and the organic layer was dried over MgS0 , and concecntrated in vacuo to give pale yellow oil. This oil was triturated with IPE and EtOAc to give tert-butyl (4-{2- [2- (acetylamino) -5-formyl-l ,3- thiazol-4-yl] ethyljphenyl) carbamate as pale yellow powder (2.67g) . XH-NMR (200MHz, DMSO-d6) , δ (ppm) : 1.46 (9H, s) , 2.19 (3H, s) , 2.90(2H, t, J=7.3 Hz), 3.22(2H, t, J=7.3 Hz), 7.01(2H, d, J=8.5 Hz), 7.32(2H, d, J=8.5 Hz), 9.22(1H, s) , 9.77(1H, s) , 12.68(1H, s) . MS: 390 (M+H) + Step 3
To a solution of the compound obtained in Step 2 (200 mg) in dichloromethane (6 mL) were added (2S)-2-(N,N- dimethylaminocarbonyl) pyrrolidine hydrochloride and diisopropylethylamine (0.27 ml) at 5 °C. The mixture was stirred at 5 °C for 10 min. Then sodium triacetoxyborohydride (327 mg) was added, and the mixture was stirred for 3 hrs. aq. NH4C1 was added, and the mixuture was extracted with dichloromethane. The organic layer was dried over MgS04. The layer was concentrated under reduced pressure. The resulting crude mixture was purified by silica gel column chlomatography with mixed solvent (dichloromethane/methanol=15/l) as an eluent to give tert-butyl (4-{2- [2- (acetylamino) -5- ({ (2S) -2- [ (N,N-dimethylamino) carbonyl] -l-pyrrolidinyljmethyl) -1 ,3- thiazol-4-yl] ethyljphenyl) carbamate as a pale yellow amorphous substance. H-NMR (200MHz, CDC13) , δ (ppm) : 1.67-1.99 (4H, m) , 2.24 (3H, s) ,
2.04(4H, s) , 2.14(3H, s) , 2.95-3.14 (5H, m) , 3.42-3.58 (2H, m) , 3.68-3.83 (IH, m) , 6.97 (2H, d, J=8.3 Hz) , 7.94(2H, d, J=8.3
Hz) .
MS: 516 (M+H) +
Step 4
(2S) -1- ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 , 3- thiazol-5-yl}methyl) -N,N-dimethyl-2-pyrrolidinecarboxamide was prepared in a similar manner according to Step 2 of Production
Example 31.
XH-NMR (200MHz, CDCI3) , δ (ppm) : 1.70-2.10 (4H, m) , 2.22 (3H, s) ,
2.39(1H, q, J=8.4 Hz) , 2.77 (4H, m) , 2.91(3H, s) , 3.03(3H, s) , 3.30-3.8K6H, m) , 6.58(2H, d, J=8.3 Hz) , 6.89(2H, d, J=8.3
Hz) , 8.82(1H, br) .
MS; 416 (M+H) +
Step 5
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( { (2S)-2- [ (N,N-dimethylamino) carbonyl] -l-pyrrolidinyljmethyl) -1 ,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production
Example 31.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.50 (9H, s) , 1.52 (9H, s) , 1.76-1.92(4H, m) , 2.04-2.14 (IH, m) , 2.43(1H, dd, J=8.1 , 8.0
Hz) , 2.45(3H, s) , 2.85(2H, s) , 3.07 (3H, s) , 3.51(1H, dd,
J=5.7, 8.0 Hz) , 3.60(1H, d, J=14.3 Hz) , 3.84(1H, d, J=14.3
Hz) , 6.37 (IH, t, J=2.0 Hz) , 7.08(2H, d, J=8.4 Hz) , 7.44(2H, d,
J=8.4 Hz) , 7.63(1H, d, J=2.0 Hz) , 10.23(1H, s) , 11.62(1H, br) . MS: 658 (M+H) +
Step 6
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. XH-NMR (200MHz, DMSO~d6) , δ (ppm): 1.60-1.98 (2H, br) , 1.98- 2.16(1H, br) , 2.16(3H, s) , 2.85(3H, s) , 2.95(7H, br) , 3.00- 3.30(1H, br) , 7.15(2H, d, J=8.3 Hz), 7.30(2H, d, J=8.3 Hz), 7.55(4H, br) , 7.85(1H, d, J=2.2 Hz), 9.65(1H, br) , 10.21(1H, s) , 12.35(1H, s) . MS: 458 (M+H) + free
Production Example 100: Synthesis of 3- [( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yljmethyl) (methyl) amino] -N,N-dimethylpropanamide dihydrochloride Step 1 tert-Butyl (4-{2- [2- (acetylamino) -5- ( { [3- (N,N- dimethylamino) -3-oxopropyl] amino Jmethyl) -1 , 3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from the compound obtained in Step 2 of Production Example 99 in a similar manner according to Step 3 of Production Example 99. XH-NMR (200MHz, CDCl3) , δ (ppm) : 1.50 (9H, s) , 2.24 (3H, s) , 2.47 (2H, t, J=6.2 Hz), 2.74(2H, t, J=6.2 Hz), 2.82-2.88 (4H, m) , 2.93(3H, s) , 2.97(3H, s) , 3.59(2H, s) , 6.94(2H, d, J=8.3 Hz), 7.21(2H, d, J=8.3 Hz), 8.02(1H, s) . MS: 490 (M+H) + Step 2
To a solution of the compound obtained in Step 1 (100 mg) in dichloromethane (1.5 mL) was added formaline (35%, 87.6 μl) . To this suspension was added 0.05 ml of MeOH. Then, sodium triacetoxyborohydride (433 mg) was added, and the mixture was stirred for 12 hrs. To the mixture were added water and IN NaOH to adjust pH of aquaous phase (ca. pH 8-9) . The mixture was extracted with dichloromethane. The organic layer was dried with MgS04 and concentrated under redused pressure.
Resulting oil was purified by silica gel column chromatograph (mixed solvent of CH2Cl2/MeOH 15/1 as an eluent) to give tert- butyl {4- [2- (2- (acetylamino) -5-{ [ [3- (N,N-dimethylamino) -3- oxopropyl] (methyl) amino] ethyl }-1 , 3-thiazol-4- yl) ethyljphenyl} carbamate as pale yellow oil (90.4 mg) .
XH-NMR (200MHz, CDC13) , δ (ppm): 1.51(9H, s) , 2.18J3H, s) ,
2.24(3H, s) , 2.45(2H, m) , 2.62(2H, m) , 2.80(4H, s) , 2.93(3H, s) , 2.99(3H, s) , 3.35(2H, s) , 6.96(2H, d, J=8.3 Hz), 7.20(2H, d, J=8.3 Hz) .
MS: 504 (M+H) +
Step 3
3- [ ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethylj -1 ,3- thiazol-5-ylJmethyl) (methyl) amino] -N,N-dimethylpropanamide was prepared in a similar manner according to Step 2 of Production
Example 31.
XH-NMR (200MHz, CDC13) , δ (ppm) : 2.19(3H, s) , 2.22(2H, s) ,
2.43-2.51 (2H, m) , 2.62-2.71 (4H, m) , 2.78(3H, s) , 2.93(3H, s) , 2.99(3H, s) , 3.33(2H, s) , 3.65(1H, m) , 3.75(1H, m) , 6.58(2H, d, J=8.3 Hz), 6.87 (2H, d, J=8.3 Hz).
MS: 404 (M+H) +
Step 4
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5-{ [ [3-(N,N- dimethylamino) -3-oxopropyl] (methyl) aminojmethyl J-l ,3-thiazol-
4-yl) ethyl]phenyl}amino) methylidenejbiscarbamate was prepared in a similar manner according to Step 3 of Production Example
31.
XH-NMR (200MHz, CDC13) , δ (ppm) : 1.50 (9H, s) , 1.53 (9H, s) , 2.20(3H, s) , 2.22(3H, s) , 2.49(2H, dd, J=6.5 , 5.5 Hz) ,
2.71(2H, dd, J=6.5, 5.5 Hz) , 2.84(4H, s) , 2.93(3H, s) ,
2.99(3H, s) , 3.43(2H, s) , 7.08(2H, d, J=8.4 Hz) , 7.46(2H, d,
J=8.4 Hz) , 7.62(1H, s) , 10.24(1H, s) , 11.62(1H, s) .
MS: 646 (M+H) + Step 5
The title compound was prepared in a similar manner according to Step 4 of Production Example 31. H-NMR (200MHz, DMSO-d6) , δ (ppm) : 2.15(3H, s) , 2.68(3H, d, J=4.0 Hz), 2.83-2.88 (6H, m) , 2.96(6H, s) , 3.05-3.15 (2H, m) , 4.44(2H, m) , 7.15(2H, d, J=8.3 Hz), 7.32(2H, d, J=8.3 Hz), 7.62(4H, br) , 9.90(1H, s) , 12.32(1H, s) . MS: 446 (M+H) + free Production Example 101: Synthesis of 4- (2-{2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl } ethyl) -N, -dimethylbenzamide hydrochloride Step 1
Methyl 4- {2- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) aminojphenyl} ethyl) -1 , 3-thiazol-5- ylj vinyl Jbenzoate was prepared from the compound obtained in Step 2 of Production Example 99 in a similar manner according to Step 1 of Production Example 53. XH-NMR (CDC13) , δ (ppm): 1.50(9Hx4/9, s) , 1.51(9Hx5/9, s) , 2.20(3Hx5/9, s) , 2.29(3Hx4/9, s) , 2.72-3.06 (4H, m) ,
3.90(3Hx5/9, s) , 3.92(3Hx4/9, s) , 6.42-6.60 (2Hx5/9 , m) , 6.69(lHx4/9, d, J=16.6Hz), 6.81-7.03 (4H + 1HX4/9, m) , 7.31(2Hx5/9, d, J=8.0Hz), 7.39(2Hx4/9, d, J=8.0Hz), 7.96(2Hx5/9, d, J=8.0Hz), 7.99(2Hx4/9, d, J=8.0Hz). MS: 522.2 (M+H) +, 544.2 (M+Na) + Step 2
Methyl 4- {2- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) aminojphenyl} ethyl) -1 , 3-thiazol-5- yl] ethyl Jbenzoate was prepared in a similar manner according to Step 6 of Production Example 45. MS: 524.25 (M+H) +
4-{2- [2- (Acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) aminojphenyl}ethyl) -1 ,3-thiazol-5- yl] ethyl jbenzoic acid was prepared in a similar manner according to Step 2 of Production Example 65. XH-NMR (DMSO-de), δ (ppm) : 1.45 (9H, s) , 2.09 (3H, s) , 2.57- 2.72(6H, m) , 2.75-2.86 (2H, m) , 6.94(2H, d, J=8.4Hz), 7.21(2H, d, J=8.4Hz), 7.32(2H, d, J=8.4Hz), 7.82(2H, d, J=8.4Hz), 9.21(1H, s) , 11.94(1H, s) , 12.41-13.20 (IH, brs). MS: 510.2 (M+H) +, 532.2 (M+Na) + Step 4 tert-Butyl (4-{2- [2- (acetylamino) -5- (2-{4- [ (methylamino) carbonyljphenyl}ethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared in a similar manner according to Step 3 of Production Example 65. XH-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.24 (3H, s) , 2.56- 2.73(4H, m) , 2.73-2.86 (4H, m) , 2.99(3H, d, J=4.8Hz), 6.05(1H, d, J=4.4Hz), 6.25-6.75(lH, brs), 6.77 (2H, d, J=6.6Hz), 7.12(2H, d, J=8.1Hz), 7.15-7.23 (2H, m) , 7.63(2H, d, J=8.1Hz), 8.43-9.18 (IH, brs) . MS: 523.29 (M+H) + Step 5
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (2-{4- [ (methylamino) carbonyljphenyl} ethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (ppm): 1.48 (9H, s) , 1.54 (9H, s) , 2.22 (3H, s) , 2.51-2.61(2H, m) , 2.61-2.71 (2H, m) , 2.79-2.90 (4H, m) , 2.97 (3H, d, J=4.8Hz), 6.20(1H, d, J=4.8Hz), 6.98(2H, d, J=8.4Hz), 7.13(2H, d, J=8.1Hz), 7.40(2H, d, J=8.4Hz), 7.64(2H, d, J=8.4Hz), 8.83-9.42 (IH, brs), 10.21(lH,s), 11.62(1H, s) . MS: 687.2 (M+Na) + Step 6
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.09 (3H, s) , 2.58-2.79 (6H, m) , 2.80- 3.02(8H, m) , 7.13(2H, d, J=8.4Hz), 7.19(2H, d, J=8.1Hz), 7.20(2H, d, J=8.4Hz), 7.29(2H, d, J=8.1Hz), 7.32(4H, s) , 9.66(1H, s) , 11.93 (IH, s) . MS: 479.2 (M+H) + free Production Example 102: Synthesis of 4- (2-{2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl } ethyl) -N-methylbenzamide hydrochloride Step 1 tert-Butyl (4-{2- [2- (Acetylamino) -5- (2-{4-
[ (dimethylamino) carbonyl] phenyl} ethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) carbamate was prepared from the compound obtained in Step 3 of Production Example 101 in a similar manner according to Step 3 of Production Example 65. "Ή-NMR (CDC13) , δ (ppm): 1.51 (9H, s) , 2.23 (3H, s) , 2.66 (4H, s) , 2.79(4H, s) , 2.93(3H, s) , 3.08(3H, s) , 6.90(2H, d, J=8.0Hz), 7.11(2H, d, J=8.0Hz), 7.18(2H, d, J=8.0Hz), 8.56-10.01 (IH, brs) . MS: 537 (M+H) +, 559.2 (M+Na) + Step 2
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (2-{4- [ (dimethylamino) carbonyljphenyl} ethyl) -1 ,3-thiazol-4- ylj ethyljphenyl) amino]methylidenejbiscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. ^-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.21 (3H, s) , 2.57-2.78 (4H, m) , 2.82(4H, s) , 2.94(3H, s) , 3.08(3H, s) , 7.03(2H, d, J=8.5Hz), 7.13(2H, d, J=8.0Hz), 7.33(2H, d, J=8.0Hz), 7.45(2H, d, J=8.5Hz), 8.28-9.61 (IH, brs), 10.24(1H, s) , 11.63 (IH, s) . MS: 679.2 (M+H) +, 701.2 (M+Na) +
The title compound was prapared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-d6), δ (ppm) : 2.10 (3H, s) , 2.60-2.72 (4H, m) , 2.72- 2.80(2H, m) , 2.76(3H, d, J=4.4Hz), 2.89 (2H, t, J=7.3Hz), 7.12(2H, d, J=8.4Hz), 7.19(2H, d, J=8.4Hz), 7.22(2H, d, J=8.1Hz), 7.33(4H, s) , 7.73(2H, d, J=8.1Hz), 8.36(1H, d, J=4.4Hz), 9.66(1H, s) , 11.93(1H, s) . MS : 465 . 2 (M+H) + free
Production Example 103: Synthesis of methyl N— [4-({2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yljmethyl) phenyl] carbamate hydrochloride Step 1
To a suspension of 4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl}ethyl) -1 ,3-thiazol-5- yl]methyl}benzoic acid (50 mg) in toluene (0.5 ml) and dioxane (0.5 ml) were added triethylamine (28.1 μl) and diphenylphosphoryl azide (39.1 μl) , and the mixture was stirred at 25 °C for 2 hrs., then stirred at 100 °C for lh. To the reaction mixture was added methanol (1 ml) , and the mixture was refluxed for 2 hrs., and concentrated in vacuo . The residue was purified by preparative thin-layer chromatography over silica gel with chloroform / methanol (20:1) as an eluent to give methyl N- (4-{ [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) amino] phenyl } ethyl) -1 ,3-thiazol-5- yl]methylJphenyl) carbamate (17.2 mg) . !H-NMR (CDC13) , δ (ppm): 1.52 (9H, s) , 2.22 (3H, s) , 2.80 (4H, s) , 3.76(3H, s) , 3.79(2H, s) , 6.62-6.78 (IH, brs), 6.83-7.05 (IH, brs), 6.90(2H, d, J=8.0Hz), 6.98(2H, d, J=8.5Hz), 7.17 (2H, d, J=8.0Hz), 7.20-7.33 (2H, m) . MS: 547.2 (M+Na) + Step 2
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{4- [ (methox carbonyl) amino] benzyl J-l ,3-thiazol-4- yl) ethyljphenyljaminojmethylidenejbiscarbamate was prepared in a similar manner according to Step 4 of Production Example 65. ifi-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.54 (9H, s) , 2.19 (3H, s) , 2.82(4H, s) , 3.76(3H, s) , 3.80(2H, s) , 6.72-6.90 (IH, brs), 6.98(2H, d, J=8.5Hz), 7.00(2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz), 7.39(2H, d, J=8.5Hz), 9.10-9.59 (IH, brs), 10.19(1H, s) , 11.64 (IH, s) .
MS: 667.2 (M+H)+, 689.2 (M+Na) +
Step 3
The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.08 (3H, s) , 2.85 (4H, s) , 3.64 (3H, s) , 3.85(2H, s) , 7.04(2H, d, J=8.5Hz), 7.14(2H, d, J=8.4Hz), 7.24(2H, d, J=8.4Hz), 7.28-7.47 (6H, m) , 9.58(1H, s) , 9.70(1H, s) , 11.96 (IH, s) . MS: 467.2 (M+H) +
Production Example 104: Synthesis of ethyl l-({2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] amino Jphenyl) ethyl] -1 , 3-thiazol-5- yl Jmethyl) -4-piperidinecarboxylate dihydrochloride Step 1
Ethyl 1- ( {2- (acetylamino) -4- [ (Z) -2- (4-nitrophenyl) vinyl] - 1 ,3-thiazol-5-yl Jmethyl) -4-piperidinecarboxylate was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2- ylj acetamide in a similar manner according to Step 1 of Production Example 67. MS: 459.17 (M+H) + Step 2
Ethyl 1- [ (2- (acetylamino) -4- {2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenylj ethyl }-l ,3-thiazol-5- yl) methyl] -4-piperidinecarboxylate was prepared in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDC13) , δ (ppm): 1.24 (3H, t, J=7.2Hz), 1.50 (9H, s) , 1.53(9H, s) , 1.65-2.09(6H, m) , 2.13-2.34 (4H, s) , 2.71-2.95 (6H, m) , 3.39(2H, s) , 4.12(2H, q, J=7.2Hz), 7.07(2H, d, J=8.5Hz), 7.46(2H, d, J=8.5Hz), 10.24(1H, s) , 11.63(1H, brs). MS: 673.3 (M+H) +, 695.3 (M+Na) + Step 3 The title compound was prepared in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 1.18 (3H, t, J=7.1Hz), 1.73-1.90 (2H, m) , 1.93-2.13 (2H, m) , 2.16(3H, s) , 2.87-3.01 (6H, m) , 3.30- 3.41(2H, m) , 4.08(2H, q, J=7.1Hz), 4.31-4.43 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.31(2H, d, J=8.4Hz), 7.42(4H, s) , 9.90(1H, s) , 10.23-10.46(1H, brs), 12.3(1H, s) . MS: 473.2 (M+H) +, 495.2 (M+Na) + free Production Example 105: Synthesis of ethyl l-({2- (acetylamino) -4- [2- (4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl Jmethyl) -4-piperidinecarboxylate hydrochloride
The title compound was prepared in a similar manner according to Example 104. Production Example 1Q6: Synthesis of 4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-4-ylJ ethyl) -N- [amino (imino) methyl]benzamide
Guanidine hydrochloride (152 mg) was dissolved in DMF (3 ml) , and then 28 % sodium methoxide methanol solution (0.3 ml) was added to the solution at r.t. The suspension was stirred at r.t. for 15 minutes, and methyl 4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-4-ylJ ethyl) benzoate (150 mg) was added to the mixture at r.t. The reaction mixture was stirred at r.t. for 14 hours, and concentrated in vacuo . The residue was dissolved in water, and neutralized with 1N-HC1. The precipitate was collected through filtration, and purified by preparative silica gel chromatography with CHCI3 / MeOH (10:1) as an eluent. The solid was washed with ethyl ether to give 4- (2- {2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 ,3- thiazol-4-yl } ethyl) -N- [amino (imino) methyl] benzamide (36.6 mg) as an off-white solid, mp. 108-109.5 °C XH-NMR (DMSO-de), δ (ppm) : 2.09 (3H, s) , 2.89 (4H, s) , 3.16 (3H, s) , 4.06(2H, s) , 7.15(2H, d, J=8.0Hz) , 7.27 (2H, d, J=8.0Hz) ,
7.78(2H, d, J=8.0Hz) , 7.95(2H, d, J=8.0Hz) , 12.04(1H, s) .
MS: 500 (M+H) +
Production Example 107: Synthesis of tert-butyl (2-{ [4- (2-{2- (acetylamino) -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-4- yljethyl) phenyl] amino}-2-oxoethyl) carbamate
The title compound was prepared from 2- (acetylamino) -4-
[2- (4-aminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3- thiazol in a similar manner according to Step 1 of Production Example 10. mp. 186-187.5 °C
XH-NMR (DMSO-d6), δ (ppm): 1.39 (9H, s) , 2.08 (3H, s) , 2.84 (4H, s) , 3.17 (3H, s) , 3.71(2H, d, J=6.0Hz), 4.00(2H, s) , 7.01(1H, t, J=6.0Hz), 7.06(2H, d, J=8.5Hz), 7.28(2H, d, J=8.5Hz), 7.46(2H, d, J=8.5Hz), 7.79(2H, d, J=8.5Hz), 9.86(1H, s) ,
12.04(1H, s) .
MS: 587 (M+H) +
Production Example 108: Synthesis of N- [4- (2- {2- (acetylamino) -
5- [4- (methylsulfonyl) enzyl] -1 ,3-thiazol-4-yl} ethyl) phenyl] -2- aminoacetamide hydrochloride
The title compound was prepared from the compound of
Production Example 107 in a similar manner according to Step 2 of Production Example 10. mp. 142.5-144 °C XH-NMR (DMSO-d6), δ (ppm) : 2.09 (3H, s) , 2.85(4H, s) , 3.18 (3H, s) , 3.78(2H, m) , 4.00(2H, s) , 7.10(2H, d, J=8.5Hz), 7.26(2H, d, J=8.5Hz), 7.50 (2H, d, J=8.5Hz), 7.79 (2H, d, J=8.5Hz),
8.22(3H, brs), 10.63(1H, s) , 12.06(1H, s) .
MS: 487 (M+H) + free Production Example 109: Synthesis of N- (4-{2- [4- (2- aminoethyl) phenyl] ethyl }-l,3-thiazol-2-yl) acetamide hydrochloride
Step 1 N- (4- {2- [4- (Cyanomethyl) phenyl] ethyl }-l,3-thiazol-2- yl) acetamide (1 g) , IN-NaOH (7 ml) and EtOH (14 ml) were combined, and the reaction mixture was refluxed for 8 hours. After cooled to r.t., the organic solvent was removed in vacuo . The aqueous solution was neutralized with 1N-HC1, and extracted with AcOEt. The organic layer was washed with water and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual yellow wax (1.03 g) was dissolved in THF (10 ml) , and then lithium aluminium hydride (266 mg) was added to the solution at 0 °C. The reaction mixture was refluxed for 3 hours, and quenched with MeOH. Then NaS04 / 10H2O was added to the mixture, the mixture was stirred at r.t. for 1 hour and filtered through a celite pad. The filtrate was concentrated in vacuo . The residual yellow amorphous (835.5 mg) was dissolved in THF (10 ml) and DMF (10 ml) under N2 atmosphere. Then di (tert-butyl) dicarbonate (841 mg) in THF (5 ml) was added to the solution at r.t. The reaction mixture was stirred at r.t. for 12 hours, and concentrated in vacuo to give tert- butyl (2- {4- [2- (2-amino-l , 3-thiazol-4- yl) ethyl] phenyl}ethyl) carbamate (171.6 mg) as yellow oil.
XH-NMR (DMSO-de), δ (ppm) : 1.38 (9H, s) , 2.60-2.70 (4H, m) , 2.79- 2.88(4H, m) , 6.82(1H, s) , 7.07 (2H, d, J=8.0Hz), 7.11(2H, d, J=8.0Hz) . MS: 348 (M+H) + Step 2 tert-Butyl [2- (4-{2- [2- (acetylamino) -1 ,3-thiazol-4- yl] ethyljphenyl) ethyl] carbamate was prepared from the compound of Step 1 in a similar manner according to Step 3 of Production Example 45. XH-NMR (DMSO-de), δ (ppm) : 1.36 (9H, s) , 2.11 (3H, s) , 2.58-
2.70(1H, m) , 2.80-2.97 (6H, m) , 3.02-3.18 (IH, m) , 6.72(1H, s) , 7.08(2H, d, J=8.0Hz), 7.23(2H, d, J=8.0Hz), 12.08(1H, s) . MS: 390 (M+H) + Step 3
The title compound was prepared from the compound of Step
2 in a similar manner according to Step 2 of Production
Example 10. mp. 165-167 °C
XH-NMR (DMSO-de), δ (ppm): 2.12 (3H, s) , 2.79-3.09 (8H, m) ,
6.75(1H, s) , 7.16(4H, s) , 8.14(2H, brs), 12.13(1H, brs).
MS: 290 (M+H) + free
Production Example 110: Synthesis of N- (4-{2- [4- (2- { [amino (iminoJmethyl] amino}ethyl) phenyl] ethyl }-l ,3-thiazol-2- yl) acetamide hydrochloride
Step 1
N- (4- {2- [4- (2-Aminoethyl) phenyl] ethyl } -1 , 3-thiazol-2- yl) acetamide hydrochloride (7 mg) , N,N'-bis (tert- butoxycarbonyl) -lH-pyrazole-1-carboxamidine (6.57 mg) , N,N- diisopropylethylamine (0.00748 ml), THF (0.5 ml) and DMF (0.1 ml) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 43 hours, and concentrated in vacuo .
The residue was purified by preparative silica gel chromatography with n-hexane / AcOEt (1:1) as an eluent to give di-tert-butyl ( (Z) -{ [2- (4-{2- [2- (acetylamino) -1 ,3- thiazol-4-yl] ethyljphenyl) ethyl] aminojmethylidenejbiscarbamate (5.9 mg) as colorless oil.
XH-NMR [CD3CI/CD3OD (1:1)], δ (ppm) : 1.50 (18H, s) , 2.24 (3H, s) , 2.86(2H, t, J=7.0Hz), 2.95(4H, s) , 3.62(2H, t, J=7.0Hz),
4.24(2H, s) , 6.50(1H, s) , 7.11(2H, d, J=8.5Hz), 7.16(2H, d,
J=8.5Hz) .
MS: 532 (M+H) +
Step 2 The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR [CD3CI/CD3OD ( 1 : 1 ) ] , δ (ppm) : 2 . 41 ( 3H , s ) , 2 . 87 (2H , t , J=7.0Hz) , 3.05(4H, s) , 3.44(2H, t, J=7.0Hz) , 6.86(1H, s) ,
7.18(4H, s) .
MS: 332 (M+H) + free
Production Example 111: Synthesis of N-(4-{4-[(2- { [amino (imino) methyl] amino}ethyl) sulfonyljphenylJ-l ,3-thiazol-
2-yl) acetamide hydrochloride
Step 1
1- [4- (Methylthio) phenyl] ethanone (5.5 g) was dissolved in
AcOH (55 ml) , and then 90 % pyridinium tribromide (11.8 g) and 30 % hydrobromic acid in AcOH (5.5 ml) were added to the solution at 0 °C. The reaction mixture was stirred at r.t. for
30 minutes, and poured into water. The mixture was extracted with AcOEt. The organic layer was washed with saturated NaHC03 and brine, dried over anhydrous MgS04, and concentrated in vacuo. The residual solid (8.03 g) , thiourea (3.78 g) and EtOH (55 ml) were combined. The reaction mixture was refluxed for
1.5 hours under N2 atmosphere. After cooled to r.t., the precipitate was filtered in vacuo. The solid was washed with
EtOH and water to give 4- [4- (methylthio) phenyl] -1 ,3-thiazol-2- amine (7.48 g) as a pale yellow solid. mp. 245-246 °C
XH-NMR (DMSO-de), δ (ppm) : 2.51 (3H, s) , 7.18 (IH, s) , 7.35 (2H, d, J=8.5Hz), 7.67 (2H, d, J=8.5Hz).
MS: 223 (M+H) + Step 2
N-{4- [4- (Methylthio) phenyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from the compound of Step 1 in a similar manner according to Step 3 of Production Example 45. mp. 235-236 °C iji-NMR (DMSO-d6) , (PPm): 2.16 (3H, s) , 2.50 (3H, s) , 7.31 (2H, d, J=8.5Hz), 7.56 (IH, s) , 7.83(2H, d, J=8.5Hz), 12.24(1H, brs) .
MS: 265 (M+H) + Step 3
N-{4- [4- (Methylthio) phenyl] -1 ,3-thiazol-2-ylJacetamide (2 g) was suspended in CH2C12 (20 ml) , and then 3- chloroperoxybenzoic acid (1.44 g) was added portionwise to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 15 minutes. The precipitate was filtered in vacuo, and the solid was washed with lN-Na2C03, water and EtOH to give N-{4- [4- (methylsulfinyl) phenyl] -1 ,3-thiazol-2-ylJ acetamide (2.80 g) as a colorless solid. mp. 274-274.5 °C
XH-NMR (DMSO-de), δ (ppm) : 2.10 (3H, s) , 2.77 (3H, s) , 7.62 (IH, s) , 7.71(2H, d, J=8.5Hz), 8.07 (2H, d, J=8.5Hz). MS: 279(M-H) + Step 4 N-{4- [4- (Methylsulfinyl) phenyl] -1 , 3-thiazol-2- yljacetamide (1.5 g) , sodium acetate (1.54 g) , and acetic anhydride (30 ml) were combined under N2 atmosphere. The reaction mixture was refluxed for 2 hours . After cooled to r.t., the mixture was diluted in AcOEt. The organic solution was washed with water and brine , dried over anhydrous MgS0 , and concentrated in vacuo. The residual solid was washed with ethyl ether / n-hexane to give ( {4- [2- (acetylamino) -1 , 3- thiazol-4-yl] phenyl} thio) methyl acetate (811.2 mg) as an off- white solid. mp. 144-145 °C
XH-NMR (DMSO-de) , δ (ppm) : 2.07 (3H, s) , 2.17 (3H, s) , 5.53 (2H, s) , 7.50(2H, d, J=8.5Hz) , 7.63(1H, s) , 7.88(2H, d, J=8.5Hz) , 12.27 (IH, brs) . MS: 323 (M+H) + Step 5
({4- [2- (Acetylamino) -l,3-thiazol-4-yljphenyl}thio) methyl acetate (40 mg) was dissolved in CH2C12 (0.6 ml) and MeOH (0.3 ml) under N2 atmosphere. Then magnesium monoperoxyphthalate (120 mg) was added to the solution at 0 °C. The reaction mixture was stirred at r.t. for 2 hours. Water and CHC13 were added to the mixture, and the mixture was extracted. The organic layer was washed with saturated NaHC03 and brine, dried over anhydrous MgS04, and concentrated in vacuo . The residual solid was washed with ethyl ether to give ({4- [2- (acetylamino) -1 , 3-thiazol-4-yl] phenyl } sulfonyl) methyl acetate (29.7 mg) as a colorless solid, mp. 237-238 °C XH-NMR (DMSO-de), δ (ppm): 2.07 (3H, s) , 2.18 (3H, s) , 5.43 (2H, s) , 7.94(1H, s) , 7.97(2H, d, J=8.5Hz), 8.17(2H, d, J=8.5Hz), 12.37 (IH, brs) . MS: 355 (M+H) + Step 6 ( {4- [2- (Acetylamino) -1 , 3-thiazol-4- yl] phenyl} sulfonylJmethyl acetate (700 mg) , THF (8 ml) , MeOH (4 ml) and IN-NaOH (1.98 ml) were combined. The reaction mixture was stirred at r.t. for 1.5 hours, and concentrated in vacuo . The residual solid was washed with ethyl ether to give sodium 4- [2- (acetylamino) -1 ,3-thiazol-4-yl]phenylsulfinate (731 mg) as a colorless solid.
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 7.52 (2H, d, J=8.0Hz), 7.54(1H, s) , 7.84(2H, d, J=8.0Hz). MS: 281(M-H)+ free Step 7
Sodium 4- [2- (acetylamino) -1 ,3-thiazol-4- yljphenylsulfinate (600 mg) was dissolved in DMF (2 ml) under N2 atmosphere. Then 2-bromoethanol (0.168 ml) was added to the solution at 0 °C. The reaction mixture was stirred at 100 °C for 7 hours. After cooled to r.t., water and AcOEt were added to the mixture. The precipitate was filtered in vacuo to give N-(4-{4-[ (2-hydroxyethyl) sulfonyl] phenyl }-1 ,3-thiazol-2- yl) acetamide (80.2 mg) as an off-white solid. mp. 258-260 °C
XH-NMR (DMSO-de), δ (ppm): 2.18 (3H, s) , 3.47 (2H, t, J=6.0Hz), 3.70(2H, q, J=6.0Hz), 4.89(1H, t, J=6.0Hz), 7.89(1H, s) , 7.94(2H, d, J=8.5Hz), 8.13(2H, d, J=8.5Hz), 12.36(1H, brs). MS: 325(M-H)+ Step 8
N- (4- {4- [ (2-Hydroxyethyl) sulfonyl] phenyl } -1 ,3-thiazol-2- yl) acetamide (200 mg) , Et3N (0.102 ml) and CH2C12 (4 ml) were combined under N2 atmosphere, and then MsCl (0.05 ml) was added to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 2 hours. MeOH/CHCl3 and water were added to the mixture, and the mixture was extracted. The organic layer was washed with brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual solid (221.6 mg) was suspended in CH3CN (10 ml) , and then 28 % ammonia solution (0.5 ml) was added to the suspension at 0 °C. The reaction mixture was stirred at r.t. for 15 hours, and concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with [MeOH/CHCls (1:30), then NH4OH/MeOH/CHCl3 (1:10:60)] as an eluent, and triturated with EtOH / ethyl ether to give N-(4- {4-[ (2-aminoethyl) sulfonyl] phenyl } -1 ,3-thiazol-2-yl) acetamide (60.4 mg) as an off-white solid, mp. 287-288 °C XH-NMR (DMSO-de), δ (ppm): 2.18 (3H, s) , 2.79 (2H, t, J=6.5Hz), 3.36(2H, q, J=6.5Hz), 7.90(1H, s) , 7.94(2H, d, J=8.5Hz), 8.15(2H, d, J=8.5Hz) . MS: 326 (M+H) + Step 9
Di-tert-butyl ( (Z)-{ [2- ({4- [2- (acetylamino) -1 ,3-thiazol- 4-yl] phenyl} sulfonyl) ethyl] amino Jmethylidene) biscarbamate was prepared from the compound of Step 8 in a similar manner according to Step 3 of Production Example 31. mp. 280-281 °C XH-NMR (DMSO-de), δ (ppm): 1.38 (9H, s) , 1.39 (9H, s) , 2.18 (3H, s) , 3.65(4H, s) , 7.88(1H, s) , 7.93(2H, d, J=8.5Hz), 8.13(2H, d, J=8.5Hz), 8.32(1H, brs), 11.32(1H, brs), 12.35(1H, brs).
MS: 568 (M+H) + Step 10
The title compound was prepared from the compound of Step
9 in a similar manner according to Step 4 of Production
Example 31. mp. 188-189.5 °C XH-NMR (DMSO-de), δ (ppm) : 2.18(3H, s) , 3.51 (2H, m) , 3.59 (2H, t, J=6.0Hz), 7.28(3H, brs), 7.62(1H, t, J=5.5Hz), 7.93(1H, s) ,
7.98(2H, d, J=8.5Hz), 8.17 (2H, d, J=8.5Hz), 12.37(1H, brs).
MS: 368 (M+H) + free
Production Example 112: Synthesis of N-{4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- [3-
(methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide hydrochloride
Step 1
N-Methoxy-N-methyl-3- (methylsulfonyl) benzamide was prepared from 3- (methylsulfonyl) benzoic acid in a similar manner according to Step 1 of Production Example 31.
XH-NMR (CDC13) , δ (ppm): 3.08 (3H, s) , 3.40 (3H, s) , 3.55 (3H, s) ,
7.64(1H, t, J=8.0Hz), 7.99(1H, dt, J=8.0 , 1.5Hz), 8.03(1H, dt,
J=8.0, 1.5Hz), 8.28(1H, t, J=1.5Hz). MS: 244 (M+H) +
Step 2
To a stirred solution of N-methoxy-N-meth l-3-
(methylsulfonyl) benzamide (5 g) in dry THF (100 ml) was added dropwise DIBALH (22.6 ml) at -78 °C under N2 atmosphere. The reaction mixture was stirred for 4 hours at r.t. and then quenched with MeOH at 0 °C. AcOEt and IN-HCl were added to the mixture, and extracted. The organic layer was washed with brine, dried over anhydrous MgS0 , and concentrated in vacuo . The residual oil (3.38 g) , methyl
(triphenylphosphoranylidene) acetate (6.87 g) and THF (68 ml) were combined at r.t. under N2 atmosphere, and the reaction mixture was refluxed for 3 hours . The solvent was removed in vacuo , and the residue was suspended in AcOEt. The solid was filtered off, and the filtrate was concentrated in vacuo . The residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (2:1) as an eluent to give methyl (2E) -3- [3- (methylsulfonyl) phenyl] acrylate (613.8 mg) as yellow oil.
XH-NMR (DMSO-de), δ (ppm): 3.28 (3H, s) , 3.75 (3H, s) , 6.85 (IH, d, J=16.0Hz), 7.74(1H, s) , 7.93(1H, t, J=8.0Hz), 7.96(1H, d, J=8.0Hz), 8.09(1H, d, J=8.0Hz), 8.32(1H, d, J=16.0Hz). Step 3 Methyl (2E) -3- [3- (methylsulfonyl) phenyl] acrylate (600 mg) , MeOH (6 ml) and then 10 % palladium carbon (99.9 mg) were combined under N2 atmosphere. The reaction mixture was stirred at r.t. for 7 hours under H2 atmosphere (1 atm) , and filtered through a celite pad. The filtrate was concentrated in vacuo . ijhg residue was purified by flash column chromatography over silica gel with n-hexane / AcOEt (1:1 - 1:2) as an eluent to give methyl 3- [3- (methylsulfonyl) phenyl] propanoate (283.3 mg) as colorless oil. XH-NMR (DMSO-de), δ (ppm): 2.70 (2H, t, J=7.5Hz), 2.97 (2H, t, J=7.5Hz), 3.20(3H, s) , 3.58(3H, s) , 7.52-7.63 (2H, m) , 7.73- 7.80 (2H, m) . Step 4
Ethyl 4- [3- (methylsulfonyl) phenyl] -2-oxobutanoate was prepared from the compound of Step 3 in a similar manner according to Step 2 of Production Example 47.
XH-NMR (CDC13) , δ (ppm): 1.35 (3H, t, J=7.0Hz), 3.05 (2H, t, J=7.0Hz), 3.06(3H, s) , 3.24(2H, t, J=7.0Hz), 4.32(2H, q, J=7.0Hz), 7.45-7.82 (4H, m) . Step 5
Ethyl 3-bromo-4- [3- (methylsulfonyl) phenyl] -2-oxobutanoate was prepared from the compound of Step 4 in a similar manner according to Step 1 of Production Example 46. XH-NMR (CDCls) , δ (ppm): 1.37 (3H, t, J=7.0Hz), 3.07 (3H, s) ,
3.34(1H, dd, J=14.5, 8.0Hz), 3.60(1H, dd, J=14.5, 6.5Hz),
4.35(2H, q, J=7.0Hz), 5.26(1H, dd, J=8.0 , 6.5Hz), 7.49-
7.88 (4H, m) .
Step 6 Ethyl 2-amino-5- [3- (methylsulfonyl) benzyl] -1 ,3-thiazole-
4-carboxylate was prepared from the compound of Step 5 in a similar manner according to Step 2 of Production Example 46.
XH-NMR (DMSO-de), δ (ppm): 1.24 (3H, t, J=7.0Hz), 3.20 (3H, s) ,
4.20(2H, q, J=7.0Hz), 4.46(2H, s) , 7.10(2H, s) , 7.57-7.61 (2H, m) , 7.76-7.83(2H, m) .
MS: 341 (M+H) +
Step 7
Ethyl 2- (acetylamino) -5- [3- (methylsulfonyl) benzyl] -1 ,3- thiazole-4-carboxylate was prepared from the compound of Step 6 in a similar manner according to Step 3 of Production
Example 45.
XH-NMR (DMSO-de), δ (ppm) : 1.27 (3H, t, J=7.0Hz), 2.10(3H, s) ,
3.20(3H, s) , 4.27(2H, q, J=7.0Hz), 4.61(2H, s) , 7.56-7.66 (2H, m) , 7.77-7.89 (2H, m) , 12.47 (IH, s) . MS: 383 (M+H) +
Step 8
Ethyl 2- (acetylamino) -5- [3- (methylsulfonyl) benzyl] -1 ,3- thiazole-4-carboxylate (54.7 mg) was suspended in THF (1 ml) under N2 atmosphere, and then lithium aluminium hydride (7.79 mg) was added portionwise to the suspension at 0 °C. The reaction mixture was refluxed for 2.5 hours , and quenched with
MeOH and IN-HCl at 0 °C. Anhydrous MgS04 was added to the mixture, and stirred at r.t. for 1 hour. The suspension was filtered in vacuo. The filtrate was concentrated in vacuo.
The residual oil (114.8 mg) , CHC13 (1 ml), CH3CN (1 ml) and
Dess-Martin periodinane (88 mg) were combined at 0 °C under N2 atmosphere. The reaction mixture was stirred at r.t. for 1 hour, and diluted in CHC13. The organic solution was washed with saturated NaHC03, water and brine, dried over anhydrous
MgS04, and concentrated in vacuo to give N-{4-formyl-5- [3-
(methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJacetamide (61.2mg) as a yellow amorphous . !H-NMR (DMSO-de), δ (ppm): 2.13 (3H, s) , 3.17 (3H, s) , 4.67 (2H, s) , 7.56-7.90 (4H, m) , 10.04(1H, s) , 12.39(1H, s) .
Step 9
N-{5- [3- (Methylsulfonyl) benzyl] -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from the compound of Step 8 in a similar manner according to
Step 5 of Production Example 45.
XH-NMR (DMSO-de), δ (ppm): 2.08(3Hx2/3, s) , 2.13(3Hxl/3, s) ,
3.18(3H, s) , 4.23(2Hx2/3, s) , 4.50(2Hxl/3, s) , 6.69-8.31 (10H, m) . Step 10
N-{4-[2-(4-Aminophenyl)ethyl]-5-[3-
(methylsulfonyl) benzyl] -1 , 3-thiazol-2-ylJ acetamide was prepared from the compound of Step 9 in a similar manner according to Step 6 of Production Example 45. MS: 430 (M+H) +
Step 11
Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [3-
(methylsulfonyl) enzyl] -1 , 3-thiazol-4- yljethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound of Step 10 in a similar manner according to
Step 3 of Production Example 31.
XH-NMR [CD3CI/CD3OD (1:1)] , δ (ppm) : 1.29 (9H, s) , 1.55 (9H, s) ,
2.23(3H, s) , 2.89(4H, m) , 3.07(3H, s) , 3.90(2H, s) , 7.11- 7 . 87 ( 8H , m) .
MS : 672 (M+H) +
Step 12
The title compound was prepared from the compound of Step 11 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (CD3OD) , δ (ppm): 2.08 (3H, s) , 2.98 (4H, m) , 3.10 (3H, s) ,
3.98(2H, s) , 7.10-7.88(8H, m) .
MS: 472 (M+H) + free Production Example 113: Synthesis of N-{4-[2-(4-
{ [amino (imino) methy1] aminojphenyl) ethyl] -5- [ (1 , l-dioxido-4- thiomorpholinyl) methyl] -1 , 3-thiazol-2-yl } acetamide dihydrochloride
Step 1 N-{5-[ (l,l-Dioxido-4-thiomorpholinyl)methylj-4-[ (Z)-2-(4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2- yljacetamide in a similar manner according to Step 1 of
Production Example 67. MS: 437.12 (M+H) +
Step 2
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [ (1 , 1- dioxido-4-thiomorpholinyl) methyl] -1 ,3-thiazol-4- ylj ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound of Step 1 in a similar manner according to
Step 2 of Production Example 68.
XH-NMR (CDCI3) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.23 (3H, s) ,
2.70-2.95(8H, m) , 2.95-3.12 (4H, s) , 3.45(2H, s) , 6.99(2H, d,
J=8.3Hz), 7.42(2H, d, J=8.3Hz), 8.94-9.24 (IH, brs), 10.24(1H, s) , 11.63 (IH, s) .
MS: 651.1 (M+H) +, 673.3 (M+Na) +
Step 3
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.15 (3H, s) , 2.97 (4H, s) , 3.77-
4.63(8H, s) , 4.45(2H,s), 7.15(2H, d, J=8.3Hz), 7.32(2H, d, 5 J=8.3Hz), 7.46(4H, s) , 9.96(1H, s) , 12.29(1H, s) .
MS: 451.3 (M+H) +, 473.2 (M+Na) +
Production Example 114: Synthesis of N-[4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- (4- morpholinylmethy1) -1 , 3-thiazol-2-yl] acetamide dihydrochloride 0 Step 1
N-{5- (4-Morpholinylmethyl) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2- yljacetamide in a similar manner according to Step 1 of 5 Production Example 67.
MS: 389.16 (M+H) + - Step 2
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- (4- morpholinylmethyl) -1 ,3-thiazol-4- 0 yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 1 in a similar manner according to
Step 2 of Production Example 68.
XH-NMR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 2.22 (3H, s) ,
2.30-2.46 (4H, m) , 2.85(4H, s) , 3.39(2H, s) , 3.58-3.75 (4H, m) , 5 7.07 (2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 8.80-9.31 (IH, brs), 10.24(1H, s) , 11.63(1H, s) .
MS: 603.3 (M+H) + ϋ CU
The title compound was prepared from the compound of Step 0 2 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de) , δ (ppm) : 2.16 (3H, s) , 2.97 (4H, s) , 3.00- 3.12(2H, m) , 3.16-3.27 (2H, m) , 3.65-3.76 (2H, m) , 3.86-3.97 (2H, m) , 4.43(2H, s) , 7.15(2H, d, J=8.4Hz) , 7.31(2H, d, J=8.4Hz) ,
7.40(4H, s) , 9.86(1H, s) , 10.54-10.84 (IH, brs) , 12.34(1H, s) .
MS: 403.1 (M+H) +, 426.1 (M+Na) +
Production Example 115: Synthesis of N-{4-[2-(4- { [amino (imino) methy1] aminojphenyl) ethyl] -5- [ (3-oxo-l- piperazinylJmethyl] -1 ,3-thiazol-2-ylJ acetamide dihydrochloride
Step 1
N-{4-[ (Z) -2- (4-Nitrophenyl) vinyl] -5- [ (3-oxo-l- piperazinyl) methyl] -1 ,3-thiazol-2-ylJacetamide was prepared from N-{4-[ (Z) -2- (4-nitrophenyl) vinyl]-l, 3-thiazol-2- yljacetamide in a similar manner according to Step 1 of
Production Example 67.
Z : E = 3 : 1
XH-NMR (DMSO-de) , δ (ppm) : 2.10(3Hx3/4, s) , 2.15(3Hxl/4, s) , 2.54-2.59 (2Hx3/4, m) , 2.61-2.67 (2Hxl/4 , m) , 2.93(2Hx3/4, s) ,
3.02(2Hxl/4, m) , 3.08-3.19 (2H, m) , 3.64(2Hx3/4, s) ,
3.95(2Hxl/4, s) , 6.72(lHx3/4, d, J=12.4Hz) , 6.78(lHx3/4, d,
J=12.4Hz) , 7.34(lHxl/4, d, J=15.7Hz) , 7.59(1x1/4, d,
J=15.7Hz) , 7.62(2Hx3/4, d, J=8.8Hz) , 7.76(lHx3/4, s) , 7.78(lHxl/4, s) , 7.90(2Hxl/4, d, J=8.8Hz) , 8.14(2Hx3/4, d,
J=8.8Hz), 8.21(2Hxl/4, d, J=8.8Hz), 11.75-12.06 (1HX3/4 , brs),
12.08-12.33 (lHxl/4, brs).
MS: 402.21 (M+H) +
Step 2 Di-tert-butyl ( (Z) -{ [4- (2-{2- (acetylamino) -5- [ (3-oxo-l- piperazinyl) methyl] -1 , 3-thiazol-4- yljethyl) phenyl] amino Jmethylidene) iscarbamate was prepared from the compound of Step 1 in a similar manner according to
Step 2 of Production Example 68. XH-NMR (CDC13), δ (ppm) : 1.49 (9H, s) , 1.53 (9H, s) , 2.24 (3H, s) ,
2.47-2.55 (2H, m) , 2.80-2. 3 (4H, m) , 3.13(2H, s) , 3.24-3.32 (2H, m) , 3.43(2H, s) , 6.02(1H, s) , 7.04(2H, d, J=8.4Hz), 7.44(2H, d, J=8.3Hz), 9.02-9.26 (IH, brs), 10.24(1H, s) , 11.62(1H, s) . MS: 616.2 (M+H) +, 638.2 (M+Na) + Step 3
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.15(3H, s) , 2.39-2.62 (2H, m) , 2.95(4H, s) , 3.08-3.86(4H, m) , 4.20-4.77 (2H, brs), 7.15(2H, d, J=8.3Hz), 7.30(2H, d, J=8.0Hz), 7.35(4H, s) , 8.04-8.62 (IH, brs), 9.70(1H, s) , 10.67-11.38 (IH, brs), 11.97-12.72 (IH, brs). MS: 416.2 (M+H) + free
Production Example 116: Synthesis of 4- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl Jmethyl) -N,N-dimethyl-l-piperazinecarboxamide dihydrochloride Step 1
9H-Fluoren-9-ylmethyl 4- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-5-yl Jmethyl) -1- piperazinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJacetamide in a similar manner according to Step 1 of Production Example 67.
XH-NMR (CDC13) , δ (ppm): 2.10 (3H, s) , 2.26-2.61 (4H, m) , 3.39- 3.64(6H, m) , 4.19-4.30 (IH, m) , 4.37-4.49 (2H, m) , 6.66(2H, s) , 7.07-7.67 (8H, m) , 7.76(2H, d, J=6.9Hz), 8.05(2H, d, J=8.9Hz), 10.03 (IH, s) . MS: 610.2 (M+H) +, 632.2 (M+Na) + Step 2
9H-Fluoren-9-ylmethyl 4- ({2- (acetylamino) -4- [2- (4- aminophenyl) ethyl] -1 ,3-thiazol-5-yl Jmethyl) -1- piperazinecarboxylate was prepared from the compound of Step 1 in a similar manner according to Step 6 of Production Example 45.
XH-NMR (CDC13) , δ (ppm) : 2.16-2.33 (7H, m) , 2.80 (4H, s) , 3.34(2H, s) , 3.36-3.84(6H, m) , 4.17-4.30 (IH, m) , 4.36-4.47 (2H, m) , 6.57 (2H, d, J=8.4Hz) , 6.86(2H, d, J=8.3Hz) , 7.26-7.46 (4H, m) , 7.56(2H, d, J=7.0Hz) , 7.76(2H, d, J=6.9Hz) , 8.60-9.52 (IH, brs) .
MS: 582.2 (M+H) +, 604.3 (M+Na) + Step 3
9H-Fluoren-9-ylmethyl 4- [ (2- (acetylamino) -4- {2- [4- ( { (Z)- [ (tert-butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methy1} amino) phenylj ethyl J-l ,3-thiazol-5- yl) methyl] -1-piperazinecarboxylate was prepared from the compound of Step 2 in a similar manner according to Step 3 of Production Example 31. H-NMR (CDC13) , δ (ppm): 1.50 (9H, s) , 1.52 (9H, s) , 2.23 (3H, s) , 2.28-2.43 (4H, m) , 2.86(4H, s) , 3.36-3.55 (6H, m) , 4.18-4.29 (IH, m) , 4.35-4.48 (2H, m) , 7.05(2H, d, J=8.5Hz), 7.13-7.66 (8H, m) , 7.75(2H, d, J=7.0Hz), 8.85-9.76 (IH, brs), 10.25(1H, Ss) , 11.63 (IH, s) .
MS: 824.2 (M+H) +, 847.3 (M+Na) + Step 4
To a solution of 9H-fluoren-9-ylmethyl 4-[(2- (acetylamino) -4-{2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl J-l ,3-thiazol-5- yl) methyl] -1-piperazinecarboxylate (400 mg) in DMF (0.8 ml) was added piperidine (0.16 ml) , and the mixture was stirred for 2 h at 20 °C. To the reaction mixture was added piperidine (0.16 ml) , stirred at 20 °C for 1 h and 40 °C for 1 h, then cooled to 20 °C, added AcOEt (50 ml) , and the mixture was washed with water (10 mlx3) and brine (10 ml) , dried over MgS0 , filtered and concentrated in vacuo to give crude pale yellow oil (463 mg) . The crude oil was purified by flash column chromatography over NH silica gel with dichloromethane / methanol (100:0) —>• (100 : 1) as an eluent to give di-tert- butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- (1-piperazinylmethyl) - 1 ,3-thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate as a colorless amorphous.
XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 2.21 (3H, s) , 2.27-2.47 (4H, m) , 2.71-3.00 (8H, m) , 3.40(2H, s) , 7.07 (2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 10.24(1H, s) , 11.47-11.74 (IH, brs) .
MS: 602.3 (M+H) +, 624.2 (M+Na) + Step 5
To a solution of di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (1-piperazinylmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate (30 mg) in dichloromethane (0.3 ml) were added N,N-diisopropylethylamine (9.55 μl) and dimethylcarbamyl chloride (4.59 μl) , and the mixture was stirred for 14 h at 20 °C. To the reaction mixture was added saturated sodium hydrogen carbonate aqueous solution (2 ml) , then the mixture was extracted with diclhloromethane (5 mlx3) and the extract was dried over diatomaceous earth. The organic layer was concentrated in vacuo to give crude oil . The residue was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as an eluent to give di-tert-butyl { (Z) -[ (4-{2- [2- (acetylamino) -5- ( {4- [ (dimethylamino) carbonyl] -1-piperazinyl Jmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate as colorless oil . ! H- MR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s) , 2.35-2.42 (4H, m) , 2.80(6H, s) , 2.81-2.89 (4H, m) , 3.17-3.27 (4H, m) , 3.41(2H, s) , 7.07(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.73-8.90 (IH, brs), 10.25(1H, s) , 11.63(1H, s) . MS: 673.3 (M+H) +, 695.2 (M+Na) + Step 6
The title compound was prepared from the compound of Step 5 in a similar manner according to Step 4 of Production Example 31. H-NMR (DMSO-de) , δ (ppm): 2.16 (3H, s) , 2.76 (6H, s) , 2.91- 3.06(6H, m) , 3.07-3.19 (2H, m) , 3.20-3.30 (2H, m) , 3.57-3.65 (2H, m) , 4.36-4.51 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.31(2H, d, J=8.4Hz), 7.41(4H, s) , 9.87(1H, s) , 10.51-10.69 (IH, brs), 12.33(1H, s) . MS: 473.2 (M+H) +
Production Example 117: Synthesis of N-(4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- { [4- (4- morpholinylcarbonyl) -1-piperazinyl] methyl J-l ,3-thiazol-2- yl) acetamide dihydrochloride Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (4- morpholinylcarbonyl) -1-piperazinylJmethyl J-l ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared from the compound of Step 4 of Production Example 116 in a similar manner according to Step 5 of Production Example 116. XH~NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s) , 2.32-2.46 (4H, m) , 2.78-2.91 (4H, m) , 3.20-3.30 (8H, m) , 3.42(2H, s) , 3.63-3.71 (4H, m) , 7.07 (2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.72-8.89 (IH, brs), 10.25(1H, s) , 11.64(1H, s) . MS: 715.3 (M+H) +, 737.2 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.90-3.07 (6H, m) , 3.11- 3.32(8H, m) , 3.48-3.76 (6H, m) , 4.42(2H, s) , 7.15(2H, d, J=8.4Hz), 7.31(2H, d, J=8.4Hz), 7.40(4H, s) , 9.85(1H, s) , 10.51-10.72 (IH, brs), 12.34(1H, s) . MS: 515.3 (M+H) + free
Production Example 118: Synthesis of N-(4-[2-(4- { [amino (imino) methyl] aminojphenyl) ethyl] -5- { [4-(l- pyrrolidinylcarbonyl) -l-piperazinyl]methyl}-l ,3-thiazol-2- yl) acetamide dihydrochloride
Step 1
Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (1- pyrrolidinylcarbonyl) -1-piperazinyl]methylJ-l ,3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared from the compound of Step 4 of Production Example 116 in a similar manner according to Step 5 of Production Example 116.
XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 1.72-
1.89(4H, m) , 2.23(3H, s) , 2.28-2.48 (4H, m) , 2.84(4H, s) , 3.19- 3.39(8H, m) , 3.41(2H, s) , 7.07 (2H, d, J=8.4Hz), 7.46(2H, d,
J=8.4Hz), 8.71-8.99 (IH, brs), 10.24(1H, s) , 11.64(1H, s) .
MS: 699.2 (M+H) +, 721.3 (M+Na) +
Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.70-1.83 (4H, m) , 2.16 (3H, s) , 2.89-
3.05(6H, m) , 3.06-3.19 (2H, m) , 3.20-3.32 (6H, m) , 3.64-3.84 (2H, m) , 4.36-4.50 (2H, m) , 7.15(2H, d, J=8.2Hz), 7.31(2H, d, J=8.3Hz), 7.42(4H, s) , 9.88(1H, s) , 10.50-10.75 (IH, brs),
12.34 (IH, s) .
MS: 499.3 (M+H) + free
Production Example 119 : Synthesis of N-[4-[2-(4-
{ [amino (imino) methyl] aminojphenyl) ethyl] -5- ( {4- [ (4-methyl-l- piperazinyl) carbonyl] -1-piperazinyl Jmethyl) -1 ,3-thiazol-2- yl] acetamide trihydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4- [ (4- methyl-1-piperazinyl) carbonyl] -1-piperazinyl Jmethyl) -1,3- thiazol-4-yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 4 of Production Example 116 in a similar manner according to Step 5 of Production Example
116. XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 2.23 (3H, s) , 2.29(3H, s) , 2.32-2.48 (8H, m) , 2.84(4H, s) , 3.16-3.35 (8H, m) , 3.42(2H, s) , 7.07 (2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.69- 9.04(1H, brs), 10.24(1H, s) , 11.64(1H, s) . MS: 728.2 (M+H) +, 750.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31. iR-NMR (DMSO-de), δ (ppm): 2.16 (3H, s) , 2.76 (3H, d, J=4.6Hz), 2.89-3.09 (8H, m) , 3.17-3.39 (8H, m) , 3.62-3.77 (4H, m) , 4.34- 4.51(2H, brs), 7.15(2H, d, J=8.3Hz), 7.31(2H, d, J=8.2Hz), 7.41(4H, s) , 9.87(1H, s) , 10.68-10.97 (IH, brs), 12.34(1H, s) . MS: 528.3 (M+H) + free Production Example 120: Synthesis of 3- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5-ylJ- N, -dimeth lpropanamide hydrochloride Step 1
Ethyl 3- [2- (acetylamino) -4- (2-{4- [ (tert- butoxycarbonyl) aminoJphenyl} ethyl) -1 ,3-thiazol-5-yl] acrylate was prepared from 2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazole-5-carbaldehyde in a similar manner according to Step 7 of Production Example 61. XH-NMR (CDCI3) , δ (ppm): 1.16-1.40 (3H, m) , 1.52 (9H, s) , 2.23- 2.38(3H, m) , 2.70-3.06 (4H, m) , 4.15-4.33 (2H, m) , 5.53-6.15 (IH, m) , 6.64-7.85 (6H, m) . MS: 482.2 (M+Na) + Step 2 A mixture of ethyl (2E) -3- [2- (acetylamino) -4- (2-{4- [ (tert-butoxycarbonyl) aminoJphenyl} ethyl) -1 ,3-thiazol-5- yl] acrylate and ethyl (2Z) -3- [2- (acetylamino) -4- (2- {4- [ (tert- butoxycarbonyl) aminoJphenyl} ethyl) -1 ,3-thiazol-5-yl] acrylate (200 mg) , THF (7 ml) and 10 % Pd/C (392 mg) were combined under nitrogen atmosphere. The mixture was stirred under 3 atm hydrogen atmosphere at 20 °C for 3 h. The reaction mixture was filtered through a celite pad, and the filtrate was concentrated in vacuo to give ethyl 3- [2- (acetylamino) -4- (2- {4- [ (tert-butoxycarbonyl) amino] phenyl} ethyl) -1 ,3-thiazol-5- yl] propanoate as a colorless amorphous.
XH-NMR (CDC13) , δ (ppm): 1.24 (3H, t, J=7.0Hz), 1.51 (9H, s) , 2.24(3H, s) , 2.41(2H, t, J=7.5Hz), 2.73-2.93 (6H, m) , 4.12(2H, q, J=7.0Hz), 6.95(2H, d, J=7.2Hz), 7.23 (2H, d, J=7.7Hz). MS: 484.1 (M+Na) + Step 3
Ethyl 3- (2- (acetylamino) -4-{2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethylJ-l ,3-thiazol-5- yl) propanoate was prepared from the compound of Step 2 in a similar manner according to Step 4 of Production Example 65. XH-NMR (CDCI3) , δ (ppm): 1.24 (3H, t, J=7.1Hz), 1.50 (9H, s) , 1.53(9H, s) , 2.21(3H, s) , 2.41(2H, t, J=7.6Hz), 2.70-3.00 (6H, m) , 4.12(2H, q, J=7.2Hz), 7.07 (2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.80-9.20(lH, brs), 10.24(1H, s) , 11.63(1H, s) . MS: 604.3 (M+H) +, 626.2 (M+Na) + Step 4
3- (2- (Acetylamino) -4-{2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} amino) phenyl] ethyl J-l , 3-thiazol-5- yl)propanoic acid was prepared from the compound of Step 3 in a similar manner according to Step 1 of Production Example 42. XH-NMR (CDCI3) , δ (ppm): 1.47 (9H, s) , 1.53 (9H, s) , 2.19 (3H, s) , 2.25-2.45(2H, m) , 2.60-3.00 (6H, m) , 6.96(2H, d, J=8.3Hz), 7.34(2H, d, J=8.3Hz), 10.17(1H, s) , 11.30-11. 0 (IH, brs). MS: 598.2 (M+Na) + Step 5 Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [3- (dimethylamino) -3-oxopropyl] -1 ,3-thiazol-4~ yl} ethyl) phenyl] amino Jmethylidene) biscarbamate was prepared from the compound of Step 4 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.21 (3H, s) , 2.28-2.43(2H, m) , 2.79-2.99 (12H, m) , 7.05(2H, d, J=8.5Hz), 7.44(2H, d, J=8.5Hz), 8.85-9.37 (IH, brs), 10.23(1H, s) , 11.62(1H, s) . MS: 603.3 (M+H) +, 625.3 (M+Na) + Step 6
The title compound was prepared from the compound of Step 5 in a similar manner according to Step 4 of Production Example 31. ^-NMR (DMSO-de), δ (ppm): 2.10 (3H, s) , 2.40 (2H, t, J=7.3Hz), 2.75(2H, t, J=7.3Hz), 2.77-2.84 (5H, m) , 2.84-2. 5 (5H, m) , 7.14(2H, d, J=8.4Hz), 7.24(2H, d, J=8.4Hz), 7.36(4H, s) , 9.72(1H, s) , 11.93(1H, s) . MS: 403.3 (M+H) + free Production Example 121: Synthesis of 3- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5-yl J- N-methylpropanamide hydrochloride Step 1
Di-tert-butyl ( (Z)-{ [4- (2-{2- (acetylamino) -5- [3- (methylamino) -3-oxopropyl] -1 ,3-thiazol-4- yljethyl) phenyl] aminoJmethylidene) biscarbamate was prepared from the compound of Step 4 of Production Example 120 in a similar manner according to Step 1 of Production Example 32. XH-NMR (CDCI3) , δ (ppm): 1.45 (9H, s) , 1.54 (9H, s) , 1.79- 1.88(2H, s) , 2.23(3H, s) , 2.65(3H, d, J=4.8Hz), 2.69-2.77 (2H, m) , 2.79-2.86(2H, m) , 2.86-2.95 (2H, m) , 6.04(2H, d, J=4.4Hz), 6.93(2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 8.79-9.17 (IH, brs), 10.28(1H, s) , 11.60(1H, s) . MS: 589.3 (M+H) +, 611.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm): 2.10(3H, s) , 2.22(2H, t, J=7.3Hz), 2.53(3H, d, J=4.8Hz), 2.72-2.82 (4H, m) , 2.82-2.90 (2H, m) , 7.15(2H, d, J=8.4Hz), 7.26(2H, d, J=8.4Hz), 7.38(4H, s) , 7.79(1H, d, J=4.5Hz), 9.76(1H, s) , 11.95(1H, s) . MS: 389.2 (M+H) +, 411.2 (M+Na) + free
Production Example 122 : Synthesis of 3- {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl]-l ,3-thiazol-5- yljpropanamide hydrochloride Step 1 Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- (3-amino-3- oxopropyl) -1 , 3-thiazol-4- ylj ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 4 of Production Example 120 in a similar manner according to Step 1 of Production Example 32. XH-NMR (CDC13) , δ (ppm): 1.47(9H, s) , 1.53(9H, s) , 1.57-
1.67 (2H, m) , 2.24(3H, s) , 2.65-2.76 (2H, m) , 2.76-2.87 (2H, m) , 2.87-2.99 (2H, m) , 5.37(1H, s) , 6.14(1H, s) , 6.90(2H, d, J=8.4Hz), 7.28(2H, d, J=8.4Hz), 8.88-9.28 (IH, brs), 10.12(1H, s) , 11.58 (IH, s) . MS: 575.0 (M+H) +, 597.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31. ! H-NMR (DMSO-de), δ (ppm): 2.10(3H, s) , 2.23 (2H, t, J=7.3Hz), 2.71-2.83(4H, m) , 2.83-2.91 (2H, m) , 6.81(1H, s) , 7.14(2H, d, J=8.4Hz), 7.26(2H, d, J=8.4Hz), 7.31(1H, s) , 7.35(4H, s) , 9.70(1H, s) , 11.94 (IH, s) . MS: 375.2 (M+H) +, 397.0 (M+Na) + free
Production Example 123: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- ylJmethyl) -N,N-dimethyl-4-piperidinecarboxamide dihydrochloride Step 1 l-[ (2- (Acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl} aminoJphenyl] ethyl }-1 ,3-thiazol-5- yl) methyl] -4-piperidinecarboxylic acid was prepared from ethyl l-[ (2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) iminoJmethyl}amino) phenyl] ethylJ-l ,3-thiazol-5- ylJmethyl] -4-piperidinecarboxylate in a similar manner according to Step 1 of Production Example 42.
XH-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.51 (9H, s) , 1.76- 2.49(10H, m) , 2.69-3.00 (6H, m) , 3.71(2H, s) , 7.04(2H, d, J=8.5Hz), 7.42(2H, d, J=8.5Hz), 10.23(1H, s) , 11.13-12.07 (IH, brs) . MS: 645.3 (M+H) +, 667.2 (M+Na) + Step 2
Di-tert-butyl { (Z)-[ (4-{2- [2- (acetylamino) -5- ( {4- [ (dimethylamino) carbonyl] -1-piperidinyl Jmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 1 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (ppm): 1.50 (9H, s) , 1.54 (9H, s) , 1.75- 1.89(2H, m) , 1.92-2.03 (2H, m) , 2.22(3H, s) , 2.37-2.49 (IH, m) , 2.80-2.95(9H, m) , 3.02(3H, s) , 3.43(2H, s) , 7.08(2H, d, J=8 . 4Hz ) , 7 . 46 (2H , d, J=8 . 4Hz ) , 8 . 61-9 . 19 ( IH , brs ) , 10 . 24 (1H , s ) , 11 . 63 ( IH , s ) . MS : 672 . 2 (M+H) + , 694 . 3 (M+Na) + Step 3 The title compound was prepared from the compound of Step
2 in a similar manner according to Step 4 of Production
Example 31. H-NMR (DMSO-de), δ (ppm): 1.71-2.01 (4H, m) , 2.16 (3H, s) , 2.76- 2.87 (4H, m) , 2.87-3.1(9H, m) , 3.3-3.4(2H, m) , 4.32-4.45 (2H, m) , 7.15(2H, d, J=4.2Hz), 7.31(2H, d, J=4.2Hz), 7.41(4H, s) ,
9.83-9.93 (IH, m) , 9.99-10.19 (IH, m) , 12.32-12.37 (IH, m) .
MS: 472.3 (M+H) +, 494.0 (M+Na) + free
Production Example 124: Synthesis of 1- ({2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl Jmethyl) -N-methyl-4-piperidinecarboxamide dihydrochloride
Step 1
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( {4-
[ (methylamino) carbonyl] -1-piperidinyl Jmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 1 of Production Example 123 in a similar manner according to- Step 1 of Production Example 32.
XH-NMR (CDC13) , δ (ppm): 1.5 (9H, s) , 1.54 (9H, s) , 1.65-1.74 (2H, m) , 1.75-1.84(2H, m) , 1.87-1.98 (2H, m) , 2-2.11(lH, m) , 2.22(3H, s) , 2.8(3H, d, J=4.8Hz), 2.82-2.91 (6H, m) , 3.39(2H, s) , 5.5(1H, d, J=4.4Hz), 7.07 (2H, d, J=8.4Hz), 7.45(2H, d,
J=8.4Hz), 8.72-8.99 (IH, brs), 10.23(1H, s) , 11.62(1H, s) .
MS: 658.3 (M+H) +, 680.3 (M+Na) +
Step 2 The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.71-2.04 (4H, m) , 2.16 (3H, s) , 2.25-
2.37 (IH, m) , 2.54-2.61 (3H, m) , 2.82-2.94 (2H, m) , 2.96(4H, s) , 3.27-3.37 (2H, m) , 4.31-4.44 (2H, m) , 7.15(2H, d, J=8.4Hz),
7.30(2H, d, J=8.4Hz), 7.41(4H, s) , 7.89-8.00 (IH, m) , 9.83-
10.16(2H, m) .
MS: 458.2 (M+H) +, 480.0 (M+Na) + free Production Example 125: Synthesis of 1- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino)methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- ylJmethyl) -4-piperidinecarboxamide dihydrochloride Step 1 Di-tert-butyl [ (Z) - ( {4- [2- (2- (acetylamino) -5-{ [4- (aminocarbonyl) -1-piperidinyl]methyl }-1 , 3-thiazol-4- yl) ethyl] phenyl} amino) methylidenejbiscarbamate was prepared from the compound of Step 1 of Production Example 123 in a similar manner according to Step 1 of Production Example 32. iR- MR (CDCls) , δ (ppm): 1.50 (9H, s) , 1.53 (9H, s) , 1.66-1.75
(2H, m) , 1.78-1.87 (2H, m) , 1.88-1.99 (2H, m) , 2.07-2.17 (IH, m) , 2.23(3H, s) , 2.77-2.92(6H, m) , 3.39(2H, s) , 5.5(2H, s) , 7.06(2H, d, J=8.4Hz), 7.45(2H, d, J=8.4Hz), 8.94-9.25 (IH, brs), 10.23(1H, s) , 11.61(1H, s) . MS: 644.2 (M+H) +, 666.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 1 in a similar manner according to Step 4 of Production Example 31. iπ-NMR (DMSO-de), δ (ppm) : 1.68-2.08 (4H, m) , 2.16 (3H, s) , 2.25- 2.36(1H, m) , 2.82-3.0 (6H, m) , 3.27-3.44 (2H, m) , 4.30-4.45 (2H, m) , 6.87-7.06 (IH, m) , 7.15(2H, d, J=8.4Hz), 7.30(2H, d, J=8.3Hz), 7.36-7.52 (5H, m) , 9.87-10.25 (2H, m) , 12.30-12.37 (IH, m) . MS. 444.2 (M+H) +, 466.2 (M+Na) + free
Production xm le 126: Synthesis of (3R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino)methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-yl Jmethyl) -N , -dimethyl-3-piperidinecarboxamide dihydrochloride Step 1
Ethyl (3R) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-5-yl Jmethyl) -3- piperidinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl]-l,3-thiazol-2-yl} acetamide in a similar manner according to Step 1 of Production Example 67. MS: 459.20 (M+H) + Step 2 Ethyl (3R)-l-[ (2- (acetylamino) -4-{2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [(tert- butoxycarbonyl) iminoJmethyl}aminoJphenyl] ethylJ-l ,3-thiazol-5- yl) methyl] -3-piperidinecarboxylate was prepared from the compound of Step 1 in a similar manner according to Step 2 of Production Example 68.
XH-NMR (CDCI3) , δ (ppm): 1.22 (3H, t, J=7.2Hz), 1.31-1.78 (21H, m) , 1.79-2.06 (2H, m) , 2.07-2.18 (IH, m) , 2.22(3H, s) , 2.43- 2.62(1H, m) , 2.62-2.75 (IH, m) , 2.84(4H, s) , 2.88-3.01 (IH, m) , 3.42(2H, s) , 4.11(2H, q, J=7.1Hz), 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.76-9.16 (IH, brs), 10.24(1H, s) , 11.64(1H, s) .
MS: 673.3 (M+H) +, 695.2 (M+Na) + Step 3
(3R)-l-[ (2- (Acetylamino) -4- {2- [4- ({ (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino] methyl} amino) phenyl] ethyl }-l ,3-thiazol-5- yl) methylJ -3-piperidinecarboxylic acid was prepared from the compound of Step 2 in a similar manner according to Step 1 of Production Example 42. MS: 645.37 (M+H) + Step 4
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (3R) -3- [ (dimethylamino) carbonyl] -1-piperidinyl Jmethyl) -1 , 3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 3 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (ppm): 1.39-1.57 (20H, m) , 1.66-1.73 (IH, m) , 1.74-1.83 (IH, m) , 1.87-1.98 (IH, m) , 2.08-2.19 (IH, m) , 2.22(3H, s) , 2.72-2.94(10H, m) , 3.02(3H, s) , 3.41(2H, s) , 7.08(2H, d,
J=8.4Hz) , 7.46(2H, d, J=8.4Hz) , 8.70-9.02 (IH, brs) , 10.24(1H, s) , 11.63(1H, s) .
MS: 672.41 (M+H) + Step 5
The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.29-1.94 (4H, m) , 2.16(3H, s) , 2.77- 3.33(15H, m) , 4.27-4.46 (2H, m) , 7.16(2H, d, J=8.3Hz), 7.27-
7.35(2H, m) , 7.36-7.48 (4H, m) , 9.8-9.98(lH, m) , 10.22-10.51
(IH, brs), 12.29-12.36 (IH, m) .
MS: 472.3 (M+H) +, 494.2 (M+Na) + free
Production Example 127 : Synthesis of (3R) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-
5-yl Jmethyl) -N-methyl-3-piperidinecarboxamide dihydrochloride
Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (3R) -3-
[ (methylamino) carbonyl] -1-piperidinylJmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 3 of Production Example 126 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCls) , δ (ppm): 1.50 (9H, s) , 1.52-1.72 (12H, m) , 1.84-
1.98(1H, m) , 2.01-2.14(1H, m) , 2.14-2.23 (IH, m) , 2.24(3H, s) , 2.43-2.51 (IH, m) , 2.64-2.76 (IH, m) , 2.76-2.94 (8H, m) , 3.32(1H, d, J=14Hz) , 3.41 (IH, d, J=14Hz) , 7.06 (2H, d, J=8.4Hz),
7.45(2H, d, J=8.4Hz), 7.53(1H, brs), 8.84(1H, brs), 10.24(1H, s) , 11.63 (IH, s) .
MS: 658.39 (M+H) + Step 2
The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31. XH-NMR (DMSO-de), δ (ppm): 1.31-1.94 (4H, m) , 2.16 (3H, s) , 2.54- 3.36(12H, m) , 4.27-4.48 (2H, m) , 7.12-7.19 (2H, m) , 7.25- 7.35(2H, m) , 7.35(4H, brs), 8.05-8.37 (IH, m) , 9.79-9.92 (IH, m) , 10.16-10.42 (IH, brs), 12.29-12.37 (IH, m) . MS: 458.2 (M+H) +, 480.1 (M+Na) + free
Production Example 128: Synthesis of (3S) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-yl Jmethyl) -N,N-dimethyl-3-piperidinecarboxamide dihydrochloride Step 1
Ethyl (3S) -1- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-5-yl Jmethyl) -3- piperidinecarboxylate was prepared from N-{4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide in a similar manner according to Step 1 of Production Example 67. MS: 459.21 (M+H) + Step 2
Ethyl (3S)-l-[ (2- (acetylamino) -4- {2- [4- ( { (Z)-[ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) imino]methyl}amino) phenyl] ethyl }-l ,3-thiazol-5- yl) methyl] -3-piperidinecarboxylate was prepared from the compound of Step 1 in a similar manner according to Step 2 of Production Example 68. XH-NMR (CDC13) , δ (ppm): 1.22 (3H, t, J=7.2Hz), 1.3-1.79 (21H, m) , 1.8-2.06(2H, m) , 2.08-2.18 (IH, m) , 2.22(3H, s) , 2.43-
2.62(1H, m) , 2.62-2.75 (IH, m) , 2.84(4H, s) , 2.88-3.01 (IH, m) , 3.42(2H, s) , 4.11(2H, q, J=7.1Hz), 7.08(2H, d, J=8.4Hz), 7.46(2H, d, J=8.4Hz), 8.71-9.23 (IH, brs), 10.24(1H, s) , 11.64(1H, s) . MS: 673.3 (M+H) +, 695.2 (M+Na) + Step 3
(3S) -1- [ (2- (Acetylamino) -4-{2- [4- ( { (Z) - [ (tert- butoxycarbonyl) amino] [ (tert- butoxycarbonyl) iminoJmethyl}amino) phenyl] ethyl}-1 , 3-thiazol-5- yl) methyl] -3-piperidinecarboxylic acid was prepared from the compound of Step 2 in a similar manner according to Step 1 of Production Example 42. 5 MS: 645.36 (M+H) + Step 4
Di-tert-butyl { (Z)-[ (4- {2- [2- (acetylamino) -5- ( { (3S)-3- [ (dimethylamino) carbonyl] -1-piperidinyl Jmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared ° from the compound of Step 3 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDC13) , δ (ppm): 1.4-1.64 (20H, m) , 1.65-1.73 (IH, m) , 1.73-1.82 (IH, m) , 1.86-1.97 (IH, m) , 2.08-2.18 (IH, m) , 2.22(3H, s) , 2.7-2.93 (10H, m) , 3.02(3H, s) , 3.41(2H, s) , 7.08(2H, d, 5 j=8.4Hz), 7.46(2H, d, J=8.3Hz), 8.61-8.99 (IH, brs), 10.24(1H, s) , 11.63 (IH, s) . MS: 672.39 (M+H) + Step 5
The title compound was prepared from the compound of Step 0 4 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.29-1.93 (4H, m) , 2.16 (3H, s) , 2.77- 3.35(15H, m) , 4.27-4.45 (2H, m) , 7.16(2H, d, J=8.4Hz), 7.28- 7.35(2H, m) , 7.35-7.47(4H, m) , 9.8-9.96(lH, m) , 10.21- 5 10.46(1H, brs), 12.29-12.36 (IH, m) . MS: 472.3 (M+H) +, 494.2 (M+Na) + free
Production Exam le 1 9 : Synthesis of (3S) -1- ( {2- (acetylamino) - 4- [2- (4-{ [amino (iminoJmethyl] aminojphenyl) ethyl] -1 ,3-thiazol- 5-yl Jmethyl) -N-methyl-3-piperidinecarboxamide dihydrochloride 0 Step 1
Di-tert-butyl { (Z) - [ (4-{2- [2- (acetylamino) -5- ( { (3S) -3- [ (methylamino) carbonyl] -1-piperidinyl Jmethyl) -1 ,3-thiazol-4- yl] ethyljphenyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 3 of Production Example 128 in a similar manner according to Step 1 of Production Example 32.
XH-NMR (CDCI3) , δ (ppm): 1.46-1.72 (21H, m) , 1.84-1.97 (IH, m) ,
1.99-2.14(1H, m) , 2.15-2.22 (IH, m) , 2.24(3H, s) , 2.43-2.51 (IH, 5 m) , 2.65-2.76(lH, m) , 2.76-2.91 (8H, m) , 3.32(1H, d, J=14Hz) ,
3.41(1H, d, J=14Hz) , 7.06(2H, d, J=8.4Hz), 7.45(2H, d,
J=8.4Hz), 7.54(1H, brs), 8.84- .02 (IH, brs), 10.24(1H, s) ,
11.63 (IH, s) .
MS: 658.40 (M+H) + ° Step 2
The title compound was prepared from the compound of Step
1 in a similar manner according to Step 4 of Production
Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.31-1.94 (4H, m) , 2.16 (3H, s) , 2.53- 5 3.36(12H, m) , 4.24-4.46 (2H, m) , 7.12-7.19 (2H, m) , 7.25-
7.35(2H, m) , 7.36(4H, brs), 8.06-8.37 (IH, m) , 9.83-9.99 (IH, m) , 10.28-10.54 (IH, brs), 12.33(1H, s) .
MS: 458.2 (M+H) +, 480.2 (M+Na) + free
Production Example 130 : Synthesis of N-{4- [2- (2-amino-lH- 0 benzimidazol-6-yl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3- thiazol-2-yl } acetamide
Step 1
N-{4-[2-(3,4-Dinitrophenyl) vinyl] -5- [4-
(methylthio) benzyl] -1 ,3-thiazol-2-ylJacetamide was prepared 5 from 2- (acetylamino) -5- [4- (methylthio) benzyl] -1 ,3-thiazole-4- carbaldehyde in a similar manner according to Step 5 of
Production Example 45.
Z : E = 3 : 1
XH-NMR(CDC13) , δ (ppm): 2.08(3Hx3/4, s) , 2.12(3Hxl/4, s) , 0 2.44(3H, s) , 4.13(2Hx3/4, s) , 4.32(2Hxl/4, s) , 6.71(lHx3/4, d,
J=12.5Hz), 6.97(lHx3/4, d, J=12.3Hz), 7.06-8.61 (7H + 2Hxl/4, m) , 11.85(lHx3/4, s) , 12.18 (lHxl/4 , s) .
MS: 471.1 (M+H) +, 493.9 (M+Na) + Step 2
N-{4- [2- (3 , 4-Diaminophenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl } acetamide was prepared from the compound of Step 1 in a similar manner according to Step 2 of Production Example 32 and Step 6 of Production Example 45.
XH-NMR (CDC13) , δ (ppm): 2.23 (3H, s) , 2.70-2.85 (4H, m) , 3.03(3H, s) , 3.88(2H, s) , 6.34(1H, d, J=1.8Hz), 6.39(1H, dd, J=1.8, 7.8Hz), 6.56(1H, d, J=7.7Hz), 7.14(2H, d, J=8.3Hz), 7.79 (2H, d, J=8.4Hz), 8.30-9.45 (IH, brs). MS: 445.0 (M+H) +, 467.0 (M+Na) + Step 3
To a suspension of N-{4- [2- (3 ,4-diaminophenyl) ethyl] -5- [4- (methylsulfonyl) enzyl] -1 ,3-thiazol-2-ylJ acetamide (70.8 mg) in MeOH (0.7 ml) was added cyanogen bromide (25.3 mg) , then the mixture was stirred for 14 h at 20 °C. To the reaction mixture was added IN-NaOH (0.239 ml) and the mixture was concentrated in vacuo . To the residue was added CHCI3 : MeOH = 10 : 1 (10 ml) , and an insoluble material was removed by filtration. The filtrate was purified by flash column chromatography over NH silica gel with CHCI3 / MeOH (100:1 - 10:1) as an eluent to give colorless oil. The oil was solidified with CH2C12 : Et20 = 2 : 1 to give N-{4- [2- (2-amino- lH-benzimidazol-6-yl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3- thiazol-2-yl J acetamide as a white solid.
XH-NMR (CDCI3) , δ (ppm): 2.09 (3H, s) , 2.85(4H, s) , 3.16 (3H, s) , 3.97(2H, s) , 6.01(2H, s) , 6.55-6.77 (IH, m) , 6.78-6.90 (IH, m) , 6.96(1H, d, J=7.8Hz), 7.10-7.30 (2H, brs), 7.72(2H, d, J=8.1Hz), 10.55(1H, d, J=10.5Hz), 11.50-12.20 (IH, brs). MS: 470.2 (M+H) +, 492.1 (M+Na) +
Production Example 131: Synthesis of N-{4- [2- (2-amino-lH- benzimidazol-6-yl) ethylJ -1 , 3-thiazol-2-yl }acetamide Step 1 N-{4-[2-(3,4-Dinitrophenyl)vinyl]-l,3-thiazol-2- yljacetamide was prepared from 2- (acetylamino) -1 ,3-thiazole-4- carbaldehyde in a similar manner according to Step 5 of Production Example 1. Z : E = 8 : 1
XH-NMR (DMSO-de), δ (ppm): 2.13(3Hx8/9, s) , 2.17(3Hxl/9, s) , 6.64(lHx8/9, d, J=12.6Hz), 6.80(lHx8/9, d, J=12.6Hz), 7.29(lHxl/9, d, J=15.7Hz), 7.33(lHx8/9, s) , 7.39(lHxl/9, s) , 7.63(lHxl/9, d, J=15.7Hz), 8.00-8.50 (3H, m) , 11.97 (1HX8/9 , s) , 12.30(lHxl/9, s) .
MS: 335.0 (M+H) +, 357.1 (M+Na) + Step 2
N-{4- [2- (3 ,4-Diaminophenyl) ethyl] -1 ,3-thiazol-2- ylj acetamide was prepared from the compound of Step 1 in a similar manner according to Step 6 of Production Example 1. XH-NMR (CDC13) , δ (ppm): 2.22 (3H, s) , 2.58-3.17 (8H, m) , 6.46- 6.56 (3H, m) , 6.62 (IH, d, J=8.3Hz), 8.84-10.42 (IH, brs). MS: 277.1 (M+H) +, 299.2 (M+Na) + Step 3 The title compound was prepared from the compound of Step
2 in a similar manner according to Step 3 of Production Example 130.
XH-NMR (CDC13) , δ (ppm): 2.11 (3H, s) , 2.79-2.97 (4H, m) , 6 (2H, s) , 6.59-6.8(2H, m) , 6.91(1H, s) , 6.97(1H, d, J=7.9Hz), 10.34- 10.73(1H, brs), 11.94-12.22 (IH, brs). MS: 302.2 (M+H) +, 324.1 (M+Na) +
Production xam e 132 : Synthesis of N- ( {2- (acetylamino) -4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3-thiazol-5- yl Jmethyl) -N-methylacetamide hydrochloride Step 1
N-{5-[ (Methylamino) methyl] -4- [ (Z)-2-(4- nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide was prepared from N-{4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 , 3-thiazol-2- yl}acetamide in a similar manner according to Step 1 of Production Example 67.
XH-NMR (CDC13) , δ (ppm): 2.05(3H, s) , 2.46 (3H, s) , 3.75 (2H, s) , 6.67 (2H, s) , 7.41(2H, d, J=8.9Hz), 8.0K2H, d, J=8.8Hz), 9.7- 5 11.69(1H, brs) .
MS: 333.1 (M+H) +, 355.1 (M+Na) + Step 2
To a suspension of N-{5- [ (methylamino)methyl] -4- [ (Z) -2- (4-nitrophenyl) vinyl] -1 ,3-thiazol-2-ylJ acetamide (46.8 mg) in ° dichloromethane (0.5 ml) were added N,N-diisopropylehtylamine (27 μl) and acethyl chloride (10 μl) , and the mixture was stirred for 2 h at 20 °C. To the reaction mixture were added dichloromethane (5 ml) , N,N-diisopropylehtylamine (27 μl) and acethyl chloride (10 μl) , and the mixture was stirred for 5 5 min. at 20 °C, then washed with saturated sodium hydrogen carbonate aqueous solution (5 ml) and brine (5 ml) , dried over MgS0 , filtered and evaporated to give a yellow solid (67.8 mg) . The crude compound was purified by preparative silica gel thin-layer chromatography with chloroform / methanol (20:1) as 0 an eluent to give N- ( {2- (acetylamino) -4- [ (Z) -2- (4- nitrophenyl) vinyl] -1 ,3-thiazol-5-yl Jmethyl) -N-methylacetamide as a yellow solid.
XH-NMR (CDCI3) , δ (ppm): 2.12(3Hx2/3, s) , 2.13(3Hxl/3, s) , 2.14(3Hx2/3, s) , 2.24(3Hxl/3, s) , 3.02(3Hx2/3, s) , 5 3.05(3Hxl/3, s) , 4.62(2Hx2/3, s) , 4.79(2Hxl/3, s) , 6.61(lHxl/3, d, J=12.6Hz), 6.70(lHx2/3, d, J=12.6Hz), 6.77(lHxl/3, d, J=12.6Hz), 6.82(lHx2/3, d, J=12.6Hz), 7.43(2Hx2/3, d, J=8.8Hz), 7.65(2Hxl/3, d, J=8.8Hz), 8.06(2Hx2/3, d, J=8.8Hz), 8.22(2Hxl/3, d, J=8.8Hz), 9.09- 0 9.26(lHxl/3, brs), 9.26-9.51 (lHx2/3 , brs). MS: 375.2 (M+H) +, 397.1 (M+Na) + Step 3
N- ( {2- (Acetylamino) -4- [2- (4-aminophenyl) ethyl] -1 ,3- thiazol-5-yl Jmethyl) -N-methylacetamide was prepared from the compound of Step 2 in a similar manner according to Step 6 of Production Example 45. MS: 347.25 (M+H) + 5 Step 4
Di-tert-butyl [ (Z) -( {4- [2- (2- (acetylamino) -5- { [acetyl (methyl) aminoJmethyl J-l , 3-thiazol-4- yl) ethylJphenyl} aminoJmethylidene] biscarbamate was prepared from the compound of Step 3 in a similar manner according to ι° Step 3 of Production Example 31.
XH-NMR (CDC13) , δ (ppm): 1.49 (9H, s) , 1.53 (9H, s) , 2.06(3Hx3/4, s) , 2.12(3Hxl/4, s) , 2.23(3H, s) , 2.77(3Hxl/4, s) , 2.81(3Hx3/4, s) , 2.90(4H, s) , 4.20(2Hxl/4, s) , 4.46(2Hx3/4, s) , 7.01(2Hxl/4, d, J=8.6Hz), 7.07(2Hx3/4, d, J=8.5Hz),
15 7.43(2Hx3/4, d, J=8.5Hz), 7.46(2Hxl/4, d, J=8.0Hz), 8.81- 9.09(1H, brs), 10.22 (1HX3/4 , s) , 10.25 (lHxl/4 , s) , 11.62(1H, s) .
MS: 589.2 (M+H) +, 611.2 (M+Na) + Step 5
20 The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production Example 31.
XH-NMR (DMSO-de), δ (ppm) : 1.98(3Hx3/4, s) , 2.02(3Hxl/4, s) , 2.11(3Hx3/4, s) , 2.12(3Hxl/4, s) , 2.60(3Hxl/4, s) ,
25 2.82(3Hx3/4, s) , 2.89(4H, s) , 4.39(2Hx3/4, s) , 4.45(2Hxl/4, s) , 7.13(2Hxl/4, d, J=8.1Hz), 7.14(2Hx3/4, d, J=8.4Hz), 7.22(2Hxl/4, d, J=8.4Hz), 7.25(2Hx3/4, d, J=8.4Hz), 7.31 (4H, s) , 9.61(1H, s) , 12.03 (lHx3/4, s) , 12.13 (lHxl/4 , s) . MS: 389.19 (M+H) + free
30 Production Example 133: Synthesis of N- [4- (2-{4- [ (2- aminoethyl) amino] phenyl} ethyl) -1 ,3-thiazol-2-yl] acetamide dihydrochloride
Step 1 To a suspension of N-{4- [2- (4-aminophenyl) ethyl] -1 ,3- thiazol-2-yl} acetamide (100 mg) in toluene were added tert- butyl (2-bromoethyl) carbamate (87.5 mg) and N,N- diisopropylethylamine (52 μl) , and the mixture was stirred at 80 °C for 24 h. The reaction mixture was allowed to cool to room temperature, water (10 ml) was added, and the organic layer was separated, washed with saturated aqueous NaCl, dried over MgS04, filtered, and concentrated in vacuo to give tert- butyl {2-[ (4- {2- [2- (acetylamino) -1,3—thiazol-4- yl] ethyljphenyl) amino] ethyl} carbamate as a pale brown amorphous .
XH-NMR (CDC13) , δ (ppm): 1.45 (9H, s) , 2.23 (3H, s) , 2.86 (4H, s) , 3.15-3.28 (2H, m) , 3.15-3.47 (2H, m) , 4.64-5.02 (IH, brs), 6.49(1H, s) , 6.52(2H, d, J=8.0Hz), 6.95(2H, d, J=8.0Hz), 9.22- 10.10(1H, brs) .
MS: 405.2 (M+H) +, 427.3 (M+Na) + Step 2
The title compound was prepared from the compound of Step 2 in a similar manner according to Step 2 of Production Example 10.
XH-NMR (DMSO-de), δ (ppm): 2.11 (3H, s) , 2.81 (4H, s) , 2.92- 3.05(2H, m) , 3.29(2H, t, J=6.2Hz), 6.67(2H, d, J=7.7Hz), 7.0K2H, d, J=8.1Hz), 7.87-8.24 (3H, brs), 12.08(1H, s) . MS: 305.2 (M+H) +, 327.2 (M+Na) + Production Ξ-xample 134: Synthesis of N-{4-[3-(2-
{ [amino (imino) methyl] amino} ethyl) phenyl] -1 ,3-thiazol-2- yl}acetamide hydrochloride Step 1
To a suspension of lithium aluminium hydride in dry tetrahydrofuran (50 ml) was added (3-bromophenyl) acetic acid (10 g) in tetrahydrofuran (100 ml) under ice cooling. The mixture was refluxed for 2 hurs . After cooling, to the reaction mixture were added water and aqueous Rochelle salt. The mixture was stirred for another 30 min. Aqueous layer was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated in vacuo to give 2- (3-bromophenyl) ethanol. This compound was used for the next reaction without further purification.
XH-NMR (200 MHz, CDCl3) , δ (ppm): 1.66(1H, brs), 2.84(2H, dd, J=6.5, 14Hz) , 3.85(2H, dt, J=6.5 , 2.6Hz), 7.13-7.39 (4H, m) . Step 2
To a solution of 2- (3-bromophenyl) ethanol (7 g) in N,N- dimethylformamide (100 ml) were added tert-butyldimethylsilyl chloride (5.77 g) and imidazole (2.84 g) at 25 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was poured into water (500 ml) and extracted with ethyl acetate (100 mlx2) . The combined organic layer was dried over magnesium sulfate and concentrated in vacuo . The residue was purified by silica gel column chromatography with mixed solvent of n- hexane and ethyl acetate to give [2- (3- bromophenyl) ethoxy] (tert-butyl) dimethylsilane as colorless oil . ^-NMR (200 MHz, CDCI3) , δ (ppm) : 0.01 (6H, s) , 0.88 (9H, s) ,
2.81(2H, dt, J=6.5, 9.5Hz), 3.81(2H, dt, J=3.0 , 6.5Hz), 7.14- 7.39 (5H, brs) . Step 3
To a solution of 1.6 g of [2- (3-bromophenyl) ethoxy] (tert- butyl) dimethylsilane in tetrahydrofuran (20 ml) was added n- BuLi in hexane (1.57M, 3.88 ml) at -70 °C, then the reaction mixture was stirred at same temperature for 30 min. To the solution was added dimethylacetamide (1.42 ml) drop wise at the same temperature. The mixture was stirred for another 1 hour. To the reaction mixture were added water and 8 ml of IN HCI under ice-cooling. The mixture was stirred for 1 hour, then extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated in vacuo . The residue was purified by silica gel column chromatography with n-hexane and ethyl acetate (20/1- 10/1) as an eluent to give 1- [3- (2-{ [tert- butyl (dimethyl) silyl] oxyJethyl) phenyl] ethanone (350 mg) as 5 colorless oil.
XH-NMR (200 MHz, CDC13) , δ (ppm): 0.03 (6H, s) , 0.85(9H, s) , 2.61(3H, s) , 2.87 (2H, t, J=6.7 Hz), 3.82(2H, t, J=6.7Hz), 7.20-7.24(lH, m) , 7.35-7.44 (2H, m) , 7.77-7.82 (2H, m) . MS: 279 (M+H) + ° Step 4
To a solution of 1- [3- (2-{ [tert- butyl (dimethyl) silyl] oxyJethyl) phenyl] ethanone (755 mg) in tetrahydrofuran (4 ml) was added bromine (168 ml) drop wise at 0 °C. The mixture was stirred at 25 °C for 1 h. To the 5 reaction mixture was added aq. saturated NaHC03, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure to give crude of 2-bromo- 1- [3- (2-hydroxyethyl) phenyl] ethanone as colorless oil. This 0 compound was used for the next reaction without further purification. Step 5
To a solution of 2-bromo-l- [3- (2- hydroxyethyl) phenyl] ethanone (crude, 658 mg) in 5 tetrahydrofuran (15 ml) was added l-acetyl-2-thiourea (320 mg) at 25 °C. The mixture was stirred at 60 °C for 2 h. The residual colorless crystals were collected by filtration. The crystals were washed with isopropyl ether, dried under reduced pressure to give N-{4- [3- (2-hydroxyethyl) phenyl] -1 ,3-thiazol- 0 2-ylJ acetamide (514 mg) as a colorless crystal.
XH-NMR (200 MHz, DMSO-d6) , δ (ppm): 2.16 (3H, s) , 2.76 (2H, t, J=6.9Hz), 3.63(2H, t, J=6.9 Hz), 4.89(1H, brs), 7.16(1H, d, J=7.7 Hz), 7.32(1H, dd, J=7.7 , 7.6Hz), 7.56(1H, s) , 7.70(2H, d , J=7 . 6 Hz ) , 7 . 76 ( 1H , s ) , 12 . 24 ( 1H , s ) . MS : 263 (M+H) + Step 6
To a suspension of N- {4- [3- (2-hydroxyethyl) phenyl] -1 ,3- thiazol-2-yl} acetamide (300 mg) in CH2C12 (10 ml) were added methansulfonyl chloride (106 μl) and triethylamine (207 μl) at 5 °C. The mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into water and extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. Resulting residue was purified by silica gel column chromatography with n-hexane and ethyl acetate (1:1) as an eluent to give 2-{3- [2- (acetylamino) -1 , 3-thiazol-4- yl] phenyl Jethyl methanesulfonate (388 mg) as a colorless solid.
XH-NMR (200 MHz, DMSO-d6) , δ (ppm) : 2.16 (3H, s) , 3.04 (2H, t, J=6.9 Hz), 3.12(3H, s) , 4.45(2H, t, J=6.9 Hz), 7.23-7.42 (2H, m) , 7.60(1H, s) , 7.75-7.81 (2H, m) , 12.26(1H, s) . MS: 341 (M+H) + Step 7
To a solution of 2- {3- [2- (acetylamino) -1 , 3-thiazol-4- ylJphenyl Jethyl methanesulfonate (388 mg) in N,N- dimethylformamide (5 ml) were added di-tert- butyliminodicarboxylate (322 mg) and K2C03 (236 mg) at 25 °C. The mixture was stirred at 80 °C for 2 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure. Resulting colorless oil containing N-{4- (3- [2-{di- (tert- butoxycarbonyl) amino JethylJphenyl) -1 ,3-thiazol-2-ylJ acetamide was used for the next reaction without further purification. Step 8
N- { 4- [3- (2-Aminoethy1) phenyl] -1 , 3-thiazol-2-yl } acetamide was prepared from the compound of Step 7 in a similar manner according to Step 2 of Production Example 31.
XH-NMR (200 MHz, DMSO-d6) , δ (ppm): 2.16(1H, s) , 2.74(2H, dd,
J=6.8, 6.2Hz), 2.88(2H, dd, J=7 , 7.8Hz), 7.17(1H, d, J=7.7Hz), 5 7.35(1H, dd, J=7.7 , 8Hz) , 7.58(1H, s) , 7.73(1H, d, J=8Hz) ,
7.74(1H, s) .
MS: 262 (M+H) +
Step 9
Di-tert-butyl { (Z)-[ (2-{3- [2- (acetylamino) -1 ,3-thiazol-4- ι° ylJphenyl Jethyl) aminojmethylidenejbiscarbamate was prepared from the compound of Step 8 in a similar manner according to
Step 5 of Production Example 18.
XH-NMR (200 MHz, CDC13) , δ (ppm): 1.45 (9H, s) , 1.50 (3H, s) ,
2.27 (3H, s) , 2.92(2H, t, J=7.5Hz), 3.71(2H, dt, J=7.5 , 7.2Hz), 15 7.11-7.41(4H, d) , 7.65-7.78 (IH, m) .
MS: 504 (M+H) +
Step 10
The title compound was prepared from the compound of Step
9 in a similar manner according to Step 4 of Production 20 Example 31.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 2.16 (3H, s) , 2.83 (2H, t,
J=6.9Hz), 3.41(2H, m) , 7.23(1H, d, J=7.7Hz), 7.38(1H, dd,
J=7.7, 7.8 Hz), 7.52(1H, t, J=5.5Hz), 7.59(1H, s) , 7.75(1H, d,
J=8.1Hz), 7.79(1H, s) , 12.23(1H, s) . 25 MS: 304 (M+H) + free
Production Example 135: Synthesis of N-(4-[2-(4-
{ [amino (iminoJmethyl] aminojphenyl) ethyl] -5- {2- [4-
(methylsulfonyl) phenyl] ethyl J-l , 3-thiazol-2-yl) acetamide hydrochloride 0 Step 1 tert-Butyl N-{4- [2- (2- (acetylamino) -5-{ (E) -2- [4-
(methylsulfonyl) phenyl] vinyl J-l ,3-thiazol-4- yl) ethylJphenyl} carbamate was prepared from 2- (acetylamino) -4- {2- [4- (tert-butoxycarbonylamino) phenyl] ethyl J-l , 3-thiazole-5- carbaldehyde in a similar manner according to Step 5 of
Production Example 45.
MS: 542 (M+H) + free 5 Step 2 tert-Butyl N-{4- [2- (2- (acetylamino) -5-{2- [4-
(methylsulfonyl) phenyl] ethyl J-l ,3-thiazol-4- yl) ethylJphenyl} carbamate was prepared from the compound of
Step 1 in a similar manner according to Step 6 of Production ι° Example 45.
MS: 544 (M+H) +
Step 3
N- (4- [2- (4-Aminophenyl) ethyl] -5-{2- [4-
(methylsulfonyl) phenyl] ethyl J-l , 3-thiazol-2-yl) acetamide was 15 prepared from the compound of Step 2 in a similar manner according to Step 2 of Production Example 31.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 2.23 (3H, s) , 2.61 (4H, s) ,
2.78(4H, s) , 2.98(3H, s) , 3.55(2H, brs), 6.57 (2H, d, J=8.5Hz),
6.81(2H, d, J=8.5Hz), 7.25(2H, d, J=8.5Hz), 7.82(2H, d, 20 J=8.5Hz) , 8.80(1H, s) .
MS: 444 (M+H) +
Step 4
Di-tert-butyl [ (E)-({4-[2- (2- (acetylamino) -5-{2- [4-
(methylsulfonyl) phenyl] ethyl J-l ,3-thiazol-4- 25 yl) ethylJphenyl} amino) methylidenej iscarbamate was prepared from the compound of Step 3 in a similar manner according to
Step 5 of Production Example 18.
XH-NMR (200 MHz, CDC13) , δ (ppm) : 1.49 (9H, s) , 1.53 (9H, s) ,
2.22(3H, s) , 2.59-2.73 (4H, m) , 2.84(4H, s) , 2.98(3H, s) ,
30 6.99(2H, d, J=8.4Hz) , 7.28(2H, d, J=8.4Hz) , 7.44(2H, d,
J=8.4Hz) , 7.83(2H, d, J=8.4Hz) , 8.99(1H, bra) , 10.23(1H, s) ,
11.62 (IH, s) .
MS: 686 (M+H) + Step 5
The title compound was prepared from the compound of Step
4 in a similar manner according to Step 4 of Production
Example 31. XH-NMR (200 MHz, DMSO-d6) , δ (ppm): 2.16 (3H, s) , 2.67 (4H, brs),
2.82-2.94 (4H, m) , 3.14(3H, s) , 7.12(2H, d, J=8.4Hz), 7.20(2H, d, J=8.4Hz), 7.43(2H, d, J=8.4Hz), 7.82(2H, d, J=8.4Hz),
9.87 (IH, s) , 11.97 (IH, s) .
MS: 486 (M+H) +
The compounds according to the present invention useful as VAP-1 inhibitors are listed in the following tables.
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Example 1
Inhibitory Effect of Compound A on VAP-1 enzyme (SSAO) activity in human and rat plasma.
VAP-1 enzyme (SSAO) activity in both human and rat plasma was determined by a radiochemical-enzyme assay using 14C- benzylamine as artificial substrate. The enzyme suspension prepared from blood plasma was pre-incubated with Compound A in 96-well microplate at room temperature for 30 min. The enzyme suspension was then incubated with 14C-benzylamine (2xl0~5 mol/1 final concentration) in a final volume of 50 μl at 37°C for 1 hour. The enzyme reaction was terminated by adding 2 mol/1 (50 μl) citric acid. The oxidized products were directly extracted into a 200 μl toluene scintillator, and its radioactivity was measured by a scintillation spectrometer. Monoamine oxidase (MAO) and diamine oxidase (DAO, histaminase) activities were also determined by similar method using 1C- phenylethylamine and 14C-putrescine as substrate, respectively. Cloned DAO from cDNA libraries was used in human DAO assay.
Inhibition activity was expressed as ICso (μmol/1) value. Compound A completely inhibited the enzyme activity of human and rat plasma SSAO, but not the enzyme activities of other amine oxidases , such as human platelet MAO and cloned DAO, shown in Table 1.
Table 1. Inhibitory effect (ICso values, μM) of Compound A on various amine oxidase activities
Figure imgf000249_0001
Example 2 Effect of Compound A on ocular permeability in diabetic rats Diabetes in rat was induced with an intraperitoneal (i.p.) injection of 65 mg/ml/kg of streptozotocin (STZ) in 2 mmol/1 citrate buffer (pH 4.5) after a 20-h fast. At the same time control rat were injected with an equal volume of 2 mmol/1 citrate buffer. Plasma glucose level was checked by a colorimetric method. At day 3 of STZ treatment, the -rat was diagnosed with diabetes showing a plasma glucose level of 350 mg/dl.
The treatment of Compound A was given daily from 2 weeks after STZ treatment for 2 weeks. At 24 hrs after final treatment of Compound A, the vascular permeability in oculus was investigated based on the leakage of dye into the vitreous 30 min after intravenous injection of fluorescein solution (40 mg/ml/kg) . Permeability was expressed as vitreous/plasma ratio of fluorescein concentration measured by a fluorophotometer . At the same time, the plasma SSAO activity was checked by the radiochemical-enzyme assay using 1C-benzylamine (2xl0-5 mol/1 final concentration) as substrate.
The significant increase of ocular permeability in diabetic rats was examined at 4 weeks after treatment of STZ and compared with that of normoglycemic normal rats . The treatment of Compound A (10 mg/kg, s.c. u.i.d.) given daily from 2 weeks after STZ treatment improved the ocular permeability, in comparison with the STZ control group (Table 2) . Plasma SSAO enzyme activity also increased in diabetic rats at 4 weeks after STZ treatment, but the treatment with Compound A exhibited dose-dependent inhibition of the increased plasma SSAO activity (Table 3) . Table 2. Vitreous/Plasma Ratio of Fluorescein Concentration (xl0~3)
Figure imgf000251_0001
Values are mean ± S.E.M.s for 10 rats. **p<0.01 vs corresponding value for STZ control by Dunnetfs test.
Table 3. Plasma SSAO activity (pmol/min/ml)
Figure imgf000251_0002
Values are mean ± S.E.M.s for 10 rats. **p<0.01 vs corresponding value for STZ control by Dunnetfs test.
INDUSTRIAL APPLICABILITY The present invention provides a compound of the formula (I): R1—NH—X—Y—Z (I) wherein each symbol is as defined above, or a parmaceutically acceptable salt thereof useful as a VAP-1 inhibitor, a pharmaceutical composition, a method for preventing or treating a VAP-1 associated disease, especially macular edema such as diabetic macular edema and non-diabetic macular edema, which method comprises administering to a patient in need- thereof a VAP-1 inhibitor in an amount sufficient to treat the patient for the VAP-1 associated disease, and the like.

Claims

1. A compound of the formula (I) :
5 R1—NH—X—Y—Z (I) wherein
R1 is acyl;
X is a bivalent residue derived from optionally substituted thiazole; ° Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
Figure imgf000252_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; 5 B is a bond, lower alkylene, -CO- or -0-;
D is a bond, lower alkylene, -NH- or -CH2NH-; and E is optionally protected amino, -N=CH2,
Figure imgf000252_0002
wherein 0 Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl ; or a pharmaceutically acceptable salt thereof. 5
2. The compound of claim 1 , wherein Z is a group of the formula:
Figure imgf000252_0003
wherein R2 is a group of the formula : NH
A 4
-G-NH NH-R
(wherein G is a bond, -NHCOCH2- or lower alkylene and R4 is hydrogen, -NH2 or lower alkyl) ; -NH2; -CH2NH2; -CH2ONH2;
-CH2ON=CH2 ;
Figure imgf000253_0001
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 2 , wherein R2 is a group of the formula:
NH
-G-NH ANH-R
(wherein G is a bond , -NHCOCH2- or lower alkylene and R4 is hydrogen or lower alkyl) ; -CH2NH2 ; -CH2ONH2 ; -CH2ON=CH2 ;
H N H N NH NH NH
-N- . "N-< NJ' . X ^NH ;; _-NNHHΛ CCHH3, oorr __NNHHAS-CH3 ' H or a pharmaceutically acceptable salt thereof.
4. The compound of any of claims 1 to 3 , wherein R1 is alkylcarbonyl and X is a bivalent residue derived from thiazole optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1, wherein the compound is N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3- thiazol-2-yl} acetamide,
N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl}acetamide , N-{4- [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl }acetamide , N-{4- [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -1,3- thiazol-2-yl} acetamide, or 5 N- (4-{2- [4- (2-{ [amino (imino) methyl] aminojethyl) phenyl] ethylj- 1 , 3-thiazol-2-yl) acetamide , or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 or a pharmaceutically acceptable ° salt thereof for use as a medicament.
7. A pharmaceutical composition, which comprises, as an active ingredient, the compound of claim 1 or a pharmaceutically acceptable salt thereof. 5
8 . A method for producing a compound of the formula ( I ) :
R1 — NH— X— Y— Z ( I ) wherein 0 R1 is acyl ;
X is a bivalent residue derived from optionally substituted thiazole ;
Y is a bond, lower alkylene, lower alkenylene or -CONH-; and
Z is a group of the formula:
5
Figure imgf000254_0001
wherein R2 is a group of the formula: -A-B-D-E wherein A is a bond, lower alkylene, -NH- or -S02-; B is a bond, lower alkylene, -CO- or -0-; D is a bond, lower alkylene, -NH- or -CH2NH-; and 0 E is optionally protected amino, -N=CH2 , ^ JIH
- or -
Q wherein
Q is -S- or -NH-; and
R3 is hydrogen, lower alkyl, lower alkylthio or -NH-R4 wherein R4 is hydrogen, -NH2 or lower alkyl; or a pharmaceutically acceptable salt thereof, which method comprises at least one step selected from the group consisting of (i) to (v) : (i) reacting Compound (1) :
Figure imgf000255_0001
with Compound (2) :
Figure imgf000255_0002
wherein Li is a leaving group and Z is as defined above, or a salt thereof;
(ii) reacting Compound (3) : H2N-X-Z wherein X and Z are as defined above, or a salt thereof with
Compound (4) : Rx-L2 wherein R1 is as defined above and L2 is a leaving group; (iii) reacting Compound (6) : R1-NH-X-CHO wherein R1 and X are as defined above, or a salt thereof with
Compound (7) : L3-CH2-Z wherein L3 is a leaving group and Z is as defined above, or a salt thereof; (iv) reduction of Compound (10): R1-NH-X- (lower alkenylene) -Z wherein R1 , X and Z are as defined above, or a salt thereof to Compound (11): RX-NH-X- (lower alkylene) -Z wherein R1 , X and Z are as defined above, or a salt thereof; and (v) reacting Compound (12) : R1-NH-X-COOH or a reactive derivative thereof, wherein R1 and X are as defined above, or a salt thereof with Compound (13) : L4-NH-Z wherein L4 is a hydrogen atom or a protecting group and Z is as defined above, or a salt thereof.
9. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament as a VAP-1 inhibitor.
10. The use of claim 9, wherein the compound is
N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -1 ,3- thiazol-2-yl } acetamide ,
N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-yl} acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 ,3-thiazol-2-ylJ acetamide,
N-{4- [2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -1 ,3- thiazol-2-yl} acetamide, or N- (4-{2- [4- (2-{ [amino (imino) methyl] aminojethyl) phenyl] ethyl }-
1 ,3-thiazol-2-yl) acetamide.
11. A use of the compound of claim 1 or a pharmaceutically acceptable salt thereof for preparing a medicament for the prophylaxis or treatment of a VAP-1 associated disease.
12. The use of claim 11, wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, essential stabilized hypertension, diabetes, arthrosis , endothelium damage (in diabetes, atherosclerosis and hypertension), a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients) , an (connective tissue) inflammatory disease or condition (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcet's syndrome, relapsing polychondritis , systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis , dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, egener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris), a disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection), a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases , skin dermatoses , diabetes mellitus, SSAO- ediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] and macular edema (diabetic and non-diabetic macular edema) .
13. The use of claim 12, wherein said VAP-1 associated disease is macular edema.
14. The use of claim 13, wherein said macular edema is diabetic macular edema.
15. The use of claim 13, wherein said macular edema is non- diabetic macular edema.
16. A VAP-1 inhibitor, which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof.
17. A method for preventing or treating macular edema, which method comprises administering to a subject in need thereof a VAP-1 inhibitor in an amount sufficient to treat said subject for macular edema.
18. The method of claim 17, wherein the VAP-1 inhibitor is N-{4- [2- (4-{ [amino (iminoJmethyl] aminojphenyl) ethyl] -1 ,3- thiazol-2-yl }acetamide ,
N-{4- [2- (4-{ [amino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) enzyl] -1 , 3-thiazol-2-yl } acetamide , N-{4-[2- (4-{ [hydrazino (imino) methyl] aminojphenyl) ethyl] -5- [4- (methylsulfonyl) benzyl] -1 , 3-thiazol-2-yl}acetamide , N-{4-[2- (4-{ [hydrazino (iminoJmeth l] aminojphenyl) ethyl] -1,3- thiazol-2-yl}acetamide, or
N- (4-{2- [4- (2-{ [amino (imino) methyl] aminojethyl) phenyl] ethyl - 5 1 ,3-thiazol-2-yl) acetamide, or a pharmaceutically acceptable salt thereof.
19. A method for preventing or treating a VAP-1 associated disease, which method comprises administering an effective ° amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal.
20. The method of claim 19, wherein said VAP-1 associated disease is selected from the group consisting of cirrhosis, 5 essential stabilized hypertension, diabetes, arthrosis, endothelium damage (in diabetes, atherosclerosis and hypertension) , a cardiovascular disorder associated with diabetes and uraemia, pain associated with gout and arthritis, retinopathy (in diabetes patients), an 0 (connective tissue) inflammatory disease or condition
(rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and osteoarthritis or degenerative joint disease, Reiter's syndrome, Sjogren's syndrome, Behcef s syndrome, relapsing polychondritis , systemic lupus erythematosus, 5 discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis , polymyositis , dermatomyositis , polymyalgia rheumatica, vasculitis, temporal arteritis, polyarteritis nodosa, egener's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid 0 arthritis) , a gastrointestinal inflammatory disease or condition [Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon) , fibrotic conditions of the liver, inflammation of the oral mucosa (stomatitis) , and recurrent aphtous stomatitis] , a central nervous system inflammatory disease or condition (multiple sclerosis, Alzheimer's disease, and ischaemia-reperfusion injury associated with ischemic stroke) , a pulmonary inflammatory 5 disease or condition (asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease), a (chronic) skin inflammatory disease or condition (psoriasis, allegic lesions, lichen planus, pityriasis rosea, contact dermatitis, atopic dermatitis, pityriasis rubra pilaris) , a ° disease related to carbohydrate metabolism (diabetes and complications from diabetes) including microvascular and macrovascular disease (atherosclerosis, vascular retinopathies , retinopathy, nephropathy, nephrotic syndrome and neuropathy (polyneuropathy, mononeuropathies and 5 autonomic neuropathy), foot ulcers, joint problems, and increased risk of infection) , a disease related to aberrations in adipocyte differentiation or function or smooth muscle cell function (atherosclerosis and obesity) , a vascular disease [atheromatous ateriosclerosis, 0 nonatheromatous ateriosclerosis, ischemic heart disease including myocardial infarction and peripheral arterial occlusion, Raynaud's disease and phenomenon, thromboangiitis obliterans (Buerger's disease)], chronic arthritis, inflammatory bowel diseases, skin dermatoses, diabetes 5 mellitus, SSAO-mediated complication [diabetes (insulin dependent diabetes mellitus (IDDM) and non-insulin dependent diabetes mellitus (NIDDM) ) and vascular complication (heart attack, angina, strokes, amputations, blindness and renal failure) ] and macular edema (diabetic and non-diabetic 0 macular edema) .
21. The method of claim 20, wherein said VAP-1 associated disease is macular edema.
22. The method of claim 21, wherein said macular edema is diabetic macular edema.
23. The method of claim 21, wherein said macular edema is non-diabetic macular edema.
PCT/JP2004/000708 2003-01-27 2004-01-27 Thiazole derivatives and their use as vap-1 inhibitors WO2004067521A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002514573A CA2514573A1 (en) 2003-01-27 2004-01-27 Thiazole derivatives and their use as vap-1 inhibitors
KR1020057013750A KR101154163B1 (en) 2003-01-27 2004-01-27 Thiazole derivatives and their use as vap-1 inhibitors
JP2006502657A JP4650412B2 (en) 2003-01-27 2004-01-27 Thiazole derivatives and their use as VAP-1 inhibitors
EP04705519A EP1587800A1 (en) 2003-01-27 2004-01-27 Thiazole derivatives and their use as vap-1 inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US44250903P 2003-01-27 2003-01-27
US60/442,509 2003-01-27
US45836903P 2003-03-31 2003-03-31
US60/458,369 2003-03-31
US51737703P 2003-11-06 2003-11-06
US60/517,377 2003-11-06

Publications (1)

Publication Number Publication Date
WO2004067521A1 true WO2004067521A1 (en) 2004-08-12

Family

ID=32830859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/000708 WO2004067521A1 (en) 2003-01-27 2004-01-27 Thiazole derivatives and their use as vap-1 inhibitors

Country Status (8)

Country Link
US (3) US7125901B2 (en)
EP (1) EP1587800A1 (en)
JP (1) JP4650412B2 (en)
KR (2) KR20120030601A (en)
AR (1) AR042941A1 (en)
CA (1) CA2514573A1 (en)
TW (1) TWI336696B (en)
WO (1) WO2004067521A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2006028269A2 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
EP1708711A1 (en) † 2004-01-30 2006-10-11 Faron Pharmaceuticals OY Compositions useful especially for treatment or prevention of metabolic syndrome
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
JP2007529413A (en) * 2004-03-18 2007-10-25 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
WO2011034078A1 (en) 2009-09-16 2011-03-24 アステラス製薬株式会社 Glycine compound
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CA2514573A1 (en) 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
CA2520957C (en) * 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease
JP4140630B2 (en) * 2005-11-10 2008-08-27 Ｔｄｋ株式会社 Magnetic head assembly and method of manufacturing magnetic head assembly
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US8372399B2 (en) 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
US8906642B2 (en) 2008-09-03 2014-12-09 Universitat Autonoma De Barcelona Methods and compositions for the treatment and diagnosis of haemorrhagic conversion
WO2016043260A1 (en) * 2014-09-19 2016-03-24 塩野義製薬株式会社 Cyclic guanidine or amidine compound
BR112020022790A2 (en) * 2018-05-09 2021-02-02 Lg Chem, Ltd new compound that exhibits enteropeptidase inhibitory activity
KR102533471B1 (en) * 2020-11-23 2023-05-19 (주) 메디프론디비티 COMPOUNDS hAVING O-GLCNACASE INHIBITORY ACTIVITY AND USE THEREOF

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068033A1 (en) * 1981-01-08 1983-01-05 Mitsui Toatsu Kagaku Kabushiki Kaisha N-(4-phenyl-2-thiazolyl)carbamate derivatives, process for their preparation, and medicinal composition containing same
WO1992021666A1 (en) * 1991-05-31 1992-12-10 Laboratoires Upsa Angiotensin ii receptor antagonist thiazole devivatives
EP0519449A1 (en) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
WO1996030350A1 (en) * 1995-03-27 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
WO1997024343A1 (en) * 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
EP0928790A1 (en) * 1998-01-02 1999-07-14 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2002014311A2 (en) * 2000-08-15 2002-02-21 Amgen Inc. Urea compounds and methods of uses
WO2002028835A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors
EP1277729A1 (en) * 2000-04-28 2003-01-22 Sankyo Company, Limited Ppar (gamma) modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116056A (en) * 1981-01-08 1982-07-19 Mitsui Toatsu Chem Inc N-(4-phenyl-2-thiazolyl)carbamate derivative, its preparation and medicinal composition containing the same
IT1181871B (en) 1985-04-01 1987-09-30 Consiglio Nazionale Ricerche SELECTIVE INHIBITORS OF BENZYLAMINOXIDE COMPARED TO OTHER AMINOXIDE
EP0639972A1 (en) 1992-05-15 1995-03-01 University Of Saskatchewan Method for preventing endothelium damage in mammals and for alleviating pain associated with gout and arthritis
ES2196396T3 (en) * 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co HETEROAROMATIC COMPOUNDS OF 5 MEMBERS CONTAINING OXYGEN OR SULFUR AS INHIBITORS OF THE XA FACTOR.
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9901875D0 (en) * 1999-05-25 1999-05-25 Astra Pharma Prod Novel compounds
DE19940389A1 (en) * 1999-08-25 2001-03-01 Wilex Biotechnology Gmbh Selective inhibitors of the urokinase plasminogen activator
HUP0301336A3 (en) 2000-07-05 2005-04-28 Biotie Therapies Corp Inhibitors of copper-containing amine oxidases and their use for preparation of pharmaceutical compositions
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
ES2168084B1 (en) 2000-11-07 2003-11-16 Univ Barcelona COMBINATION OF AMINAS AND VANADIUM COMPOUNDS (IV) (V) FOR THE TREATMENT AND / OR PREVENTION OF MELLITUS DIABETES.
WO2002038153A1 (en) 2000-11-09 2002-05-16 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives
WO2002098839A1 (en) 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides and process for preparation thereof
US6982286B2 (en) * 2001-07-12 2006-01-03 Biotie Therapies Corp. Carbocyclic hydrazino inhibitors of copper-containing amine oxidases
CA2514573A1 (en) 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
CA2520957C (en) 2003-03-31 2013-08-06 Sucampo Ag Method for treating vascular hyperpermeable disease

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068033A1 (en) * 1981-01-08 1983-01-05 Mitsui Toatsu Kagaku Kabushiki Kaisha N-(4-phenyl-2-thiazolyl)carbamate derivatives, process for their preparation, and medicinal composition containing same
WO1992021666A1 (en) * 1991-05-31 1992-12-10 Laboratoires Upsa Angiotensin ii receptor antagonist thiazole devivatives
EP0519449A1 (en) * 1991-06-21 1992-12-23 Boehringer Mannheim Italia S.P.A. 2-Amino-4-aryl thiazoles with antiasthmatic and antiinflammatory activities on the respiratory tract
WO1996030350A1 (en) * 1995-03-27 1996-10-03 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
WO1997024343A1 (en) * 1995-12-29 1997-07-10 Boehringer Ingelheim Pharmaceuticals, Inc. Phenyl thiazole derivatives with anti herpes virus properties
EP0928790A1 (en) * 1998-01-02 1999-07-14 F. Hoffmann-La Roche Ag Thiazole derivatives
EP1277729A1 (en) * 2000-04-28 2003-01-22 Sankyo Company, Limited Ppar (gamma) modulators
WO2002014311A2 (en) * 2000-08-15 2002-02-21 Amgen Inc. Urea compounds and methods of uses
WO2002028835A1 (en) * 2000-10-05 2002-04-11 Fujisawa Pharmaceutical Co., Ltd. Benzamide compounds as apo b secretion inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BHARGAVA P N ET AL: "Synthesis of new local anaesthetics. Part II", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 37, no. 4, 1960, pages 241 - 243, XP008031880 *
MATTAMMAL M B ET AL: "Mass spectrometry of 2,4-substituted carcinogenic thiazoles and their metabolites", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 22, no. 5, September 1985 (1985-09-01), pages 1157 - 1163, XP009010468 *
OHKUBO M ET AL: "Studies on cerebral protective agents. VIII. Synthesis of 2-aminothiazoles and 2-thiazolecarboxamides with anti-anoxic activity", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 43, no. 9, September 1995 (1995-09-01), pages 1497 - 1504, XP002285257 *
ZHANG M Q ET AL: "Quinolone antibacterials. 1. 7-(2-Substituted-4-thiazolyl and thiazolidinyl)quinolones", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 28, no. 3, 1991, pages 673 - 683, XP002285258 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1708711A1 (en) † 2004-01-30 2006-10-11 Faron Pharmaceuticals OY Compositions useful especially for treatment or prevention of metabolic syndrome
JP2007529413A (en) * 2004-03-18 2007-10-25 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
JP4881159B2 (en) * 2004-03-18 2012-02-22 株式会社アールテック・ウエノ Aqueous composition comprising a thiazole derivative
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2006011631A3 (en) * 2004-07-27 2006-04-20 Astellas Pharma Inc Thiazole derivatives having vap-1 inhibitory activity
WO2006028269A3 (en) * 2004-09-09 2006-06-29 Astellas Pharma Inc Thiazole derivatives having vap-1 ihibitory activity
WO2006028269A2 (en) * 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 ihibitory activity
EP1797084A1 (en) * 2004-09-20 2007-06-20 4Sc Ag NOVEL HETEROCYCLIC NF-kB INHIBITORS
JP2008513386A (en) * 2004-09-20 2008-05-01 ４エスシー アーゲー Novel heterocyclic NF-κB inhibitor
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
WO2009001857A1 (en) * 2007-06-25 2008-12-31 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
JPWO2009001857A1 (en) * 2007-06-25 2010-08-26 株式会社アールテック・ウエノ Composition for ophthalmic diseases associated with hypoxia or ischemia
EP2599498A1 (en) 2007-06-25 2013-06-05 R-Tech Ueno, Ltd. Composition for ophthalmic disease associated with hypoxia or ischemia
WO2009051223A1 (en) 2007-10-19 2009-04-23 R-Tech Ueno, Ltd. Pharmaceutical composition for treatment of cataract
EP2650287A1 (en) * 2008-01-31 2013-10-16 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
AU2009209885B2 (en) * 2008-01-31 2013-12-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
KR101622414B1 (en) 2008-01-31 2016-05-18 가부시키가이샤 아루떼꾸 우에노 Thiazole derivative and use thereof as VAP-1 inhibitor
EP2676955A1 (en) 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
EP2639229A3 (en) * 2008-01-31 2013-12-25 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
RU2496776C2 (en) * 2008-01-31 2013-10-27 Р-Тек Уено, Лтд. Thiazol derivative and using it as vap-1 inhibitor
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
EP2639229A2 (en) 2008-01-31 2013-09-18 R-Tech Ueno, Ltd. Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2009096609A1 (en) * 2008-01-31 2009-08-06 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor
KR20110022574A (en) 2008-05-30 2011-03-07 가부시키가이샤 아루떼꾸 우에노 Benzene or thiophene derivative and use thereof as vap-1 inhibitor
US8999989B2 (en) 2008-05-30 2015-04-07 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
EP2886534A1 (en) 2008-05-30 2015-06-24 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US9795671B2 (en) 2009-09-08 2017-10-24 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
US10576148B2 (en) 2009-09-08 2020-03-03 Biotie Therapies Corp. Use of VAP-1 inhibitors for treating fibrotic conditions
WO2011029996A1 (en) 2009-09-08 2011-03-17 Biotie Therapies Corp. Use of vap-1 inhibitors for treating fibrotic conditions
US8802679B2 (en) 2009-09-16 2014-08-12 Astellas Pharma Inc. Glycine compound
WO2011034078A1 (en) 2009-09-16 2011-03-24 アステラス製薬株式会社 Glycine compound
WO2012120195A1 (en) 2011-03-08 2012-09-13 Biotie Therapies Corporation New pyridazinone and pyridone compounds
KR20140014153A (en) 2011-03-15 2014-02-05 아스테라스 세이야쿠 가부시키가이샤 Guanidine compound
EP3002278A1 (en) 2011-03-15 2016-04-06 Astellas Pharma Inc. Guanidine compound
US8716470B2 (en) 2011-03-15 2014-05-06 Astellas Pharma Inc. Guanidine compound
US9556160B2 (en) 2011-03-15 2017-01-31 Astellas Pharma Inc. Guanidine compound
WO2012124696A1 (en) 2011-03-15 2012-09-20 アステラス製薬株式会社 Guanidine compound
US9051283B2 (en) 2011-03-15 2015-06-09 Astellas Pharma Inc. Guanidine compound
WO2014199171A1 (en) 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
WO2015159112A1 (en) 2014-04-15 2015-10-22 Pécsi Tudományegyetem Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
WO2015189534A1 (en) 2014-06-12 2015-12-17 Proximagen Limited Vap-1 inhibitors for treating muscular dystrophy
WO2016194390A1 (en) 2015-06-05 2016-12-08 R-Tech Ueno, Ltd. Pharmaceutical composition for use in the treatment of cancer
EP3777846A1 (en) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Vap-1 inhibitors for treating pain
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

Also Published As

Publication number Publication date
US20060276521A1 (en) 2006-12-07
US7125901B2 (en) 2006-10-24
US20060128770A1 (en) 2006-06-15
EP1587800A1 (en) 2005-10-26
TWI336696B (en) 2011-02-01
JP2006516611A (en) 2006-07-06
KR20050095875A (en) 2005-10-04
US20040259923A1 (en) 2004-12-23
JP4650412B2 (en) 2011-03-16
TW200420549A (en) 2004-10-16
KR101154163B1 (en) 2012-06-14
US7442715B2 (en) 2008-10-28
AR042941A1 (en) 2005-07-06
KR20120030601A (en) 2012-03-28
CA2514573A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
US7442715B2 (en) Thiazole derivatives
EP1608365B1 (en) Method for treating vascular hyperpermeable disease
EP1786792B1 (en) Thiazole derivatives having vap-1 inhibitory activity
US20080015202A1 (en) Thiazole Derivatives Having Vap-1 Inhibitory Activity
AU2009209885B2 (en) Thiazole derivative and use thereof as VAP-1 inhibitor
JP2008508188A5 (en)
JP2008512346A5 (en)
WO2005089755A1 (en) Aqueous composition comprising thiazole derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020057013750

Country of ref document: KR

Ref document number: 2006502657

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2514573

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004705519

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048076823

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057013750

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004705519

Country of ref document: EP